U.S. patent number 9,091,651 [Application Number 13/725,098] was granted by the patent office on 2015-07-28 for selected reaction monitoring assays.
This patent grant is currently assigned to Integrated Diagnostics, Inc.. The grantee listed for this patent is Integrated Diagnostics, Inc.. Invention is credited to Miguel Dominguez Geeraerts, Clive Hayward, Paul Edward Kearney, Xiao-Jun Li.
United States Patent |
9,091,651 |
Kearney , et al. |
July 28, 2015 |
Selected reaction monitoring assays
Abstract
Provided herein are methods for developing selected reaction
monitoring mass spectrometry (LC-SRM-MS) assays.
Inventors: |
Kearney; Paul Edward (Montreal,
CA), Li; Xiao-Jun (Bellevue, WA), Hayward;
Clive (Seattle, WA), Geeraerts; Miguel Dominguez
(Pierrefonds, CA) |
Applicant: |
Name |
City |
State |
Country |
Type |
Integrated Diagnostics, Inc. |
Seattle |
WA |
US |
|
|
Assignee: |
Integrated Diagnostics, Inc.
(Seattle, WA)
|
Family
ID: |
47522959 |
Appl.
No.: |
13/725,098 |
Filed: |
December 21, 2012 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20130203096 A1 |
Aug 8, 2013 |
|
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
61578718 |
Dec 21, 2011 |
|
|
|
|
61614818 |
Mar 23, 2012 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K
7/08 (20130101); C07K 7/06 (20130101); G01N
27/62 (20130101); G01N 33/57484 (20130101); G01N
33/6848 (20130101); G01N 2800/2821 (20130101); G01N
2333/705 (20130101); G01N 2560/00 (20130101); G01N
2458/15 (20130101); G01N 2570/00 (20130101) |
Current International
Class: |
C12Q
1/37 (20060101); G01N 27/62 (20060101); G01N
33/68 (20060101) |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
Other References
Ostroff et al. Unlocking Biomarker Discovery: Large Scale
Application of Aptamer Proteomic Technology for Early Detection of
Lung Cancer, PLOS One, Dec. 2010, vol. 5, No. 12, 10 pages. cited
by examiner .
Li et al. A Blood-Based Proteomic Classifier for the Molecular
Characterization of Pulmonary Nodules. Sci Transl Med 2013 vol. 5,
No. 207, pp. 1-10. cited by examiner .
Zeng et al. Abstract 4564: Lung cancer serum biomarker discovery
using label free LC-MS/MS. Cancer Research: Apr. 15, 2010. vol. 70,
Isssue 8, Supplement 1, Proceedings from the AACR 101st Annual
Meeting, 2010, Apr. 17-21, 2010. Washington DC. 1 page. cited by
examiner .
Lin et al. Malignant pleural effusion cells show aberrant glucose
metabolism gene expression. Eur Respir J 2011, vol. 37, pp.
1453-1465. cited by examiner .
Huttenhaim et al. "Reproducible Quantification of Cancer-Associated
Proteins in Body Fluids using Targeted Proteomics." Sci. Transl.
Med. 4.142(2012):149ra194. cited by applicant .
Kearney et al. "Protein Identification and Peptide Expression
Resolver: Harmonizing Protein Identification with Protein
Expression Data." J. Proteome Res. 7.1(2008):234-244. cited by
applicant .
Lange et al. "Selected Reaction Monitoring for Quantitative
Proteomics: A Tutorial." Mol. Sys. Biol. 4(2008):222. cited by
applicant .
Perkins et al. "Probability-Based Protein Identification by
Searching Sequence Databases Using Mass Spectrometry Data."
Electrophoresis. 20.18(1999):3551-3567. cited by applicant .
Picotti et al. "High-Throughput Generation of Selected
Reaction-Monitoring Assays for Proteins and Proteomes." Nat. Meth.
7.1(2010):43-46. cited by applicant .
Cho et al. "Verification of a Biomarker Discovery Approach for
Detection of Down Syndrome in Amniotic Fluid via Multiplex Selected
Reaction Monitoring (SRM) Assay." J. Prot. 74.10(2011):2052-2059.
cited by applicant .
Gallien et al. "Selected Reaction Monitoring Applied to
Proteomics." J. Mass Spectrom. 46.3(2011):298-312. cited by
applicant .
Kiyonami et al. "Increased Selectivity, Analytical Precision, and
Throughput in Targeted Proteomics." Mol. Cell. Proteomics.
10.2(2011):M110. cited by applicant.
|
Primary Examiner: Garcia; Marcela M Cordero
Attorney, Agent or Firm: Cooley LLP Elrifi; Ivor Pavao;
Matthew
Parent Case Text
RELATED APPLICATIONS
This application claims priority and benefit of U.S. Provisional
Application No. 61/578,718 filed Dec. 21, 2011, and U.S.
Provisional Application No. 61/614,818 filed Mar. 23, 2012, the
contents of each of which are incorporated herein by reference in
their entireties.
INCORPORATION-BY-REFERENCE OF SEQUENCE LISTING
The contents of the text file named "Corrected SEQ ID
IDIA-004.sub.--001US_ST25.txt", which was created on Feb. 24, 2015
and is 404,170 bytes in size, are hereby incorporated by reference
in their entireties.
Claims
The invention claimed is:
1. A composition comprising at least 5 transition ion pairs said
composition comprising at least one transition ion pair of at least
5 proteins selected from LRP1, BGH3, COIA1, TETN, TSP1, ALDOA,
GRP78, ISLR, FRIL, LG3BP, PRDX1, FIBA, or GSLG1, wherein the at
least one transition ion pair consists of a precursor ion with a
corresponding m/z and a fragment ion with a corresponding m/z, and
wherein the transition ion pairs are selected from precursor
ADDGRPFPQVIK (SEQ ID NO: 57) transition pair 671.86-260.2,
671.86-584.4, or 671.86-528.5; precursor ALQASALK (SEQ ID NO: 58)
transition pair 401.25-260.2, 401.25-331.2, 401.25-489.3, or
401.25-617.4; precursor QLLLTADDR (SEQ ID NO: 60) transition pair
522.79-355.2, 522.79-577.3, 522.79-690.3, or 522.79-803.4;
precursor ADHHATNGVVHLIDK (SEQ ID NO: 136) transition pair
542.95-262.1, 542.95-488.3, 542.95-625.4, or 542.95-724.4;
precursor DILATNGVIHYIDELLIPDSAK (SEQ ID NO: 137) transition pair
804.1-305.2, 804.1-514.3, 804.1-517.3, or 804.1-630.3; precursor
LTLLAPLNSVFK (SEQ ID NO: 139) transition pair 658.4-328.2,
658.4-804.5, 658.4-875.5, or 658.4-988.6; precursor SPYQLVLQHSR
(SEQ ID NO: 140) transition pair 443.24-527.3, 443.24-589.3,
443.24-640.4, or 443.24-852.5; precursor ADDILASPPR (SEQ ID NO:
331) transition pair 527.78-302.1, 527.78-369.2, 527.78-369.2,
527.78-456.3, or 527.78-640.4; precursor AVGLAGTFR (SEQ ID NO: 332)
transition pair 446.26-480.3, 446.26-551.3, 446.26-664.4, or
446.26-721.4; precursor TEAPSATGQASSLLGGR (SEQ ID NO: 335)
transition pair 801.91-289.2, 801.91-302.1, 801.91-760.4, or
801.91-945.5; precursor GGSTSYGTGSETESPR (SEQ ID NO 554) transition
pair 786.84-359.2, 786.84-589.3, 786.84-862.4, or 786.84-963.4;
precursor NSLFEYQK (SEQ ID NO: 556) transition pair 514.76-315.2,
514.76-567.3, 514.76-714.3, or 514.76-827.4, precursor TVIGPDGHK
(SEQ ID NO: 557) transition pair 308.5-341.2, 308.5-456.2,
308.5-553.3, or 308.5-610.3; precursor VQHIQLLQK (SEQ ID NO: 558)
transition pair 369.56-501.3, 369.56-606.3, 369.56-629.4, or
369.56-742.5; precursor ALFQDIK (SEQ ID NO: 593) transition pair
417.74-260.2, 417.74-503.3, 417.74-650.4, or 417.74-763.4;
precursor DDVALEGVSHFFR (SEQ ID NO: 594) transition pair
497.91-469.3, 497.91-693.3, 497.91-849.4, or 497.91-978.5;
precursor KPAEDEWGK (SEQ ID NO: 595) transition pair 353.84-297.2,
353.84-390.2, 353.84-541.3, or 353.84-634.3; precursor
LGGPEAGLGEYLFER (SEQ ID NO: 596) transition pair 804.41-451.2,
804.41-525.3, 804.41-564.3, or 804.41-913.4; precursor
LNQALLDLHALGSAR (SEQ ID NO: 597) transition pair 531.3-356.2,
531.3-427.2, 531.3-574.3, or 531.3-711.4; precursor MGDHLTNLHR (SEQ
ID NO: 598) transition pair 398.53-312.2, 398.53-539.3,
398.53-640.53, or 398.53-753.4; precursor LYGSAGPPPTGEEDTAEK (SEQ
ID NO: 663) transition pair 909.92-334.2, 909.92-492.2,
909.92-549.3, or 909.92-878.4; precursor TWNDPSVQQDIK (SEQ ID NO:
664) transition pair 715.85-260.2, 715.85-288.1, 715.85-517.2, or
715.85-914.5; precursor VYEGERPLTK (SEQ ID NO: 665) transition pair
397.88-458.3, 397.88-614.4, 397.88-800.5, or 397.88-929.5;
precursor IIIQESALDYR (SEQ ID NO: 666) transition pair
660.86-338.2, 660.86-724.4, 660.86-853.4, or 660.86-981.5;
precursor LDPALQDK (SEQ ID NO: 667) transition pair 450.25-503.3,
450.25-574.3, 450.25-671.4, or 450.25-786.4; precursor LIAQDYK (SEQ
ID NO: 668) transition pair 425.74-310.2, 425.74-553.3,
425.74-624.3, or 425.74-737.4; precursor NDINILK (SEQ ID NO: 669)
transition pair 415.24-260.2, 415.24-487.3, 415.24-600.4, or
415.24-715.4; precursor VAELSSDDFHLDR (SEQ ID NO: 670) transition
pair 501.91-403.2, 501.91-540.3, 501.91-687.4, 501.91-702.3;
precursor ALPGTPVASSQPR (SEQ ID NO: 839) transition pair
640.85-440.3, 640.85-440.3, 640.85-574.3, 640.85-841.5, or
640.85-999.5; precursor EVPLLQSLWLAHNEIR (SEQ ID NO: 840)
transition pair 640.02-531.3, 640.02-668.3, 640.02-739.4, or
640.02-852.5; precursor LPGLPEGAFR (SEQ ID NO: 841) transition pair
528.8-268.2, 528.8-381.3, 528.8-676.3, or 528.8-846.4; precursor
TVAAGALASLSHLK (SEQ ID NO: 843) transition pair 446.93-343.2,
446.93-684.4, 446.93-755.4, or 446.93-868.5; precursor ASHEEVEGLVEK
(SEQ ID NO: 938) transition pair 442.89-545.3, 442.89-554.2,
442.89-653.3, or 442.89-674.4; precursor STHTLDLSR (SEQ ID NO: 940)
transition pair 343.85-262.2, 343.85-375.2, 343.85-490.3, or
343.85-655.3; precursor VEIFYR (SEQ ID NO: 941) transition pair
413.73-338.2, 413.73-485.3, 413.73-598.3, or 413.73-727.4;
precursor YSSDYFQAPSDYR (SEQ ID NO: 942) transition pair
799.84-637.3, 799.84-708.3, 799.84-836.4, or 799.84-983.5;
precursor AALSGANVLTLIEK (SEQ ID NO: 958) transition pair
700.4-1057.6, 700.4-1144.7, 700.4-716.5, or 700.4-929.6; precursor
TVLWPNGLSLDIPAGR (SEQ ID NO: 959) transition pair 854.972-1209.7,
854.972-400.231, 854.972-500.3, 854.972-500.3, or 854.972-605.333;
precursor VFFTDYGQIPK (SEQ ID NO: 960) transition pair
657.84-1068.54, 657.84-244.2, 657.84-820.4, or 657.84-921.468;
precursor ADEGISFR (SEQ ID NO: 1321) transition pair 447.72-409.2,
447.72-552.3, 447.72-579.3, or 447.72-708.4; precursor ATAVMPDGQFK
(SEQ ID NO: 1322) transition pair 582.79-691.3, 582.79-822.4,
582.79-921.5, or 582.79-992.5; precursor DISLSDYK (SEQ ID NO: 1323)
transition pair 470.74-310.2, 470.74-512.2, 470.74-625.3, or
470.74-712.4; precursor GLFIIDDK (SEQ ID NO: 1324) transition pair
460.76-377.2, 460.76-490.3, 460.76-603.3, or 460.76-750.76;
precursor IGHPAPNFK (SEQ ID NO: 1325) transition pair 327.52-294.2,
327.52-505.3, 327.52-576.3, or 327.52-673.4; precursor LVQAFQFTDK
(SEQ ID NO: 1326) transition pair 598.82-341.2, 598.82-785.4,
598.82-856.4, or 598.82-984.5; precursor QGGLGPMNIPLVSDPK (SEQ ID
NO: 1327) transition pair 811.93-356.2, 811.93-446.2, 811.93-545.3,
or 811.93-658.4; precursor QITVNDLPVGR (SEQ ID NO: 1328) transition
pair 606.34-428.3, 606.34-770.4, 606.34-869.5, or 606.34-970.5;
precursor SVDETLR (SEQ ID NO: 1329) transition pair 410.21-288.2,
410.21-389.3, 410.21-518.3, or 410.21-633.3; precursor TIAQDYGVLK
(SEQ ID NO: 1330) transition pair 554.31-579.4, 554.31-694.4,
554.31-822.4, or 554.31-893.5; precursor GGTLSTPQTGSENDALYEYLR (SEQ
ID NO: 1588) transition pair 758.03-451.3, 758.03-580.3,
758.03-856.5, or 758.03-927.5; precursor LDTLAQEVALLK (SEQ ID NO:
1589) transition pair 657.39-330.2, 657.39-543.4, 657.39-800.5, or
657.39-871.5; precursor NWETEITAQPDGGK (SEQ ID NO: 1590) transition
pair 773.36-301.1, 773.36-430.2, 773.36-473.2, or 773.36-886.5;
precursor FQDLVDAVR (SEQ ID NO: 1641) transition pair 531.78-391.2,
531.78-559.3, 531.78-672.4, or 531.78-787.4; precursor
FTGSQPFGQGVEHATANK (SEQ ID NO: 1642) transition pair 625.97-261.2,
625.97-504.3, 625.97-521.2, or 625.97-926.5; precursor FVFGTIPEDILR
(SEQ ID NO: 1643) transition pair 465.58-288.2, 465.58-516.3,
465.58-645.4, or 465.58-742.4; precursor GFLLLASLR (SEQ ID NO:
1644) transition pair 495.31-318.2, 495.31-375.2, 495.31-446.3, or
495.31-559.4; or precursor GTSQNDPNWVVR (SEQ ID NO: 1645)
transition pair 686.83-373.3, 686.83-770.4, 686.83-885.5, or
686.83-999.5, wherein each of the precursor ions has a double or
triple charge.
2. The composition of claim 1, further comprising an additional
five transition ion pairs comprising one transition ion pair of at
least one protein selected from LRP1, BGH3, COIA1, TETN, TSP1,
ALDOA, GRP78, ISLR, FRIL, LG3BP, PRDX1, FIBA, or GSLG1.
3. A composition comprising at least 10 isolated synthetic peptides
said composition comprising at least 2 isolated synthetic peptides
of at least 5 proteins selected from LRP1, BGH3, COIA1, TETN, TSP1,
ALDOA, GRP78, ISLR, FRIL, LG3BP, PRDX1, FIBA, or GSLG1, wherein the
at least two isolated synthetic peptides are selected from
ADDGRPFPQVIK (SEQ ID NO: 57), ALQASALK (SEQ ID NO: 58), QLLLTADDR
(SEQ ID NO: 60), ADHHATNGVVHLIDK (SEQ ID NO: 136),
DILATNGVIHYIDELLIPDSAK (SEQ ID NO: 137), LTLLAPLNSVFK (SEQ ID NO:
139), SPYQLVLQHSR (SEQ ID NO: 140), ADDILASPPR (SEQ ID NO: 331),
AVGLAGTFR (SEQ ID NO: 332), TEAPSATGQASSLLGGR (SEQ ID NO: 335),
GGSTSYGTGSETESPR (SEQ ID NO 554), NSLFEYQK (SEQ ID NO: 556),
TVIGPDGHK (SEQ ID NO: 557), VQHIQLLQK (SEQ ID NO: 558), ALFQDIK
(SEQ ID NO: 593), DDVALEGVSHFFR (SEQ ID NO: 594), KPAEDEWGK (SEQ ID
NO: 595), LGGPEAGLGEYLFER (SEQ ID NO: 596), LNQALLDLHALGSAR (SEQ ID
NO: 597), MGDHLTNLHR (SEQ ID NO: 598), LYGSAGPPPTGEEDTAEK (SEQ ID
NO: 663), TWNDPSVQQDIK (SEQ ID NO: 664), VYEGERPLTK (SEQ ID NO:
665), IIIQESALDYR (SEQ ID NO: 666), LDPALQDK (SEQ ID NO: 667),
LIAQDYK (SEQ ID NO: 668), NDINILK (SEQ ID NO: 669), VAELSSDDFHLDR
(SEQ ID NO: 670), ALPGTPVASSQPR (SEQ ID NO: 839), EVPLLQSLWLAHNEIR
(SEQ ID NO: 840), LPGLPEGAFR (SEQ ID NO: 841), TVAAGALASLSHLK (SEQ
ID NO: 843), ASHEEVEGLVEK (SEQ ID NO: 938), STHTLDLSR (SEQ ID NO:
940), VEIFYR (SEQ ID NO: 941), YSSDYFQAPSDYR (SEQ ID NO: 942),
AALSGANVLTLIEK (SEQ ID NO: 958), TVLWPNGLSLDIPAGR (SEQ ID NO: 959),
VFFTDYGQIPK (SEQ ID NO: 960), ADEGISFR (SEQ ID NO: 1321),
ATAVMPDGQFK (SEQ ID NO: 1322), DISLSDYK (SEQ ID NO: 1323), GLFIIDDK
(SEQ ID NO: 1324), IGHPAPNFK (SEQ ID NO: 1325), LVQAFQFTDK (SEQ ID
NO: 1326), QGGLGPMNIPLVSDPK (SEQ ID NO: 1327), QITVNDLPVGR (SEQ ID
NO: (1328), SVDETLR (SEQ ID NO: 1329), TIAQDYGVLK (SEQ ID NO:
1330), GGTLSTPQTGSENDALYEYLR (SEQ ID NO: 1588), LDTLAQEVALLK (SEQ
ID NO: 1589), NWETEITAQPDGGK (SEQ ID NO: 1590), FQDLVDAVR (SEQ ID
NO: 1641), FTGSQPFGQGVEHATANK (SEQ ID NO: 1642), FVFGTIPEDILR (SEQ
ID NO: 1643), GFLLLASLR (SEQ ID NO: 1644), or GTSQNDPNWVVR (SEQ ID
NO: 1645).
4. The composition of claim 3, wherein at least one of the isolated
synthetic peptides is isotopically labeled.
5. The composition of claim 3, wherein the amount of each of the at
least 2 isolated synthetic peptides of at least 5 proteins is
known.
6. The composition of claim 3, further comprising one or more polar
solvents.
7. The composition of claim 3, further comprising an additional
five isolated synthetic peptides of at least one protein selected
from LRP1, BGH3, COIA1, TETN, TSP1, ALDOA, GRP78, ISLR, FRIL,
LG3BP, PRDX1, FIBA, or GSLG1.
8. The composition of claim 1, further comprising an additional
five transition ion pairs comprising one transition ion pair of at
least one protein selected from APOE, BASP1, CD14, FOXA2 or HSPB1,
wherein the additional one transition ion pair consists of a
precursor ion with a corresponding m/z and a fragment ion with a
corresponding m/z, and wherein the transition ion pairs are
selected from precursor AATVGSLAGQPLQER (SEQ ID NO: 82) transition
pair 479.4-600.3, 479.4-642.4, 479.4-827.4, or 479.4-898.5;
precursor ALMDETMK (SEQ ID NO: 83) transition pair 469.72-508.2,
469.72-469.72, 469.72-508.2, 469.72-623.3, 469.72-754.3, or
469.72-867.4; precursor GEVQAMLGQSTEELR (SEQ ID NO: 85) transition
pair 824.4-616.3, 824.4-729.4, 824.4-734.4, or 824.4-919.4;
precursor LAVYQAGAR (SEQ ID NO: 86) transition pair 474.77-502.3,
474.77-665.3, 474.77-764.4, or 474.77-835.4; precursor LGPLVEQGR
(SEQ ID NO: 87) transition pair 484.78-588.3, 484.78-701.4,
484.78-798.4, or 484.78-855.5; precursor SELEEQLTPVAEETR (SEQ ID
NO: 88) transition pair 865.93-459.2, 865.93-801.4, 865.93-902.5,
or 865.93-930.4; precursor SWFEPLVEDMQR (SEQ ID NO: 89) transition
pair 768.86-274.1, 768.86-421.2, 768.86-678.3, or 768.86-987.5;
precursor WELALGR (SEQ ID NO: 90) transition pair 422.74-316.1,
422.74-345.2, 422.74-529.3, or 422.74-658.4; precursor
AAEAAAAPAESAAPAAGEEPSK (SEQ ID NO: 118) transition pair
983.97-414.2, 983.97-485.2, 983.97-556.3, or 983.97-885.4;
precursor AEGAATEEEGTPK (SEQ ID NO: 119) transition pair
645.3-258.1, 645.3-789.4, 645.3-890.4, or 645.3-961.4; precursor
APEQEQAAPGPAAGGEAPK (SEQ ID NO: 120) transition pair 592.62-629.3,
592.62-754.3, 592.62-825.4, or 592.62-951.5; precursor EKPDQDAEGK
(SEQ ID NO: 122) transition pair 558.76-404.2, 558.76-647.3,
558.76-859.4, or 558.76-913.4; precursor ESEPQAAAEPAEAK (SEQ ID NO:
123) transition pair 714.34-515.3, 714.34-644.3, 714.34-786.4, or
714.34-857.4; precursor ETPAATEAPSSTPK (SEQ ID NO: 124) transition
pair 693.84-616.3, 693.84-816.4, 693.84-917.5, or 693.84-988.5;
precursor GYNVNDEK (SEQ ID NO: 125) transition pair 469.71-276.2,
469.71-505.2, 469.71-604.3, or 469.71-718.3; precursor
SDGAPASDSKPGSSEAAPSSK (SEQ ID NO: 126) transition pair
644.96-260.1, 644.96-331.1, 644.96-418.2, or 644.96-586.2;
precursor TEAPAAPAAQETK (SEQ ID NO: 127) transition pair
642.83-541.3, 642.83-744.4, 642.83-815.4, or 642.83-983.5;
precursor AFPALTSLDLSDNPGLGER (SEQ ID NO: 206) transition pair
987-500.3, 987-628.3, 987-742.4, or 987-944.4; precursor ATVNPSAPR
(SEQ ID NO: 207) transition pair 456.75-386.2, 456.75-430.2,
456.75-527.3, or 456.75-740.4; precursor ELTLEDLK (SEQ ID NO: 208)
transition pair 480.77-260.2, 480.77-504.3, 480.77 617.4, or
480.77-718.4; precursor FPAIQNLALR (SEQ ID NO: 209) transition pair
571.84-714.4, 571.84-827.5, 571.84-898.5, or 571.84-995.6;
precursor LTVGAAQVPAQLLVGALR (SEQ ID NO: 211) transition pair
593.03-416.3, 593.03-515.3, 593.03-628.4, or 593.03-740.4;
precursor NVSWATGR (SEQ ID NO: 212) transition pair 445.73-301.2,
445.73-404.2, 5, 445.73-590.3, or 445.73-677.3; precursor
STLSVGVSGTLVLLQGAR (SEQ ID NO: 213) transition pair 879.51-431.2,
879.51-544.3, 879.51-657.4, or 879.51-970.6; precursor
SWLAELQQWLKPGLK (SEQ ID NO: 214) transition pair 599.67-274.1,
599.67-414.3, 599.67-542.4, or 599.67-841.5; precursor VDADADPR
(SEQ ID NO: 215) transition pair 429.7-272.2, 429.7-573.3,
429.7-644.3, or 429.7-759.3; precursor AYEQVMHYPGYGSPMPGSLAMGPVTNK
(SEQ ID NO: 577) transition pair 961.45-558.3, 961.45-615.3,
961.45-817.4, or 961.45-930.5; precursor EAAGAAGSGK (SEQ ID NO:
578) transition pair 409.7-348.2, 409.7-490.3, 409.7-547.3, or
409.7-618.3; precursor MHSASSMLGAVK (SEQ ID NO: 579) transition
pair 406.87-374.2, 406.87-487.3, 406.87-601.2, or 406.87-732.3;
precursor TGLDASPLAADTSYYQGVYSRPIMNSS (SEQ ID NO: 582) transition
pair 955.45-387.2, 955.45-545.3, 955.45-648.3, or 955.45-826.4;
precursor AQLGGPEAAK (SEQ ID NO: 731) transition pair 471.26-313.2,
471.26-427.2, 471.26-629.3, or 471.26-742.4; precursor DGVVEITGK
(SEQ ID NO: 732) transition pair 459.25-305.2, 459.25-418.3,
459.25-547.3, or 459.25-646.4; precursor GPSWDPFR (SEQ ID NO: 733)
transition pair 481.23-419.2, 481.23-534.3, 481.23-720.3, or
481.23-807.4; precursor LATQSNEITIPVTFESR (SEQ ID NO: 734)
transition pair 953.5-639.3, 953.5-744.4, 953.5-835.4, or
953.5-857.4; precursor LFDQAFGLPR (SEQ ID NO: 735) transition pair
582.31-272.2; 582.31-442.3, 582.31-660.4, or 582.31-903.5;
precursor QDEHGYISR (SEQ ID NO: 736) transition pair 368.84-262.2,
368.84-538.3, 368.84-595.3, 368.84-730.3, 368.84-504.3,
368.84-660.4, 368.84-747.4, or 368.84-834.4; precursor VPFSLLR (SEQ
ID NO: 738) transition pair 416.26-488.3, 416.26-488.3,
416.26-635.4, or 416.26-732.4; or precursor VSLDVNHFAPDELTVK (SEQ
ID NO: 739) transition pair 595.31-347.2, 595.31-460.3,
595.31-801.4, or 595.31-872.5, wherein each of the precursor ions
has a double or triple charge.
9. The composition of claim 3, further comprising an additional
five isolated synthetic peptides of at least one protein selected
from APOE, BASP1, CD14, FOXA2 or HSPB1.
10. The composition of claim 1, wherein the at least five
transition ion pairs are selected from precursor GFLLLASLR (SEQ ID
NO: 1644) (495.31-559.40), precursor AVGLAGTFR (SEQ ID NO: 332)
transition pair (446.26-721.40), precursor ALPGTPVASSQPR (SEQ ID
NO: 839) transition pair (640.85-841.50), precursor LDTLAQEVALLK
(SEQ ID NO: 1589) transition pair (657.39-330.20), precursor
LGGPEAGLGEYLFER (SEQ ID NO: 596) transition pair (804.40-913.40),
precursor TWNDPSVQQDIK (SEQ ID NO: 664) transition pair
(715.85-260.20), precursor ALQASALK (SEQ ID NO: 58) transition pair
(401.25-617.40), precursor LTLLAPLNSVFK (SEQ ID NO: 139) transition
pair (658.40-804.50), precursor VEIFYR (SEQ ID NO: 941) transition
pair (413.73-598.30), precursor TVLWPNGLSLDIPAGR (SEQ ID NO: 959)
transition pair (855.00-400.20), precursor NSLFEYQK (SEQ ID NO:
556) transition pair (514.76-714.30), precursor QITVNDLPVGR (SEQ ID
NO: 1328) transition pair (606.30-428.30), and precursor
IIIQESALDYR (SEQ ID NO: 666) transition pair (660.86-338.20).
11. A composition comprising at least 25 isolated synthetic
peptides said composition comprising at least five isolated
synthetic peptides of at least five proteins selected from LRP1,
BGH3, COIA1, TETN, TSP1, ALDOA, GRP78, ISLR, FRIL, LG3BP, PRDX1,
FIBA, or GSLG1, wherein the at least five isolated synthetic
peptides are selected from ADDGRPFPQVIK (SEQ ID NO: 57), ALQASALK
(SEQ ID NO: 58), QLLLTADDR (SEQ ID NO: 60), ADHHATNGVVHLIDK (SEQ ID
NO: 136), DILATNGVIHYIDELLIPDSAK (SEQ ID NO: 137), LTLLAPLNSVFK
(SEQ ID NO: 139), SPYQLVLQHSR (SEQ ID NO: 140), ADDILASPPR (SEQ ID
NO: 331), AVGLAGTFR (SEQ ID NO: 332), TEAPSATGQASSLLGGR (SEQ ID NO:
335), GGSTSYGTGSETESPR (SEQ ID NO 554), NSLFEYQK (SEQ ID NO: 556),
TVIGPDGHK (SEQ ID NO: 557), VQHIQLLQK (SEQ ID NO: 558), ALFQDIK
(SEQ ID NO: 593), DDVALEGVSHFFR (SEQ ID NO: 594), KPAEDEWGK (SEQ ID
NO: 595), LGGPEAGLGEYLFER (SEQ ID NO: 596), LNQALLDLHALGSAR (SEQ ID
NO: 597), MGDHLTNLHR (SEQ ID NO: 598), LYGSAGPPPTGEEDTAEK (SEQ ID
NO: 663), TWNDPSVQQDIK (SEQ ID NO: 664), VYEGERPLTK (SEQ ID NO:
665), IIIQESALDYR (SEQ ID NO: 666), LDPALQDK (SEQ ID NO: 667),
LIAQDYK (SEQ ID NO: 668), NDINILK (SEQ ID NO: 669), VAELSSDDFHLDR
(SEQ ID NO: 670), ALPGTPVASSQPR (SEQ ID NO: 839), EVPLLQSLWLAHNEIR
(SEQ ID NO: 840), LPGLPEGAFR (SEQ ID NO: 841), TVAAGALASLSHLK (SEQ
ID NO: 843), ASHEEVEGLVEK (SEQ ID NO: 938), STHTLDLSR (SEQ ID NO:
940), VEIFYR (SEQ ID NO: 941), YSSDYFQAPSDYR (SEQ ID NO: 942),
AALSGANVLTLIEK (SEQ ID NO: 958), TVLWPNGLSLDIPAGR (SEQ ID NO: 959),
VFFTDYGQIPK (SEQ ID NO: 960), ADEGISFR (SEQ ID NO: 1321),
ATAVMPDGQFK (SEQ ID NO: 1322), DISLSDYK (SEQ ID NO: 1323), GLFIIDDK
(SEQ ID NO: 1324), IGHPAPNFK (SEQ ID NO: 1325), LVQAFQFTDK (SEQ ID
NO: 1326), QGGLGPMNIPLVSDPK (SEQ ID NO: 1327), QITVNDLPVGR (SEQ ID
NO: 1328), SVDETLR (SEQ ID NO: 1329), TIAQDYGVLK (SEQ ID NO: 1330),
GGTLSTPQTGSENDALYEYLR (SEQ ID NO: 1588), LDTLAQEVALLK (SEQ ID NO:
1589), NWETEITAQPDGGK (SEQ ID NO: 1590), FQDLVDAVR (SEQ ID NO:
1641), FTGSQPFGQGVEHATANK (SEQ ID NO: 1642), FVFGTIPEDILR (SEQ ID
NO: 1643), GFLLLASLR (SEQ ID NO: 1644), or GTSQNDPNWVVR (SEQ ID NO:
1645).
12. The composition of claim 11, wherein the at least five isolated
synthetic peptides are selected from GFLLLASLR (SEQ ID NO: 1644),
AVGLAGTFR (SEQ ID NO: 332), ALPGTPVASSQPR (SEQ ID NO: 839),
LDTLAQEVALLK (SEQ ID NO: 1589), LGGPEAGLGEYLFER (SEQ ID NO: 596),
TWNDPSVQQDIK (SEQ ID NO: 664), ALQASALK (SEQ ID NO: 58),
LTLLAPLNSVFK (SEQ ID NO: 139), VEIFYR (SEQ ID NO: 941),
TVLWPNGLSLDIPAGR (SEQ ID NO: 959), NSLFEYQK (SEQ ID NO: 556),
QITVNDLPVGR (SEQ ID NO: 1328), and IIIQESALDYR (SEQ ID NO: 666).
Description
BACKGROUND
Liquid Chromatography Selected Reaction Monitoring Mass
Spectrometry (LC-SRM-MS) has emerged as an alternative technology
to immunoassays for quantification of target proteins in biological
samples. LC-SRM-MS methods are highly desirable because LC-SRM-MS
methods provide both absolute structural specificity for the target
protein and relative or absolute measurement of the target protein
concentration when suitable internal standards are utilized. In
contrast to immunoassays, LC-SRM-MS does not involve the
manufacturing of biologics. LC-SRM-MS protein assays can be rapidly
and inexpensively developed in contrast to the development of
immunoassays. LC-SRM-MS are highly multiplexed, with simultaneous
assays for hundreds of proteins performed in a single sample
analysis. Using LC-SRM-MS in contrast to other proteomic
technologies allows for complex assays for the identification
diagnostic proteins in complex diseases such as cancer, autoimmune,
and metabolic disease. In particular, the development of a highly
multiplexed LC-SRM-MS assay that reproducibly identifies a specific
set of proteins relevant to a clinical disease presents diagnostic
advantages and efficiencies. To date, proteomic techniques have not
enabled such inventions to exist where hundreds of proteins can be
accurately quantified within a single sample. The present invention
provides accurate measurement of hundreds of lung cancer associated
proteins within a single sample using multiplexed techniques.
SUMMARY OF THE INVENTION
The present invention comprises a LC-SRM-MS assay for the
measurement proteins in a single sample and in a single LC-SRM-MS
assay. The assay was optimized for protein quantification and
minimal interference among proteins in the assay. This LC-SRM-MS
assay is novel because measurement of a large number of proteins in
a single sample specifically associated with lung cancer has not
been accomplished. Simultaneous measurement of such a large number
of proteins without interference among the proteins requires
specific techniques to distinguish among the proteins. The current
invention provides clinical utility as this assay was used for
development of lung cancer diagnostic tests for the early detection
of lung cancer, managing disease treatment, as well as testing for
disease recurrence.
The object of the present invention is to provide improved methods
for the use of LC-SRM-MS in the development of assays. Accordingly,
provided herein is a method for developing peptides and transitions
for a plurality of at least 200 proteins for a single sample
selected reaction monitoring mass spectrometry (LC-SRM-MS) assay,
including the steps of providing a set of 200 or more proteins;
generating transitions for each protein; assessing LC-SRM-MS data
by Mascot score; performing collision energy optimization on the
transitions; selecting peptides with transitions showing the
greatest peak areas of their transitions; selecting a set of
transitions for each peptide, wherein the transitions for each
peptide have one of the four most intense b or y transition ions;
the transitions for each peptide have m/z values of at least 30 m/z
above or below those of the precursor ion; the transitions for each
peptide do not interfere with transitions from other peptides; and
the transitions represent transitions due to breakage of peptide
bond at different sites of the protein.
In one embodiment of the method, each selected peptide in the set
of peptides has a monoisotopic mass of 700-5000 Da; and does not
contain a cysteine or a methionine; or may contain cysteine or
methionine. In another embodiment, the transitions for each peptide
have one of the four most intense b or y transition ions; have m/z
values of at least 30 m/z above or below those of a precursor ion;
do not interfere with transitions from other peptides; and
represent transitions due to breakage of peptide bond at different
sites of the protein.
In another embodiment of the method, the peptides do not include
any peptide that is bounded by KK, KR, RK or RR (either upstream or
downstream) in the corresponding protein sequence. Specifically,
the amino acid is charged at pH 7.0. These amino acids include
arginine and lysine. In another embodiment, each peptide of said
set of peptides is unique to the corresponding protein. In yet
another embodiment, the peptides do not include peptides which were
observed in post-translational modified forms. In still another
embodiment, each set of peptides is prioritized according to one or
more of the following ordered set of criteria: unique peptides
first, then non-unique; peptides with no observed
post-translational modifications first, then those observed with
post-translational modifications; peptides within the mass range
800-3500 Da first, then those outside of 800-3500 Da; and sorted by
decreasing number of variant residues. In certain embodiments, The
peptides are unique in that they only appear once among the
peptides run in a single assay.
In one embodiment, each set of peptides is prioritized according to
all of the ordered set of criteria. In another embodiment, each
prioritized set of peptides contains 1-5 peptides.
In certain embodiments of the preceding methods, the two best
peptides per protein and the two best transitions per peptide are
selected based on experimental data resulting from LC-SRM-MS
analysis of one or more of the following experimental samples: a
biological disease sample, a biological control sample, and a
mixture of synthetic peptides of interest. In a particular
embodiment, the biological disease and biological control samples
are processed using an immunodepletion method prior to LC-SRM-MS
analysis. In another embodiment, the experimental samples contain
internal standard peptides. In yet another embodiment, the
LC-SRM-MS analysis method specifies a maximum of 7000 transitions,
including transitions of the internal standard peptides and
transitions. In other embodiments the method specifies a maximum of
between 1000-7000, 2000-6000, 3000-5000 and about 3500
transitions.
In one embodiment of the method, the top two transitions per
peptide are selected according to one or more of the following
criteria the transitions exhibit the largest peak areas measured in
either of the two biological experimental samples; the transitions
are not interfered with by other ions; the transitions do not
exhibit an elution profile that visually differs from those of
other transitions of the same peptide; or the transitions are not
beyond the detection limit of both of the two biological
experimental samples.
In another embodiment of the method, the top two peptides per
protein are selected according to one or more of the following
criteria: one or more peptides exhibit two transitions and
represent the largest combined peak areas of the two transitions;
or one or more peptides exhibit one transition and represent the
largest combined peak areas of the two transitions.
In another aspect, provided herein is an assay developed according
to the foregoing method, and embodiments thereof.
In yet another aspect provided herein is the use of an assay
developed according to the foregoing method, and embodiments
thereof, to detect a plurality of at least 200 proteins in a single
biological sample.
In another aspect, provided herein is an assay developed according
to the foregoing method, and embodiments thereof.
The disclosure provides a composition comprising at least five
transition ions selected from the listing of transition ions in
Table 2. In one embodiment of the assay each transition ion
independently corresponds to a unique protein. The five transition
ions corresponded to proteins selected from the group consisting of
LRP1, BGH3, COIA1, TETN, TSP1, ALDOA, GRP78, ISLR, FRIL, LG3BP,
PRDX1, FIBA, and GSLG1. (see: U.S. application Ser. No. 13/306,823
PCT/US11/62461). The composition can further include an additional
five transition ions selected from the listing of transition ions
in Table 2. The additional five transition ions can corresponded to
the proteins APOE, BASP1, CD14, FOXA2 and HSPB1.
The disclosure provides a composition comprising at least five
synthetic peptides selected from the listing of peptides and
proteins in Table 2. In one embodiment, each peptide can
independently correspond to a unique protein. At least one of the
peptides was isotopically labeled. The amount of each of the at
least five synthetic peptides is known. In another embodiment, the
composition included one or more polar solvents. The five synthetic
peptides can correspond to the proteins LRP1, BGH3, COIA1, TETN,
TSP1, ALDOA, GRP78, ISLR, FRIL, LG3BP, PRDX1, FIBA, and GSLG1. The
composition can also include an additional five synthetic peptides
selected from the listing of peptides and proteins in Table 2. The
additional five synthetic peptides can correspond to the proteins
APOE, BASP1, CD14, FOXA2 and HSPB1.
The disclosure provides a use of a composition, as described above,
for the development of an assay to detect a disease, disorder or
condition in a mammal.
The disclosure provides a method comprising analyzing a
composition, as described above, using mass spectrometry. The
method can use selected reaction monitoring mass spectrometry.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 depicts candidate protein cohort by source. 217 tissue
proteins were identified using proteomics analysis. 319 proteins
were identified by review of the literature. Between the two
sources, there was an overlap of 148 proteins.
FIG. 2 is a bar diagram showing Pearson correlations for peptides
from the same peptide, from the same protein and from different
proteins.
DETAILED DESCRIPTION OF THE INVENTION
The present disclosure relates to methods for developing peptides
and transitions for a single sample selected reaction monitoring
mass spectrometry (LC-SRM-MS) assay, generally comprising the steps
of providing a set of proteins; identifying representative
proteolytic peptides for each protein according to a set of
criteria; identifying representative transitions for each peptide
according to another set of criteria; and selecting the optimum
peptides per protein and the optimum transitions per peptide.
Selected reaction monitoring mass spectrometry is capable of highly
sensitive and accurate protein quantification based on the
quantification of proteolytic peptides. In terms of clinical
utility, mass spectrometry-based assays are often compared to
immunoassays (e.g., Enzyme-Linked Immunosorbent Assay, or ELISA),
which have the ability to quantify specific analytes in large
sample sets (e.g., 96 or 384 samples in parallel microtitre
plate-based format). Until recently, mass spectrometry-based
protein assays were not able to match these sample sizes or
quantitative accuracy. Considerable time and expense is required to
generate and characterize antibodies required for immunoassays.
Increasingly efficient LC-SRM-MS assays, therefore, may surpass
immunoassays such as ELISA in the rapid development of clinically
useful, multiplexed protein assays.
LC-SRM-MS is a highly selective method of tandem mass spectrometry
which has the potential to effectively filter out all molecules and
contaminants except the desired analyte(s). This is particularly
beneficial if the analysis sample is a complex mixture which may
comprise several isobaric species within a defined analytical
window. LC-SRM-MS methods may utilize a triple quadrupole mass
spectrometer which, as is known in the art, includes three
quadrupole rod sets. A first stage of mass selection is performed
in the first quadrupole rod set, and the selectively transmitted
ions are fragmented in the second quadrupole rod set. The resultant
transition (product) ions are conveyed to the third quadrupole rod
set, which performs a second stage of mass selection. The product
ions transmitted through the third quadrupole rod set are measured
by a detector, which generates a signal representative of the
numbers of selectively transmitted product ions. The RF and DC
potentials applied to the first and third quadrupoles are tuned to
select (respectively) precursor and product ions that have m/z
values lying within narrow specified ranges. By specifying the
appropriate transitions (m/z values of precursor and product ions),
a peptide corresponding to a targeted protein may be measured with
high degrees of sensitivity and selectivity. Signal-to-noise ratio
in LC-SRM-MS is often superior to conventional tandem mass
spectrometry (MS/MS) experiments that do not selectively target
(filter) particular analytes but rather aim to survey all analytes
in the sample.
Accordingly, provided herein is a method for developing peptides
and transitions for a plurality of proteins for use in selected
reaction monitoring mass spectrometry (LC-SRM-MS) assay. In a
preferred embodiment, the assay involves the analysis of a single
sample containing all analytes of interest (e.g., a proteolytic
digest of plasma proteins). As to the selection of the protease(s)
used, trypsin, which cleaves exclusively C-terminal to arginine and
lysine residues, is a preferred choice to generate peptides because
the masses of generated peptides are compatible with the detection
ability of most mass spectrometers (up to 2000 m/z), the number and
average length of generated peptides, and also the availability of
efficient algorithms for the generation of databases of theoretical
trypsin-generated peptides. High cleavage specificity,
availability, and cost are other advantages of trypsin. Other
suitable proteases will be known to those of skill in the art.
Miscleavage is a factor for failure or ambiguous protein
identification. A miscleavage can be defined as partial enzymatic
protein cleavages generating peptides with internal missed cleavage
sites reflecting the allowed number of sites (targeted amino acids)
per peptide that were not cut. The presence of post-translational
modifications (PTMs) is also a potential contributor to the problem
of miscleavages.
LC-SRM-MS mass spectrometry involves the fragmentation of gas phase
ions and occurs between the different stages of mass analysis.
There are many methods used to fragment the ions and these can
result in different types of fragmentation and thus different
information about the structure and composition of the molecule.
The transition ions observed in an LC-SRM-MS spectrum result from
several different factors, which include, but are not limited to,
the primary sequence, the amount of internal energy, the means of
introducing the energy, and charge state. Transitions must carry at
least one charge to be detected. An ion is categorized as either a,
b or c if the charge is on a transition comprising the original N
terminus of the peptide, whereas the ion is categorized as either
x, y or z if the charge is on a transition comprising the original
C terminus of the peptide. A subscript indicates the number of
residues in the transition (e.g., one peptide residue in x.sub.1,
two peptide residues in y.sub.2, and three peptide residues in
z.sub.3, etc.).
In a generic peptide repeat unit represented --N--C(O)--C--, an x
ion and an a ion resulting from cleavage of the carbonyl-carbon
bond (i.e., C(O)--C). The x ion is an acylium ion, and the a ion is
an iminium ion. A y ion and a b ion result from cleavage of the
carbonyl-nitrogen bond (i.e., C(O)--N, also known as the amide
bond). In this case, the y ion is an ammonium ion and the b ion is
an acylium ion. Finally, a z ion and a c ion result from cleavage
of the nitrogen-carbon (i.e., C--N) bond. The z ion is a
carbocation and the c ion is an ammonium ion.
Superscripts are sometimes used to indicate neutral losses in
addition to the backbone fragmentation, for example, * for loss of
ammonia and .degree. for loss of water. In addition to protons, c
ions and y ions may abstract an additional proton from the
precursor peptide. In electrospray ionization, tryptic peptides may
carry more than one charge.
Internal transitions arise from double backbone cleavage. These may
be formed by a combination of b-type and y-type cleavage (i.e.,
cleavage producing b and y ions). Internal cleavage ions may also
be formed by a combination of a-type and y-type cleavage. An
internal transition with a single side chain formed by a
combination of a-type and y-type cleavage is called an iminium ion
(sometimes also referred to as an imonium or immonium ion). These
ions are labeled with the one letter code for the corresponding
amino acid.
Low energy CID (i.e., collision induced dissociation in a triple
quadrupole or an ion trap) involves the fragmentation of a peptide
carrying a positive charge, primarily along its backbone, to
generate primarily a, b and y ions.
In one aspect, provided herein is a method for developing peptides
and transitions for a plurality of proteins for a single sample
selected reaction monitoring mass spectrometry (LC-SRM-MS) assay,
by: (a) providing a panel of a plurality of proteins; (b)
identifying a set of peptides for each protein, wherein (i) each
peptide in the set of peptides corresponds to a transition of said
protein; (ii) the peptides have a monoisotopic mass of 700-5000 Da;
and (iii) the peptides do not contain a cysteine or a methionine;
or may contain cysteine or methionine; (c) identifying a set of
transitions for each peptide, wherein (i) the transitions for each
peptide have one of the four most intense b or y transition ions;
(ii) the transitions for each peptide have m/z values of at least
30 m/z above or below those of the precursor ion; (iii) the
transitions for each peptide do not interfere with transitions from
other peptides; and (iv) the transitions represent transitions due
to breakage of peptide bond at different sites of the protein; and
(d) selecting the peptides for each protein that best fit the
criteria of step (b) and the transitions per peptide that best fit
the criteria of step (c); thereby developing peptides and
transitions for a LC-SRM-MS assay.
By plurality of proteins it is meant at least 2, 3, 4, 5, 6, 7, 8,
9, 10, 15, 20, 25, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500
or more In certain embodiments, the plurality of proteins can
encompass between 2 and 10. 10 and 20, 20 and 50, 50 and 100, 100
and 200, or 200 and 500 proteins. In other embodiments, the
plurality of proteins can encompass between 250 and 450; or 300 and
400 proteins.
Trypsin-like proteases cleave peptide bonds following a positively
charged amino acid (e.g., lysine (K) or arginine (R)). This
specificity is driven by the residue which lies at the base of the
enzyme's SI pocket (generally a negatively charged aspartic acid or
glutamic acid). Accordingly, in one embodiment of the method, the
peptides do not include any peptide that is bounded by KK, KR, RK
or RR, either upstream of downstream in the corresponding protein
sequence. In another embodiment, each peptide of said set of
peptides is unique to the corresponding protein.
Post-translational modification (PTM) is the chemical modification
of a protein after its translation. It can include any modification
following translation, including cleavage. It is one of the later
steps in protein biosynthesis, and thus gene expression, for many
proteins. It is desirable to avoid such peptides for the purpose of
protein identification. Thus, in another embodiment, the peptides
do not include peptides which were observed in post-translational
modified forms.
In still another embodiment, each set of peptides is prioritized
according to one or more of the following ordered set of criteria:
(a) unique peptides first, then non-unique; (b) peptides with no
observed post-translational modifications first, then those
observed with post-translational modifications; (c) peptides within
the mass range 800-3500 Da first, then those outside of 800-3500
Da; and (d) sorted by decreasing number of variant residues. In one
embodiment, each set of peptides is prioritized according to all of
the ordered set of criteria. In another embodiment, each
prioritized set of peptides contains 1-5 peptides.
In certain embodiments, one or more liquid chromatography (LC)
purification steps are performed prior to a subsequent LC-SRM-MS
analysis step. Traditional LC analysis relies on the chemical
interactions between sample components and column packing
materials, where laminar flow of the sample through the column is
the basis for separation of the analyte of interest from the test
sample. The skilled artisan will understand that separation in such
columns is a diffusional process. A variety of column packing
materials are available for chromatographic separation of samples,
and selection of an appropriate separation protocol is an empirical
process that depends on the sample characteristics, the analyte of
interest, the interfering substances present and their
characteristics, etc. Various packing chemistries can be used
depending on the needs (e.g., structure, polarity, and solubility
of compounds being purified). In various embodiments the columns
are polar, ion exchange (both cation and anion), hydrophobic
interaction, phenyl, C-2, C-8, C-18 columns, polar coating on
porous polymer, or others that are commercially available. During
chromatography, the separation of materials is effected by
variables such as choice of eluant (also known as a "mobile
phase"), choice of gradient elution and the gradient conditions,
temperature, etc. In certain embodiments, an analyte may be
purified by applying a sample to a column under conditions where
the analyte of interest is reversibly retained by the column
packing material, while one or more other materials are not
retained. In these embodiments, a first mobile phase condition can
be employed where the analyte of interest is retained by the
column, and a second mobile phase condition can subsequently be
employed to remove retained material from the column, once the
non-retained materials are washed through. Alternatively, an
analyte may be purified by applying a sample to a column under
mobile phase conditions where the analyte of interest elutes at a
differential rate in comparison to one or more other materials. As
discussed above, such procedures may enrich the amount of one or
more analytes of interest relative to one or more other components
of the sample.
The following parameters are used to specify an LC-SRM-MS assay of
a protein under a particular LC-SRM-MS system: (1) a tryptic
peptide of the protein; (2) the retention time (RT) of the peptide;
(3) the m/z value of the peptide precursor ion; (4) the
declustering potential used to ionize the precursor ion; (5) the
m/z value of a fragment ion generated from the peptide precursor
ion; and (6) the collision energy (CE) used to fragment the peptide
precursor ion that is optimized for the particular peptide.
In certain embodiments of the preceding methods, the two best
peptides per protein and the two best transitions per peptide are
selected based on experimental data resulting from LC-SRM-MS
analysis of one or more of the following experimental samples: a
biological disease sample, a biological control sample, and a
mixture of synthetic peptides of interest. Biological samples
include body fluids, tissue samples and cell samples. Body fluid
samples can include blood, serum, sputum, genital secretions,
cerebrospinal fluid, sweat or excreta such as urine. Body tissue
samples can include lung, skin, brain, spine, bone, muscle,
epithelial, liver, kidney, pancreas, gastrointestinal tract,
cardiovascular tissue, heart or nervous tissue. Biological disease
samples can include cancer, benign tumors, infected tissue and
tissue subject to trauma. In a particular embodiment, the
biological disease and biological control samples are processed
using an immunodepletion method prior to LC-SRM-MS analysis.
Immunodepletion involves removal of one or more proteins through
the use of antibodies. Numerous immunodepletion techniques are
known to those of skill in the art. In another embodiment, the
biological disease and biological control samples are processed
using an immunocapture method prior to LC-SRM-MS analysis.
Immunocapture involves selection of one or more proteins through
the use of antibodies. Numerous immunocapture techniques are known
to those of skill in the art.
To facilitate accurate quantification of the peptide transitions by
the methods disclosed herein, a set of isotopically-labeled
synthetic versions of the peptides of interest may be added in
known amounts to the sample for use as internal standards. Since
the isotopically-labeled peptides have physical and chemical
properties identical to the corresponding surrogate peptide, they
co-elute from the chromatographic column and are easily
identifiable on the resultant mass spectrum. The addition of the
labeled standards may occur before or after proteolytic digestion.
Methods of synthesizing isotopically-labeled peptides will be known
to those of skill in the art. Thus, in another embodiment, the
experimental samples contain internal standard peptides. Other
embodiments may utilize external standards or other expedients for
peptide quantification.
In yet another embodiment, the LC-SRM-MS analysis method specifies
a maximum of 7000 transitions, including transitions of the
internal standard peptides and transitions. As used herein, the
term "transition" refers to the specific pair of m/z
(mass-to-charge) values associated with the precursor and
transition ions corresponding to a specific peptide and, therefore,
to a specific protein.
In one embodiment of the method, the top two transitions per
peptide are selected according to one or more of the following
criteria (A): (1) the transitions exhibit the largest peak areas
measured in either of the two biological experimental samples; (2)
the transitions are not interfered with by other ions; (3) the
transitions do not exhibit an elution profile that visually differs
from those of other transitions of the same peptide; (4) the
transitions are not beyond the detection limit of both of the two
biological experimental samples; (5) the transitions do not exhibit
interferences.
For the mass spectrometric analysis of a particular peptide, the
quantities of the peptide transitions in the sample may be
determined by integration of the relevant mass spectral peak areas,
as known in the prior art. When isotopically-labeled internal
standards are used, as described above, the quantities of the
peptide transitions of interest are established via an
empirically-derived or predicted relationship between peptide
transition quantity (which may be expressed as concentration) and
the area ratio of the peptide transition and internal standard
peaks at specified transitions.
In another embodiment of the method, the top two peptides per
protein are selected according to one or more of the following
criteria (B): (1) one or more peptides exhibit two transitions
according to criteria (A) and represent the largest combined peak
areas of the two transitions according to criteria (A); and (2) one
or more peptides exhibit one transition according to criteria (A)
and represent the largest combined peak areas of the two
transitions according to criteria (A).
Assays
The methods of the present disclosure allow the quantification of
high abundance and low abundance plasma proteins that serve as
detectable markers for various health states (including diseases
and disorders), thus forming the basis for assays that can be used
to determine the differences between normal levels of detectable
markers and changes of such detectable markers that are indicative
of changes in health status. In one aspect of the invention,
provided herein is an assay developed according to the foregoing
method, and embodiments thereof. In another aspect, provided herein
is the use of an assay developed according to the foregoing method,
and embodiments thereof, to detect a plurality of at least 200,
300, or more proteins in a single sample. In a merely illustration
embodiment, 388 proteins in the following table 1 are detected
utilizing the method of present invention.
Of the 388 proteins, the 36 most cooperative proteins are listed in
Table 2.
SRM assays for the 388 proteins were developed using standard
synthetic peptide techniques. Of the 388 candidates, SRM assays
were successfully developed for 371 candidates. The 371 SRM assays
were applied to benign and lung cancer plasma samples to evaluate
detection rate in blood. The summary of the SRM assay for these 371
proteins is listed in table 3 (see also Example III).
DEFINITIONS
As used herein, "transition" refers to a pair of m/z values
associated with a peptide. Normally, labeled synthetic peptides are
used as quality controls in SRM assays. However, for very large SRM
assays such as the 371 protein lung cancer assay, labeled peptides
are not feasible. However, correlation techniques (Kearney, Butler
et al. 2008) were used to confirm the identity of protein
transitions with high confidence. In FIG. 2 a histogram of the
Pearson correlations between every pair of transitions in the assay
is presented. The correlation between a pair of transitions is
obtained from their expression profiles over all samples (143) in
the training study detailed below. As expected, transitions from
the same peptide are highly correlated. Similarly, transitions from
different peptide fragments of the same protein are also highly
correlated. In contrast, transitions from different proteins are
not highly correlated. This methodology enables a statistical
analysis of the quality of a protein's SRM assay. For example, if
the correlation of transitions from two peptides from the same
protein is above 0.5 then there is less than a 5% probability that
the assay is false.
As used herein, a "tryptic peptide" refers to the peptide that is
formed by the treatment of a protein with trypsin.
As used herein, "RT" refers to "retention time", the elapsed time
between injection and elution of an analyte.
As used herein, "m/z" indicates the mass-to-charge ratio of an
ion.
As used herein, "DP" refers to "declustering potential", a voltage
potential to dissolvate and dissociate ion clusters. It is also
known as "fragmentor voltage" or "ion transfer capillary offset
voltage" depending on the manufacture.
As used herein, "CE" refers to "collision energy", the amount of
energy precursor ions receive as they are accelerated into the
collision cell.
As used herein, "LC-SRM-MS" is an acronym for "selected reaction
monitoring" and may be used interchangeably with "LC-MRM-MS".
As used herein, "MS/MS" represents tandem mass spectrometry, which
is a type of mass spectrometry involving multiple stages of mass
analysis with some form of fragmentation occurring in between the
stages.
As used herein, "ISP" refers to "internal standard peptides".
As used herein, "HGS" refers to "human gold standard", which is
comprised of a pool of plasma from healthy individuals.
As used herein, "MGF" refers to "Mascot generic file". Mascot is a
search engine that uses mass spectrometry data to identify proteins
from primary sequence databases. A Mascot generic file is a plain
text (ASCII) file containing peak list information and, optionally,
search parameters.
Mascot is a web-based tool for deriving protein sequences from mass
spectrometry data. This data can be acquired from any mass
spectrometry technique including MALDI-TOF and MS/MS (including
LC-SRM-MS) data. Mascot uses a `probability-based MOWSE` algorithm
to estimate the significance of a match (i.e., that the observed
transitions correspond to a particular protein). The total score is
the absolute probability that the observed match is a random event.
They are reported as -10.times.LOG 10(P), where P is the absolute
probability. Lower probabilities, therefore, are reported as higher
scores. For example, if the absolute probability that an observed
match is random is 1.times.10.sup.-12, Mascot reports it as
120.
The disclosure also provides compositions. These compositions can
include any of the transition ions described in Table 2. These
transition ions exist while peptides derived from the proteins in
Table 2 are undergoing analysis with LC-SRM-MS. In one embodiment,
the composition includes any of the transition ions described in
Table 2. In another embodiment, the composition includes any two
transition ions described in Table 2. In other embodiments, the
composition includes, any 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75,
80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190,
200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300 or 331
transition ions described in Table 2.
In another embodiment, the transition ions correspond with human
proteins including LRP1, BGH3, COIA1, TETN, TSP1, ALDOA, GRP78,
ISLR, FRIL, LG3BP, PRDX1, FIBA, and GSLG1. In another embodiment,
the transition ions are derived from human proteins including LRP1,
BGH3, COIA1, TETN, TSP1, ALDOA, GRP78, ISLR, FRIL, LG3BP, PRDX1,
FIBA, and GSLG1. These proteins can further include transition ions
corresponding with and/or derived from any number of additional
proteins from Table 2. Thus, the composition can include, any
additional 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85,
90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210,
220, 230, 240, 250, 260, 270, 280, 290, 300 or 331 transition ions
described in Table 2.
In another embodiment, each of the transition ions in the
composition corresponds and/or is derived from a different protein.
In another embodiment, 90% of the transition ions in the
composition correspond with and/or are derived from a protein that
no other transition ion in the composition corresponds. In other
embodiments, 80, 70, 60, 50, 40, 30, 20, 10 or 0% of the transition
ions in the composition correspond and/or are derived from a
protein that no other transition ion in the composition
corresponds.
The compositions described herein included synthetic peptides.
Synthetic peptides can be used as controls for the abundance of
proteins they are derived from and/or correspond. In certain
embodiments, the abundance of the synthetic peptides is defined and
the results are compared to LC-SRM-MS results from a peptide found
in a sample to the LC-SRM-MS results in the corresponding synthetic
peptide. This allows for the calculation of the abundance of the
peptide in the sample. In certain embodiments, by knowing the
abundance of a peptide in a sample, the abundance of the protein it
corresponded to is determined.
Synthetic peptides can be generated using any method known in the
art. These methods can include recombinant expression techniques
such as expression in bacteria or in vitro expression in eukaryotic
cell lysate. These methods can also include solid phase
synthesis.
In one embodiment, the composition includes synthetic peptides
selected from any of the peptides described in Table 2. In another
embodiment, the composition included any two peptides described in
Table 2. In other embodiments, the composition included, any 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30,
35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120,
130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250,
260, 270, 280, 290, 300 or more peptides described in Table 2.
In another embodiment, the peptides corresponded with human genes
including LRP1, BGH3, COIA1, TETN, TSP1, ALDOA, GRP78, ISLR, FRIL,
LG3BP, PRDX1, FIBA, and GSLG1 as described in corresponding patent
application. These genes can further include peptides corresponding
with any number of additional genes from Table 2. Thus, the
composition can include, any additional 1, 2, 3, 4, 5, 6, 7, 8, 9,
10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50,
55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150,
160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280,
290, 300 or more peptides described in Table 2.
In another embodiment, each of the peptides in the composition each
corresponds with a different protein. In another embodiment, 90% of
the peptides in the composition correspond with a protein that no
other peptide in the composition corresponds with. In other
embodiments, 80, 70, 60, 50, 40, 30, 20, 10 or 0% of the peptides
in the composition correspond with from a protein that no other
peptide in the composition corresponds with.
The peptides can be isotopically labeled. The isotopes with which
they can be labeled include .sup.13C, .sup.2H, .sup.15N and
.sup.18O. The peptides can also include a polar solvent. Polar
solvents can include water and mixtures of ethanol and water.
In certain embodiments, the samples described herein are taken from
mammals. These mammals include rats, mice, rabbits, dogs, non-human
primates and humans. Samples can be isolated from any tissue or
organ or from any bodily fluid. Organs from which samples can be
taken include skin, heart, lung, brain, kidney, liver, pancreas,
spleen, testes, ovaries, gall bladder, thymus, thyroid, eye, ear,
nose, mouth, tongue, penis, vagina, bladder or larynx. Tissues
include nervous tissue, vascular tissue, muscle, bone,
gastrointestinal tract, epithelial tissue, fibroblastic tissue,
mucous membranes, hair, skin, reproductive tissue and connective
tissue. Body fluids and excretions include, blood, serum, saliva,
urine, semen, vaginal secretions, excrement, bile, tears, lymph,
ear wax, mucous, shed skin, finger nails, toe nails, skin oils,
sweat and dandruff.
The relative abundance of one or more of the proteins represented
by the transition ions and synthetic peptides described above can
be used to diagnose, determine likelihood of the presence of,
develop prognoses for and/or stage various diseases and
pathologies. Often the organ, tissue or bodily fluid or excretion
from which the sample is taken is distinct from the organ, tissue
or bodily fluid or excretion involved with the disease or
pathology. For example, the presence of lung cancer can be
determined from a sample taken from blood. Any type of body fluid
may be used in the assays.
Diseases and pathologies that status, diagnosis, presence or
prognosis can be found using the transition ions and/or synthetic
peptides described herein include cancer, metabolic diseases,
neurological disorders, infectious diseases and cardiovascular
disorders.
EXAMPLES
Exemplary Standard Operating Procedure
Protein Selection
Proteins known to be over-expressed on the cell surface of lung
cancer tumors were obtained (through literature searching,
experimental data or proprietary databases). This was referred to
as set `A`. Proteins known to be over-secreted by lung cancer tumor
cells were obtained (through literature searching, experimental
data or proprietary databases). This was referred to as set `B`.
Proteins associated with lung cancer in the literature were mined.
This was referred to as set `C`. Proteins of interest (sets A, B
and C are merged resulting in over 700 proteins) were assembled.
The set of proteins was reduced to a set of 388 proteins (see Table
4) by prioritizing those proteins that have been previously
detected my LC-MS/MS in blood (serum or plasma).
Selected proteins were then identified by their UniProt protein
name and accession, their Entrez gene symbol and gene name, the
isoform accession and their amino acid sequence. The canonical
isoform in UniProt was selected if a protein has more than one
isoform.
Peptide Selection for Synthesis
The five best peptides per protein for LC-SRM-MS assay were
selected for as follows. Fully tryptic peptides having a
monoisotopic mass of 800-3500 mass units, without miscleavages, not
containing a cysteine (C) or a methionine (M), without having high
miscleavage probability were selected. Further, any peptide that
was bounded by KK, KR, RK or RR (either upstream or downstream) in
the corresponding protein sequence was not selected.
Peptides were selected that were unique to the protein of interest.
Peptides were only selected that match only one protein or protein
family including analogues of the one protein, when searched in
protein databases. Further, peptides which were observed in
post-translational modified forms were not selected. Databases were
assessed that showed expression of the proteins from which the
peptides were isolated in human blood. Also databases of good
quality MS peptides were searched. Peptides that appeared in human
blood and were good quality MS peptides were favored. If these
methods did not result in a sufficient number of peptides, rules
were relaxed in a step wise manner to allow a greater number of
peptides until a sufficient number was reached. The purity of the
synthesized peptides was >75% and the amount of material was
.gtoreq.25 .mu.g. Peptides did not need to be desalted.
The four best transitions per peptide are then selected and
optimized based on experimental results from a mixture of synthetic
peptides. LC-SRM-MS-triggered MS/MS spectra were acquired for each
synthetic peptide, using a QTRAP 5500 instrument. One spectrum for
the doubly- and one for the triply-charged precursor ion was
collected for each peptide For the identified peptides (Mascot
score .gtoreq.15), retention time was recorded for the four most
intense b or y transition ions. The selected transition ions
possessed m/z values were at least 30 m/z above or below those of
the precursor ions; they did not interfere with other synthetic
peptides; and they were transition ions due to breakage of peptide
bond at different sites.
If an insufficient percentage of the synthetic peptides were
acquired, the steps were repeated. In some cases, the second
transition with first with theoretical y+ ions with m/z values at
least 30 m/z above those of the doubly charged precursor ion was
selected if an insufficient percentage was acquired. Peptides that
failed to trigger the acquisition of MS/MS spectrum were
discarded.
Collision energy (CE) for each selected transition (See Table 4)
was optimized.
Exemplary Protein List
The abundance of the following proteins can be assessed
substantially simultaneously using the MS-LC-SRM-MS system
described herein. Transitions from these proteins can be used to
diagnose diseases including lung cancer when their abundance is
measured in a biological specimen from a subject to be diagnosed
for lung cancer. In one embodiment, the abundances of these
proteins are measured in the blood serum of the subject.
TABLE-US-00001 TABLE 1 Sources of Subcellular Evidence for UniProt
Protein Gene Tissue Biomarkers Location Presence in Protein Name
Symbol Biomarkers in Literature (UniProt) Blood 1433B_HUMAN 14-3-3
YWHAB Secreted, LungCancers Cytoplasm. Literature, protein EPI
Melanosome. Detection beta/alpha Note = Identified by mass
spectrometry in melanosome fractions from stage I to stage IV.
1433E_HUMAN 14-3-3 YWHAE ENDO LungCancers, Cytoplasm (By
Literature, protein BenignNodules similarity). Detection epsilon
Melanosome. Note = Identified by mass spectrometry in melanosome
fractions from stage I to stage IV. 1433S_HUMAN 14-3-3 SFN
Secreted, LungCancers Cytoplasm. UniProt, protein EPI Nucleus (By
Literature, sigma similarity). Detection Secreted. Note = May be
secreted by a non-classical secretory pathway. 1433T_HUMAN 14-3-3
YWHAQ EPI LungCancers, Cytoplasm. Detection protein BenignNodules
Note = In theta neurons, axonally transported to the nerve
terminals. 1433Z_HUMAN 14-3-3 YWHAZ EPI LungCancers, Cytoplasm.
Detection protein BenignNodules Melanosome. zeta/delta Note =
Located to stage I to stage IV melanosomes. 6PGD_HUMAN 6- PGD EPI,
ENDO Cytoplasm (By Detection phosphogluconate similarity).
dehydrogenase, decarboxylating A1AG1_HUMAN Alpha-1- ORM1 EPI
Symptoms Secreted. UniProt, acid Literature, glycoprotein 1
Detection, Prediction ABCD1_HUMAN ATP- ABCD1 ENDO Peroxisome
Detection, binding membrane; Prediction cassette Multi-pass
sub-family membrane D member 1 protein. ADA12_HUMAN Disintegrin
ADAM12 LungCancers, Isoform 1: Cell UniProt, and BenignNodules,
membrane; Detection, metalloproteinase Symptoms Single-pass
Prediction domain- type I containing membrane protein 12
protein.|Isoform 2: Secreted.|Isoform 3: Secreted
(Potential).|Isoform 4: Secreted (Potential). ADML_HUMAN ADM ADM
LungCancers, Secreted. UniProt, BenignNodules, Literature, Symptoms
Detection, Prediction AGR2_HUMAN Anterior AGR2 EPI LungCancers
Secreted. UniProt, gradient Endoplasmic Prediction protein 2
reticulum (By homolog similarity). AIFM1_HUMAN Apoptosis- AIFM1
EPI, ENDO LungCancers Mitochondrion Detection, inducing
intermembrane Prediction factor 1, space. Nucleus. mitochondrial
Note = Translocated to the nucleus upon induction of apoptosis.
ALDOA_HUMAN Fructose- ALDOA Secreted, LungCancers, Literature,
bisphosphate EPI Symptoms Detection aldolase A AMPN_HUMAN
Aminopeptidase N ANPEP EPI, ENDO LungCancers, Cell membrane;
UniProt, BenignNodules, Single-pass Detection Symptoms type II
membrane protein. Cytoplasm, cytosol (Potential). Note = A soluble
form has also been detected. ANGP1_HUMAN Angiopoietin-1 ANGPT1
LungCancers, Secreted. UniProt, BenignNodules Literature,
Prediction ANGP2_HUMAN Angiopoietin-2 ANGPT2 LungCancers, Secreted.
UniProt, BenignNodules Literature, Prediction APOA1_HUMAN
Apolipoprotein APOA1 LungCancers, Secreted. UniProt, A-I
BenignNodules, Literature, Symptoms Detection, Prediction
APOE_HUMAN Apolipoprotein E APOE EPI, ENDO LungCancers, Secreted.
UniProt, BenignNodules, Literature, Symptoms Detection, Prediction
ASM3B_HUMAN Acid SMPDL3B EPI, ENDO Secreted (By UniProt,
sphingomyelinase- similarity). Prediction like phosphodiesterase 3b
AT2A2_HUMAN Sarcoplasmic/ ATP2A2 EPI, ENDO LungCancers, Endoplasmic
Detection endoplasmic BenignNodules reticulum reticulum membrane;
calcium Multi-pass ATPase 2 membrane protein. Sarcoplasmic
reticulum membrane; Multi-pass membrane protein. ATS1_HUMAN A
ADAMTS1 LungCancers, Secreted, UniProt, disintegrin BenignNodules,
extracellular Literature, and Symptoms space, Prediction
metalloproteinase extracellular with matrix (By thrombospondin
similarity). motifs 1 ATS12_HUMAN A ADAMTS12 LungCancers Secreted,
UniProt, disintegrin extracellular Detection, and space, Prediction
metalloproteinase extracellular with matrix (By thrombospondin
similarity). motifs 12 ATS19_HUMAN A ADAMTS19 LungCancers Secreted,
UniProt, disintegrin extracellular Prediction and space,
metalloproteinase extracellular with matrix (By thrombospondin
similarity). motifs 19 BAGE1_HUMAN B BAGE LungCancers Secreted
UniProt, melanoma (Potential). Prediction antigen 1 BAGE2_HUMAN B
BAGE2 LungCancers Secreted UniProt, melanoma (Potential).
Prediction antigen 2 BAGE3_HUMAN B BAGE3 LungCancers Secreted
UniProt, melanoma (Potential). Prediction antigen 3 BAGE4_HUMAN B
BAGE4 LungCancers Secreted UniProt, melanoma (Potential).
Prediction antigen 4 BAGE5_HUMAN B BAGE5 LungCancers Secreted
UniProt, melanoma (Potential). Prediction antigen 5 BASP1_HUMAN
Brain acid BASP1 Secreted, Cell membrane; Detection soluble EPI
Lipid-anchor. protein 1 Cell projection, growth cone. Note =
Associated with the membranes of growth cones that form the tips of
elongating axons. BAX_HUMAN Apoptosis BAX EPI LungCancers, Isoform
Alpha: UniProt, regulator BenignNodules Mitochondrion Literature,
BAX membrane; Prediction Single-pass membrane protein. Cytoplasm.
Note = Colocalizes with 14-3-3 proteins in the cytoplasm. Under
stress conditions, redistributes to the mitochondrion membrane
through the release from JNK- phosphorylated 14-3-3
proteins|Isoform Beta: Cytoplasm.|Isoform Gamma: Cytoplasm|Isoform
Delta: Cytoplasm (Potential). BDNF_HUMAN Brain- BDNF BenignNodules,
Secreted. UniProt, derived Symptoms Literature, neurotrophic
Prediction factor BGH3_HUMAN Transforming TGFBI LungCancers,
Secreted, UniProt, growth BenignNodules extracellular Detection
factor-beta- space, induced extracellular protein ig- matrix. h3
Note = May be associated both with microfibrils and with the cell
surface. BMP2_HUMAN Bone BMP2 LungCancers, Secreted. UniProt,
morphogenetic BenignNodules, Literature protein 2 Symptoms
BST1_HUMAN ADP- BST1 EPI Symptoms Cell membrane; Detection, ribosyl
Lipid-anchor, Prediction cyclase 2 GPI-anchor. C163A_HUMAN
Scavenger CD163 EPI Symptoms Soluble CD163: UniProt, receptor
Secreted.|Cell Detection cysteine- membrane; rich type 1
Single-pass protein type I M130 membrane protein. Note = Isoform 1
and isoform 2 show a lower surface expression when expressed in
cells.
C4BPA_HUMAN C4b- C4BPA LungCancers, Secreted. UniProt, binding
Symptoms Detection, protein Prediction alpha chain CAH9_HUMAN
Carbonic CA9 LungCancers, Nucleus. UniProt anhydrase 9
BenignNodules, Nucleus, Symptoms nucleolus. Cell membrane;
Single-pass type I membrane protein. Cell projection, microvillus
membrane; Single-pass type I membrane protein. Note = Found on the
surface microvilli and in the nucleus, particularly in nucleolus.
CALR_HUMAN Calreticulin CALR EPI Symptoms Endoplasmic UniProt,
reticulum Literature, lumen. Detection, Cytoplasm, Prediction
cytosol. Secreted, extracellular space, extracellular matrix. Cell
surface. Note = Also found in cell surface (T cells), cytosol and
extracellular matrix. Associated with the lytic granules in the
cytolytic T- lymphocytes. CALU_HUMAN Calumenin CALU EPI Symptoms
Endoplasmic UniProt, reticulum Detection, lumen. Prediction
Secreted. Melanosome. Sarcoplasmic reticulum lumen (By similarity).
Note = Identified by mass spectrometry in melanosome fractions from
stage I to stage IV. CALX_HUMAN Calnexin CANX Secreted,
BenignNodules Endoplasmic UniProt, EPI, ENDO reticulum Literature,
membrane; Detection Single-pass type I membrane protein.
Melanosome. Note = Identified by mass spectrometry in melanosome
fractions from stage I to stage IV. CAP7_HUMAN Azurocidin AZU1 EPI
Symptoms Cytoplasmic Prediction granule. Note = Cytoplasmic
granules of neutrophils. CATB_HUMAN Cathepsin B CTSB Secreted
LungCancers Lysosome. Literature, Melanosome. Detection, Note =
Identified Prediction by mass spectrometry in melanosome fractions
from stage I to stage IV. CATG_HUMAN Cathepsin G CTSG Secreted,
BenignNodules Cell surface. Detection, ENDO Prediction CBPB2_HUMAN
Carboxypeptidase CPB2 LungCancers, Secreted. UniProt, B2
BenignNodules, Detection, Symptoms Prediction CCL22_HUMAN C-C motif
CCL22 LungCancers, Secreted. UniProt, chemokine BenignNodules
Prediction 22 CD14_HUMAN Monocyte CD14 EPI LungCancers, Cell
membrane; Literature, differentiation BenignNodules, Lipid-anchor,
Detection, antigen Symptoms GPI-anchor. Prediction CD14 CD24_HUMAN
Signal CD24 LungCancers, Cell membrane; Literature transducer
BenignNodules Lipid-anchor, CD24 GPI-anchor. CD2A2_HUMAN Cyclin-
CDKN2A LungCancers, Cytoplasm. Literature, dependent BenignNodules
Nucleus.|Nucleus, Prediction kinase nucleolus inhibitor (By
similarity). 2A, isoform 4 CD38_HUMAN ADP- CD38 EPI, ENDO Symptoms
Membrane; UniProt, ribosyl Single-pass Literature cyclase 1 type II
membrane protein. CD40L_HUMAN CD40 CD40LG LungCancers, Cell
membrane; UniProt, ligand BenignNodules, Single-pass Literature
Symptoms type II membrane protein.|CD40 ligand, soluble form:
Secreted. CD44_HUMAN CD44 CD44 EPI LungCancers, Membrane; UniProt,
antigen BenignNodules, Single-pass Literature, Symptoms type I
Detection, membrane Prediction protein. CD59_HUMAN CD59 CD59
LungCancers, Cell membrane; UniProt, glycoprotein BenignNodules,
Lipid-anchor, Literature, Symptoms GPI-anchor. Detection, Secreted.
Prediction Note = Soluble form found in a number of tissues.
CD97_HUMAN CD97 CD97 EPI, ENDO Symptoms Cell membrane; UniProt
antigen Multi-pass membrane protein.|CD97 antigen subunit alpha:
Secreted, extracellular space. CDCP1_HUMAN CUB CDCP1 LungCancers
Isoform 1: Cell UniProt, domain- membrane; Prediction containing
Single-pass protein 1 membrane protein (Potential). Note = Shedding
may also lead to a soluble peptide.|Isoform 3: Secreted. CDK4_HUMAN
Cell CDK4 LungCancers, Literature division Symptoms protein kinase
4 CEAM5_HUMAN Carcinoembryonic CEACAM5 EPI LungCancers, Cell
membrane; Literature, antigen- BenignNodules, Lipid-anchor,
Prediction related cell Symptoms GPI-anchor. adhesion molecule 5
CEAM8_HUMAN Carcinoembryonic CEACAM8 EPI LungCancers Cell membrane;
Detection, antigen- Lipid-anchor, Prediction related cell
GPI-anchor. adhesion molecule 8 CERU_HUMAN Ceruloplasmin CP EPI
LungCancers, Secreted. UniProt, Symptoms Literature, Detection,
Prediction CH10_HUMAN 10 kDa HSPE1 ENDO LungCancers Mitochondrion
Literature, heat shock matrix. Detection, protein, Prediction
mitochondrial CH60_HUMAN 60 kDa HSPD1 Secreted, LungCancers,
Mitochondrion Literature, heat shock EPI, ENDO Symptoms matrix.
Detection protein, mitochondrial CKAP4_HUMAN Cytoskeleton- CKAP4
EPI, ENDO LungCancers Endoplasmic UniProt associated
reticulum-Golgi protein 4 intermediate compartment membrane;
Single-pass membrane protein (Potential). CL041_HUMAN
Uncharacterized C12orf41 ENDO Prediction protein C12orf41
CLCA1_HUMAN Calcium- CLCA1 LungCancers, Secreted, UniProt,
activated BenignNodules extracellular Prediction chloride space.
Cell channel membrane; regulator 1 Peripheral membrane protein;
Extracellular side. Note = Protein that remains attached to the
plasma membrane appeared to be predominantly localized to
microvilli. CLIC1_HUMAN Chloride CLIC1 EPI Nucleus. UniProt,
intracellular Nucleus Literature, channel membrane; Detection
protein 1 Single-pass membrane protein (Probable). Cytoplasm. Cell
membrane; Single-pass membrane protein (Probable). Note = Mostly in
the nucleus including in the nuclear membrane. Small amount in the
cytoplasm and the plasma membrane. Exists both as soluble
cytoplasmic protein and as membrane protein with probably a single
transmembrane domain. CLUS_HUMAN Clusterin CLU EPI, ENDO
LungCancers, Secreted. UniProt,
BenignNodules, Literature, Symptoms Detection, Prediction
CMGA_HUMAN Chromogranin-A CHGA LungCancers, Secreted. UniProt,
BenignNodules Note = Neuroendocrine Literature, and Detection,
endocrine Prediction secretory granules. CNTN1_HUMAN Contactin-1
CNTN1 LungCancers Isoform 1: Cell Detection, membrane; Prediction
Lipid-anchor, GPI-anchor; Extracellular side.|Isoform 2: Cell
membrane; Lipid-anchor, GPI-anchor; Extracellular side. C04A1_HUMAN
Collagen COL4A1 LungCancers Secreted, UniProt, alpha-1(IV)
extracellular Detection, chain space, Prediction extracellular
matrix, basement membrane. C05A2_HUMAN Collagen COL5A2 LungCancers
Secreted, UniProt, alpha-2(V) extracellular Detection, chain space,
Prediction extracellular matrix (By similarity). C06A3_HUMAN
Collagen COL6A3 Secreted Symptoms Secreted, UniProt, alpha-3(VI)
extracellular Detection, chain space, Prediction extracellular
matrix (By similarity). COCA1_HUMAN Collagen COL12A1 ENDO
LungCancers, Secreted, UniProt, alpha- Symptoms extracellular
Prediction 1(XII) space, chain extracellular matrix (By
similarity). COF1_HUMAN Cofilin-1 CFL1 Secreted, LungCancers,
Nucleus matrix. Detection, EPI BenignNodules Cytoplasm, Prediction
cytoskeleton. Note = Almost completely in nucleus in cells exposed
to heat shock or 10% dimethyl sulfoxide. COIA1_HUMAN Collagen
COL18A1 LungCancers, Secreted, UniProt, alpha- BenignNodules
extracellular Literature, 1(XVIII) space, Detection, chain
extracellular Prediction matrix (By similarity). COX5A_HUMAN
Cytochrome COX5A Secreted, Mitochondrion Prediction c oxidase ENDO
inner subunit 5A, membrane. mitochondrial CRP_HUMAN C-reactive CRP
LungCancers, Secreted. UniProt, protein BenignNodules, Literature,
Symptoms Detection, Prediction CS051_HUMAN UPF0470 C19orf51 ENDO
Prediction protein C19orf51 CSF1_HUMAN Macrophage CSF1 LungCancers,
Cell membrane; UniProt, colony- BenignNodules Single-pass
Literature, stimulating membrane Detection factor 1 protein (By
similarity).|Processed macrophage colony- stimulating factor 1:
Secreted, extracellular space (By similarity). CSF2_HUMAN
Granulocyte- CSF2 LungCancers, Secreted. UniProt, macrophage
BenignNodules Literature, colony- Prediction stimulating factor
CT085_HUMAN Uncharacterized C20orf85 LungCancers, Prediction
protein BenignNodules C20orf85 CTGF_HUMAN Connective CTGF
LungCancers, Secreted, UniProt, tissue BenignNodules extracellular
Literature, growth space, Detection, factor extracellular
Prediction matrix (By similarity). Secreted (By similarity).
CYR61_HUMAN Protein CYR61 LungCancers, Secreted. UniProt, CYR61
BenignNodules Prediction CYTA_HUMAN Cystatin-A CSTA LungCancers
Cytoplasm. Literature, Detection CYTB_HUMAN Cystatin-B CSTB
Secreted Cytoplasm. Literature, Nucleus. Detection DDX17_HUMAN
Probable DDX17 ENDO LungCancers, Nucleus. Detection, ATP-
BenignNodules Prediction dependent RNA helicase DDX17 DEFB1_HUMAN
Beta- DEFB1 LungCancers, Secreted. UniProt, defensin 1
BenignNodules Prediction DESP_HUMAN Desmoplakin DSP EPI, ENDO
LungCancers Cell junction, Detection desmosome. Cytoplasm,
cytoskeleton. Note = Innermost portion of the desmosomal plaque.
DFB4A_HUMAN Beta- DEFB4A LungCancers, Secreted. UniProt defensin
BenignNodules 4A DHI1L_HUMAN Hydroxysteroid HSD11B1L LungCancers
Secreted UniProt, 11- (Potential). Prediction beta- dehydrogenase
1-like protein DMBT1_HUMAN Deleted in DMBT1 LungCancers, Secreted
(By UniProt, malignant BenignNodules similarity). Detection, brain
Note = Some Prediction tumors 1 isoforms may protein be membrane-
bound. Localized to the lumenal aspect of crypt cells in the small
intestine. In the colon, seen in the lumenal aspect of surface
epithelial cells. Formed in the ducts of von Ebner gland, and
released into the fluid bathing the taste buds contained in the
taste papillae (By similarity). DMKN_HUMAN Dermokine DMKN
LungCancers Secreted. UniProt, Detection, Prediction DPP4_HUMAN
Dipeptidyl DPP4 EPI LungCancers, Dipeptidyl UniProt, peptidase 4
BenignNodules, peptidase 4 Detection Symptoms soluble form:
Secreted.|Cell membrane; Single-pass type II membrane protein.
DSG2_HUMAN Desmoglein-2 DSG2 ENDO Symptoms Cell membrane; UniProt,
Single-pass Detection type I membrane protein. Cell junction,
desmosome. DX39A_HUMAN ATP- DDX39A EPI Nucleus (By Prediction
dependent similarity). RNA helicase DDX39A DX39B_HUMAN Spliceosome
DDX39B EPI Nucleus. Prediction RNA Nucleus helicase speckle. DDX39B
DYRK2_HUMAN Dual DYRK2 ENDO LungCancers Cytoplasm. Literature
specificity Nucleus. tyrosine- Note = Translocates phosphorylation-
into the regulated nucleus kinase 2 following DNA damage.
EDN2_HUMAN Endothelin-2 EDN2 LungCancers Secreted. UniProt,
Prediction EF1A1_HUMAN Elongation EEF1A1 Secreted, LungCancers,
Cytoplasm. Detection factor 1- EPI BenignNodules alpha 1 EF1D_HUMAN
Elongation EEF1D Secreted, LungCancers Prediction factor 1- EPI
delta EF2_HUMAN Elongation EEF2 Secreted, Cytoplasm. Literature,
factor 2 EPI Detection EGF_HUMAN Pro- EGF LungCancers, Membrane;
UniProt, epidermal BenignNodules, Single-pass Literature growth
Symptoms type I factor membrane protein. EGFL6_HUMAN Epidermal
EGFL6 LungCancers Secreted, UniProt, growth extracellular
Detection, factor-like space, Prediction protein 6 extracellular
matrix, basement membrane (By similarity). ENOA_HUMAN Alpha- ENO1
Secreted, LungCancers, Cytoplasm. Cell Literature, enolase EPI,
ENDO BenignNodules, membrane. Detection, Symptoms Cytoplasm,
Prediction myofibril, sarcomere, M- band. Note = Can translocate to
the plasma membrane in either the homodimeric (alpha/alpha) or
heterodimeric (alpha/gamma) form. ENO1 is localized to the M-
band.|Isoform MBP-1: Nucleus. ENOG_HUMAN Gamma- ENO2 EPI
LungCancers, Cytoplasm (By Literature, enolase Symptoms
similarity). Cell Detection, membrane (By Prediction similarity).
Note = Can translocate to the plasma membrane in either the
homodimeric (alpha/alpha) or heterodimeric (alpha/gamma) form
(By
similarity). ENOX2_HUMAN Ecto-NOX ENOX2 LungCancers Cell membrane.
UniProt, disulfide- Secreted, Detection thiol extracellular
exchanger 2 space. Note = Extracellular and plasma membrane-
associated. ENPL_HUMAN Endoplasmin HSP90B1 Secreted, LungCancers,
Endoplasmic Literatu- re, EPI, ENDO BenignNodules, reticulum
Detection, Symptoms lumen. Prediction Melanosome. Note = Identified
by mass spectrometry in melanosome fractions from stage I to stage
IV. EPHB6_HUMAN Ephrin EPHB6 LungCancers Membrane; UniProt, type-B
Single-pass Literature receptor 6 type I membrane protein.|Isoform
3: Secreted (Probable). EPOR_HUMAN Erythropoietin EPOR LungCancers,
Cell membrane; UniProt, receptor BenignNodules, Single-pass
Literature, Symptoms type I Detection membrane protein.|Isoform
EPOR-S: Secreted. Note = Secreted and located to the cell surface.
ERBB3_HUMAN Receptor ERBB3 LungCancers, Isoform 1: Cell UniProt,
tyrosine- BenignNodules membrane; Literature, protein Single-pass
Prediction kinase type I erbB-3 membrane protein.|Isoform 2:
Secreted. EREG_HUMAN Proepiregulin EREG LungCancers Epiregulin:
UniProt Secreted, extracellular space.|Proepiregulin: Cell
membrane; Single-pass type I membrane protein. ERO1A_HUMAN
ERO1-like ERO1L Secreted, Symptoms Endoplasmic Prediction protein
EPI, ENDO reticulum alpha membrane; Peripheral membrane protein;
Lumenal side. Note = The association with ERP44 is essential for
its retention in the endoplasmic reticulum. ESM1_HUMAN Endothelial
ESM1 LungCancers, Secreted. UniProt, cell- BenignNodules Prediction
specific molecule 1 EZRI_HUMAN Ezrin EZR Secreted LungCancers,
Apical cell Literature, BenignNodules membrane; Detection,
Peripheral Prediction membrane protein; Cytoplasmic side. Cell
projection. Cell projection, microvillus membrane; Peripheral
membrane protein; Cytoplasmic side. Cell projection, ruffle
membrane; Peripheral membrane protein; Cytoplasmic side. Cytoplasm,
cell cortex. Cytoplasm, cytoskeleton. Note = Localization to the
apical membrane of parietal cells depends on the interaction with
MPP5. Localizes to cell extensions and peripheral processes of
astrocytes (By similarity). Microvillar peripheral membrane protein
(cytoplasmic side). F10A1_HUMAN Hsc70- ST13 EPI Cytoplasm (By
Detection, interacting similarity).|Cytoplasm Prediction protein
(Probable). FAM3C_HUMAN Protein FAM3C EPI, ENDO Secreted UniProt,
FAM3C (Potential). Detection FAS_HUMAN Fatty acid FASN EPI
LungCancers, Cytoplasm. Literature, synthase BenignNodules,
Melanosome. Detection Symptoms Note = Identified by mass
spectrometry in melanosome fractions from stage I to stage IV.
FCGR1_HUMAN High FCGR1A EPI LungCancers, Cell membrane; UniProt
affinity BenignNodules, Single-pass immunoglobulin Symptoms type I
gamma Fc membrane receptor I protein. Note = Stabilized at the cell
membrane through interaction with FCER1G. FGF10_HUMAN Fibroblast
FGF10 LungCancers Secreted UniProt, growth (Potential). Prediction
factor 10 FGF2_HUMAN Heparin- FGF2 LungCancers, Literature binding
BenignNodules, growth Symptoms factor 2 FGF7_HUMAN Keratinocyte
FGF7 LungCancers, Secreted. UniProt, growth BenignNodules
Literature, factor Prediction FGF9_HUMAN Glia- FGF9 LungCancers
Secreted. UniProt, activating Literature, factor Prediction
FGFR2_HUMAN Fibroblast FGFR2 LungCancers, Cell membrane; UniProt,
growth BenignNodules Single-pass Literature, factor type I
Prediction receptor 2 membrane protein.|Isoform 14:
Secreted.|Isoform 19: Secreted. FGFR3_HUMAN Fibroblast FGFR3
LungCancers Membrane; UniProt, growth Single-pass Literature,
factor type I Prediction receptor 3 membrane protein. FGL2_HUMAN
Fibroleukin FGL2 BenignNodules, Secreted. UniProt, Symptoms
Detection, Prediction FHIT_HUMAN Bis(5'- FHIT LungCancers,
Cytoplasm. Literature adenosyl)- BenignNodules, triphosphatase
Symptoms FIBA_HUMAN Fibrinogen FGA LungCancers, Secreted. UniProt,
alpha chain BenignNodules, Literature, Symptoms Detection,
Prediction FINC_HUMAN Fibronectin FN1 Secreted, LungCancers,
Secreted, UniProt, EPI, ENDO BenignNodules, extracellular
Literature, Symptoms space, Detection, extracellular Prediction
matrix. FKB11_HUMAN Peptidyl- FKBP11 EPI, ENDO Membrane; UniProt,
prolyl cis- Single-pass Prediction trans membrane isomerase protein
FKBP11 (Potential). FOLH1_HUMAN Glutamate FOLH1 ENDO LungCancers,
Cell membrane; UniProt, carboxypeptidase 2 Symptoms Single-pass
Literature type II membrane protein.|Isoform PSMA': Cytoplasm.
FOLR1_HUMAN Folate FOLR1 LungCancers Cell membrane; UniProt
receptor Lipid-anchor, alpha GPI-anchor. Secreted (Probable).
FOXA2_HUMAN Hepatocyte FOXA2 LungCancers Nucleus. Detection,
nuclear Prediction factor 3- beta FP100_HUMAN Fanconi C17orf70 ENDO
Symptoms Nucleus. Prediction anemia- associated protein of 100 kDa
FRIH_HUMAN Ferritin FTH1 EPI LungCancers, Literature, heavy
BenignNodules Detection, chain Prediction FRIL_HUMAN Ferritin FTL
Secreted, BenignNodules, Literature, light chain EPI, ENDO Symptoms
Detection G3P_HUMAN Glyceraldehyde- GAPDH Secreted, LungCancers,
Cytoplasm. Detectio- n 3- EPI, ENDO BenignNodules, Cytoplasm,
phosphate Symptoms perinuclear dehydrogenase region. Membrane. Note
= Postnuclear and Perinuclear regions. G6PD_HUMAN Glucose-6- G6PD
Secreted, LungCancers, Literature, phosphate EPI Symptoms Detection
1- dehydrogenase G6PI_HUMAN Glucose-6- GPI Secreted, Symptoms
Cytoplasm. UniProt, phosphate EPI Secreted. Literature, isomerase
Detection GA2L1_HUMAN GAS2-like GAS2L1 ENDO Cytoplasm, Prediction
protein 1 cytoskeleton (Probable). GALT2_HUMAN Polypeptide GALNT2
EPI, ENDO Golgi UniProt, N- apparatus, Detection
acetylgalactosaminyl- Golgi stack transferase 2 membrane;
Single-pass type II membrane protein. Secreted. Note = Resides
preferentially in the trans and medial parts of the Golgi
stack.
A secreted form also exists. GAS6_HUMAN Growth GAS6 LungCancers
Secreted. UniProt, arrest- Detection, specific Prediction protein 6
GDIR2_HUMAN Rho GDP- ARHGDIB EPI Cytoplasm. Detection dissociation
inhibitor 2 GELS_HUMAN Gelsolin GSN LungCancers, Isoform 2:
UniProt, BenignNodules Cytoplasm, Literature, cytoskeleton.|Isoform
Detection, 1: Prediction Secreted. GGH_HUMAN Gamma- GGH LungCancers
Secreted, UniProt, glutamyl extracellular Detection, hydrolase
space. Prediction Lysosome. Melanosome. Note = While its
intracellular location is primarily the lysosome, most of the
enzyme activity is secreted. Identified by mass spectrometry in
melanosome fractions from stage I to stage IV. GPC3_HUMAN
Glypican-3 GPC3 LungCancers, Cell membrane; UniProt, Symptoms
Lipid-anchor, Literature, GPI-anchor; Prediction Extracellular side
(By similarity).|Secreted glypican-3: Secreted, extracellular space
(By similarity). GRAN_HUMAN Grancalcin GCA EPI Cytoplasm.
Prediction Cytoplasmic granule membrane; Peripheral membrane
protein; Cytoplasmic side. Note = Primarily cytosolic in the
absence of calcium or magnesium ions. Relocates to granules and
other membranes in response to elevated calcium and magnesium
levels. GREB1_HUMAN Protein GREB1 ENDO Membrane; UniProt, GREB1
Single-pass Prediction membrane protein (Potential). GREM1_HUMAN
Gremlin-1 GREM1 LungCancers, Secreted UniProt, BenignNodules
(Probable). Prediction GRP_HUMAN Gastrin- GRP LungCancers,
Secreted. UniProt, releasing Symptoms Prediction peptide
GRP78_HUMAN 78 kDa HSPA5 Secreted, LungCancers, Endoplasmic
Detection, glucose- EPI, ENDO BenignNodules reticulum Prediction
regulated lumen. protein Melanosome. Note = Identified by mass
spectrometry in melanosome fractions from stage I to stage IV.
GSLG1_HUMAN Golgi GLG1 EPI, ENDO BenignNodules Golgi apparatus
UniProt apparatus membrane; protein 1 Single-pass type I membrane
protein. GSTP1_HUMAN Glutathione GSTP1 Secreted LungCancers,
Literature, S- BenignNodules, Detection, transferase P Symptoms
Prediction GTR1_HUMAN Solute SLC2A1 EPI, ENDO LungCancers, Cell
membrane; Literature carrier BenignNodules, Multi-pass family 2,
Symptoms membrane facilitated protein (By glucose similarity).
transporter Melanosome. member 1 Note = Localizes primarily at the
cell surface (By similarity). Identified by mass spectrometry in
melanosome fractions from stage I to stage IV. GTR3_HUMAN Solute
SLC2A3 EPI Membrane; Detection carrier Multi-pass family 2,
membrane facilitated protein. glucose transporter member 3
H2A1_HUMAN Histone HIST1H2AG Secreted Nucleus. Detection, H2A type
1 Prediction H2A1B_HUMAN Histone HIST1H2AB Secreted Nucleus.
Detection, H2A type Prediction 1-B/E H2A1C_HUMAN Histone HIST1H2AC
Secreted Nucleus. Literature, H2A type Detection, 1-C Prediction
H2A1D_HUMAN Histone HIST1H2AD Secreted Nucleus. Detection, H2A type
Prediction 1-D HG2A_HUMAN HLA class CD74 LungCancers, Membrane;
UniProt, II BenignNodules, Single-pass Literature
histocompatibility Symptoms type II antigen membrane gamma protein
chain (Potential). HGF_HUMAN Hepatocyte HGF LungCancers,
Literature, growth BenignNodules, Prediction factor Symptoms
HMGA1_HUMAN High HMGA1 LungCancers, Nucleus. Literature mobility
BenignNodules, group Symptoms protein HMG- I/HMG-Y HPRT_HUMAN
Hypoxanthine- HPRT1 EPI Cytoplasm. Detection, guanine Prediction
phosphoribosyltransferase HPSE_HUMAN Heparanase HPSE LungCancers,
Lysosome UniProt, BenignNodules, membrane; Prediction Symptoms
Peripheral membrane protein. Secreted. Note = Secreted,
internalised and transferred to late endosomes/lysosomes as a
proheparanase. In lysosomes, it is processed into the active form,
the heparanase. The uptake or internalisation of proheparanase is
mediated by HSPGs. Heparin appears to be a competitor and retain
proheparanase in the extracellular medium. HPT_HUMAN Haptoglobin HP
LungCancers, Secreted. UniProt, BenignNodules, Literature, Symptoms
Detection, Prediction HS90A_HUMAN Heat shock HSP90AA1 Secreted,
LungCancers, Cytoplasm. Literature, protein EPI Symptoms
Melanosome. Detection HSP 90- Note = Identified alpha by mass
spectrometry in melanosome fractions from stage I to stage IV.
HS90B_HUMAN Heat shock HSP90AB1 Secreted, LungCancers Cytoplasm.
Literature, protein EPI Melanosome. Detection HSP 90- Note =
Identified beta by mass spectrometry in melanosome fractions from
stage I to stage IV. HSPB1_HUMAN Heat shock HSPB1 Secreted,
LungCancers, Cytoplasm. Literature, protein EPI BenignNodules
Nucleus. Detection, beta-1 Cytoplasm, Prediction cytoskeleton,
spindle. Note = Cytoplasmic in interphase cells. Colocalizes with
mitotic spindles in mitotic cells. Translocates to the nucleus
during heat shock. HTRA1_HUMAN Serine HTRA1 LungCancers Secreted.
UniProt, protease Prediction HTRA1 HXK1_HUMAN Hexokinase-1 HK1 ENDO
Symptoms Mitochondrion Literature, outer Detection membrane. Note =
Its hydrophobic N- terminal sequence may be involved in membrane
binding. HYAL2_HUMAN Hyaluronidase-2 HYAL2 LungCancers Cell
membrane; Prediction Lipid-anchor, GPI-anchor. HYOU1_HUMAN Hypoxia
HYOU1 EPI, ENDO Symptoms Endoplasmic Detection up- reticulum
regulated lumen. protein 1 IBP2_HUMAN Insulin-like IGFBP2
LungCancers Secreted. UniProt, growth Literature, factor-
Detection, binding Prediction protein 2 IBP3_HUMAN Insulin-like
IGFBP3 LungCancers, Secreted. UniProt, growth BenignNodules,
Literature,
factor- Symptoms Detection, binding Prediction protein 3
ICAM1_HUMAN Intercellular ICAM1 LungCancers, Membrane; UniProt,
adhesion BenignNodules, Single-pass Literature, molecule 1 Symptoms
type I Detection membrane protein. ICAM3_HUMAN Intercellular ICAM3
EPI, ENDO LungCancers, Membrane; UniProt, adhesion BenignNodules,
Single-pass Detection molecule 3 Symptoms type I membrane protein.
IDHP_HUMAN Isocitrate IDH2 Secreted, Mitochondrion. Prediction
dehydrogenase ENDO [NADP], mitochondrial IF4A1_HUMAN Eukaryotic
EIF4A1 Secreted, Detection, initiation EPI, ENDO Prediction factor
4A-I IGF1_HUMAN Insulin-like IGF1 LungCancers, Secreted.|Secreted.
UniProt, growth BenignNodules, Literature, factor I Symptoms
Detection, Prediction IKIP_HUMAN Inhibitor of IKIP ENDO Symptoms
Endoplasmic UniProt, nuclear reticulum Prediction factor membrane;
kappa-B Single-pass kinase- membrane interacting protein. protein
Note = Isoform 4 deletion of the hydrophobic, or transmembrane
region between AA 45-63 results in uniform distribution troughout
the cell, suggesting that this region is responsible for
endoplasmic reticulum localization. IL18_HUMAN Interleukin- IL18
LungCancers, Secreted. UniProt, 18 BenignNodules, Literature,
Symptoms Prediction IL19_HUMAN Interleukin- IL19 LungCancers
Secreted. UniProt, 19 Detection, Prediction IL22_HUMAN Interleukin-
IL22 LungCancers, Secreted. UniProt, 22 BenignNodules Prediction
IL32_HUMAN Interleukin- IL32 LungCancers, Secreted. UniProt, 32
BenignNodules Prediction IL7_HUMAN Interleukin-7 IL7 LungCancers,
Secreted. UniProt, BenignNodules Literature, Prediction IL8_HUMAN
Interleukin-8 IL8 LungCancers, Secreted. UniProt, BenignNodules,
Literature Symptoms ILEU_HUMAN Leukocyte SERPINB1 Secreted,
Cytoplasm (By Detection, elastase EPI similarity). Prediction
inhibitor ILK_HUMAN Integrin- ILK Secreted LungCancers, Cell
junction, Literature, linked BenignNodules, focal adhesion.
Detection protein Symptoms Cell membrane; kinase Peripheral
membrane protein; Cytoplasmic side. INHBA_HUMAN Inhibin INHBA
LungCancers, Secreted. UniProt, beta A BenignNodules Literature,
chain Prediction ISLR_HUMAN Immunoglobulin ISLR LungCancers
Secreted UniProt, superfamily (Potential). Detection, containing
Prediction leucine- rich repeat protein ITA5_HUMAN Integrin ITGA5
EPI LungCancers, Membrane; UniProt, alpha-5 BenignNodules,
Single-pass Literature, Symptoms type I Detection membrane protein.
ITAM_HUMAN Integrin ITGAM EPI, ENDO LungCancers, Membrane; UniProt,
alpha-M BenignNodules, Single-pass Literature Symptoms type I
membrane protein. K0090_HUMAN Uncharacterized KIAA0090 EPI Symptoms
Membrane; UniProt, protein Single-pass Prediction KIAA0090 type I
membrane protein (Potential). K1C18_HUMAN Keratin, KRT18 Secreted
LungCancers, Cytoplasm, Literature, type I BenignNodules
perinuclear Detection, cytoskeletal region. Prediction 18
K1C19_HUMAN Keratin, KRT19 LungCancers, Literature, type I
BenignNodules Detection, cytoskeletal Prediction 19 K2C8_HUMAN
Keratin, KRT8 EPI LungCancers Cytoplasm. Literature, type II
Detection cytoskeletal 8 KIT_HUMAN Mast/stem KIT LungCancers
Membrane; UniProt, cell growth Single-pass Literature, factor type
I Detection receptor membrane protein. KITH_HUMAN Thymidine TK1
LungCancers Cytoplasm. Literature, kinase, Prediction cytosolic
KLK11_HUMAN Kallikrein- KLK11 LungCancers Secreted. UniProt, 11
Literature, Prediction KLK13_HUMAN Kallikrein- KLK13 LungCancers
Secreted UniProt, 13 (Probable). Literature, Detection, Prediction
KLK14_HUMAN Kallikrein- KLK14 LungCancers, Secreted, UniProt, 14
Symptoms extracellular Literature, space. Prediction KLK6_HUMAN
Kallikrein-6 KLK6 LungCancers, Secreted. UniProt, BenignNodules,
Nucleus, Literature, Symptoms nucleolus. Detection, Cytoplasm.
Prediction Mitochondrion. Microsome. Note = In brain, detected in
the nucleus of glial cells and in the nucleus and cytoplasm of
neurons. Detected in the mitochondrial and microsomal fractions of
HEK-293 cells and released into the cytoplasm following cell
stress. KNG1_HUMAN Kininogen-1 KNG1 LungCancers, Secreted, UniProt,
BenignNodules, extracellular Detection, Symptoms space. Prediction
KPYM_HUMAN Pyruvate PKM2 Secreted, LungCancers, Cytoplasm.
Literature, kinase EPI Symptoms Nucleus. Detection isozymes Note =
Translocates M1/M2 to the nucleus in response to different
apoptotic stimuli. Nuclear translocation is sufficient to induce
cell death that is caspase independent, isoform-specific and
independent of its enzymatic actvity. KRT35_HUMAN Keratin, KRT35
ENDO Detection, type I Prediction cuticular Ha5 LAMB2_HUMAN Laminin
LAMB2 ENDO LungCancers, Secreted, UniProt, subunit Symptoms
extracellular Detection, beta-2 space, Prediction extracellular
matrix, basement membrane. Note = S-laminin is concentrated in the
synaptic cleft of the neuromuscular junction. LDHA_HUMAN L-lactate
LDHA Secreted, LungCancers Cytoplasm. Literature, dehydrogenase
EPI, ENDO Detection, A chain Prediction LDHB_HUMAN L-lactate LDHB
EPI LungCancers Cytoplasm. Detection, dehydrogenase Prediction B
chain LEG1_HUMAN Galectin-1 LGALS1 Secreted LungCancers Secreted,
UniProt, extracellular Detection space, extracellular matrix.
LEG3_HUMAN Galectin-3 LGALS3 LungCancers, Nucleus. Literature,
BenignNodules Note = Cytoplasmic Detection, in Prediction adenomas
and carcinomas. May be secreted by a non- classical secretory
pathway and associate with the cell surface. LEG9_HUMAN Galectin-9
LGALS9 ENDO Symptoms Cytoplasm (By UniProt similarity). Secreted
(By similarity). Note = May also be secreted by a non-classical
secretory pathway (By similarity). LG3BP_HUMAN Galectin-3- LGALS3BP
Secreted LungCancers, Secreted. UniProt, binding BenignNodules,
Secreted, Literature, protein Symptoms extracellular Detection,
space, Prediction extracellular matrix. LPLC3_HUMAN Long C20orf185
LungCancers Secreted (By UniProt, palate, lung similarity).
Prediction and nasal Cytoplasm. epithelium Note = According
carcinoma- to associated PubMed: 12837268 protein 3 it is
cytoplasmic. LPLC4_HUMAN Long C20orf186 LungCancers Secreted (By
UniProt, palate, lung similarity). Prediction and nasal Cytoplasm.
epithelium carcinoma- associated protein 4 LPPRC_HUMAN Leucine-
LRPPRC Secreted, LungCancers, Mitochondrion. Predicti- on rich PPR
ENDO Symptoms Nucleus, motif- nucleoplasm. containing Nucleus inner
protein, membrane. mitochondrial Nucleus outer
membrane. Note = Seems to be predominantly mitochondrial.
LRP1_HUMAN Prolow- LRP1 EPI LungCancers, Low-density UniProt,
density Symptoms lipoprotein Detection lipoprotein receptor-related
receptor- protein 1 85 kDa related subunit: protein 1 Cell
membrane; Single-pass type I membrane protein. Membrane, coated
pit.|Low- density lipoprotein receptor-related protein 1 515 kDa
subunit: Cell membrane; Peripheral membrane protein; Extracellular
side. Membrane, coated pit.|Low- density lipoprotein
receptor-related protein 1 intracellular domain: Cytoplasm.
Nucleus. Note = After cleavage, the intracellular domain (LRPICD)
is detected both in the cytoplasm and in the nucleus. LUM_HUMAN
Lumican LUM Secreted, LungCancers, Secreted, UniProt, EPI
BenignNodules, extracellular Detection, Symptoms space, Prediction
extracellular matrix (By similarity). LY6K_HUMAN Lymphocyte LY6K
LungCancers, Secreted. UniProt, antigen Symptoms Cytoplasm. Cell
Prediction 6K membrane; Lipid-anchor, GPI-anchor (Potential).
LYAM2_HUMAN E-selectin SELE LungCancers, Membrane; UniProt,
BenignNodules, Single-pass Literature, Symptoms type I Detection
membrane protein. LYAM3_HUMAN P-selectin SELP LungCancers,
Membrane; UniProt, BenignNodules, Single-pass Literature, Symptoms
type I Detection membrane protein. LYOX_HUMAN Protein- LOX
LungCancers, Secreted, UniProt, lysine 6- BenignNodules
extracellular Detection, oxidase space. Prediction LYPD3_HUMAN
Ly6/PLAUR LYPD3 LungCancers Cell membrane; Detection, domain-
Lipid-anchor, Prediction containing GPI-anchor. protein 3
MAGA4_HUMAN Melanoma- MAGEA4 LungCancers Literature, associated
Prediction antigen 4 MASP1_HUMAN Mannan- MASP1 LungCancers,
Secreted. UniProt, binding Symptoms Detection, lectin Prediction
serine protease 1 MDHC_HUMAN Malate MDH1 Secreted Cytoplasm.
Literature, dehydrogenase, Detection, cytoplasmic Prediction
MDHM_HUMAN Malate MDH2 ENDO LungCancers Mitochondrion Detection,
dehydrogenase, matrix. Prediction mitochondrial MIF_HUMAN
Macrophage MIF Secreted LungCancers, Secreted. UniProt, migration
BenignNodules, Cytoplasm. Literature, inhibitory Symptoms Note =
Does not Prediction factor have a cleavable signal sequence and is
secreted via a specialized, non-classical pathway. Secreted by
macrophages upon stimulation by bacterial lipopolysaccharide (LPS),
or by M. tuberculosis antigens. MLH1_HUMAN DNA MLH1 ENDO
LungCancers, Nucleus. Literature mismatch BenignNodules, repair
Symptoms protein Mlh1 MMP1_HUMAN Interstitial MMP1 LungCancers,
Secreted, UniProt, collagenase BenignNodules, extracellular
Literature, Symptoms space, Prediction extracellular matrix
(Probable). MMP11_HUMAN Stromelysin-3 MMP11 LungCancers, Secreted,
UniProt, Symptoms extracellular Literature, space, Prediction
extracellular matrix (Probable). MMP12_HUMAN Macrophage MMP12
LungCancers, Secreted, UniProt, metalloelastase BenignNodules,
extracellular Literature, Symptoms space, Prediction extracellular
matrix (Probable). MMP14_HUMAN Matrix MMP14 ENDO LungCancers,
Membrane; UniProt, metalloproteinase- BenignNodules, Single-pass
Literature, 14 Symptoms type I Detection membrane protein
(Potential). Melanosome. Note = Identified by mass spectrometry in
melanosome fractions from stage I to stage IV. MMP2_HUMAN 72 kDa
MMP2 LungCancers, Secreted, UniProt, type IV BenignNodules,
extracellular Literature, collagenase Symptoms space, Detection,
extracellular Prediction matrix (Probable). MMP26_HUMAN Matrix
MMP26 LungCancers Secreted, UniProt, metalloproteinase-
extracellular Prediction 26 space, extracellular matrix. MMP7_HUMAN
Matrilysin MMP7 LungCancers, Secreted, UniProt, BenignNodules,
extracellular Literature, Symptoms space, Prediction extracellular
matrix (Probable). MMP9_HUMAN Matrix MMP9 LungCancers, Secreted,
UniProt, metalloproteinase-9 BenignNodules, extracellular
Literature, Symptoms space, Detection, extracellular Prediction
matrix (Probable). MOGS_HUMAN Mannosyl- MOGS ENDO Endoplasmic
UniProt, oligosaccharide reticulum Prediction glucosidase membrane;
Single-pass type II membrane protein. MPRI_HUMAN Cation- IGF2R EPI,
ENDO LungCancers, Lysosome UniProt, independent Symptoms membrane;
Literature, mannose- Single-pass Detection 6- type I phosphate
membrane receptor protein. MRP3_HUMAN Canalicular ABCC3 EPI
LungCancers Membrane; Literature, multispecific Multi-pass
Detection organic membrane anion protein. transporter 2 MUC1_HUMAN
Mucin-1 MUC1 EPI LungCancers, Apical cell UniProt, BenignNodules,
membrane; Literature, Symptoms Single-pass Prediction type I
membrane protein. Note = Exclusively located in the apical domain
of the plasma membrane of highly polarized epithelial cells. After
endocytosis, internalized and recycled to the cell membrane.
Located to microvilli and to the tips of long filopodial
protusions.|Isoform 5: Secreted.|Isoform 7: Secreted.|Isoform 9:
Secreted.|Mucin- 1 subunit beta: Cell membrane. Cytoplasm. Nucleus.
Note = On EGF and PDGFRB stimulation, transported to the nucleus
through interaction with CTNNB1, a process which is stimulated by
phosphorylation. On HRG stimulation, colocalizes with JUP/gamma-
catenin at the nucleus. MUC16_HUMAN Mucin-16 MUC16 LungCancers Cell
membrane; UniProt, Single-pass Detection type I membrane protein.
Secreted, extracellular space. Note = May be liberated into the
extracellular space following the phosphorylation
of the intracellular C- terminus which induces the proteolytic
cleavage and liberation of the extracellular domain. MUC4_HUMAN
Mucin-4 MUC4 LungCancers, Membrane; UniProt BenignNodules
Single-pass membrane protein (Potential). Secreted. Note = Isoforms
lacking the Cys- rich region, EGF-like domains and transmembrane
region are secreted. Secretion occurs by splicing or proteolytic
processing.|Mucin- 4 beta chain: Cell membrane; Single-pass
membrane protein.|Mucin- 4 alpha chain: Secreted.|Isoform 3: Cell
membrane; Single-pass membrane protein.|Isoform 15: Secreted.
MUC5B_HUMAN Mucin-5B MUC5B LungCancers, Secreted. UniProt,
BenignNodules Detection, Prediction MUCL1_HUMAN Mucin-like MUCL1
LungCancers Secreted UniProt, protein 1 (Probable). Prediction
Membrane (Probable). NAMPT_HUMAN Nicotinamide NAMPT EPI
LungCancers, Cytoplasm (By Literature, phosphoribosyltransferase
BenignNodules, similarity). Detection Symptoms NAPSA_HUMAN Napsin-A
NAPSA Secreted LungCancers Prediction NCF4_HUMAN Neutrophil NCF4
ENDO Cytoplasm. Prediction cytosol factor 4 NDKA_HUMAN Nucleoside
NME1 Secreted LungCancers, Cytoplasm. Literature, diphosphate
BenignNodules, Nucleus. Detection kinase A Symptoms Note = Cell-
cycle dependent nuclear localization which can be induced by
interaction with Epstein-barr viral proteins or by degradation of
the SET complex by GzmA. NDKB_HUMAN Nucleoside NME2 Secreted,
BenignNodules Cytoplasm. Literature, diphosphate EPI Nucleus.
Detection kinase B Note = Isoform 2 is mainly cytoplasmic and
isoform 1 and isoform 2 are excluded from the nucleolus.
NDUS1_HUMAN NADH- NDUFS1 Secreted, Symptoms Mitochondrion
Prediction ubiquinone ENDO inner oxidoreductase membrane. 75 kDa
subunit, mitochondrial NEBL_HUMAN Nebulette NEBL ENDO Prediction
NEK4_HUMAN Serine/threonine- NEK4 ENDO LungCancers Nucleus
Prediction protein (Probable). kinase Nek4 NET1_HUMAN Netrin-1 NTN1
LungCancers, Secreted, UniProt, BenignNodules extracellular
Literature, space, Prediction extracellular matrix (By similarity).
NEU2_HUMAN Vasopressin- AVP LungCancers, Secreted. UniProt,
neurophysin Symptoms Prediction 2- copeptin NGAL_HUMAN Neutrophil
LCN2 EPI LungCancers, Secreted. UniProt, gelatinase- BenignNodules,
Detection, associated Symptoms Prediction lipocalin NGLY1_HUMAN
Peptide- NGLY1 ENDO Cytoplasm. Detection, N(4)-(N- Prediction
acetyl-beta- glucosaminyl)asparagine amidase NHRF1_HUMAN Na(+)/H(+)
SLC9A3R1 EPI BenignNodules Endomembrane Detection exchange system;
regulatory Peripheral cofactor membrane NHE-RF1 protein. Cell
projection, filopodium. Cell projection, ruffle. Cell projection,
microvillus. Note = Colocalizes with actin in microvilli-rich
apical regions of the syncytiotrophoblast. Found in microvilli,
ruffling membrane and filopodia of HeLa cells. Present in lipid
rafts of T-cells. NIBAN_HUMAN Protein FAM129A EPI Cytoplasm.
Literature, Niban Detection NMU_HUMAN Neuromedin-U NMU LungCancers
Secreted. UniProt, Prediction NRP1_HUMAN Neuropilin-1 NRP1
LungCancers, Cell membrane; UniProt, BenignNodules, Single-pass
Literature, Symptoms type I Detection, membrane Prediction
protein.|Isoform 2: Secreted. ODAM_HUMAN Odontogenic ODAM
LungCancers Secreted (By UniProt, ameloblast- similarity).
Prediction associated protein OSTP_HUMAN Osteopontin SPP1
LungCancers, Secreted. UniProt, BenignNodules, Literature, Symptoms
Detection, Prediction OVOS2_HUMAN Ovostatin OVOS2 ENDO Secreted (By
UniProt, homolog 2 similarity). Prediction P5CS_HUMAN Delta-1-
ALDH18A1 ENDO Mitochondrion Prediction pyrroline- inner 5-
membrane. carboxylate synthase PA2GX_HUMAN Group 10 PLA2G10
Symptoms Secreted. UniProt secretory phospholipase A2 PAPP1_HUMAN
Pappalysin-1 PAPPA LungCancers, Secreted. UniProt, BenignNodules,
Literature, Symptoms Prediction PBIP1_HUMAN Pre-B-cell PBXIP1 EPI
Cytoplasm, Prediction leukemia cytoskeleton. transcription Nucleus.
factor- Note = Shuttles interacting between the protein 1 nucleus
and the cytosol. Mainly localized in the cytoplasm, associated with
microtubules. Detected in small amounts in the nucleus. PCBP1_HUMAN
Poly(rC)- PCBP1 EPI, ENDO Nucleus. Detection, binding Cytoplasm.
Prediction protein 1 Note = Loosely bound in the nucleus. May
shuttle between the nucleus and the cytoplasm. PCBP2_HUMAN
Poly(rC)- PCBP2 EPI Nucleus. Detection, binding Cytoplasm.
Prediction protein 2 Note = Loosely bound in the nucleus. May
shuttle between the nucleus and the cytoplasm. PCD15_HUMAN
Protocadherin- PCDH15 ENDO Cell membrane; UniProt, 15 Single-pass
Detection type I membrane protein (By similarity).|Isoform 3:
Secreted. PCNA_HUMAN Proliferating PCNA EPI LungCancers, Nucleus.
Literature, cell BenignNodules, Prediction nuclear Symptoms antigen
PCYOX_HUMAN Prenylcysteine PCYOX1 Secreted LungCancers, Lysosome.
Detectio- n, oxidase 1 Symptoms Prediction PDGFA_HUMAN Platelet-
PDGFA LungCancers Secreted. UniProt, derived Literature, growth
Prediction factor subunit A PDGFB_HUMAN Platelet- PDGFB
LungCancers, Secreted. UniProt, derived BenignNodules, Literature,
growth Symptoms Detection, factor Prediction subunit B PDGFD_HUMAN
Platelet- PDGFD LungCancers Secreted. UniProt, derived Prediction
growth factor D PDIA3_HUMAN Protein PDIA3 ENDO LungCancers
Endoplasmic Detection, disulfide- reticulum Prediction isomerase
lumen (By A3 similarity). Melanosome. Note = Identified by mass
spectrometry in melanosome fractions from stage I to stage IV.
PDIA4_HUMAN Protein PDIA4 Secreted, Endoplasmic Detection,
disulfide- EPI, ENDO reticulum Prediction isomerase lumen. A4
Melanosome. Note = Identified by mass spectrometry in melanosome
fractions from stage I to stage IV. PDIA6_HUMAN Protein PDIA6
Secreted, Endoplasmic Detection, disulfide- EPI, ENDO reticulum
Prediction isomerase lumen (By
A6 similarity). Melanosome. Note = Identified by mass spectrometry
in melanosome fractions from stage I to stage IV. PECA1_HUMAN
Platelet PECAM1 LungCancers, Membrane; UniProt, endothelial
BenignNodules, Single-pass Literature, cell Symptoms type I
Detection adhesion membrane molecule protein. PEDF_HUMAN Pigment
SERPINF1 LungCancers, Secreted. UniProt, epithelium- Symptoms
Melanosome. Literature, derived Note = Enriched Detection, factor
in stage I Prediction melanosomes. PERM_HUMAN Myeloperoxidase MPO
Secreted, LungCancers, Lysosome. Literature- , EPI, ENDO
BenignNodules, Detection Symptoms Prediction PERP1_HUMAN Plasma
PACAP EPI, ENDO Secreted UniProt, cell- (Potential). Detection,
induced Cytoplasm. Prediction resident Note = In endoplasmic
(PubMed: 11350957) reticulum diffuse protein granular localization
in the cytoplasm surrounding the nucleus. PGAM1_HUMAN
Phosphoglycerate PGAM1 Secreted, LungCancers, Detection mutase 1
EPI Symptoms PLAC1_HUMAN Placenta- PLAC1 LungCancers Secreted
UniProt, specific (Probable). Prediction protein 1 PLACL_HUMAN
Placenta- PLAC1L LungCancers Secreted UniProt, specific 1-
(Potential). Prediction like protein PLIN2_HUMAN Perilipin-2 ADFP
ENDO LungCancers Membrane; Prediction Peripheral membrane protein.
PLIN3_HUMAN Perilipin-3 M6PRBP1 EPI Cytoplasm. Detection, Endosome
Prediction membrane; Peripheral membrane protein; Cytoplasmic side
(Potential). Lipid droplet (Potential). Note = Membrane associated
on endosomes. Detected in the envelope and the core of lipid bodies
and in lipid sails. PLOD1_HUMAN Procollagen- PLOD1 EPI, ENDO Rough
Prediction lysine,2- endoplasmic oxoglutarate reticulum 5-
membrane; dioxygenase 1 Peripheral membrane protein; Lumenal side.
PLOD2_HUMAN Procollagen- PLOD2 ENDO BenignNodules, Rough Prediction
lysine,2- Symptoms endoplasmic oxoglutarate reticulum 5- membrane;
dioxygenase 2 Peripheral membrane protein; Lumenal side. PLSL_HUMAN
Plastin-2 LCP1 Secreted, LungCancers Cytoplasm, Detection, EPI
cytoskeleton. Prediction Cell junction. Cell projection. Cell
projection, ruffle membrane; Peripheral membrane protein;
Cytoplasmic side (By similarity). Note = Relocalizes to the
immunological synapse between peripheral blood T lymphocytes and
antibody- presenting cells in response to costimulation through
TCR/CD3 and CD2 or CD28. Associated with the actin cytoskeleton at
membrane ruffles (By similarity). Relocalizes to actin-rich cell
projections upon serine phosphorylation. PLUNC_HUMAN Protein PLUNC
LungCancers, Secreted (By UniProt, Plunc BenignNodules similarity).
Prediction Note = Found in the nasal mucus (By similarity). Apical
side of airway epithelial cells. Detected in nasal mucus (By
similarity). PLXB3_HUMAN Plexin-B3 PLXNB3 ENDO Membrane; UniProt,
Single-pass Detection, type I Prediction membrane protein.
PLXC1_HUMAN Plexin-C1 PLXNC1 EPI Membrane; UniProt, Single-pass
Detection type I membrane protein (Potential). POSTN_HUMAN
Periostin POSTN Secreted, LungCancers, Secreted, UniProt, ENDO
BenignNodules, extracellular Literature, Symptoms space, Detection,
extracellular Prediction matrix. PPAL_HUMAN Lysosomal ACP2 EPI
Symptoms Lysosome UniProt, acid membrane; Prediction phosphatase
Single-pass membrane protein; Lumenal side. Lysosome lumen. Note =
The soluble form arises by proteolytic processing of the membrane-
bound form. PPBT_HUMAN Alkaline ALPL EPI LungCancers, Cell
membrane; Literature, phosphatase, BenignNodules, Lipid-anchor,
Detection, tissue- Symptoms GPI-anchor. Prediction nonspecific
isozyme PPIB_HUMAN Peptidyl- PPIB Secreted, Endoplasmic Detection,
prolyl cis- EPI, ENDO reticulum Prediction trans lumen. isomerase B
Melanosome. Note = Identified by mass spectrometry in melanosome
fractions from stage I to stage IV. PRDX1_HUMAN Peroxiredoxin-1
PRDX1 EPI LungCancers Cytoplasm. Detection, Melanosome. Prediction
Note = Identified by mass spectrometry in melanosome fractions from
stage I to stage IV. PRDX4_HUMAN Peroxiredoxin-4 PRDX4 Secreted,
Cytoplasm. Literature, EPI, ENDO Detection, Prediction PROF1_HUMAN
Profilin-1 PFN1 Secreted, LungCancers Cytoplasm, Detection EPI
cytoskeleton. PRP31_HUMAN U4/U6 PRPF31 ENDO Nucleus Prediction
small speckle. nuclear Nucleus, Cajal ribonucleo body. protein Note
= Predominantly Prp31 found in speckles and in Cajal bodies.
PRS6A_HUMAN 26S PSMC3 EPI BenignNodules Cytoplasm Detection
protease (Potential). regulatory Nucleus subunit 6A (Potential).
PSCA_HUMAN Prostate PSCA LungCancers Cell membrane; Literature,
stem cell Lipid-anchor, Prediction antigen GPI-anchor. PTGIS_HUMAN
Prostacyclin PTGIS EPI LungCancers, Endoplasmic UniProt, synthase
BenignNodules reticulum Detection, membrane; Prediction Single-pass
membrane protein. PTPA_HUMAN Serine/threonine- PPP2R4 ENDO Symptoms
Detection, protein Prediction phosphatase 2A activator PTPRC_HUMAN
Receptor- PTPRC Secreted, LungCancers Membrane; UniProt, type EPI,
ENDO Single-pass Detection, tyrosine- type I Prediction protein
membrane phosphatase C protein. PTPRJ_HUMAN Receptor- PTPRJ EPI
LungCancers, Membrane; UniProt, type Symptoms Single-pass
Detection, tyrosine- type I Prediction protein membrane phosphatase
protein. eta PVR_HUMAN Poliovirus PVR Symptoms Isoform Alpha:
UniProt, receptor Cell membrane; Detection, Single-pass Prediction
type I membrane protein.|Isoform Delta: Cell membrane; Single-pass
type I membrane protein.|Isoform Beta: Secreted.|Isoform Gamma:
Secreted. RAB32_HUMAN Ras-related RAB32 EPI Mitochondrion.
Prediction protein Rab-32 RAGE_HUMAN Advanced AGER Secreted
LungCancers, Isoform 1: Cell UniProt, glycosylation BenignNodules
membrane; Literature end Single-pass product- type I
specific membrane receptor protein.|Isoform 2: Secreted. RAN_HUMAN
GTP- RAN Secreted, LungCancers, Nucleus. Detection, binding EPI
BenignNodules Cytoplasm. Prediction nuclear Melanosome. protein Ran
Note = Becomes dispersed throughout the cytoplasm during mitosis.
Identified by mass spectrometry in melanosome fractions from stage
I to stage IV. RAP2B_HUMAN Ras-related RAP2B EPI Cell membrane;
Prediction protein Lipid-anchor; Rap-2b Cytoplasmic side
(Potential). RAP2C_HUMAN Ras-related RAP2C EPI Cell membrane;
Prediction protein Lipid-anchor; Rap-2c Cytoplasmic side
(Potential). RCN3_HUMAN Reticulocalbin-3 RCN3 EPI Symptoms
Endoplasmic Prediction reticulum lumen (Potential). RL24_HUMAN 60S
RPL24 EPI Prediction ribosomal protein L24 S10A1_HUMAN Protein
S100A1 Symptoms Cytoplasm. Literature, S100-A1 Prediction
S10A6_HUMAN Protein S100A6 Secreted LungCancers Nucleus Literature,
S100-A6 envelope. Detection, Cytoplasm. Prediction S10A7_HUMAN
Protein S100A7 LungCancers Cytoplasm. UniProt, S100-A7 Secreted.
Literature, Note = Secreted Detection, by a non- Prediction
classical secretory pathway. SAA_HUMAN Serum SAA1 Symptoms
Secreted. UniProt, amyloid A Literature, protein Detection,
Prediction SCF_HUMAN Kit ligand KITLG LungCancers, Isoform 1: Cell
UniProt, Symptoms membrane; Literature Single-pass type I membrane
protein (By similarity). Secreted (By similarity). Note = Also
exists as a secreted soluble form (isoform 1 only) (By
similarity).|Isoform 2: Cell membrane; Single-pass type I membrane
protein (By similarity). Cytoplasm, cytoskeleton (By similarity).
SDC1_HUMAN Syndecan-1 SDC1 LungCancers, Membrane; UniProt,
BenignNodules, Single-pass Literature, Symptoms type I Detection
membrane protein. SEM3G_HUMAN Semaphorin- SEMA3G LungCancers
Secreted (By UniProt, 3G similarity). Prediction SEPR_HUMAN Seprase
FAP ENDO Symptoms Cell membrane; UniProt, Single-pass Literature,
type II Detection membrane protein. Cell projection, lamellipodium
membrane; Single-pass type II membrane protein. Cell projection,
invadopodium membrane; Single-pass type II membrane protein. Note =
Found in cell surface lamellipodia, invadopodia and on shed
vesicles. SERPH_HUMAN Serpin H1 SERPINH1 Secreted, LungCancers,
Endoplasmic Detection, EPI, ENDO BenignNodules reticulum Prediction
lumen. SFPA2_HUMAN Pulmonary SFTPA2 Secreted LungCancers, Secreted,
UniProt, surfactant- BenignNodules extracellular Prediction
associated space, protein A2 extracellular matrix. Secreted,
extracellular space, surface film. SFTA1_HUMAN Pulmonary SFTPA1
Secreted LungCancers, Secreted, UniProt, surfactant- BenignNodules,
extracellular Prediction associated Symptoms space, protein A1
extracellular matrix. Secreted, extracellular space, surface film.
SG3A2_HUMAN Secretoglobin SCGB3A2 LungCancers, Secreted. UniProt,
family BenignNodules Prediction 3A member 2 SGPL1_HUMAN
Sphingosine- SGPL1 ENDO Endoplasmic UniProt, 1- reticulum
Prediction phosphate membrane; lyase 1 Single-pass type III
membrane protein. SIAL_HUMAN Bone IBSP LungCancers Secreted.
UniProt, sialoprotein 2 Literature, Prediction SLPI_HUMAN
Antileukoproteinase SLPI LungCancers, Secreted. UniProt,
BenignNodules Literature, Detection, Prediction SMD3_HUMAN Small
SNRPD3 Secreted BenignNodules Nucleus. Prediction nuclear
ribonucleo protein SmD3 SMS_HUMAN Somatostatin SST LungCancers
Secreted. UniProt, Literature, Prediction SODM_HUMAN Superoxide
SOD2 Secreted LungCancers, Mitochondrion Literature,- dismutase
BenignNodules, matrix. Detection, [Mn], Symptoms Prediction
mitochondrial SORL_HUMAN Sortilin- SORL1 EPI LungCancers, Membrane;
UniProt, related Symptoms Single-pass Detection receptor type I
membrane protein (Potential). SPB3_HUMAN Serpin B3 SERPINB3
LungCancers, Cytoplasm. Literature, BenignNodules Note = Seems to
Detection also be secreted in plasma by cancerous cells but at a
low level. SPB5_HUMAN Serpin B5 SERPINB5 LungCancers Secreted,
UniProt, extracellular Detection space. SPON2_HUMAN Spondin-2 SPON2
LungCancers, Secreted, UniProt, BenignNodules extracellular
Prediction space, extracellular matrix (By similarity). SPRC_HUMAN
SPARC SPARC LungCancers, Secreted, UniProt, BenignNodules,
extracellular Literature, Symptoms space, Detection, extracellular
Prediction matrix, basement membrane. Note = In or around the
basement membrane. SRC_HUMAN Proto- SRC ENDO LungCancers,
Literature oncogene BenignNodules, tyrosine- Symptoms protein
kinase Src SSRD_HUMAN Translocon- SSR4 Secreted, Endoplasmic
UniProt, associated ENDO reticulum Prediction protein membrane;
subunit Single-pass delta type I membrane protein. STAT1_HUMAN
Signal STAT1 EPI LungCancers, Cytoplasm. Detection transducer
BenignNodules Nucleus. and Note = Translocated activator of into
the transcription nucleus in 1- response to alpha/beta IFN-gamma-
induced tyrosine phosphorylation and dimerization. STAT3_HUMAN
Signal STAT3 ENDO LungCancers, Cytoplasm. Prediction transducer
BenignNodules, Nucleus. and Symptoms Note = Shuttles activator of
between the transcription 3 nucleus and the cytoplasm. Constitutive
nuclear presence is independent of tyrosine phosphorylation.
STC1_HUMAN Stanniocalcin-1 STC1 LungCancers, Secreted. UniProt,
Symptoms Prediction STT3A_HUMAN Dolichyl- STT3A EPI Symptoms
Endoplasmic Literature diphosphooligosaccharide-- reticulum protein
membrane; glycosyltransferase Multi-pass subunit membrane STT3A
protein. TAGL_HUMAN Transgelin TAGLN EPI LungCancers Cytoplasm
Literature, (Probable). Prediction TARA_HUMAN TRIO and TRIOBP ENDO
Nucleus. Detection, F-actin- Cytoplasm, Prediction binding
cytoskeleton. protein Note = Localized to F-actin in a periodic
pattern. TBA1B_HUMAN Tubulin TUBA1B EPI LungCancers Detection
alpha-1B chain TBB2A_HUMAN Tubulin TUBB2A EPI LungCancers,
Detection, beta-2A BenignNodules Prediction chain TBB3_HUMAN
Tubulin TUBB3 EPI LungCancers, Detection beta-3 BenignNodules
chain
TBB5_HUMAN Tubulin TUBB EPI LungCancers, Detection beta chain
BenignNodules TCPA_HUMAN T-complex TCP1 EPI Cytoplasm. Prediction
protein 1 subunit alpha TCPD_HUMAN T-complex CCT4 EPI Cytoplasm.
Detection, protein 1 Melanosome. Prediction subunit Note =
Identified delta by mass spectrometry in melanosome fractions from
stage I to stage IV. TCPQ_HUMAN T-complex CCT8 Secreted, Cytoplasm.
Prediction protein 1 EPI subunit theta TCPZ_HUMAN T-complex CCT6A
Secreted, Cytoplasm. Detection protein 1 EPI subunit zeta
TDRD3_HUMAN Tudor TDRD3 ENDO Cytoplasm. Prediction domain- Nucleus.
containing Note = Predominantly protein 3 cytoplasmic. Associated
with actively translating polyribosomes and with mRNA stress
granules. TENA_HUMAN Tenascin TNC ENDO LungCancers, Secreted,
UniProt, BenignNodules, extracellular Literature, Symptoms space,
Detection extracellular matrix. TENX_HUMAN Tenascin-X TNXB ENDO
LungCancers, Secreted, UniProt, Symptoms extracellular Detection,
space, Prediction extracellular matrix. TERA_HUMAN Transitional VCP
EPI LungCancers, Cytoplasm, Detection endoplasmic BenignNodules
cytosol. reticulum Nucleus. ATPase Note = Present in the neuronal
hyaline inclusion bodies specifically found in motor neurons from
amyotrophic lateral sclerosis patients. Present in the Lewy bodies
specifically found in neurons from Parkinson disease patients.
TETN_HUMAN Tetranectin CLEC3B LungCancers Secreted. UniProt,
Literature, Detection, Prediction TF_HUMAN Tissue F3 LungCancers,
Membrane; UniProt, factor BenignNodules, Single-pass Literature
Symptoms type I membrane protein. TFR1_HUMAN Transferrin TFRC
Secreted, LungCancers, Cell membrane; UniProt, receptor EPI, ENDO
BenignNodules, Single-pass Literature, protein 1 Symptoms type II
Detection membrane protein. Melanosome. Note = Identified by mass
spectrometry in melanosome fractions from stage I to stage
IV.|Transferrin receptor protein 1, serum form: Secreted.
TGFA_HUMAN Protransforming TGFA LungCancers, Transforming UniProt,
growth BenignNodules growth factor Literature factor alpha alpha:
Secreted, extracellular space.|Protransforming growth factor alpha:
Cell membrane; Single-pass type I membrane protein. THAS_HUMAN
Thromboxane-A TBXAS1 EPI, ENDO LungCancers, Membrane; Prediction
synthase BenignNodules, Multi-pass Symptoms membrane protein.
THY1_HUMAN Thy-1 THY1 EPI Symptoms Cell membrane; Detection,
membrane Lipid-anchor, Prediction glycoprotein GPI-anchor (By
similarity). TIMP1_HUMAN Metalloproteinase TIMP1 LungCancers,
Secreted. UniProt, inhibitor 1 BenignNodules, Literature, Symptoms
Detection, Prediction TIMP3_HUMAN Metalloproteinase TIMP3
LungCancers, Secreted, UniProt, inhibitor 3 BenignNodules
extracellular Literature, space, Prediction extracellular matrix.
TLL1_HUMAN Tolloid- TLL1 ENDO Secreted UniProt, like protein 1
(Probable). Prediction TNF12_HUMAN Tumor TNFSF12 LungCancers, Cell
membrane; UniProt necrosis BenignNodules Single-pass factor type II
ligand membrane superfamily protein.|Tumor member necrosis factor
12 ligand superfamily member 12, secreted form: Secreted.
TNR6_HUMAN Tumor FAS LungCancers, Isoform 1: Cell UniProt, necrosis
BenignNodules, membrane; Literature, factor Symptoms Single-pass
Prediction receptor type I superfamily membrane member 6
protein.|Isoform 2: Secreted.|Isoform 3: Secreted.|Isoform 4:
Secreted.|Isoform 5: Secreted.|Isoform 6: Secreted. TPIS_HUMAN
Triosephosphate TPI1 Secreted, Symptoms Literature, isomerase EPI
Detection, Prediction TRFL_HUMAN Lactotransferrin LTF Secreted,
LungCancers, Secreted. UniProt, EPI, ENDO BenignNodules,
Literature, Symptoms Detection, Prediction TSP1_HUMAN
Thrombospondin-1 THBS1 LungCancers, Literature, BenignNodules,
Detection, Symptoms Prediction TTHY_HUMAN Transthyretin TTR
LungCancers, Secreted. UniProt, BenignNodules Cytoplasm.
Literature, Detection, Prediction TYPH_HUMAN Thymidine TYMP EPI
LungCancers, Literature, phosphorylase BenignNodules, Detection,
Symptoms Prediction UGGG1_HUMAN UDP- UGGT1 Secreted, Endoplasmic
Detection, glucose:glycoprotein ENDO reticulum Prediction
glucosyltransferase 1 lumen. Endoplasmic reticulum-Golgi
intermediate compartment. UGGG2_HUMAN UDP- UGGT2 ENDO Endoplasmic
Prediction glucose:glycoprotein reticulum glucosyltransferase 2
lumen. Endoplasmic reticulum-Golgi intermediate compartment.
UGPA_HUMAN UTP-- UGP2 EPI Symptoms Cytoplasm. Detection glucose-1-
phosphate uridylyltransferase UPAR_HUMAN Urokinase PLAUR
LungCancers, Isoform 1: Cell UniProt, plasminogen BenignNodules,
membrane; Literature, activator Symptoms Lipid-anchor, Prediction
surface GPI- receptor anchor.|Isoform 2: Secreted (Probable).
UTER_HUMAN Uteroglobin SCGB1A1 LungCancers, Secreted. UniProt,
BenignNodules, Literature, Symptoms Detection, Prediction
VA0D1_HUMAN V-type ATP6V0D1 EPI Prediction proton ATPase subunit d
1 VAV3_HUMAN Guanine VAV3 ENDO Prediction nucleotide exchange
factor VAV3 VEGFA_HUMAN Vascular VEGFA LungCancers, Secreted.
UniProt, endothelial BenignNodules, Note = VEGF121 Literature,
growth Symptoms is acidic and Prediction factor A freely secreted.
VEGF165 is more basic, has heparin-binding properties and, although
a signicant proportion remains cell- associated, most is freely
secreted. VEGF189 is very basic, it is cell-associated after
secretion and is bound avidly by heparin and the extracellular
matrix, although it may be released as a soluble form by heparin,
heparinase or plasmin. VEGFC_HUMAN Vascular VEGFC LungCancers,
Secreted. UniProt, endothelial BenignNodules Literature, growth
Prediction factor C VEGFD_HUMAN Vascular FIGF LungCancers Secreted.
UniProt, endothelial Literature, growth Prediction factor D
VGFR1_HUMAN Vascular FLT1 LungCancers, Isoform Flt1: UniProt,
endothelial BenignNodules, Cell membrane; Literature, growth
Symptoms Single-pass Detection, factor type I Prediction receptor 1
membrane protein.|Isoform sFlt1: Secreted. VTNC_HUMAN Vitronectin
VTN ENDO Symptoms Secreted, UniProt, extracellular Literature,
space. Detection,
Prediction VWC2_HUMAN Brorin VWC2 LungCancers Secreted, UniProt,
extracellular Prediction space, extracellular matrix, basement
membrane (By similarity). WNT3A_HUMAN Protein WNT3A LungCancers,
Secreted, UniProt, Wnt-3a Symptoms extracellular Prediction space,
extracellular matrix. WT1_HUMAN Wilms WT1 LungCancers, Nucleus.
Literature, tumor BenignNodules, Cytoplasm (By Prediction protein
Symptoms similarity). Note = Shuttles between nucleus and cytoplasm
(By similarity).|Isoform 1: Nucleus speckle.|Isoform 4: Nucleus,
nucleoplasm. ZA2G_HUMAN Zinc-alpha- AZGP1 LungCancers, Secreted.
UniProt, 2- Symptoms Literature, glycoprotein Detection, Prediction
ZG16B_HUMAN Zymogen ZG16B LungCancers Secreted UniProt, granule
(Potential). Prediction protein 16 homolog B
SRM Assay
SRM assays for 388 targeted proteins were developed based on
synthetic peptides, using a protocol similar to those described in
the literature (Lange, Picotti et al. 2008, Picotti, Rinner et al.
2010, Huttenhain, Soste et al. 2012). Up to five SRM suitable
peptides per protein were identified from public sources such as
the PeptideAtlas, Human Plasma Proteome Database or by proteotypic
prediction tools (Mallick, Schirle et al. 2007) and synthesized.
SRM triggered MS/MS spectra were collected on an ABSciex 5500 QTrap
for both doubly and triply charged precursor ions. The obtained
MS/MS spectra were assigned to individual peptides using MASCOT
(cutoff score .gtoreq.15) (Perkins, Pappin et al. 1999). Up to four
transitions per precursor ion were selected for optimization. The
resulting corresponding optimal retention time, declustering
potential and collision energy were assembled for all transitions.
Optimal transitions were measured on a mixture of all synthetic
peptides, a pooled sample of benign patients and a pooled sample of
cancer patients. Transitions were analyzed in batches, each
containing up to 1750 transitions. Both biological samples were
immuno-depleted and digested by trypsin. All three samples were
analyzed on an ABSciex 5500 QTrap coupled with a reversed-phase
(RP) high-performance liquid chromatography (HPLC) system. The
obtained SRM data were manually reviewed to select the two best
peptides per protein and the two best transitions per peptide.
Transitions having interference with other transitions were not
selected. Ratios between intensities of the two best transitions of
peptides in the synthetic peptide mixture were also used to assess
the specificity of the transitions in the biological samples. The
intensity ratio was considered as an important metric defining the
SRM assays. The complete transition table is shown below in Table
2.
TABLE-US-00002 Lengthy table referenced here
US09091651-20150728-T00001 Please refer to the end of the
specification for access instructions.
Exemplary Protein Detection
The following 164 proteins and their peptides were detected
simultaneously in a large-scale experiment of 158 samples using the
MS-LC-SRM-MS system described herein.
TABLE-US-00003 TABLE 3 SEQ ID Protein Peptide Protein Peptide NO:
Detection Detection 1433E_HUMAN EDLVYQAK 7 16 16 1433E_HUMAN
IISSIEQK 9 16 0 1433T_HUMAN AVTEQGAELSNEER 16 127 0 1433T_HUMAN
TAFDEAIAELDTLNEDSYK 19 127 127 1433Z_HUMAN FLIPNASQAESK 21 157 157
1433Z_HUMAN SVTEQGAELSNEER 23 157 0 6PGD_HUMAN AGQAVDDFIEK 25 90 0
6PGD_HUMAN LVPLLDTGDIIIDGGNSEYR 27 90 90 A1AG1_HUMAN WFYIASAFR 32
157 0 A1AG1_HUMAN YVGGQEHFAHLLILR 33 157 157 ABCD1_HUMAN
DAGIALLSITHRPSLWK 34 9 0 ABCD1_HUMAN GLQAPAGEPTQEASGVAAAK 36 9 0
ABCD1_HUMAN NLLTAAADAIER 37 9 9 ADML_HUMAN LAHQIYQFTDK 44 27 27
ADML_HUMAN SPEDSSPDAAR 45 27 0 AIFM1_HUMAN ELWFSDDPNVTK 53 158 158
AIFM1_HUMAN GVIFYLR 54 158 0 ALDOA_HUMAN ADDGRPFPQVIK 57 158 141
ALDOA_HUMAN ALQASALK 58 158 17 AMPN_HUMAN ALEQALEK 62 158 158
AMPN_HUMAN DHSAIPVINR 63 158 0 APOA1_HUMAN AKPALEDLR 78 158 158
APOA1_HUMAN ATEHLSTLSEK 79 158 0 APOE_HUMAN AATVGSLAGQPLQER 82 158
158 APOE_HUMAN LGPLVEQGR 87 158 0 BGH3_HUMAN LTLLAPLNSVFK 139 158 0
BGH3_HUMAN SPYQLVLQHSR 140 158 158 BST1_HUMAN GEGTSAHLR 149 157 0
BST1_HUMAN GFFADYEIPNLQK 150 157 157 C163A_HUMAN INPASLDK 153 158
11 C163A_HUMAN LEVFYNGAWGTVGK 154 158 49 C163A_HUMAN TSYQVYSK 155
158 98 CALU_HUMAN EQFVEFR 172 120 120 CALU_HUMAN TFDQLTPEESK 174
120 0 CATB_HUMAN LPASFDAR 188 62 62 CATB_HUMAN TDQYWEK 190 62 0
CATG_HUMAN NVNPVALPR 192 14 0 CATG_HUMAN SSGVPPEVFTR 193 14 14
CBPB2_HUMAN DTGTYGFLLPER 198 158 158 CBPB2_HUMAN EAFAAVSK 199 158 0
CD14_HUMAN ATVNPSAPR 207 158 0 CD14_HUMAN SWLAELQQVVLKPGLK 214 158
158 CD44_HUMAN FAGVFHVEK 227 158 158 CD44_HUMAN YGFIEGHVVIPR 231
158 0 CD59_HUMAN AGLQVYNK 232 156 156 CD59_HUMAN TVLLLVTPFLAAAWSLHP
233 156 0 CDCP1_HUMAN EEGVFTVTPDTK 239 157 0 CDCP1_HUMAN LSLVLVPAQK
241 157 157 CEAM8_HUMAN LFIPNITTK 256 79 79 CEAM8_HUMAN TLTLLSVTR
257 79 0 CERU_HUMAN GAYPLSIEPIGVR 258 158 0 CERU_HUMAN
GPEEEHLGILGPVIWAEVGDTIR 259 158 158 CERU_HUMAN NNEGTYYSPNYNPQSR 261
158 0 CH10_HUMAN GGEIQPVSVK 265 158 0 CH10_HUMAN VLLPEYGGTK 266 158
158 CLIC1_HUMAN FSAYIK 288 137 8 CLIC1_HUMAN LAALNPESNTAGLDIFAK 290
137 129 CLIC1_HUMAN NSNPALNDNLEK 291 137 0 CLUS_HUMAN ASSIIDELFQDR
293 158 0 CLUS_HUMAN EIQNAVNGVK 294 158 158 CNTN1_HUMAN
AHSDGGDGVVSQVK 303 158 157 CNTN1_HUMAN DGEYVVEVR 304 158 1
CO6A3_HUMAN IGDLHPQIVNLLK 319 158 0 CO6A3_HUMAN VAVVQYSDR 321 158
158 CO6A3_HUMAN WYYDPNTK 322 158 0 COF1_HUMAN EILVGDVGQTVDDPYATFVK
328 127 0 COF1_HUMAN LGGSAVISLEGKPL 329 127 0 COF1_HUMAN
YALYDATYETK 330 127 127 COIA1_HUMAN AVGLAGTFR 332 158 37
COIA1_HUMAN TEAPSATGQASSLLGGR 335 158 121 CRP_HUMAN APLTKPLK 341
153 21 CRP_HUMAN ESDTSYVSLK 342 153 132 CRP_HUMAN YEVQGEVFTKPQLWP
343 153 0 CSF1_HUMAN FNSVPLTDTGHER 351 134 113 CSF1_HUMAN
ISSLRPQGLSNPSTLSAQPQLSR 352 134 21 CYTB_HUMAN SQLEEK 372 100 0
CYTB_HUMAN SQVVAGTNYFIK 373 100 100 DESP_HUMAN YGDGIQLTR 384 131
131 DMKN_HUMAN QVPGFGVADALGNR 395 128 0 DMKN_HUMAN VSEALGQGTR 397
128 128 DSG2_HUMAN GQIIGNFQAFDEDTGLPAHAR 404 158 1 DSG2_HUMAN
ILDVNDNIPWENK 405 158 157 EF1A1_HUMAN IGGIGTVPVGR 423 158 158
EF1A1_HUMAN QTVAVGVIK 426 158 0 EF2_HUMAN FSVSPVVR 439 125 125
EF2_HUMAN GVQYLNEIK 441 125 0 ENOA_HUMAN AVEHINK 452 156 0
ENOA_HUMAN YISPDQLADLYK 455 156 156 ENOA_HUMAN YNQLLR 456 156 0
ENPL_HUMAN SGTSEFLNK 469 158 1 ENPL_HUMAN SGYLLPDTK 470 158 157
EPHB6_HUMAN RPHFDQLVAAFDK 472 157 0 EPHB6_HUMAN WAAPEVIAHGK 476 157
157 ERBB3_HUMAN GESIEPLDPSEK 483 105 0 ERBB3_HUMAN LAEVPDLLEK 484
105 105 EREG_HUMAN VAQVSITK 487 115 115 EREG_HUMAN VTSGDPELPQV 488
115 0 ERO1A_HUMAN AVLQWTK 489 121 0 ERO1A_HUMAN LLESDYFR 491 121 0
ERO1A_HUMAN NLLQNIH 492 121 0 ERO1A_HUMAN VLPFFERPDFQLFTGNK 493 121
121 F10A1_HUMAN AIDLFTDAIK 501 35 0 F10A1_HUMAN LQKPNAAIR 503 35 35
FAM3C_HUMAN GINVALANGK 505 97 88 FAM3C_HUMAN SALDTAAR 507 97 9
FAM3C_HUMAN TGEVLDTK 509 97 0 FCGR1_HUMAN HLEEELK 517 39 0
FCGR1_HUMAN VFTEGEPLALR 519 39 39 FIBA_HUMAN GGSTSYGTGSETESPR 554
147 108 FIBA_HUMAN NSLFEYQK 556 147 39 FINC_HUMAN SYTITGLQPGTDYK
561 154 135 FINC_HUMAN VPGTSTSATLTGLTR 562 154 19 FKB11_HUMAN
ANYWLK 565 23 0 FKB11_HUMAN DPLVIELGQK 566 23 23 FOLH1_HUMAN
GVILYSDPADYFAPGVK 569 138 0 FOLH1_HUMAN LGSGNDFEVFFQR 570 138 138
FRIL_HUMAN DDVALEGVSHFFR 594 151 0 FRIL_HUMAN LGGPEAGLGEYLFER 596
151 151 G3P_HUMAN GALQNIIPASTGAAK 599 150 149 G3P_HUMAN
LISWYDNEFGYSNR 600 150 1 G6PD_HUMAN DGLLPENTFIVGYAR 603 43 43
G6PD_HUMAN GGYFDEFGIIR 604 43 0 G6PI_HUMAN AVLHVALR 608 39 6
G6PI_HUMAN TLAQLNPESSLFIIASK 610 39 33 GDIR2_HUMAN DIVSGLK 629 158
158 GDIR2_HUMAN LNYKPPPQK 630 158 0 GELS_HUMAN
AQPVQVAEGSEPDGFWEALGGK 634 158 0 GELS_HUMAN TASDFITK 637 158 158
GGH_HUMAN NLDGISHAPNAVK 640 158 158 GGH_HUMAN YYIAASYVK 643 158 0
GRP78_HUMAN TWNDPSVQQDIK 664 158 90 GRP78_HUMAN VYEGERPLTK 665 158
68 GSLG1_HUMAN IIIQESALDYR 666 158 158 GSLG1_HUMAN LDPALQDK 667 158
0 GSLG1_HUMAN LIAQDYK 668 158 0 GSLG1_HUMAN NDINILK 669 158 0
GSTP1_HUMAN ALPGQLKPFETLLSQNQGGK 672 123 123 GSTP1_HUMAN
YISLIYTNYEAGK 675 123 0 HPSE_HUMAN LPYPFSNK 714 49 0 HPSE_HUMAN
SVQLNGLTLK 715 49 49 HPT_HUMAN VGYVSGWGR 719 158 0 HPT_HUMAN
VTSIQDWVQK 720 158 158 HS90A_HUMAN SLTNDWEDHLAVK 724 32 32
HS90B_HUMAN ADHGEPIGR 726 121 0 HS90B_HUMAN IDIIPNPQER 728 121 121
HS90B_HUMAN NPDDITQEEYGEFYK 730 121 0 HSPB1_HUMAN DEVVEITGK 732 30
0 HSPB1_HUMAN GPSWDPFR 733 30 30 HTRA1_HUMAN LHRPPVIVLQR 741 40 40
HTRA1_HUMAN LPVLLLGR 742 40 0 HTRA1_HUMAN VTAGISFAIPSDK 744 40 0
HXK1_HUMAN FLLSESGSGK 747 117 17 HXK1_HUMAN LVDEYSLNAGK 749 117 47
HXK1_HUMAN SANLVAATLGAILNR 750 117 53 HYOU1_HUMAN FPEHELTFDPQR 757
156 0 HYOU1_HUMAN LPATEKPVLLSK 760 156 156 IBP2_HUMAN AEVLFR 762
158 0 IBP2_HUMAN ELAVFR 763 158 158 IBP2_HUMAN LIQGAPTIR 765 158 0
IBP3_HUMAN FHPLHSK 768 158 0 IBP3_HUMAN FLNVLSPR 769 158 0
IBP3_HUMAN YGQPLPGYTTK 771 158 158 ICAM1_HUMAN ASVSVTAEDEGTQR 772
114 0 ICAM1_HUMAN VELAPLPSWQPVGK 776 114 114 ICAM3_HUMAN IALETSLSK
780 158 0 ICAM3_HUMAN TFVLPVTPPR 783 158 158 IF4A1_HUMAN
GYDVIAQAQSGTGK 792 58 0 IF4A1_HUMAN VLITTDLLAR 796 58 58 IGF1_HUMAN
EGTEASLQIR 797 40 0 IGF1_HUMAN ISSLPTQLFK 798 40 40 IL18_HUMAN
SDIIFFQR 807 45 45 IL18_HUMAN SVPGHDNK 808 45 0 ILEU_HUMAN
EATTNAPFR 824 88 13 ILEU_HUMAN TYNFLPEFLVSTQK 828 88 75 ILK_HUMAN
HSGIDFK 830 90 15 ILK_HUMAN QLNFLTK 832 90 75 ILK_HUMAN WQGNDIVVK
833 90 0 INHBA_HUMAN AEVWLFLK 834 32 0 INHBA_HUMAN EGSDLSVVER 835
32 32 ISLR_HUMAN ALPGTPVASSQPR 839 158 0 ISLR_HUMAN
EVPLLQSLWLAHNEIR 840 158 0 ISLR_HUMAN LPGLPEGAFR 841 158 158
ITA5_HUMAN SLQWFGATVR 846 114 114 ITA5_HUMAN SSASSGPQILK 847 114 0
K1C18_HUMAN LASYLDR 861 72 0 K1C18_HUMAN LQLETEIEALK 862 72 72
K1C18_HUMAN VVSETNDTK 863 72 0 K1C19_HUMAN FGAQLAHIQALISGIEAQLGDVR
865 158 158 K1C19_HUMAN FGPGVAFR 866 158 0 KIT_HUMAN QATLTISSAR 876
158 158 KIT_HUMAN YVSELHLTR 878 158 0 KLK14_HUMAN VLGSGTWPSAPK 889
27 27 KLK14_HUMAN VSGWGTISSPIAR 890 27 0 KPYM_HUMAN APIIAVTR 899
158 13 KPYM_HUMAN LDIDSPPITAR 903 158 145 LAMB2_HUMAN IQGTLQPHAR
910 69 0 LAMB2_HUMAN SLADVDAILAR 911 69 31 LAMB2_HUMAN
VLELSIPASAEQIQHLAGAIAER 913 69 38 LDHA_HUMAN FIIPNVVK 915 157 0
LDHA_HUMAN LVIITAGAR 917 157 157 LDHB_HUMAN FIIPQIVK 920 158 157
LDHB_HUMAN GLTSVINQK 921 158 1 LEG1_HUMAN GEVAPDAK 925 146 0
LEG1_HUMAN LPDGYEFK 926 146 0 LEG1_HUMAN SFVLNLGK 927 146 146
LG3BP_HUMAN ASHEEVEGLVEK 938 158 158 LG3BP_HUMAN VEIFYR 941 158 0
LG3BP_HUMAN YSSDYFQAPSDYR 942 158 0 LRP1_HUMAN TVLWPNGLSLDIPAGR 959
158 158 LRP1_HUMAN VFFTDYGQIPK 960 158 0 LUM_HUMAN
NIPTVNENLENYYLEVNQLEK 962 158 158 LUM_HUMAN SLEDLQLTHNK 964 158 0
LYOX_HUMAN HWFQAGYSTSR 975 121 0 LYOX_HUMAN TPILLIR 977 121 121
MASP1_HUMAN APGELEHGLITFSTR 991 158 151 MASP1_HUMAN TGVITSPDFPNPYPK
994 158 7 MDHC_HUMAN LGVTANDVK 997 130 130 MDHC_HUMAN
VLVTGAAGQIAYSLLYSIGNGSVFGK 999 130 0 MDHM_HUMAN VDFPQDQLTALTGR 1002
158 158 MDHM_HUMAN VSSFEEK 1004 158 0 MMP12_HUMAN
FLLILLLQATASGALPLNSSTSLEK 1021 158 158 MMP12_HUMAN GIQSLYGDPK 1022
158 0 MMP12_HUMAN IDAVFYSK 1023 158 0 MMP2_HUMAN AFQVWSDVTPLR 1031
153 152 MMP2_HUMAN IIGYTPDLDPETVDDAFAR 1033 153 1 MMP7_HUMAN
LSQDDIK 1042 102 102 MMP7_HUMAN NANSLEAK 1043 102 0 MMP9_HUMAN
AFALWSAVTPLTFTR 1044 158 50 MMP9_HUMAN FQTFEGDLK 1046 158 108
MMP9_HUMAN SLGPALLLLQK 1048 158 0 MPRI_HUMAN GHQAFDVGQPR 1055 158
23 MPRI_HUMAN TYHSVGDSVLR 1056 158 4 MPRI_HUMAN VPIDGPPIDIGR 1057
158 131 NCF4_HUMAN AEALFDFTGNSK 1095 138 43 NCF4_HUMAN DAEGDLVR
1096 138 0 NCF4_HUMAN DIAVEEDLSSTPLLK 1097 138 0 NCF4_HUMAN
GATGIFPLSFVK 1098 138 95 NDKB_HUMAN DRPFFPGLVK 1105 24 0 NDKB_HUMAN
NIIHGSDSVK 1107 24 24 NRP1_HUMAN FVSDYETHGAGFSIR 1149 158 0
NRP1_HUMAN FVTAVGTQGAISK 1150 158 158 NRP1_HUMAN SFEGNNNYDTPELR
1152 158 0 OSTP_HUMAN AIPVAQDLNAPSDWDSR 1156 108 108 OSTP_HUMAN
DSYETSQLDDQSAETHSHK 1157 108 0
OSTP_HUMAN YPDAVATWLNPDPSQK 1160 108 0 PCBP2_HUMAN IANPVEGSTDR 1189
52 0 PCBP2_HUMAN IITLAGPTNAIFK 1190 52 52 PCYOX_HUMAN
IAIIGAGIGGTSAAYYLR 1207 37 0 PCYOX_HUMAN IFSQETLTK 1208 37 37
PCYOX_HUMAN TLLETLQK 1209 37 0 PDGFB_HUMAN SFDDLQR 1216 111 99
PDGFB_HUMAN SHSGGELESLAR 1217 111 12 PDIA3_HUMAN ELSDFISYLQR 1225
129 129 PDIA3_HUMAN SEPIPESNDGPVK 1227 129 0 PDIA4_HUMAN FDVSGYPTIK
1231 81 81 PDIA4_HUMAN FHHTFSTEIAK 1232 81 0 PECA1_HUMAN
SELVTVTESFSTPK 1241 77 0 PECA1_HUMAN STESYFIPEVR 1242 77 77
PEDF_HUMAN LQSLFDSPDFSK 1246 158 0 PEDF_HUMAN TVQAVLTVPK 1248 158
158 PGAM1_HUMAN HGESAWNLENR 1259 14 14 PLIN2_HUMAN DAVTTTVTGAK 1264
138 0 PLIN2_HUMAN EVSDSLLTSSK 1265 138 138 PLSL_HUMAN IGNFSTDIK
1284 158 0 PLSL_HUMAN ISFDEFIK 1285 158 158 PLXB3_HUMAN
ELPVPIYVTQGEAQR 1294 77 0 PLXB3_HUMAN GPVDAVTGK 1296 77 77
PLXC1_HUMAN FWVNILK 1299 158 0 PLXC1_HUMAN LNTIGHYEISNGSTIK 1300
158 158 POSTN_HUMAN GFEPGVTNILK 1302 158 158 POSTN_HUMAN
IIDGVPVEITEK 1303 158 0 POSTN_HUMAN IIHGNQIATNGVVHVIDR 1304 158 0
PPIB_HUMAN VIFGLFGK 1319 158 0 PPIB_HUMAN VYFDLR 1320 158 158
PRDX1_HUMAN IGHPAPNFK 1325 158 116 PRDX1_HUMAN QITVNDLPVGR 1328 158
42 PROF1_HUMAN STGGAPTFNVTVTK 1338 158 157 PROF1_HUMAN
TFVNITPAEVGVLVGK 1339 158 1 PRS6A_HUMAN VDILDPALLR 1349 13 13
PTGIS_HUMAN DPEIYTDPEVFK 1352 158 0 PTGIS_HUMAN LLLFPFLSPQR 1357
158 158 PTPA_HUMAN FGSLLPIHPVTSG 1361 103 103 PTPA_HUMAN
TGPFAEHSNQLWNISAVPSWSK 1363 103 0 PTPA_HUMAN VDDQIAIVFK 1364 103 0
PTPA_HUMAN WIDETPPVDQPSR 1365 103 0 PTPRJ_HUMAN AVSISPTNVILTWK 1372
158 0 PTPRJ_HUMAN VITEPIPVSDLR 1374 158 158 PVR_HUMAN SVDIWLR 1379
158 158 PVR_HUMAN VLAKPQNTAEVQK 1380 158 0 RAB32_HUMAN
VHLPNGSPIPAVLLANK 1384 22 0 RAB32_HUMAN VLVIGELGVGK 1385 22 22
RAN_HUMAN FNVWDTAGQEK 1391 116 2 RAN_HUMAN LVLVGDGGTGK 1392 116 114
RAN_HUMAN NVPNWHR 1393 116 0 RAP2B_HUMAN EVSYGEGK 1395 145 0
RAP2B_HUMAN VDLEGER 1397 145 145 S10A1_HUMAN DVDAVDK 1408 128 128
S10A1_HUMAN ELLQTELSGFLDAQK 1409 128 0 S10A6_HUMAN ELTIGSK 1411 154
154 S10A6_HUMAN LQDAEIAR 1412 154 0 SAA_HUMAN EANYIGSDK 1414 143 0
SAA_HUMAN SFFSFLGEAFDGAR 1416 143 143 SCF_HUMAN LFTPEEFFR 1418 143
143 SCF_HUMAN LVANLPK 1419 143 0 SEM3G_HUMAN DYPDEVLQ FAR 1426 155
0 SEM3G_HUMAN LFLGGLDALYSLR 1428 155 155 SIAL_HUMAN AYEDEYSYFK 1449
19 19 SIAL_HUMAN TTSPPFGK 1452 19 0 SODM_HUMAN GDVTAQIALQPALK 1460
154 151 SODM_HUMAN NVRPDYLK 1462 154 3 SPON2_HUMAN WSQTAFPK 1478 63
0 SPON2_HUMAN YSITFTGK 1479 63 63 STAT1_HUMAN TELISVSEVHPSR 1494 38
29 STAT1_HUMAN YTYEHDPITK 1496 38 9 TBA1B_HUMAN AVFVDLEPTVIDEVR
1519 119 119 TBA1B_HUMAN EIIDLVLDR 1520 119 0 TBB3_HUMAN
ISVYYNEASSHK 1533 158 158 TBB3_HUMAN YLTVATVFR 1535 158 0
TCPA_HUMAN IHPTSVISGYR 1540 158 4 TCPA_HUMAN SSLGPVGLDK 1542 158
154 TCPQ_HUMAN DIDEVSSLLR 1550 48 0 TCPQ_HUMAN NVGLDIEAEVPAVK 1553
48 48 TCPZ_HUMAN GIDPFSLDALSK 1557 6 6 TCPZ_HUMAN GLVLDHGAR 1558 6
0 TENA_HUMAN GLEPGQEYNVLLTAEK 1570 140 140 TENA_HUMAN
TVSGNTVEYALTDLEPATEYTLR 1572 140 0 TENX_HUMAN DAQGQPQAVPVSGDLR 1574
158 158 TENX_HUMAN YEVTVVSVR 1578 158 0 TERA_HUMAN GILLYGPPGTGK
1579 106 94 TERA_HUMAN LDQLIYIPLPDEK 1582 106 12 TETN_HUMAN
GGTLSTPQTGSENDALYEYLR 1588 158 118 TETN_HUMAN LDTLAQEVALLK 1589 158
40 TFR1_HUMAN LTVSNVLK 1598 157 0 TFR1_HUMAN SSGLPNIPVQTISR 1600
157 157 TIMP1_HUMAN GFQALGDAADIR 1610 151 151 TIMP1_HUMAN SEEFLIAGK
1611 151 0 TNF12_HUMAN AAPFLTYFGLFQVH 1621 156 156 TNF12_HUMAN
INSSSPLR 1622 156 0 TPIS_HUMAN VVFEQTK 1634 157 157 TPIS_HUMAN
VVLAYEPVWAIGTGK 1635 157 0 TRFL_HUMAN FQLFGSPSGQK 1637 48 22
TRFL_HUMAN LRPVAAEVYGTER 1638 48 4 TRFL_HUMAN VPSHAVVAR 1639 48 5
TRFL_HUMAN YYGYTGAFR 1640 48 17 TSP1_HUMAN GFLLLASLR 1644 158 6
TSP1_HUMAN GTSQNDPNWVVR 1645 158 152 TTHY_HUMAN
TSESGELHGLTTEEEFVEGIYK 1646 27 27 TTHY_HUMAN VEIDTK 1647 27 0
TYPH_HUMAN ALQEALVLSDR 1648 59 0 TYPH_HUMAN TLVGVGASLGLR 1651 59 59
UGGG1_HUMAN DLSQNFPTK 1653 58 58 UGGG1_HUMAN FTILDSQGK 1654 58 0
UGPA_HUMAN LVEIAQVPK 1669 97 97 UGPA_HUMAN NENTFLDLTVQQIEHLNK 1670
97 0 VA0D1_HUMAN LLFEGAGSNPGDK 1679 13 13 VA0D1_HUMAN NVADYYPEYK
1681 13 0 VEGFC_HUMAN DLEEQLR 1689 21 21 VEGFC_HUMAN
EAPAAAAAFESGLDLSDAEPDAGEA 1690 21 0 TAYASK VEGFC_HUMAN FAAAHYNTEILK
1692 21 0 VEGFC_HUMAN NQPLNPGK 1693 21 0 VTNC_HUMAN AVRPGYPK 1705
145 0 VTNC_HUMAN DVWGIEGPIDAAFTR 1707 145 145 ZA2G_HUMAN
EIPAWVPFDPAAQITK 1724 158 158 ZA2G_HUMAN WEAEPVYVQR 1725 158 0
Exemplary Biomarker Protein
The following 36 proteins were identified as biomarker candidates
in a large-scale experiment of 72 lung cancer samples and 71 benign
lung nodule samples using the MS-LC-SRM-MS system described
herein.
TABLE-US-00004 TABLE 4 Coefficient Coefficient (Discovery) (Final)
Predicted Protein Official Gene Cooperative Partial Coefficient SEQ
ID alpha = alpha = Tissue Concentration Category (UniProt) Name
Score AUC CV Transition NO: 36.16 26.25 Candidate - (ng/ml)
Classifier TSP1_HUMAN THBS1 1.8 0.25 0.24 GFLLLASLR_495.31_559.40
1644 0.5- 3 0.44 510 Classifier COIA1_HUMAN COL18A1 3.7 0.16 0.25
AVGLAGTFR_446.26_721.40 332 -- 1.56 -0.91 35 Classifier ISLR_HUMAN
ISLR 1.4 0.32 0.25 ALPGTPVASSQPR_640.85_841.50 839 1- .40 0.83 --
Classifier TETN_HUMAN CLEC3B 2.5 0.26 0.26
LDTLAQEVALLK_657.39_330.20 1589- -1.79 -1.02 58000 Classifier
FRIL_HUMAN FTL 2.8 0.31 0.26 LGGPEAGLGEYLFER_804.40_913.40 596 -
0.39 0.17 Secreted, 12 Epi, Endo Classifier GRP78_HUMAN HSPA5 1.4
0.27 0.27 TWNDPSVQQDIK_715.85_260.20 664 - 1.41 0.55 Secreted, 100
Epi, Endo Classifier ALDOA_HUMAN ALDOA 1.3 0.26 0.28
ALQASALK_401.25_617.40 58 -0.80- -0.26 Secreted, 250 Epi Classifier
BGH3_HUMAN TGFBI 1.8 0.21 0.28 LTLLAPLNSVFK_658.40_804.50 139 1-
.73 0.54 Epi 140 Classifier LG3BP_HUMAN LGALS3BP 4.3 0.29 0.29
VEIFYR_413.73_598.30 941 -0.- 58 -0.21 Secreted 440 Classifier
LRP1_HUMAN LRP1 4.0 0.13 0.32 TVLWPNGLSLDIPAGR_855.00_400.20 95- 9
-1.59 -0.83 Epi 20 Classifier FIBA_HUMAN FGA 1.1 0.31 0.35
NSLFEYQK_514.76_714.30 556 0.31 0.- 13 130000 Classifier
PRDX1_HUMAN PRDX1 1.5 0.32 0.37 QITVNDLPVGR_606.30_428.30 1328 -
-0.34 -0.26 Epi 60 Classifier GSLG1_HUMAN GLG1 1.2 0.34 0.45
IIIQESALDYR_660.86_338.20 666 -0- .70 -0.44 Epi, -- Endo Robust
KIT_HUMAN KIT 1.4 0.33 0.46 8.2 Robust CD14_HUMAN CD14 4.0 0.33
0.48 Epi 420 Robust EF1A1_HUMAN EEF1A1 1.2 0.32 0.56 Secreted, 61
Epi Robust TENX_HUMAN TNXB 1.1 0.30 0.56 Endo 70 Robust AIFM1_HUMAN
AIFM1 1.4 0.32 0.70 Epi, 1.4 Endo Robust GGH_HUMAN GGH 1.3 0.32
0.81 250 Robust IBP3_HUMAN IGFBP3 3.4 0.32 1.82 5700 Robust
ENPL_HUMAN HSP90B1 1.1 0.29 5.90 Secreted, 88 Epi, Endo Non-Robust
ERO1A_HUMAN ERO1L 6.2 Secreted, -- Epi, Endo Non-Robust 6PGD_HUMAN
PGD 4.3 Epi, 29 Endo Non-Robust ICAM1_HUMAN ICAM1 3.9 71 Non-Robust
PTPA_HUMAN PPP2R4 2.1 Endo 3.3 Non-Robust NCF4_HUMAN NCF4 2.0 Endo
-- Non-Robust SEM3G_HUMAN SEMA3G 1.9 -- Non-Robust 1433T_HUMAN
YWHAQ 1.5 Epi 180 Non-Robust RAP2B_HUMAN RAP2B 1.5 Epi --
Non-Robust MMP9_HUMAN MMP9 1.4 28 Non-Robust FOLH1_HUMAN FOLH1 1.3
-- Non-Robust GSTP1_HUMAN GSTP1 1.3 Endo 32 Non-Robust EF2_HUMAN
EEF2 1.3 Secreted, 30 Epi Non-Robust RAN_HUMAN RAN 1.2 Secreted,
4.6 Epi Non-Robust SODM_HUMAN SOD2 1.2 Secreted 7.1 Non-Robust
DSG2_HUMAN DSG2 1.1 Endo 2.7
TABLE-US-LTS-00001 LENGTHY TABLES The patent contains a lengthy
table section. A copy of the table is available in electronic form
from the USPTO web site
(http://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US09091651B2).
An electronic copy of the table will also be available from the
USPTO upon request and payment of the fee set forth in 37 CFR
1.19(b)(3).
SEQUENCE LISTINGS
1
1731114PRTArtificial SequenceSynthetic Polypeptide 1Ala Val Thr Glu
Gln Gly His Glu Leu Ser Asn Glu Glu Arg 1 5 10 222PRTArtificial
SequenceSynthetic Polypeptide 2Asp Asn Leu Thr Leu Trp Thr Ser Glu
Asn Gln Gly Asp Glu Gly Asp 1 5 10 15 Ala Gly Glu Gly Glu Asn 20
36PRTArtificial SequenceSynthetic Polypeptide 3Ser Glu Leu Val Gln
Lys 1 5 419PRTArtificial SequenceSynthetic Polypeptide 4Thr Ala Phe
Asp Glu Ala Ile Ala Glu Leu Asp Thr Leu Asn Glu Glu 1 5 10 15 Ser
Tyr Lys 512PRTArtificial SequenceSynthetic Polypeptide 5Tyr Leu Ile
Pro Asn Ala Thr Gln Pro Glu Ser Lys 1 5 10 619PRTArtificial
SequenceSynthetic Polypeptide 6Ala Ala Phe Asp Asp Ala Ile Ala Glu
Leu Asp Thr Leu Ser Glu Glu 1 5 10 15 Ser Tyr Lys 78PRTArtificial
SequenceSynthetic Polypeptide 7Glu Asp Leu Val Tyr Gln Ala Lys 1 5
812PRTArtificial SequenceSynthetic Polypeptide 8His Leu Ile Pro Ala
Ala Asn Thr Gly Glu Ser Lys 1 5 10 98PRTArtificial
SequenceSynthetic Polypeptide 9Ile Ile Ser Ser Ile Glu Gln Lys 1 5
105PRTArtificial SequenceSynthetic Polypeptide 10Val Phe Tyr Tyr
Lys 1 5 1124PRTArtificial SequenceSynthetic Polypeptide 11Asp Asn
Leu Thr Leu Trp Thr Ala Asp Asn Ala Gly Glu Glu Gly Gly 1 5 10 15
Glu Ala Pro Gln Glu Pro Gln Ser 20 128PRTArtificial
SequenceSynthetic Polypeptide 12Glu Ala Gly Asp Ala Glu Ser Arg 1 5
1326PRTArtificial SequenceSynthetic Polypeptide 13Leu Gly Leu Ala
Leu Asn Phe Ser Val Phe His Tyr Glu Ile Ala Asn 1 5 10 15 Ser Pro
Glu Glu Ala Ile Ser Leu Ala Lys 20 25 149PRTArtificial
SequenceSynthetic Polypeptide 14Ser Asn Glu Glu Gly Ser Glu Glu Lys
1 5 158PRTArtificial SequenceSynthetic Polypeptide 15Val Leu Ser
Ser Ile Glu Gln Lys 1 5 1614PRTArtificial SequenceSynthetic
Polypeptide 16Ala Val Thr Glu Gln Gly Ala Glu Leu Ser Asn Glu Glu
Arg 1 5 10 179PRTArtificial SequenceSynthetic Polypeptide 17Glu Met
Gln Pro Thr His Pro Ile Arg 1 5 1818PRTArtificial SequenceSynthetic
Polypeptide 18Gln Thr Ile Asp Asn Ser Gln Gly Ala Tyr Gln Glu Ala
Phe Asp Ile 1 5 10 15 Ser Lys 1919PRTArtificial SequenceSynthetic
Polypeptide 19Thr Ala Phe Asp Glu Ala Ile Ala Glu Leu Asp Thr Leu
Asn Glu Asp 1 5 10 15 Ser Tyr Lys 2012PRTArtificial
SequenceSynthetic Polypeptide 20Tyr Leu Ile Ala Asn Ala Thr Asn Pro
Glu Ser Lys 1 5 10 2112PRTArtificial SequenceSynthetic Polypeptide
21Phe Leu Ile Pro Asn Ala Ser Gln Ala Glu Ser Lys 1 5 10
2218PRTArtificial SequenceSynthetic Polypeptide 22Gly Ile Val Asp
Gln Ser Gln Gln Ala Tyr Gln Glu Ala Phe Glu Ile 1 5 10 15 Ser Lys
2314PRTArtificial SequenceSynthetic Polypeptide 23Ser Val Thr Glu
Gln Gly Ala Glu Leu Ser Asn Glu Glu Arg 1 5 10 2419PRTArtificial
SequenceSynthetic Polypeptide 24Thr Ala Phe Asp Glu Ala Ile Ala Glu
Leu Asp Thr Leu Ser Glu Glu 1 5 10 15 Ser Tyr Lys 2511PRTArtificial
SequenceSynthetic Polypeptide 25Ala Gly Gln Ala Val Asp Asp Phe Ile
Glu Lys 1 5 10 2613PRTArtificial SequenceSynthetic Polypeptide
26His Glu Met Leu Pro Ala Ser Leu Ile Gln Ala Gln Arg 1 5 10
2720PRTArtificial SequenceSynthetic Polypeptide 27Leu Val Pro Leu
Leu Asp Thr Gly Asp Ile Ile Ile Asp Gly Gly Asn 1 5 10 15 Ser Glu
Tyr Arg 20 2811PRTArtificial SequenceSynthetic Polypeptide 28Tyr
Gly Pro Ser Leu Met Pro Gly Gly Asn Lys 1 5 10 2915PRTArtificial
SequenceSynthetic Polypeptide 29Asn Trp Gly Leu Ser Val Tyr Ala Asp
Lys Pro Glu Thr Thr Lys 1 5 10 15 3016PRTArtificial
SequenceSynthetic Polypeptide 30Ser Val Gln Glu Ile Gln Ala Thr Phe
Phe Tyr Phe Thr Pro Asn Lys 1 5 10 15 318PRTArtificial
SequenceSynthetic Polypeptide 31Thr Glu Asp Thr Ile Phe Leu Arg 1 5
329PRTArtificial SequenceSynthetic Polypeptide 32Trp Phe Tyr Ile
Ala Ser Ala Phe Arg 1 5 3315PRTArtificial SequenceSynthetic
Polypeptide 33Tyr Val Gly Gly Gln Glu His Phe Ala His Leu Leu Ile
Leu Arg 1 5 10 15 3417PRTArtificial SequenceSynthetic Polypeptide
34Asp Ala Gly Ile Ala Leu Leu Ser Ile Thr His Arg Pro Ser Leu Trp 1
5 10 15 Lys 3514PRTArtificial SequenceSynthetic Polypeptide 35Glu
Leu Glu Asp Ala Gln Ala Gly Ser Gly Thr Ile Gly Arg 1 5 10
3620PRTArtificial SequenceSynthetic Polypeptide 36Gly Leu Gln Ala
Pro Ala Gly Glu Pro Thr Gln Glu Ala Ser Gly Val 1 5 10 15 Ala Ala
Ala Lys 20 3712PRTArtificial SequenceSynthetic Polypeptide 37Asn
Leu Leu Thr Ala Ala Ala Asp Ala Ile Glu Arg 1 5 10
3815PRTArtificial SequenceSynthetic Polypeptide 38Tyr His Thr His
Leu Leu Gln Phe Asp Gly Glu Gly Gly Trp Lys 1 5 10 15
3919PRTArtificial SequenceSynthetic Polypeptide 39Ala Asp Glu Val
Val Ser Ala Ser Val Gly Ser Gly Asp Leu Trp Ile 1 5 10 15 Pro Val
Lys 4013PRTArtificial SequenceSynthetic Polypeptide 40Phe Gly Phe
Gly Gly Ser Thr Asp Ser Gly Pro Ile Arg 1 5 10 4110PRTArtificial
SequenceSynthetic Polypeptide 41Leu Ile Glu Ile Ala Asn His Val Asp
Lys 1 5 10 429PRTArtificial SequenceSynthetic Polypeptide 42Asn His
Pro Glu Val Leu Asn Ile Arg 1 5 4311PRTArtificial SequenceSynthetic
Polypeptide 43Tyr Val Glu Leu Val Ile Val Ala Asp Asn Arg 1 5 10
4411PRTArtificial SequenceSynthetic Polypeptide 44Leu Ala His Gln
Ile Tyr Gln Phe Thr Asp Lys 1 5 10 4511PRTArtificial
SequenceSynthetic Polypeptide 45Ser Pro Glu Asp Ser Ser Pro Asp Ala
Ala Arg 1 5 10 4624PRTArtificial SequenceSynthetic Polypeptide
46Thr Leu Val Ser Ser Lys Pro Gln Ala His Gly Ala Pro Ala Pro Pro 1
5 10 15 Ser Gly Ser Ala Pro His Phe Leu 20 4718PRTArtificial
SequenceSynthetic Polypeptide 47Gly Trp Gly Asp Gln Leu Ile Trp Thr
Gln Thr Tyr Glu Glu Ala Leu 1 5 10 15 Tyr Lys 4811PRTArtificial
SequenceSynthetic Polypeptide 48His Leu Ser Pro Asp Gly Gln Tyr Val
Pro Arg 1 5 10 4918PRTArtificial SequenceSynthetic Polypeptide
49Ile Pro Val Ser Ala Phe Leu Leu Leu Val Ala Leu Ser Tyr Thr Leu 1
5 10 15 Ala Arg 5017PRTArtificial SequenceSynthetic Polypeptide
50Leu Ala Glu Gln Phe Val Leu Leu Asn Leu Val Tyr Glu Thr Thr Asp 1
5 10 15 Lys 517PRTArtificial SequenceSynthetic Polypeptide 51Leu
Pro Gln Thr Leu Ser Arg 1 5 5213PRTArtificial SequenceSynthetic
Polypeptide 52Ala Leu Gly Thr Glu Val Ile Gln Leu Phe Pro Glu Lys 1
5 10 5312PRTArtificial SequenceSynthetic Polypeptide 53Glu Leu Trp
Phe Ser Asp Asp Pro Asn Val Thr Lys 1 5 10 547PRTArtificial
SequenceSynthetic Polypeptide 54Gly Val Ile Phe Tyr Leu Arg 1 5
5511PRTArtificial SequenceSynthetic Polypeptide 55Leu Asn Asp Gly
Ser Gln Ile Thr Tyr Glu Lys 1 5 10 5614PRTArtificial
SequenceSynthetic Polypeptide 56Thr Gly Gly Leu Glu Ile Asp Ser Asp
Phe Gly Gly Phe Arg 1 5 10 5712PRTArtificial SequenceSynthetic
Polypeptide 57Ala Asp Asp Gly Arg Pro Phe Pro Gln Val Ile Lys 1 5
10 588PRTArtificial SequenceSynthetic Polypeptide 58Ala Leu Gln Ala
Ser Ala Leu Lys 1 5 5923PRTArtificial SequenceSynthetic Polypeptide
59Gly Val Val Pro Leu Ala Gly Thr Asn Gly Glu Thr Thr Thr Gln Gly 1
5 10 15 Leu Asp Gly Leu Ser Glu Arg 20 609PRTArtificial
SequenceSynthetic Polypeptide 60Gln Leu Leu Leu Thr Ala Asp Asp Arg
1 5 6122PRTArtificial SequenceSynthetic Polypeptide 61Tyr Thr Pro
Ser Gly Gln Ala Gly Ala Ala Ala Ser Glu Ser Leu Phe 1 5 10 15 Val
Ser Asn His Ala Tyr 20 628PRTArtificial SequenceSynthetic
Polypeptide 62Ala Leu Glu Gln Ala Leu Glu Lys 1 5 6310PRTArtificial
SequenceSynthetic Polypeptide 63Asp His Ser Ala Ile Pro Val Ile Asn
Arg 1 5 10 6416PRTArtificial SequenceSynthetic Polypeptide 64Glu
Asn Ser Leu Leu Phe Asp Pro Leu Ser Ser Ser Ser Ser Asn Lys 1 5 10
15 6512PRTArtificial SequenceSynthetic Polypeptide 65Glu Val Val
Leu Gln Trp Phe Thr Glu Asn Ser Lys 1 5 10 669PRTArtificial
SequenceSynthetic Polypeptide 66Ser Ile Gln Leu Pro Thr Thr Val Arg
1 5 6713PRTArtificial SequenceSynthetic Polypeptide 67Asp Ala Pro
His Val Glu Pro Asp Phe Ser Ser Gln Lys 1 5 10 6814PRTArtificial
SequenceSynthetic Polypeptide 68Leu Glu Ile Gln Leu Leu Glu Asn Ser
Leu Ser Thr Tyr Lys 1 5 10 6911PRTArtificial SequenceSynthetic
Polypeptide 69Gln Leu Leu Gln Gln Thr Asn Glu Ile Leu Lys 1 5 10
7014PRTArtificial SequenceSynthetic Polypeptide 70Gln Ser Ser Leu
Ile Leu His Gly Ala Asp Phe Ser Thr Lys 1 5 10 7110PRTArtificial
SequenceSynthetic Polypeptide 71Gln Thr Tyr Ile Ile Gln Glu Leu Glu
Lys 1 5 10 7212PRTArtificial SequenceSynthetic Polypeptide 72Asp
Ala Pro Leu Glu Tyr Asp Asp Ser Val Gln Arg 1 5 10 739PRTArtificial
SequenceSynthetic Polypeptide 73Asp Gln Leu Gln Val Leu Val Ser Lys
1 5 7414PRTArtificial SequenceSynthetic Polypeptide 74Ile Ser Ser
Ile Ser Gln Pro Gly Asn Asp Phe Ser Thr Lys 1 5 10
7511PRTArtificial SequenceSynthetic Polypeptide 75Gln Ile Leu Asp
Gln Thr Ser Glu Ile Asn Lys 1 5 10 7613PRTArtificial
SequenceSynthetic Polypeptide 76Ser Ser Ser Ser Pro Tyr Val Ser Asn
Ala Val Gln Arg 1 5 10 778PRTArtificial SequenceSynthetic
Polypeptide 77Ala Glu Leu Gln Glu Gly Ala Arg 1 5 789PRTArtificial
SequenceSynthetic Polypeptide 78Ala Lys Pro Ala Leu Glu Asp Leu Arg
1 5 7911PRTArtificial SequenceSynthetic Polypeptide 79Ala Thr Glu
His Leu Ser Thr Leu Ser Glu Lys 1 5 10 807PRTArtificial
SequenceSynthetic Polypeptide 80Leu Ala Glu Tyr His Ala Lys 1 5
817PRTArtificial SequenceSynthetic Polypeptide 81Leu His Glu Leu
Gln Glu Lys 1 5 8215PRTArtificial SequenceSynthetic Polypeptide
82Ala Ala Thr Val Gly Ser Leu Ala Gly Gln Pro Leu Gln Glu Arg 1 5
10 15 838PRTArtificial SequenceSynthetic Polypeptide 83Ala Leu Met
Asp Glu Thr Met Lys 1 5 846PRTArtificial SequenceSynthetic
Polypeptide 84Phe Trp Asp Tyr Leu Arg 1 5 8515PRTArtificial
SequenceSynthetic Polypeptide 85Gly Glu Val Gln Ala Met Leu Gly Gln
Ser Thr Glu Glu Leu Arg 1 5 10 15 869PRTArtificial
SequenceSynthetic Polypeptide 86Leu Ala Val Tyr Gln Ala Gly Ala Arg
1 5 879PRTArtificial SequenceSynthetic Polypeptide 87Leu Gly Pro
Leu Val Glu Gln Gly Arg 1 5 8815PRTArtificial SequenceSynthetic
Polypeptide 88Ser Glu Leu Glu Glu Gln Leu Thr Pro Val Ala Glu Glu
Thr Arg 1 5 10 15 8912PRTArtificial SequenceSynthetic Polypeptide
89Ser Trp Phe Glu Pro Leu Val Glu Asp Met Gln Arg 1 5 10
907PRTArtificial SequenceSynthetic Polypeptide 90Trp Glu Leu Ala
Leu Gly Arg 1 5 9123PRTArtificial SequenceSynthetic Polypeptide
91Trp Val Gln Thr Leu Ser Glu Gln Val Gln Glu Glu Leu Leu Ser Ser 1
5 10 15 Gln Val Thr Gln Glu Leu Arg 20 9223PRTArtificial
SequenceSynthetic Polypeptide 92Glu Ile Glu Pro Glu Pro Asp Phe Ile
Leu Trp Thr Gly Asp Asp Thr 1 5 10 15 Pro His Val Pro Asp Glu Lys
20 9314PRTArtificial SequenceSynthetic Polypeptide 93Phe Trp His
Ile Ala Asp Leu His Leu Asp Pro Asp Tyr Lys 1 5 10
9410PRTArtificial SequenceSynthetic Polypeptide 94Ile Ala Gly Asp
Gln Ser Thr Leu Gln Arg 1 5 10 9512PRTArtificial SequenceSynthetic
Polypeptide 95Leu Gly Glu Ala Ala Val Leu Glu Ile Val Glu Arg 1 5
10 9616PRTArtificial SequenceSynthetic Polypeptide 96Val Ile Ala
Gly Gln Phe Phe Gly His His His Thr Asp Ser Phe Arg 1 5 10 15
9715PRTArtificial SequenceSynthetic Polypeptide 97Ala Glu Ile Gly
Ile Ala Met Gly Ser Gly Thr Ala Val Ala Lys 1 5 10 15
9813PRTArtificial SequenceSynthetic Polypeptide 98Ile Gly Ile Phe
Gly Gln Asp Glu Asp Val Thr Ser Lys 1 5 10 9913PRTArtificial
SequenceSynthetic Polypeptide 99Asn Met Leu Phe Ser Gly Thr Asn Ile
Ala Ala Gly Lys 1 5 10 10014PRTArtificial SequenceSynthetic
Polypeptide 100Ala Ser Phe Gly Ser Gly Pro Ala Val Glu Trp Ile Pro
Lys 1 5 10 10121PRTArtificial SequenceSynthetic Polypeptide 101Gly
Ala Phe Tyr Leu Leu Gly Glu Ala Tyr Phe Ile Gln Pro Leu Pro 1 5 10
15 Ala Ala Ser Glu Arg 20 10211PRTArtificial SequenceSynthetic
Polypeptide 102Gly Ile Gly Tyr Phe Phe Val Leu Gln Pro Lys 1 5 10
10313PRTArtificial SequenceSynthetic Polypeptide 103Gly Pro Glu Val
Thr Ser Asn Ala Ala Leu Thr Leu Arg 1 5 10 10412PRTArtificial
SequenceSynthetic Polypeptide 104His Tyr Leu Leu Thr Leu Phe Ser
Val Ala Ala Arg 1 5 10 10513PRTArtificial SequenceSynthetic
Polypeptide 105Glu Gly Ser Gly Tyr Val Asp Ile Gly Leu Ile Pro Lys
1 5 10 10612PRTArtificial SequenceSynthetic Polypeptide 106Leu Ile
Leu Leu Glu Glu Glu Glu Gln Gly Leu Lys 1 5 10 10713PRTArtificial
SequenceSynthetic Polypeptide 107Gln Leu Gln Tyr Asp Pro Thr Pro
Leu Thr Trp Ser Lys 1 5 10 10814PRTArtificial SequenceSynthetic
Polypeptide 108Gln Trp Gln Asp Ser Ser Thr Gln Pro Glu Leu Ser Ser
Arg 1 5 10 10911PRTArtificial SequenceSynthetic Polypeptide 109Trp
Val Glu Thr Leu Val Val Ala Asp Thr Lys 1 5 10 1109PRTArtificial
SequenceSynthetic Polypeptide 110Glu Gln Pro Ile Leu Leu Ser Glu
Lys 1 5 11111PRTArtificial SequenceSynthetic Polypeptide 111Gly Gln
Asn Leu Gly Asp Val Ser Trp Ser Arg 1 5 10 11222PRTArtificial
SequenceSynthetic Polypeptide 112Leu Arg Pro Pro Pro Pro Ser Glu
Gly Glu Glu Asp Glu Glu Leu Glu 1 5 10 15 Ser Gln Glu Leu Pro Arg
20 1139PRTArtificial SequenceSynthetic Polypeptide 113Asn Ile Ser
Ile Val Asp Asn Glu Lys 1 5 11414PRTArtificial SequenceSynthetic
Polypeptide 114Ser Val Ala Pro Val Pro Leu Glu Glu Pro Val Glu Gly
Arg 1 5 10 11514PRTArtificial SequenceSynthetic Polypeptide 115Ala
Val Phe Leu Ala Leu Ser Ala Gln Leu Leu Gln Ala Arg 1 5 10
1169PRTArtificial SequenceSynthetic Polypeptide 116Glu Glu Ser Pro
Val Val Ser Trp Arg 1 5 11718PRTArtificial
SequenceSynthetic Polypeptide 117Glu Glu Ser Pro Val Val Ser Trp
Trp Leu Glu Pro Glu Asp Gly Thr 1 5 10 15 Ala Leu
11822PRTArtificial SequenceSynthetic Polypeptide 118Ala Ala Glu Ala
Ala Ala Ala Pro Ala Glu Ser Ala Ala Pro Ala Ala 1 5 10 15 Gly Glu
Glu Pro Ser Lys 20 11913PRTArtificial SequenceSynthetic Polypeptide
119Ala Glu Gly Ala Ala Thr Glu Glu Glu Gly Thr Pro Lys 1 5 10
12019PRTArtificial SequenceSynthetic Polypeptide 120Ala Pro Glu Gln
Glu Gln Ala Ala Pro Gly Pro Ala Ala Gly Gly Glu 1 5 10 15 Ala Pro
Lys 12128PRTArtificial SequenceSynthetic Polypeptide 121Ala Gln Gly
Pro Ala Ala Ser Ala Glu Glu Pro Lys Pro Val Glu Ala 1 5 10 15 Pro
Ala Ala Asn Ser Asp Gln Thr Val Thr Val Lys 20 25
12210PRTArtificial SequenceSynthetic Polypeptide 122Glu Lys Pro Asp
Gln Asp Ala Glu Gly Lys 1 5 10 12314PRTArtificial SequenceSynthetic
Polypeptide 123Glu Ser Glu Pro Gln Ala Ala Ala Glu Pro Ala Glu Ala
Lys 1 5 10 12414PRTArtificial SequenceSynthetic Polypeptide 124Glu
Thr Pro Ala Ala Thr Glu Ala Pro Ser Ser Thr Pro Lys 1 5 10
1258PRTArtificial SequenceSynthetic Polypeptide 125Gly Tyr Asn Val
Asn Asp Glu Lys 1 5 12621PRTArtificial SequenceSynthetic
Polypeptide 126Ser Asp Gly Ala Pro Ala Ser Asp Ser Lys Pro Gly Ser
Ser Glu Ala 1 5 10 15 Ala Pro Ser Ser Lys 20 12713PRTArtificial
SequenceSynthetic Polypeptide 127Thr Glu Ala Pro Ala Ala Pro Ala
Ala Gln Glu Thr Lys 1 5 10 12813PRTArtificial SequenceSynthetic
Polypeptide 128Thr Gly Ala Leu Leu Leu Gln Gly Phe Ile Gln Asp Arg
1 5 10 1296PRTArtificial SequenceSynthetic Polypeptide 129Val Pro
Glu Leu Ile Arg 1 5 13010PRTArtificial SequenceSynthetic
Polypeptide 130Val Val Ala Leu Phe Tyr Phe Ala Ser Lys 1 5 10
1318PRTArtificial SequenceSynthetic Polypeptide 131Asp Ala Asp Leu
Tyr Thr Ser Arg 1 5 13222PRTArtificial SequenceSynthetic
Polypeptide 132Gly Leu Thr Ser Leu Ala Asp Thr Phe Glu His Val Ile
Glu Glu Leu 1 5 10 15 Leu Asp Glu Asp Gln Lys 20 13311PRTArtificial
SequenceSynthetic Polypeptide 133Gly Gln Gly Gly Leu Ala Tyr Pro
Gly Val Arg 1 5 10 1347PRTArtificial SequenceSynthetic Polypeptide
134Gln Tyr Phe Tyr Glu Thr Lys 1 5 13512PRTArtificial
SequenceSynthetic Polypeptide 135Thr His Gly Thr Leu Glu Ser Val
Asn Gly Pro Lys 1 5 10 13615PRTArtificial SequenceSynthetic
Polypeptide 136Ala Asp His His Ala Thr Asn Gly Val Val His Leu Ile
Asp Lys 1 5 10 15 13722PRTArtificial SequenceSynthetic Polypeptide
137Asp Ile Leu Ala Thr Asn Gly Val Ile His Tyr Ile Asp Glu Leu Leu
1 5 10 15 Ile Pro Asp Ser Ala Lys 20 13815PRTArtificial
SequenceSynthetic Polypeptide 138Glu Gly Val Tyr Thr Val Phe Ala
Pro Thr Asn Glu Ala Phe Arg 1 5 10 15 13912PRTArtificial
SequenceSynthetic Polypeptide 139Leu Thr Leu Leu Ala Pro Leu Asn
Ser Val Phe Lys 1 5 10 14011PRTArtificial SequenceSynthetic
Polypeptide 140Ser Pro Tyr Gln Leu Val Leu Gln His Ser Arg 1 5 10
14115PRTArtificial SequenceSynthetic Polypeptide 141Ile Asn Ile Tyr
Glu Ile Ile Lys Pro Ala Thr Ala Asn Ser Lys 1 5 10 15
1428PRTArtificial SequenceSynthetic Polypeptide 142Leu Val Asn Gln
Asn Ala Ser Arg 1 5 14317PRTArtificial SequenceSynthetic
Polypeptide 143Ser Phe His His Glu Glu Ser Leu Glu Glu Leu Pro Glu
Thr Ser Gly 1 5 10 15 Lys 14424PRTArtificial SequenceSynthetic
Polypeptide 144Ser Leu His Gln Asp Glu His Ser Trp Ser Gln Ile Arg
Pro Leu Leu 1 5 10 15 Val Thr Phe Gly His Asp Gly Lys 20
14521PRTArtificial SequenceSynthetic Polypeptide 145Trp Thr Ala Gln
Gly His Ala Asn His Gly Phe Val Val Glu Val Ala 1 5 10 15 His Leu
Glu Glu Lys 20 14614PRTArtificial SequenceSynthetic Polypeptide
146Ala Gly Leu Ile Ile Pro Leu Phe Leu Val Leu Ala Ser Arg 1 5 10
1478PRTArtificial SequenceSynthetic Polypeptide 147Ala Leu Leu Ser
Pro Glu Gln Arg 1 5 1486PRTArtificial SequenceSynthetic Polypeptide
148Asp Ile Phe Leu Gly Arg 1 5 1499PRTArtificial SequenceSynthetic
Polypeptide 149Gly Glu Gly Thr Ser Ala His Leu Arg 1 5
15013PRTArtificial SequenceSynthetic Polypeptide 150Gly Phe Phe Ala
Asp Tyr Glu Ile Pro Asn Leu Gln Lys 1 5 10 15117PRTArtificial
SequenceSynthetic Polypeptide 151Glu Ala Glu Phe Gly Gln Gly Thr
Gly Pro Ile Trp Leu Asn Glu Val 1 5 10 15 Lys 15211PRTArtificial
SequenceSynthetic Polypeptide 152Gly Glu Asn Leu Val His Gln Ile
Gln Tyr Arg 1 5 10 1538PRTArtificial SequenceSynthetic Polypeptide
153Ile Asn Pro Ala Ser Leu Asp Lys 1 5 15414PRTArtificial
SequenceSynthetic Polypeptide 154Leu Glu Val Phe Tyr Asn Gly Ala
Trp Gly Thr Val Gly Lys 1 5 10 1558PRTArtificial SequenceSynthetic
Polypeptide 155Thr Ser Tyr Gln Val Tyr Ser Lys 1 5
15611PRTArtificial SequenceSynthetic Polypeptide 156Glu Asp Val Tyr
Val Val Gly Thr Val Leu Arg 1 5 10 1579PRTArtificial
SequenceSynthetic Polypeptide 157Gly Tyr Ile Leu Val Gly Gln Ala
Lys 1 5 1587PRTArtificial SequenceSynthetic Polypeptide 158Ile Ala
His Gly His Tyr Lys 1 5 15912PRTArtificial SequenceSynthetic
Polypeptide 159Leu Ser Leu Glu Ile Glu Gln Leu Glu Leu Gln Arg 1 5
10 1608PRTArtificial SequenceSynthetic Polypeptide 160Thr Trp Tyr
Pro Glu Val Pro Lys 1 5 16116PRTArtificial SequenceSynthetic
Polypeptide 161Phe Pro Ala Glu Ile His Val Val His Leu Ser Thr Ala
Phe Ala Arg 1 5 10 15 16215PRTArtificial SequenceSynthetic
Polypeptide 162Gly Gly Val Ser Tyr Arg Pro Ala Glu Val Ala Glu Thr
Gly Ala 1 5 10 15 16328PRTArtificial SequenceSynthetic Polypeptide
163Leu Glu Glu Ile Ala Glu Glu Gly Ser Glu Thr Gln Val Pro Gly Leu
1 5 10 15 Asp Ile Ser Ala Leu Leu Pro Ser Asp Phe Ser Arg 20 25
16415PRTArtificial SequenceSynthetic Polypeptide 164Val Ile Glu Ala
Ser Phe Pro Ala Gly Val Asp Ser Ser Pro Arg 1 5 10 15
1659PRTArtificial SequenceSynthetic Polypeptide 165Tyr Gly Gly Asp
Pro Pro Trp Pro Arg 1 5 16621PRTArtificial SequenceSynthetic
Polypeptide 166Asp Asp Glu Phe Thr His Leu Tyr Thr Leu Ile Val Arg
Pro Asp Asn 1 5 10 15 Thr Tyr Glu Val Lys 20 16713PRTArtificial
SequenceSynthetic Polypeptide 167Asp Pro Asp Ala Ser Lys Pro Glu
Asp Trp Asp Glu Arg 1 5 10 1687PRTArtificial SequenceSynthetic
Polypeptide 168Phe Tyr Gly Asp Glu Glu Lys 1 5 1699PRTArtificial
SequenceSynthetic Polypeptide 169Gly Leu Gln Thr Ser Gln Asp Ala
Arg 1 5 17011PRTArtificial SequenceSynthetic Polypeptide 170Gly Gln
Thr Leu Val Val Gln Phe Thr Val Lys 1 5 10 17116PRTArtificial
SequenceSynthetic Polypeptide 171Asp Trp Ile Leu Pro Ser Asp Tyr
Asp His Ala Glu Ala Glu Ala Arg 1 5 10 15 1727PRTArtificial
SequenceSynthetic Polypeptide 172Glu Gln Phe Val Glu Phe Arg 1 5
17316PRTArtificial SequenceSynthetic Polypeptide 173Gly His Asp Leu
Asn Glu Asp Gly Leu Val Ser Trp Glu Glu Tyr Lys 1 5 10 15
17411PRTArtificial SequenceSynthetic Polypeptide 174Thr Phe Asp Gln
Leu Thr Pro Glu Glu Ser Lys 1 5 10 17522PRTArtificial
SequenceSynthetic Polypeptide 175Val His Asn Asp Ala Gln Ser Phe
Asp Tyr Asp His Asp Ala Phe Leu 1 5 10 15 Gly Ala Glu Glu Ala Lys
20 1769PRTArtificial SequenceSynthetic Polypeptide 176Ala Glu Glu
Asp Glu Ile Leu Asn Arg 1 5 17716PRTArtificial SequenceSynthetic
Polypeptide 177Ala Pro Val Pro Thr Gly Glu Val Tyr Phe Ala Asp Ser
Phe Asp Arg 1 5 10 15 17810PRTArtificial SequenceSynthetic
Polypeptide 178Gly Thr Leu Ser Gly Trp Ile Leu Ser Lys 1 5 10
17919PRTArtificial SequenceSynthetic Polypeptide 179Ile Pro Asp Pro
Glu Ala Val Lys Pro Asp Asp Trp Asp Glu Asp Ala 1 5 10 15 Pro Ala
Lys 1807PRTArtificial SequenceSynthetic Polypeptide 180Thr Gly Ile
Tyr Glu Glu Lys 1 5 18115PRTArtificial SequenceSynthetic
Polypeptide 181Asp Trp Ile Asp Gly Val Leu Asn Asn Pro Gly Pro Gly
Pro Ala 1 5 10 15 18225PRTArtificial SequenceSynthetic Polypeptide
182Glu Ala Asn Leu Thr Ser Ser Val Thr Ile Leu Pro Leu Pro Leu Gln
1 5 10 15 Asn Ala Thr Val Glu Ala Gly Thr Arg 20 25
1837PRTArtificial SequenceSynthetic Polypeptide 183Gly Pro Asp Phe
Phe Thr Arg 1 5 18415PRTArtificial SequenceSynthetic Polypeptide
184Leu Thr Val Leu Ala Leu Leu Ala Gly Leu Leu Ala Ser Ser Arg 1 5
10 15 18513PRTArtificial SequenceSynthetic Polypeptide 185Gln Phe
Pro Phe Leu Ala Ser Ile Gln Asn Gln Gly Arg 1 5 10
18614PRTArtificial SequenceSynthetic Polypeptide 186His Tyr Gly Tyr
Asn Ser Tyr Ser Val Ser Asn Ser Glu Lys 1 5 10 18730PRTArtificial
SequenceSynthetic Polypeptide 187Ile Leu Gly Trp Gly Val Glu Asn
Gly Thr Pro Tyr Trp Leu Val Ala 1 5 10 15 Asn Ser Trp Asn Thr Asp
Trp Gly Asp Asn Gly Phe Phe Lys 20 25 30 1888PRTArtificial
SequenceSynthetic Polypeptide 188Leu Pro Ala Ser Phe Asp Ala Arg 1
5 18918PRTArtificial SequenceSynthetic Polypeptide 189Asn Gly Pro
Val Glu Gly Ala Phe Ser Val Tyr Ser Asp Phe Leu Leu 1 5 10 15 Tyr
Lys 1907PRTArtificial SequenceSynthetic Polypeptide 190Thr Asp Gln
Tyr Trp Glu Lys 1 5 1917PRTArtificial SequenceSynthetic Polypeptide
191His Pro Gln Tyr Asn Gln Arg 1 5 1929PRTArtificial
SequenceSynthetic Polypeptide 192Asn Val Asn Pro Val Ala Leu Pro
Arg 1 5 19311PRTArtificial SequenceSynthetic Polypeptide 193Ser Ser
Gly Val Pro Pro Glu Val Phe Thr Arg 1 5 10 1949PRTArtificial
SequenceSynthetic Polypeptide 194Val Ser Ser Phe Leu Pro Trp Ile
Arg 1 5 19525PRTArtificial SequenceSynthetic Polypeptide 195Ala Ser
Ala Ser Tyr Tyr Glu Gln Tyr His Ser Leu Asn Glu Ile Tyr 1 5 10 15
Ser Trp Ile Glu Phe Ile Thr Glu Arg 20 25 19620PRTArtificial
SequenceSynthetic Polypeptide 196Ala Tyr Ile Ser Met His Ser Tyr
Ser Gln His Ile Val Phe Pro Tyr 1 5 10 15 Ser Tyr Thr Arg 20
19714PRTArtificial SequenceSynthetic Polypeptide 197Asp His Glu Glu
Leu Ser Leu Val Ala Ser Glu Ala Val Arg 1 5 10 19812PRTArtificial
SequenceSynthetic Polypeptide 198Asp Thr Gly Thr Tyr Gly Phe Leu
Leu Pro Glu Arg 1 5 10 1998PRTArtificial SequenceSynthetic
Polypeptide 199Glu Ala Phe Ala Ala Val Ser Lys 1 5
2009PRTArtificial SequenceSynthetic Polypeptide 200Ile His Ile Gly
Ser Ser Phe Glu Lys 1 5 20120PRTArtificial SequenceSynthetic
Polypeptide 201Leu Val Asp Phe Tyr Val Met Pro Val Val Asn Val Asp
Gly Tyr Asp 1 5 10 15 Tyr Ser Trp Lys 20 20215PRTArtificial
SequenceSynthetic Polypeptide 202Gln Val His Phe Phe Val Asn Ala
Ser Asp Val Asp Asn Val Lys 1 5 10 15 2037PRTArtificial
SequenceSynthetic Polypeptide 203Tyr Pro Leu Tyr Val Leu Lys 1 5
20427PRTArtificial SequenceSynthetic Polypeptide 204Tyr Thr His Gly
His Gly Ser Glu Thr Leu Tyr Leu Ala Pro Gly Gly 1 5 10 15 Gly Asp
Asp Trp Ile Tyr Asp Leu Gly Ile Lys 20 25 2056PRTArtificial
SequenceSynthetic Polypeptide 205Xaa Xaa Xaa Xaa Xaa Xaa 1 5
20619PRTArtificial SequenceSynthetic Polypeptide 206Ala Phe Pro Ala
Leu Thr Ser Leu Asp Leu Ser Asp Asn Pro Gly Leu 1 5 10 15 Gly Glu
Arg 2079PRTArtificial SequenceSynthetic Polypeptide 207Ala Thr Val
Asn Pro Ser Ala Pro Arg 1 5 2088PRTArtificial SequenceSynthetic
Polypeptide 208Glu Leu Thr Leu Glu Asp Leu Lys 1 5
20910PRTArtificial SequenceSynthetic Polypeptide 209Phe Pro Ala Ile
Gln Asn Leu Ala Leu Arg 1 5 10 21021PRTArtificial SequenceSynthetic
Polypeptide 210Ile Thr Gly Thr Met Pro Pro Leu Pro Leu Glu Ala Thr
Gly Leu Ala 1 5 10 15 Leu Ser Ser Leu Arg 20 21118PRTArtificial
SequenceSynthetic Polypeptide 211Leu Thr Val Gly Ala Ala Gln Val
Pro Ala Gln Leu Leu Val Gly Ala 1 5 10 15 Leu Arg 2128PRTArtificial
SequenceSynthetic Polypeptide 212Asn Val Ser Trp Ala Thr Gly Arg 1
5 21318PRTArtificial SequenceSynthetic Polypeptide 213Ser Thr Leu
Ser Val Gly Val Ser Gly Thr Leu Val Leu Leu Gln Gly 1 5 10 15 Ala
Arg 21415PRTArtificial SequenceSynthetic Polypeptide 214Ser Trp Leu
Ala Glu Leu Gln Gln Trp Leu Lys Pro Gly Leu Lys 1 5 10 15
2158PRTArtificial SequenceSynthetic Polypeptide 215Val Asp Ala Asp
Ala Asp Pro Arg 1 5 21624PRTArtificial SequenceSynthetic
Polypeptide 216Ala Ala Gly Gly Ala Leu Gln Ser Thr Ala Ser Leu Phe
Val Val Ser 1 5 10 15 Leu Ser Leu Leu His Leu Tyr Ser 20
2176PRTArtificial SequenceSynthetic Polypeptide 217His Ser His Pro
Thr Arg 1 5 2188PRTArtificial SequenceSynthetic Polypeptide 218Val
Phe Val Val His Ile Pro Arg 1 5 21911PRTArtificial
SequenceSynthetic Polypeptide 219Asp Leu Ala His Gln Phe Thr Gln
Val Gln Arg 1 5 10 2206PRTArtificial SequenceSynthetic Polypeptide
220Ile Leu Leu Trp Ser Arg 1 5 2217PRTArtificial SequenceSynthetic
Polypeptide 221Asn Ile Tyr Arg Pro Asp Lys 1 5 22216PRTArtificial
SequenceSynthetic Polypeptide 222Asn Ser Thr Phe Gly Ser Val Glu
Val His Asn Leu Gln Pro Glu Lys 1 5 10 15 22313PRTArtificial
SequenceSynthetic Polypeptide 223Val Gln Thr Leu Glu Ala Trp Val
Ile His Gly Gly Arg 1 5 10 22418PRTArtificial SequenceSynthetic
Polypeptide 224Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser
Glu Ala Ser 1 5 10 15 Ser Lys 2258PRTArtificial SequenceSynthetic
Polypeptide 225Ser Gln Phe Glu Gly Phe Val Lys 1 5
22610PRTArtificial SequenceSynthetic Polypeptide 226Thr Thr Ser Val
Leu Gln Trp Ala Glu Lys 1 5 10 2279PRTArtificial SequenceSynthetic
Polypeptide 227Phe Ala Gly Val Phe His Val Glu Lys 1 5
22825PRTArtificial SequenceSynthetic Polypeptide 228His Leu Ser Phe
Ser Gly Ser Gly Ile Asp Asp Asp Glu Asp Phe Ile 1 5 10 15 Ser Ser
Thr Ile Ser Thr Thr Pro Arg 20 25 22911PRTArtificial
SequenceSynthetic Polypeptide 229Lys Pro Ser Gly Leu Asn Gly Glu
Ala Ser Lys 1
5 10 23024PRTArtificial SequenceSynthetic Polypeptide 230Thr Asn
Pro Glu Asp Ile Tyr Pro Ser Asn Pro Thr Asp Asp Asp Val 1 5 10 15
Ser Ser Gly Ser Ser Ser Glu Arg 20 23112PRTArtificial
SequenceSynthetic Polypeptide 231Tyr Gly Phe Ile Glu Gly His Val
Val Ile Pro Arg 1 5 10 2328PRTArtificial SequenceSynthetic
Polypeptide 232Ala Gly Leu Gln Val Tyr Asn Lys 1 5
23318PRTArtificial SequenceSynthetic Polypeptide 233Thr Val Leu Leu
Leu Val Thr Pro Phe Leu Ala Ala Ala Trp Ser Leu 1 5 10 15 His Pro
23422PRTArtificial SequenceSynthetic Polypeptide 234Glu Leu Asn Ser
Pro Ile Leu Phe Ala Phe Ser His Leu Glu Ser Ser 1 5 10 15 Asp Gly
Glu Ala Gly Arg 20 2357PRTArtificial SequenceSynthetic Polypeptide
235Phe Ile Pro Glu Asp Pro Lys 1 5 23613PRTArtificial
SequenceSynthetic Polypeptide 236Thr Ser Ser Ala Glu Val Thr Ile
Gln Asn Val Ile Lys 1 5 10 23710PRTArtificial SequenceSynthetic
Polypeptide 237Val Phe Gln Gly Gln Gly Leu Ser Thr Arg 1 5 10
23817PRTArtificial SequenceSynthetic Polypeptide 238Tyr Ser Glu Phe
Thr Ser Thr Thr Ser Gly Thr Gly His Asn Gln Thr 1 5 10 15 Arg
23912PRTArtificial SequenceSynthetic Polypeptide 239Glu Glu Gly Val
Phe Thr Val Thr Pro Asp Thr Lys 1 5 10 24010PRTArtificial
SequenceSynthetic Polypeptide 240Ile Tyr Val Val Asp Leu Ser Asn
Glu Arg 1 5 10 24110PRTArtificial SequenceSynthetic Polypeptide
241Leu Ser Leu Val Leu Val Pro Ala Gln Lys 1 5 10
24223PRTArtificial SequenceSynthetic Polypeptide 242Ser Pro Pro Glu
Ser Glu Ser Glu Pro Tyr Thr Phe Ser His Pro Asn 1 5 10 15 Asn Gly
Asp Val Ser Ser Lys 20 24316PRTArtificial SequenceSynthetic
Polypeptide 243Val Glu Tyr Tyr Ile Pro Gly Ser Thr Thr Asn Pro Glu
Val Phe Lys 1 5 10 15 24412PRTArtificial SequenceSynthetic
Polypeptide 244Ala Pro Pro Pro Gly Leu Pro Ala Glu Thr Ile Lys 1 5
10 24516PRTArtificial SequenceSynthetic Polypeptide 245Asp Leu Lys
Pro Glu Asn Ile Leu Val Thr Ser Gly Gly Thr Val Lys 1 5 10 15
24615PRTArtificial SequenceSynthetic Polypeptide 246Ile Phe Asp Leu
Ile Gly Leu Pro Pro Glu Asp Asp Trp Pro Arg 1 5 10 15
24717PRTArtificial SequenceSynthetic Polypeptide 247Val Pro Asn Gly
Gly Gly Gly Gly Gly Gly Leu Pro Ile Ser Thr Val 1 5 10 15 Arg
24813PRTArtificial SequenceSynthetic Polypeptide 248Val Thr Leu Val
Phe Glu His Val Asp Gln Asp Leu Arg 1 5 10 24920PRTArtificial
SequenceSynthetic Polypeptide 249Glu Val Leu Leu Leu Val His Asn
Leu Pro Gln His Leu Phe Gly Tyr 1 5 10 15 Ser Trp Tyr Lys 20
25016PRTArtificial SequenceSynthetic Polypeptide 250Ile Asn Gly Ile
Pro Gln Gln His Thr Gln Val Leu Phe Ile Ala Lys 1 5 10 15
25114PRTArtificial SequenceSynthetic Polypeptide 251Leu Thr Ile Glu
Ser Thr Pro Phe Asn Val Ala Glu Gly Lys 1 5 10 25221PRTArtificial
SequenceSynthetic Polypeptide 252Gln Ile Ile Gly Tyr Val Ile Gly
Thr Gln Gln Ala Thr Pro Gly Pro 1 5 10 15 Ala Tyr Ser Gly Arg 20
25313PRTArtificial SequenceSynthetic Polypeptide 253Ser Asp Leu Val
Asn Glu Glu Ala Thr Gly Gln Phe Arg 1 5 10 25414PRTArtificial
SequenceSynthetic Polypeptide 254Glu Val Leu Leu Leu Val His Asn
Leu Pro Gln Asp Pro Arg 1 5 10 2556PRTArtificial SequenceSynthetic
Polypeptide 255Gly Tyr Asn Trp Tyr Lys 1 5 2569PRTArtificial
SequenceSynthetic Polypeptide 256Leu Phe Ile Pro Asn Ile Thr Thr
Lys 1 5 2579PRTArtificial SequenceSynthetic Polypeptide 257Thr Leu
Thr Leu Leu Ser Val Thr Arg 1 5 25813PRTArtificial
SequenceSynthetic Polypeptide 258Gly Ala Tyr Pro Leu Ser Ile Glu
Pro Ile Gly Val Arg 1 5 10 25923PRTArtificial SequenceSynthetic
Polypeptide 259Gly Pro Glu Glu Glu His Leu Gly Ile Leu Gly Pro Val
Ile Trp Ala 1 5 10 15 Glu Val Gly Asp Thr Ile Arg 20
26010PRTArtificial SequenceSynthetic Polypeptide 260Ile Tyr His Ser
His Ile Asp Ala Pro Lys 1 5 10 26116PRTArtificial SequenceSynthetic
Polypeptide 261Asn Asn Glu Gly Thr Tyr Tyr Ser Pro Asn Tyr Asn Pro
Gln Ser Arg 1 5 10 15 26223PRTArtificial SequenceSynthetic
Polypeptide 262Ser Val Pro Pro Ser Ala Ser His Val Ala Pro Thr Glu
Thr Phe Thr 1 5 10 15 Tyr Glu Trp Thr Val Pro Lys 20
2637PRTArtificial SequenceSynthetic Polypeptide 263Asp Gly Asp Ile
Leu Gly Lys 1 5 2646PRTArtificial SequenceSynthetic Polypeptide
264Asp Tyr Phe Leu Phe Arg 1 5 26510PRTArtificial SequenceSynthetic
Polypeptide 265Gly Gly Glu Ile Gln Pro Val Ser Val Lys 1 5 10
26610PRTArtificial SequenceSynthetic Polypeptide 266Val Leu Leu Pro
Glu Tyr Gly Gly Thr Lys 1 5 10 26714PRTArtificial SequenceSynthetic
Polypeptide 267Val Leu Gln Ala Thr Val Val Ala Val Gly Ser Gly Ser
Lys 1 5 10 2687PRTArtificial SequenceSynthetic Polypeptide 268Gly
Ile Ile Asp Pro Thr Lys 1 5 26912PRTArtificial SequenceSynthetic
Polypeptide 269Gly Tyr Ile Ser Pro Tyr Phe Ile Asn Thr Ser Lys 1 5
10 27025PRTArtificial SequenceSynthetic Polypeptide 270Leu Val Gln
Asp Val Ala Asn Asn Thr Asn Glu Glu Ala Gly Asp Gly 1 5 10 15 Thr
Thr Thr Ala Thr Val Leu Ala Arg 20 25 27125PRTArtificial
SequenceSynthetic Polypeptide 271Thr Ala Leu Leu Asp Ala Ala Gly
Val Ala Ser Leu Leu Thr Thr Ala 1 5 10 15 Glu Val Val Val Thr Glu
Ile Pro Lys 20 25 27212PRTArtificial SequenceSynthetic Polypeptide
272Thr Val Ile Ile Glu Gln Ser Trp Gly Ser Pro Lys 1 5 10
27312PRTArtificial SequenceSynthetic Polypeptide 273Asp Phe Thr Ser
Leu Glu Asn Thr Val Glu Glu Arg 1 5 10 27412PRTArtificial
SequenceSynthetic Polypeptide 274Ile Glu Thr Asn Glu Asn Asn Leu
Glu Ser Ala Lys 1 5 10 27519PRTArtificial SequenceSynthetic
Polypeptide 275Leu Glu Gly Leu Gly Ser Ser Glu Ala Asp Gln Asp Gly
Leu Ala Ser 1 5 10 15 Thr Val Arg 2769PRTArtificial
SequenceSynthetic Polypeptide 276Leu Pro Pro Gln Asp Phe Leu Asp
Arg 1 5 27716PRTArtificial SequenceSynthetic Polypeptide 277Val Gln
Ser Leu Gln Ala Thr Phe Gly Thr Phe Glu Ser Ile Leu Arg 1 5 10 15
27823PRTArtificial SequenceSynthetic Polypeptide 278Ala Ser Ala Pro
Leu Ser Gln Ser Gly Leu Ala Thr Ala Asn Gly Lys 1 5 10 15 Pro Glu
Pro Thr Ser Ile Ser 20 27919PRTArtificial SequenceSynthetic
Polypeptide 279Gly Asp Pro Asp Ser Glu Ala Asp Ser Ile Asp Ser Asp
Gln Glu Asp 1 5 10 15 Pro Leu Lys 28022PRTArtificial
SequenceSynthetic Polypeptide 280Ile Leu Asp Glu Asp Ser Trp Ser
Asp Gly Glu Gln Glu Pro Ile Thr 1 5 10 15 Val Asp Gln Thr Trp Arg
20 28112PRTArtificial SequenceSynthetic Polypeptide 281Thr Glu Leu
Gly Ser Gln Thr Pro Glu Ser Ser Arg 1 5 10 2829PRTArtificial
SequenceSynthetic Polypeptide 282Tyr Gly Val Glu Ala Leu Leu His
Arg 1 5 28313PRTArtificial SequenceSynthetic Polypeptide 283Ala Ser
Val Thr Ala Leu Ile Glu Ser Val Asn Gly Lys 1 5 10
2848PRTArtificial SequenceSynthetic Polypeptide 284Ser Glu Ile Ser
Asn Ile Ala Arg 1 5 28530PRTArtificial SequenceSynthetic
Polypeptide 285Thr Ser Ser Gly Gly Ser Phe Val Ala Ser Asp Val Pro
Asn Ala Pro 1 5 10 15 Ile Pro Asp Leu Phe Pro Pro Gly Gln Ile Thr
Asp Leu Lys 20 25 30 28617PRTArtificial SequenceSynthetic
Polypeptide 286Thr Val Thr Leu Glu Leu Leu Asp Asn Gly Ala Gly Ala
Asp Ala Thr 1 5 10 15 Lys 28712PRTArtificial SequenceSynthetic
Polypeptide 287Trp Gly Val Phe Asp Glu Tyr Asn Asn Asp Glu Lys 1 5
10 2886PRTArtificial SequenceSynthetic Polypeptide 288Phe Ser Ala
Tyr Ile Lys 1 5 2899PRTArtificial SequenceSynthetic Polypeptide
289Gly Phe Thr Ile Pro Glu Ala Phe Arg 1 5 29018PRTArtificial
SequenceSynthetic Polypeptide 290Leu Ala Ala Leu Asn Pro Glu Ser
Asn Thr Ala Gly Leu Asp Ile Phe 1 5 10 15 Ala Lys
29112PRTArtificial SequenceSynthetic Polypeptide 291Asn Ser Asn Pro
Ala Leu Asn Asp Asn Leu Glu Lys 1 5 10 2928PRTArtificial
SequenceSynthetic Polypeptide 292Tyr Leu Ser Asn Ala Tyr Ala Arg 1
5 29312PRTArtificial SequenceSynthetic Polypeptide 293Ala Ser Ser
Ile Ile Asp Glu Leu Phe Gln Asp Arg 1 5 10 29410PRTArtificial
SequenceSynthetic Polypeptide 294Glu Ile Gln Asn Ala Val Asn Gly
Val Lys 1 5 10 2959PRTArtificial SequenceSynthetic Polypeptide
295Ile Asp Ser Leu Leu Glu Asn Asp Arg 1 5 29614PRTArtificial
SequenceSynthetic Polypeptide 296Leu Ala Asn Leu Thr Gln Gly Glu
Asp Gln Tyr Tyr Leu Arg 1 5 10 29723PRTArtificial SequenceSynthetic
Polypeptide 297Val Thr Thr Val Ala Ser His Thr Ser Asp Ser Asp Val
Pro Ser Gly 1 5 10 15 Val Thr Glu Val Val Val Lys 20
29831PRTArtificial SequenceSynthetic Polypeptide 298Ala Glu Gly Asn
Asn Gln Ala Pro Gly Glu Glu Glu Glu Glu Glu Glu 1 5 10 15 Glu Ala
Thr Asn Thr His Pro Pro Ala Ser Leu Pro Ser Gln Lys 20 25 30
2999PRTArtificial SequenceSynthetic Polypeptide 299Glu Ala Val Glu
Glu Pro Ser Ser Lys 1 5 30023PRTArtificial SequenceSynthetic
Polypeptide 300Ser Glu Ala Leu Ala Val Asp Gly Ala Gly Lys Pro Gly
Ala Glu Glu 1 5 10 15 Ala Gln Asp Pro Glu Gly Lys 20
30110PRTArtificial SequenceSynthetic Polypeptide 301Ser Gly Glu Leu
Glu Gln Glu Glu Glu Arg 1 5 10 30220PRTArtificial SequenceSynthetic
Polypeptide 302Tyr Pro Gly Pro Gln Ala Glu Gly Asp Ser Glu Gly Leu
Ser Gln Gly 1 5 10 15 Leu Val Asp Arg 20 30314PRTArtificial
SequenceSynthetic Polypeptide 303Ala His Ser Asp Gly Gly Asp Gly
Val Val Ser Gln Val Lys 1 5 10 3049PRTArtificial SequenceSynthetic
Polypeptide 304Asp Gly Glu Tyr Val Val Glu Val Arg 1 5
3059PRTArtificial SequenceSynthetic Polypeptide 305His Ser Ile Glu
Val Pro Ile Pro Arg 1 5 30623PRTArtificial SequenceSynthetic
Polypeptide 306Ser Thr Glu Ala Thr Leu Ser Phe Gly Tyr Leu Asp Pro
Phe Pro Pro 1 5 10 15 Glu Glu Arg Pro Glu Val Arg 20
30714PRTArtificial SequenceSynthetic Polypeptide 307Thr Thr Lys Pro
Tyr Pro Ala Asp Ile Val Val Gln Phe Lys 1 5 10 30811PRTArtificial
SequenceSynthetic Polypeptide 308Gly Asp Pro Gly Thr Pro Gly Val
Pro Gly Lys 1 5 10 30911PRTArtificial SequenceSynthetic Polypeptide
309Gly Glu Pro Gly Val Gly Leu Pro Gly Leu Lys 1 5 10
31012PRTArtificial SequenceSynthetic Polypeptide 310Gly Pro Pro Gly
Gly Val Gly Phe Pro Gly Ser Arg 1 5 10 31121PRTArtificial
SequenceSynthetic Polypeptide 311Gly Pro Pro Gly Pro Gln Gly Pro
Pro Gly Glu Ile Gly Phe Pro Gly 1 5 10 15 Gln Pro Gly Ala Lys 20
31216PRTArtificial SequenceSynthetic Polypeptide 312Ile Leu Tyr His
Gly Tyr Ser Leu Leu Tyr Val Gln Gly Asn Glu Arg 1 5 10 15
31319PRTArtificial SequenceSynthetic Polypeptide 313Asp Gly Glu Val
Gly Pro Ser Gly Pro Val Gly Pro Pro Gly Leu Ala 1 5 10 15 Gly Glu
Arg 31417PRTArtificial SequenceSynthetic Polypeptide 314Gly Pro Glu
Gly Pro Pro Gly Lys Pro Gly Glu Asp Gly Glu Pro Gly 1 5 10 15 Arg
31517PRTArtificial SequenceSynthetic Polypeptide 315Gly Thr Gln Gly
Pro Pro Gly Ala Thr Gly Phe Pro Gly Ser Ala Gly 1 5 10 15 Arg
31622PRTArtificial SequenceSynthetic Polypeptide 316Leu Gly Pro Leu
Gly Ala Pro Gly Glu Asp Gly Arg Pro Gly Pro Pro 1 5 10 15 Gly Ser
Ile Gly Ile Arg 20 31721PRTArtificial SequenceSynthetic Polypeptide
317Val Gly Pro Pro Gly Pro Ala Gly Ala Pro Gly Pro Ala Gly Pro Leu
1 5 10 15 Gly Glu Pro Gly Lys 20 31821PRTArtificial
SequenceSynthetic Polypeptide 318Ala Leu Gly Ser Ala Ile Glu Tyr
Thr Ile Glu Asn Val Phe Glu Ser 1 5 10 15 Ala Pro Asn Pro Arg 20
31913PRTArtificial SequenceSynthetic Polypeptide 319Ile Gly Asp Leu
His Pro Gln Ile Val Asn Leu Leu Lys 1 5 10 32025PRTArtificial
SequenceSynthetic Polypeptide 320Asn Ala Asp Pro Ala Glu Leu Glu
Gln Ile Val Leu Ser Pro Ala Phe 1 5 10 15 Ile Leu Ala Ala Glu Ser
Leu Pro Lys 20 25 3219PRTArtificial SequenceSynthetic Polypeptide
321Val Ala Val Val Gln Tyr Ser Asp Arg 1 5 3228PRTArtificial
SequenceSynthetic Polypeptide 322Trp Tyr Tyr Asp Pro Asn Thr Lys 1
5 32316PRTArtificial SequenceSynthetic Polypeptide 323Gly Pro Gly
Asp Leu Glu Ala Pro Ser Asn Leu Val Ile Ser Glu Arg 1 5 10 15
32412PRTArtificial SequenceSynthetic Polypeptide 324Ile Thr Val Asp
Pro Thr Thr Asp Gly Pro Thr Lys 1 5 10 32511PRTArtificial
SequenceSynthetic Polypeptide 325Ser Leu Tyr Asp Asp Val Asp Thr
Gly Glu Lys 1 5 10 32610PRTArtificial SequenceSynthetic Polypeptide
326Ser Gln Asp Glu Val Glu Ile Pro Ala Arg 1 5 10
32710PRTArtificial SequenceSynthetic Polypeptide 327Val Thr Asp Glu
Thr Thr Asp Ser Phe Lys 1 5 10 32820PRTArtificial SequenceSynthetic
Polypeptide 328Glu Ile Leu Val Gly Asp Val Gly Gln Thr Val Asp Asp
Pro Tyr Ala 1 5 10 15 Thr Phe Val Lys 20 32914PRTArtificial
SequenceSynthetic Polypeptide 329Leu Gly Gly Ser Ala Val Ile Ser
Leu Glu Gly Lys Pro Leu 1 5 10 33011PRTArtificial SequenceSynthetic
Polypeptide 330Tyr Ala Leu Tyr Asp Ala Thr Tyr Glu Thr Lys 1 5 10
33110PRTArtificial SequenceSynthetic Polypeptide 331Ala Asp Asp Ile
Leu Ala Ser Pro Pro Arg 1 5 10 3329PRTArtificial SequenceSynthetic
Polypeptide 332Ala Val Gly Leu Ala Gly Thr Phe Arg 1 5
33324PRTArtificial SequenceSynthetic Polypeptide 333Asp Glu Leu Leu
Phe Pro Ser Trp Glu Ala Leu Phe Ser Gly Ser Glu 1 5 10 15 Gly Pro
Leu Lys Pro Gly Ala Arg 20 33430PRTArtificial SequenceSynthetic
Polypeptide 334Leu Ser Gly Val Gln Asp Gly His Gln Asp Ile Ser Leu
Leu Tyr Thr 1 5 10 15 Glu Pro Gly Ala Gly Gln Thr His Thr Ala Ala
Ser Phe Arg 20 25 30 33517PRTArtificial SequenceSynthetic
Polypeptide
335Thr Glu Ala Pro Ser Ala Thr Gly Gln Ala Ser Ser Leu Leu Gly Gly
1 5 10 15 Arg 33629PRTArtificial SequenceSynthetic Polypeptide
336Glu Ile Tyr Pro Tyr Val Ile Gln Glu Leu Arg Pro Thr Leu Asn Glu
1 5 10 15 Leu Gly Ile Ser Thr Pro Glu Glu Leu Gly Leu Asp Lys 20 25
3377PRTArtificial SequenceSynthetic Polypeptide 337Gly Leu Leu His
Ser Ala Arg 1 5 3387PRTArtificial SequenceSynthetic Polypeptide
338Ile Ile Asp Ala Ala Leu Arg 1 5 3396PRTArtificial
SequenceSynthetic Polypeptide 339Ile Leu Glu Val Val Lys 1 5
34012PRTArtificial SequenceSynthetic Polypeptide 340Thr Pro Gly Pro
Ala Val Ala Ile Gln Ser Val Arg 1 5 10 3418PRTArtificial
SequenceSynthetic Polypeptide 341Ala Pro Leu Thr Lys Pro Leu Lys 1
5 34210PRTArtificial SequenceSynthetic Polypeptide 342Glu Ser Asp
Thr Ser Tyr Val Ser Leu Lys 1 5 10 34315PRTArtificial
SequenceSynthetic Polypeptide 343Tyr Glu Val Gln Gly Glu Val Phe
Thr Lys Pro Gln Leu Trp Pro 1 5 10 15 34415PRTArtificial
SequenceSynthetic Polypeptide 344Ala Gln Ala Asp Leu Leu Ala His
Leu Val Pro Glu Pro Asp Arg 1 5 10 15 3459PRTArtificial
SequenceSynthetic Polypeptide 345Asp Thr Gly Val Ala Phe Glu Leu
Arg 1 5 34625PRTArtificial SequenceSynthetic Polypeptide 346Gly Tyr
Trp Gly Asp Ile Ala Thr Gly Pro Phe Val Ala Phe Gly Ile 1 5 10 15
Glu Ala Asp Asp Glu Ser Leu Leu Arg 20 25 34711PRTArtificial
SequenceSynthetic Polypeptide 347Leu Glu Glu Gln Leu Pro Trp Leu
Ser Leu Arg 1 5 10 34815PRTArtificial SequenceSynthetic Polypeptide
348Thr Ala Gly Glu Ile Thr Gln His Asn Val Thr Glu Leu Leu Arg 1 5
10 15 34918PRTArtificial SequenceSynthetic Polypeptide 349Asp Asn
Thr Pro Asn Ala Ile Ala Ile Val Gln Leu Gln Glu Leu Ser 1 5 10 15
Leu Arg 3509PRTArtificial SequenceSynthetic Polypeptide 350Asp Pro
Pro Glu Pro Gly Ser Pro Arg 1 5 35113PRTArtificial
SequenceSynthetic Polypeptide 351Phe Asn Ser Val Pro Leu Thr Asp
Thr Gly His Glu Arg 1 5 10 35223PRTArtificial SequenceSynthetic
Polypeptide 352Ile Ser Ser Leu Arg Pro Gln Gly Leu Ser Asn Pro Ser
Thr Leu Ser 1 5 10 15 Ala Gln Pro Gln Leu Ser Arg 20
35312PRTArtificial SequenceSynthetic Polypeptide 353Thr Phe Tyr Glu
Thr Pro Leu Gln Leu Leu Glu Lys 1 5 10 3546PRTArtificial
SequenceSynthetic Polypeptide 354Ile Glu Leu Pro Glu Arg 1 5
3559PRTArtificial SequenceSynthetic Polypeptide 355Ile Arg Pro Val
Thr Pro Val Glu Lys 1 5 35619PRTArtificial SequenceSynthetic
Polypeptide 356Gln Asn Trp Pro Gln Asn Trp Gly Phe Leu Thr Thr Pro
Phe Glu Glu 1 5 10 15 Leu Ile Lys 3578PRTArtificial
SequenceSynthetic Polypeptide 357Ser Ala Val Pro Gly Leu Asn Lys 1
5 35818PRTArtificial SequenceSynthetic Polypeptide 358Val Phe Pro
Ser Pro Pro Val Pro Gln Thr Thr Gln Gly Phe Ile Gly 1 5 10 15 Trp
Arg 35913PRTArtificial SequenceSynthetic Polypeptide 359Asp Gln Thr
Val Val Gly Pro Ala Leu Ala Ala Tyr Arg 1 5 10 3609PRTArtificial
SequenceSynthetic Polypeptide 360Thr Thr Thr Leu Pro Val Glu Phe
Lys 1 5 36113PRTArtificial SequenceSynthetic Polypeptide 361Ala Leu
Ala Leu Val Val Thr Leu Leu His Leu Thr Arg 1 5 10
36213PRTArtificial SequenceSynthetic Polypeptide 362Glu Leu Gly Phe
Asp Ala Ser Glu Val Glu Leu Thr Arg 1 5 10 36310PRTArtificial
SequenceSynthetic Polypeptide 363Ile Leu Tyr Asn Pro Leu Gln Gly
Gln Lys 1 5 10 3647PRTArtificial SequenceSynthetic Polypeptide
364Leu Phe Asn Asp Ile His Lys 1 5 3659PRTArtificial
SequenceSynthetic Polypeptide 365Asn Asn Glu Leu Ile Ala Val Gly
Lys 1 5 3667PRTArtificial SequenceSynthetic Polypeptide 366Leu Glu
Ala Val Gln Tyr Lys 1 5 36718PRTArtificial SequenceSynthetic
Polypeptide 367Ser Leu Pro Gly Gln Asn Glu Asp Leu Val Leu Thr Gly
Tyr Gln Val 1 5 10 15 Asp Lys 3687PRTArtificial SequenceSynthetic
Polypeptide 368Thr Asn Glu Thr Tyr Gly Lys 1 5 36912PRTArtificial
SequenceSynthetic Polypeptide 369Thr Gln Val Val Ala Gly Thr Asn
Tyr Tyr Ile Lys 1 5 10 3708PRTArtificial SequenceSynthetic
Polypeptide 370Val Lys Pro Gln Leu Glu Glu Lys 1 5
3717PRTArtificial SequenceSynthetic Polypeptide 371His Asp Glu Leu
Thr Tyr Phe 1 5 3726PRTArtificial SequenceSynthetic Polypeptide
372Ser Gln Leu Glu Glu Lys 1 5 37312PRTArtificial SequenceSynthetic
Polypeptide 373Ser Gln Val Val Ala Gly Thr Asn Tyr Phe Ile Lys 1 5
10 37421PRTArtificial SequenceSynthetic Polypeptide 374Val Phe Gln
Ser Leu Pro His Glu Asn Lys Pro Leu Thr Leu Ser Asn 1 5 10 15 Tyr
Gln Thr Asn Lys 20 37512PRTArtificial SequenceSynthetic Polypeptide
375Val His Val Gly Asp Glu Asp Phe Val His Leu Arg 1 5 10
3768PRTArtificial SequenceSynthetic Polypeptide 376Asp Trp Val Leu
Asn Glu Phe Arg 1 5 37717PRTArtificial SequenceSynthetic
Polypeptide 377Phe Val Ile Asn Tyr Asp Tyr Pro Asn Ser Ser Glu Asp
Tyr Val His 1 5 10 15 Arg 3789PRTArtificial SequenceSynthetic
Polypeptide 378Leu Ile Asp Phe Leu Glu Ser Gly Lys 1 5
37914PRTArtificial SequenceSynthetic Polypeptide 379Ser Ser Gln Ser
Ser Ser Gln Gln Phe Ser Gly Ile Gly Arg 1 5 10 38012PRTArtificial
SequenceSynthetic Polypeptide 380Val Leu Glu Glu Ala Asn Gln Ala
Ile Asn Pro Lys 1 5 10 38110PRTArtificial SequenceSynthetic
Polypeptide 381Ile Gln Ser Gln Phe Thr Asp Ala Gln Lys 1 5 10
38215PRTArtificial SequenceSynthetic Polypeptide 382Ile Thr Asn Leu
Thr Gln Gln Leu Glu Gln Ala Ser Ile Val Lys 1 5 10 15
38312PRTArtificial SequenceSynthetic Polypeptide 383Asn Met Pro Leu
Gln His Leu Leu Glu Gln Ile Lys 1 5 10 3849PRTArtificial
SequenceSynthetic Polypeptide 384Tyr Gly Asp Gly Ile Gln Leu Thr
Arg 1 5 3859PRTArtificial SequenceSynthetic Polypeptide 385Ala Leu
Pro Ser Leu Thr Asp Ser Lys 1 5 38612PRTArtificial
SequenceSynthetic Polypeptide 386Gly Ser Leu Val Val Val Ser Ser
Leu Leu Gly Arg 1 5 10 38720PRTArtificial SequenceSynthetic
Polypeptide 387Leu Gly Gly Leu Asp Tyr Leu Val Leu Asn His Ile Gly
Gly Ala Pro 1 5 10 15 Ala Gly Thr Arg 20 38817PRTArtificial
SequenceSynthetic Polypeptide 388Asn Asp Gly His Leu Glu Pro Val
Thr Ala Trp Glu Val Gln Val Pro 1 5 10 15 Arg 38913PRTArtificial
SequenceSynthetic Polypeptide 389Val Pro Thr Ser Phe Ser Thr Pro
Tyr Ser Ala Ala Lys 1 5 10 39014PRTArtificial SequenceSynthetic
Polypeptide 390Phe Gly Gln Gly Ser Gly Pro Ile Val Leu Asp Asp Val
Arg 1 5 10 3919PRTArtificial SequenceSynthetic Polypeptide 391Ile
Asn Leu Gly Phe Ser Asn Leu Lys 1 5 39215PRTArtificial
SequenceSynthetic Polypeptide 392Val Asp Val Val Leu Gly Pro Ile
Gln Leu Gln Thr Pro Pro Arg 1 5 10 15 39311PRTArtificial
SequenceSynthetic Polypeptide 393Gly Gly Val Ser Pro Ser Ser Ser
Ala Ser Arg 1 5 10 39411PRTArtificial SequenceSynthetic Polypeptide
394Leu Gly Phe Ile Asn Trp Asp Ala Ile Asn Lys 1 5 10
39514PRTArtificial SequenceSynthetic Polypeptide 395Gln Val Pro Gly
Phe Gly Val Ala Asp Ala Leu Gly Asn Arg 1 5 10 39617PRTArtificial
SequenceSynthetic Polypeptide 396Val Gly Glu Ala Ala His Ala Leu
Gly Asn Thr Gly His Glu Ile Gly 1 5 10 15 Arg 39710PRTArtificial
SequenceSynthetic Polypeptide 397Val Ser Glu Ala Leu Gly Gln Gly
Thr Arg 1 5 10 39814PRTArtificial SequenceSynthetic Polypeptide
398Leu Gly Thr Phe Glu Val Glu Asp Gln Ile Glu Ala Ala Arg 1 5 10
39910PRTArtificial SequenceSynthetic Polypeptide 399Met Leu Gln Asn
Val Gln Met Pro Ser Lys 1 5 10 40011PRTArtificial SequenceSynthetic
Polypeptide 400Trp Glu Tyr Tyr Asp Ser Val Tyr Thr Glu Arg 1 5 10
40110PRTArtificial SequenceSynthetic Polypeptide 401Trp Ile Ser Asp
His Glu Tyr Leu Tyr Lys 1 5 10 40215PRTArtificial SequenceSynthetic
Polypeptide 402Tyr Met Gly Leu Pro Thr Pro Glu Asp Asn Leu Asp His
Tyr Arg 1 5 10 15 40311PRTArtificial SequenceSynthetic Polypeptide
403Gly Asn Asn Val Glu Lys Pro Leu Glu Leu Arg 1 5 10
40421PRTArtificial SequenceSynthetic Polypeptide 404Gly Gln Ile Ile
Gly Asn Phe Gln Ala Phe Asp Glu Asp Thr Gly Leu 1 5 10 15 Pro Ala
His Ala Arg 20 40514PRTArtificial SequenceSynthetic Polypeptide
405Ile Leu Asp Val Asn Asp Asn Ile Pro Val Val Glu Asn Lys 1 5 10
40611PRTArtificial SequenceSynthetic Polypeptide 406Asn Leu Asp Phe
Ser Val Ile Val Ala Asn Lys 1 5 10 40724PRTArtificial
SequenceSynthetic Polypeptide 407Val Tyr Ala Pro Ala Ser Thr Leu
Val Asp Gln Pro Tyr Ala Asn Glu 1 5 10 15 Gly Thr Val Val Val Thr
Glu Arg 20 40810PRTArtificial SequenceSynthetic Polypeptide 408Asp
Phe Leu Leu Lys Pro Glu Leu Leu Arg 1 5 10 40922PRTArtificial
SequenceSynthetic Polypeptide 409Phe Glu Val Asn Val Ala Glu Leu
Pro Glu Glu Ile Asp Ile Ser Thr 1 5 10 15 Tyr Ile Glu Gln Ser Arg
20 41014PRTArtificial SequenceSynthetic Polypeptide 410Gly Leu Ala
Ile Thr Phe Val Ser Asp Glu Asn Asp Ala Lys 1 5 10
4118PRTArtificial SequenceSynthetic Polypeptide 411Ile Leu Asn Asp
Val Gln Asp Arg 1 5 4126PRTArtificial SequenceSynthetic Polypeptide
412Leu Thr Pro His Glu Lys 1 5 4138PRTArtificial SequenceSynthetic
Polypeptide 413Glu Leu Ala Phe Gln Ile Ser Lys 1 5
41422PRTArtificial SequenceSynthetic Polypeptide 414Phe Glu Val Asn
Ile Ser Glu Leu Pro Asp Glu Ile Asp Ile Ser Ser 1 5 10 15 Tyr Ile
Glu Gln Thr Arg 20 4159PRTArtificial SequenceSynthetic Polypeptide
415Ala Pro Glu Val Ile Leu Gly Ala Arg 1 5 41615PRTArtificial
SequenceSynthetic Polypeptide 416Ala Ser Asn Ala Ala Ala Ala Ala
His Thr Ile Gly Gly Ser Lys 1 5 10 15 41714PRTArtificial
SequenceSynthetic Polypeptide 417Gln Leu Gln Ala Ser Pro Gly Leu
Gly Ala Gly Ala Thr Arg 1 5 10 41817PRTArtificial SequenceSynthetic
Polypeptide 418Ser Gly Val Gly Thr Gly Pro Pro Ser Pro Ile Ala Leu
Pro Pro Leu 1 5 10 15 Arg 4199PRTArtificial SequenceSynthetic
Polypeptide 419Thr Gly Leu Pro Val Val Pro Glu Arg 1 5
42022PRTArtificial SequenceSynthetic Polypeptide 420Gly Gln Ala Ala
Ala Thr Leu Glu Gln Pro Ala Ser Ser Ser His Ala 1 5 10 15 Gln Gly
Thr His Leu Arg 20 42111PRTArtificial SequenceSynthetic Polypeptide
421Thr Gly Ala Thr Thr Gly Glu Leu Leu Gln Arg 1 5 10
42212PRTArtificial SequenceSynthetic Polypeptide 422Glu His Ala Leu
Leu Ala Tyr Thr Leu Gly Val Lys 1 5 10 42311PRTArtificial
SequenceSynthetic Polypeptide 423Ile Gly Gly Ile Gly Thr Val Pro
Val Gly Arg 1 5 10 4248PRTArtificial SequenceSynthetic Polypeptide
424Leu Pro Leu Gln Asp Val Tyr Lys 1 5 42511PRTArtificial
SequenceSynthetic Polypeptide 425Met Asp Ser Thr Glu Pro Pro Tyr
Ser Gln Lys 1 5 10 4269PRTArtificial SequenceSynthetic Polypeptide
426Gln Thr Val Ala Val Gly Val Ile Lys 1 5 42710PRTArtificial
SequenceSynthetic Polypeptide 427Ser Thr Thr Thr Gly His Leu Ile
Tyr Lys 1 5 10 42815PRTArtificial SequenceSynthetic Polypeptide
428Thr His Ile Asn Ile Val Val Ile Gly His Val Asp Ser Gly Lys 1 5
10 15 42924PRTArtificial SequenceSynthetic Polypeptide 429Val Glu
Thr Gly Val Leu Lys Pro Gly Met Val Val Thr Phe Ala Pro 1 5 10 15
Val Asn Val Thr Thr Glu Val Lys 20 4307PRTArtificial
SequenceSynthetic Polypeptide 430Tyr Ala Trp Val Leu Asp Lys 1 5
43112PRTArtificial SequenceSynthetic Polypeptide 431Tyr Tyr Val Thr
Ile Ile Asp Ala Pro Gly His Arg 1 5 10 43215PRTArtificial
SequenceSynthetic Polypeptide 432Phe Glu Glu His Val Gln Ser Val
Asp Ile Ala Ala Phe Asn Lys 1 5 10 15 43312PRTArtificial
SequenceSynthetic Polypeptide 433Gly Val Val Gln Glu Leu Gln Gln
Ala Ile Ser Lys 1 5 10 4346PRTArtificial SequenceSynthetic
Polypeptide 434Leu Asn Val Leu Glu Lys 1 5 43513PRTArtificial
SequenceSynthetic Polypeptide 435Ser Ile Gln Leu Asp Gly Leu Val
Trp Gly Ala Ser Lys 1 5 10 43612PRTArtificial SequenceSynthetic
Polypeptide 436Val Gly Thr Asp Leu Leu Glu Glu Glu Ile Thr Lys 1 5
10 43712PRTArtificial SequenceSynthetic Polypeptide 437Asp Ser Val
Val Ala Gly Phe Gln Trp Ala Thr Lys 1 5 10 43812PRTArtificial
SequenceSynthetic Polypeptide 438Glu Gly Ile Pro Ala Leu Asp Asn
Phe Leu Asp Lys 1 5 10 4398PRTArtificial SequenceSynthetic
Polypeptide 439Phe Ser Val Ser Pro Val Val Arg 1 5
44010PRTArtificial SequenceSynthetic Polypeptide 440Gly Glu Gly Gln
Leu Gly Pro Ala Glu Arg 1 5 10 4419PRTArtificial SequenceSynthetic
Polypeptide 441Gly Val Gln Tyr Leu Asn Glu Ile Lys 1 5
44214PRTArtificial SequenceSynthetic Polypeptide 442Phe Ile Phe Trp
Ser Ser Glu Val Ala Gly Ser Leu Tyr Arg 1 5 10 44314PRTArtificial
SequenceSynthetic Polypeptide 443Ile Asn Leu His Ser Ser Phe Val
Pro Leu Gly Glu Leu Lys 1 5 10 44422PRTArtificial SequenceSynthetic
Polypeptide 444Leu Val Ile Ala Ser Ser Asp Leu Ile Trp Pro Ser Gly
Ile Thr Ile 1 5 10 15 Asp Phe Leu Thr Asp Lys 20 44511PRTArtificial
SequenceSynthetic Polypeptide 445Asn Gln Val Thr Pro Leu Asp Ile
Leu Ser Lys 1 5 10 44612PRTArtificial SequenceSynthetic Polypeptide
446Tyr Pro Ala Asn Val Ala Val Asp Pro Val Glu Arg 1 5 10
44711PRTArtificial SequenceSynthetic Polypeptide 447Glu Asp Asp Phe
Asp Trp Asn Pro Ala Asp Arg 1 5 10 4487PRTArtificial
SequenceSynthetic Polypeptide 448Gly Asp Val Phe Phe Pro Lys 1 5
44911PRTArtificial SequenceSynthetic Polypeptide 449Ile Gln Leu Tyr
Gln Gly Thr Asp Ala Thr Lys 1 5 10 45010PRTArtificial
SequenceSynthetic Polypeptide 450Asn Ser Asn Asn Ala Leu Ala Trp
Glu Lys 1 5 10 45114PRTArtificial SequenceSynthetic Polypeptide
451Val Asn Leu Gln Pro Phe Asn Tyr Glu Glu Ile Val Ser Arg 1 5 10
4527PRTArtificial SequenceSynthetic Polypeptide 452Ala Val Glu His
Ile Asn Lys 1 5
45313PRTArtificial SequenceSynthetic Polypeptide 453Gly Asn Pro Thr
Val Glu Val Asp Leu Phe Thr Ser Lys 1 5 10 45410PRTArtificial
SequenceSynthetic Polypeptide 454Ile Gly Ala Glu Val Tyr His Asn
Leu Lys 1 5 10 45512PRTArtificial SequenceSynthetic Polypeptide
455Tyr Ile Ser Pro Asp Gln Leu Ala Asp Leu Tyr Lys 1 5 10
4566PRTArtificial SequenceSynthetic Polypeptide 456Tyr Asn Gln Leu
Leu Arg 1 5 45726PRTArtificial SequenceSynthetic Polypeptide 457Asp
Ala Thr Asn Val Gly Asp Glu Gly Gly Phe Ala Pro Asn Ile Leu 1 5 10
15 Glu Asn Ser Glu Ala Leu Glu Leu Val Lys 20 25 45813PRTArtificial
SequenceSynthetic Polypeptide 458Gly Asn Pro Thr Val Glu Val Asp
Leu Tyr Thr Ala Lys 1 5 10 45910PRTArtificial SequenceSynthetic
Polypeptide 459Ile Glu Glu Glu Leu Gly Asp Glu Ala Arg 1 5 10
46010PRTArtificial SequenceSynthetic Polypeptide 460Leu Gly Ala Glu
Val Tyr His Thr Leu Lys 1 5 10 46116PRTArtificial SequenceSynthetic
Polypeptide 461Tyr Ile Thr Gly Asp Gln Leu Gly Ala Leu Tyr Gln Asp
Phe Val Arg 1 5 10 15 4628PRTArtificial SequenceSynthetic
Polypeptide 462Ala Leu Tyr Leu Ser Gly Tyr Arg 1 5
46315PRTArtificial SequenceSynthetic Polypeptide 463Glu Thr Glu Glu
Ser Ala Leu Val Ser Gln Ala Glu Ala Leu Lys 1 5 10 15
46414PRTArtificial SequenceSynthetic Polypeptide 464Phe Ser Glu Ala
Val Gln Thr Leu Leu Thr Trp Ile Glu Arg 1 5 10 46522PRTArtificial
SequenceSynthetic Polypeptide 465Gln Ala Leu Ser Gly Ile Leu Ile
Gln Phe Glu Gln Ile Val Ala Val 1 5 10 15 Tyr His Ser Ala Ser Lys
20 46615PRTArtificial SequenceSynthetic Polypeptide 466Trp Leu Trp
Val Tyr Glu Ile Gly Tyr Ala Ala Asp Asn Ser Arg 1 5 10 15
4678PRTArtificial SequenceSynthetic Polypeptide 467Glu Val Glu Glu
Asp Glu Tyr Lys 1 5 46819PRTArtificial SequenceSynthetic
Polypeptide 468Leu Ile Ser Leu Thr Asp Glu Asn Ala Leu Ser Gly Asn
Glu Glu Leu 1 5 10 15 Thr Val Lys 4699PRTArtificial
SequenceSynthetic Polypeptide 469Ser Gly Thr Ser Glu Phe Leu Asn
Lys 1 5 4709PRTArtificial SequenceSynthetic Polypeptide 470Ser Gly
Tyr Leu Leu Pro Asp Thr Lys 1 5 4718PRTArtificial SequenceSynthetic
Polypeptide 471Thr Asp Asp Glu Val Val Gln Arg 1 5
47213PRTArtificial SequenceSynthetic Polypeptide 472Arg Pro His Phe
Asp Gln Leu Val Ala Ala Phe Asp Lys 1 5 10 4738PRTArtificial
SequenceSynthetic Polypeptide 473Ser Phe Gly Pro Leu Thr Gln Arg 1
5 47435PRTArtificial SequenceSynthetic Polypeptide 474Val Asp Thr
Ile Ala Ala Asp Glu Ser Phe Pro Ser Ser Ser Ser Ser 1 5 10 15 Ser
Ser Ser Ser Ser Ser Ala Ala Trp Ala Val Gly Pro His Gly Ala 20 25
30 Gly Gln Arg 35 47518PRTArtificial SequenceSynthetic Polypeptide
475Val Tyr Phe Gln Thr Leu Pro Gln Gly Glu Leu Ser Ser Gln Leu Pro
1 5 10 15 Glu Arg 47611PRTArtificial SequenceSynthetic Polypeptide
476Trp Ala Ala Pro Glu Val Ile Ala His Gly Lys 1 5 10
47720PRTArtificial SequenceSynthetic Polypeptide 477Ile Trp Pro Gly
Ile Pro Ser Pro Glu Ser Glu Phe Glu Gly Leu Phe 1 5 10 15 Thr Thr
His Lys 20 47811PRTArtificial SequenceSynthetic Polypeptide 478Leu
Ala Asp Glu Ser Gly His Val Val Leu Arg 1 5 10 47919PRTArtificial
SequenceSynthetic Polypeptide 479Val Ile His Ile Asn Glu Val Val
Leu Leu Asp Ala Pro Val Gly Leu 1 5 10 15 Val Ala Arg
4809PRTArtificial SequenceSynthetic Polypeptide 480Val Thr Ala Ala
Ser Gly Ala Pro Arg 1 5 48116PRTArtificial SequenceSynthetic
Polypeptide 481Tyr Glu Val Asp Val Ser Ala Gly Asn Gly Ala Gly Ser
Val Gln Arg 1 5 10 15 48217PRTArtificial SequenceSynthetic
Polypeptide 482Gly Ala Leu Gly Pro Gln Leu Leu Leu Asn Trp Gly Val
Gln Ile Ala 1 5 10 15 Lys 48312PRTArtificial SequenceSynthetic
Polypeptide 483Gly Glu Ser Ile Glu Pro Leu Asp Pro Ser Glu Lys 1 5
10 48410PRTArtificial SequenceSynthetic Polypeptide 484Leu Ala Glu
Val Pro Asp Leu Leu Glu Lys 1 5 10 48518PRTArtificial
SequenceSynthetic Polypeptide 485Ser Leu Glu Ala Thr Asp Ser Ala
Phe Asp Asn Pro Asp Tyr Trp His 1 5 10 15 Ser Arg
48621PRTArtificial SequenceSynthetic Polypeptide 486Ser Pro Ser Gln
Val Gln Val Ala Asp Phe Gly Val Ala Asp Leu Leu 1 5 10 15 Pro Pro
Asp Asp Lys 20 4878PRTArtificial SequenceSynthetic Polypeptide
487Val Ala Gln Val Ser Ile Thr Lys 1 5 48811PRTArtificial
SequenceSynthetic Polypeptide 488Val Thr Ser Gly Asp Pro Glu Leu
Pro Gln Val 1 5 10 4897PRTArtificial SequenceSynthetic Polypeptide
489Ala Val Leu Gln Trp Thr Lys 1 5 49014PRTArtificial
SequenceSynthetic Polypeptide 490Leu Gly Ala Val Asp Glu Ser Leu
Ser Glu Glu Thr Gln Lys 1 5 10 4918PRTArtificial SequenceSynthetic
Polypeptide 491Leu Leu Glu Ser Asp Tyr Phe Arg 1 5
4927PRTArtificial SequenceSynthetic Polypeptide 492Asn Leu Leu Gln
Asn Ile His 1 5 49317PRTArtificial SequenceSynthetic Polypeptide
493Val Leu Pro Phe Phe Glu Arg Pro Asp Phe Gln Leu Phe Thr Gly Asn
1 5 10 15 Lys 49410PRTArtificial SequenceSynthetic Polypeptide
494Phe Pro Phe Phe Gln Tyr Ser Val Thr Lys 1 5 10 4958PRTArtificial
SequenceSynthetic Polypeptide 495Glu Ala Gln Asp Asp Leu Val Lys 1
5 4968PRTArtificial SequenceSynthetic Polypeptide 496Glu Leu Ser
Glu Gln Ile Gln Arg 1 5 4979PRTArtificial SequenceSynthetic
Polypeptide 497Ile Gln Val Trp His Ala Glu His Arg 1 5
4987PRTArtificial SequenceSynthetic Polypeptide 498Leu Gln Asp Tyr
Glu Glu Lys 1 5 4998PRTArtificial SequenceSynthetic Polypeptide
499Ser Gly Tyr Leu Ser Ser Glu Arg 1 5 50015PRTArtificial
SequenceSynthetic Polypeptide 500Ala Asp Glu Pro Ser Ser Glu Glu
Ser Asp Leu Glu Ile Asp Lys 1 5 10 15 50110PRTArtificial
SequenceSynthetic Polypeptide 501Ala Ile Asp Leu Phe Thr Asp Ala
Ile Lys 1 5 10 50213PRTArtificial SequenceSynthetic Polypeptide
502Ala Ile Glu Ile Asn Pro Asp Ser Ala Gln Pro Tyr Lys 1 5 10
5039PRTArtificial SequenceSynthetic Polypeptide 503Leu Gln Lys Pro
Asn Ala Ala Ile Arg 1 5 5046PRTArtificial SequenceSynthetic
Polypeptide 504Tyr Gln Ser Asn Pro Lys 1 5 50510PRTArtificial
SequenceSynthetic Polypeptide 505Gly Ile Asn Val Ala Leu Ala Asn
Gly Lys 1 5 10 50622PRTArtificial SequenceSynthetic Polypeptide
506Leu Val Val Ala Val Ala Val Phe Leu Leu Thr Phe Tyr Val Ile Ser
1 5 10 15 Gln Val Phe Glu Ile Lys 20 5078PRTArtificial
SequenceSynthetic Polypeptide 507Ser Ala Leu Asp Thr Ala Ala Arg 1
5 5088PRTArtificial SequenceSynthetic Polypeptide 508Ser Pro Phe
Glu Gln His Ile Lys 1 5 5098PRTArtificial SequenceSynthetic
Polypeptide 509Thr Gly Glu Val Leu Asp Thr Lys 1 5
51017PRTArtificial SequenceSynthetic Polypeptide 510Gly Asn Ala Gly
Gln Ser Asn Tyr Gly Phe Ala Asn Ser Ala Met Glu 1 5 10 15 Arg
51117PRTArtificial SequenceSynthetic Polypeptide 511Leu Pro Glu Asp
Pro Leu Leu Ser Gly Leu Leu Asp Ser Pro Ala Leu 1 5 10 15 Lys
51211PRTArtificial SequenceSynthetic Polypeptide 512Leu Gln Val Val
Asp Gln Pro Leu Pro Val Arg 1 5 10 51313PRTArtificial
SequenceSynthetic Polypeptide 513Met Val Val Pro Gly Leu Asp Gly
Ala Gln Ile Pro Arg 1 5 10 51411PRTArtificial SequenceSynthetic
Polypeptide 514Ser Glu Gly Val Val Ala Val Leu Leu Thr Lys 1 5 10
5159PRTArtificial SequenceSynthetic Polypeptide 515Val Leu Glu Ala
Leu Leu Pro Leu Lys 1 5 51610PRTArtificial SequenceSynthetic
Polypeptide 516Gly Trp Leu Leu Leu Gln Val Ser Ser Arg 1 5 10
5177PRTArtificial SequenceSynthetic Polypeptide 517His Leu Glu Glu
Glu Leu Lys 1 5 5189PRTArtificial SequenceSynthetic Polypeptide
518Leu Val Tyr Asn Val Leu Tyr Tyr Arg 1 5 51911PRTArtificial
SequenceSynthetic Polypeptide 519Val Phe Thr Glu Gly Glu Pro Leu
Ala Leu Arg 1 5 10 52011PRTArtificial SequenceSynthetic Polypeptide
520Tyr Thr Ser Ala Gly Ile Ser Val Thr Val Lys 1 5 10
52119PRTArtificial SequenceSynthetic Polypeptide 521Ile Glu Glu Asn
Gly Tyr Asn Thr Tyr Ala Ser Phe Asn Trp Gln His 1 5 10 15 Asn Gly
Arg 52210PRTArtificial SequenceSynthetic Polypeptide 522Ser Tyr Asn
His Leu Gln Gly Asp Val Arg 1 5 10 52310PRTArtificial
SequenceSynthetic Polypeptide 523Leu Glu Ser Asn Asn Tyr Asn Thr
Tyr Arg 1 5 10 5248PRTArtificial SequenceSynthetic Polypeptide
524Leu Gln Leu Gln Ala Glu Glu Arg 1 5 5257PRTArtificial
SequenceSynthetic Polypeptide 525Asn Gly Gly Phe Phe Leu Arg 1 5
52615PRTArtificial SequenceSynthetic Polypeptide 526Glu Leu Ile Leu
Glu Asn His Tyr Asn Thr Tyr Ala Ser Ala Lys 1 5 10 15
5276PRTArtificial SequenceSynthetic Polypeptide 527Thr Gln Trp Tyr
Leu Arg 1 5 52810PRTArtificial SequenceSynthetic Polypeptide 528Thr
Val Ala Val Gly Ile Val Ala Ile Lys 1 5 10 52913PRTArtificial
SequenceSynthetic Polypeptide 529Trp Ile Leu Thr Trp Ile Leu Pro
Thr Leu Leu Tyr Arg 1 5 10 53017PRTArtificial SequenceSynthetic
Polypeptide 530Glu Gln Phe Glu Glu Asn Trp Tyr Asn Thr Tyr Ser Ser
Asn Leu Tyr 1 5 10 15 Lys 53117PRTArtificial SequenceSynthetic
Polypeptide 531Phe Gly Ile Leu Glu Phe Ile Ser Ile Ala Val Gly Leu
Val Ser Ile 1 5 10 15 Arg 53213PRTArtificial SequenceSynthetic
Polypeptide 532Phe Thr His Phe Leu Pro Arg Pro Val Asp Pro Asp Lys
1 5 10 5338PRTArtificial SequenceSynthetic Polypeptide 533Gly Glu
Leu Tyr Gly Ser Glu Lys 1 5 53411PRTArtificial SequenceSynthetic
Polypeptide 534Gly Pro Ala Val Thr Asp Leu Asp His Leu Lys 1 5 10
5358PRTArtificial SequenceSynthetic Polypeptide 535Glu Ile Glu Val
Leu Tyr Ile Arg 1 5 5368PRTArtificial SequenceSynthetic Polypeptide
536Gln Leu Val Glu Asp Leu Asp Arg 1 5 53711PRTArtificial
SequenceSynthetic Polypeptide 537Thr Val Leu Ile Gly Glu Tyr Leu
Gln Ile Lys 1 5 10 53810PRTArtificial SequenceSynthetic Polypeptide
538Tyr Gly Pro Asp Gly Leu Pro Tyr Leu Lys 1 5 10
53920PRTArtificial SequenceSynthetic Polypeptide 539Tyr Gln Ile Ser
Gln Pro Glu Val Tyr Val Ala Ala Pro Gly Glu Ser 1 5 10 15 Leu Glu
Val Arg 20 54010PRTArtificial SequenceSynthetic Polypeptide 540Asp
Gly Thr Gly Leu Val Pro Ser Glu Arg 1 5 10 54122PRTArtificial
SequenceSynthetic Polypeptide 541Leu Ser Ser Gly Glu Gly Pro Thr
Leu Ala Asn Val Ser Glu Leu Glu 1 5 10 15 Leu Pro Ala Asp Pro Lys
20 5429PRTArtificial SequenceSynthetic Polypeptide 542Thr Ala Gly
Ala Asn Thr Thr Asp Lys 1 5 54313PRTArtificial SequenceSynthetic
Polypeptide 543Val Gly Pro Asp Gly Thr Pro Tyr Val Thr Val Leu Lys
1 5 10 5448PRTArtificial SequenceSynthetic Polypeptide 544Glu Leu
Glu Ser Glu Val Asn Lys 1 5 54515PRTArtificial SequenceSynthetic
Polypeptide 545Leu His Val Gly Asn Tyr Asn Gly Thr Ala Gly Asp Ala
Leu Arg 1 5 10 15 54611PRTArtificial SequenceSynthetic Polypeptide
546Leu Gln Ala Asp Asp Asn Gly Asp Pro Gly Arg 1 5 10
54718PRTArtificial SequenceSynthetic Polypeptide 547Asn Gly Leu Leu
Leu Pro Ser Thr Gly Ala Pro Gly Glu Val Gly Asp 1 5 10 15 Asn Arg
54814PRTArtificial SequenceSynthetic Polypeptide 548Val Ala Asn Leu
Thr Phe Val Val Asn Ser Leu Asp Gly Lys 1 5 10 5498PRTArtificial
SequenceSynthetic Polypeptide 549Glu Asp Phe Pro Ala Ser Trp Arg 1
5 55014PRTArtificial SequenceSynthetic Polypeptide 550Phe Gly Gln
His Leu Ile Lys Pro Ser Val Val Phe Leu Lys 1 5 10
55118PRTArtificial SequenceSynthetic Polypeptide 551Phe His Asp Leu
Arg Pro Asp Glu Val Ala Asp Leu Phe Gln Thr Thr 1 5 10 15 Gln Arg
55210PRTArtificial SequenceSynthetic Polypeptide 552Asn Asp Ser Ile
Tyr Glu Glu Leu Gln Lys 1 5 10 5537PRTArtificial SequenceSynthetic
Polypeptide 553Val Gly Thr Val Val Glu Lys 1 5 55416PRTArtificial
SequenceSynthetic Polypeptide 554Gly Gly Ser Thr Ser Tyr Gly Thr
Gly Ser Glu Thr Glu Ser Pro Arg 1 5 10 15 55513PRTArtificial
SequenceSynthetic Polypeptide 555Gly Leu Ile Asp Glu Val Asn Gln
Asp Phe Thr Asn Arg 1 5 10 5568PRTArtificial SequenceSynthetic
Polypeptide 556Asn Ser Leu Phe Glu Tyr Gln Lys 1 5
5579PRTArtificial SequenceSynthetic Polypeptide 557Thr Val Ile Gly
Pro Asp Gly His Lys 1 5 5589PRTArtificial SequenceSynthetic
Polypeptide 558Val Gln His Ile Gln Leu Leu Gln Lys 1 5
55918PRTArtificial SequenceSynthetic Polypeptide 559His Thr Ser Val
Gln Thr Thr Ser Ser Gly Ser Gly Pro Phe Thr Asp 1 5 10 15 Val Arg
56019PRTArtificial SequenceSynthetic Polypeptide 560Ser Ser Pro Val
Val Ile Asp Ala Ser Thr Ala Ile Asp Ala Pro Ser 1 5 10 15 Asn Leu
Arg 56114PRTArtificial SequenceSynthetic Polypeptide 561Ser Tyr Thr
Ile Thr Gly Leu Gln Pro Gly Thr Asp Tyr Lys 1 5 10
56215PRTArtificial SequenceSynthetic Polypeptide 562Val Pro Gly Thr
Ser Thr Ser Ala Thr Leu Thr Gly Leu Thr Arg 1 5 10 15
56328PRTArtificial SequenceSynthetic Polypeptide 563Val Val Thr Pro
Leu Ser Pro Pro Thr Asn Leu His Leu Glu Ala Asn 1 5 10 15 Pro Asp
Thr Gly Val Leu Thr Val Ser Trp Glu Arg 20 25 56412PRTArtificial
SequenceSynthetic Polypeptide 564Ala Glu Ala Gly Leu Glu Thr Glu
Ser Pro Val Arg 1 5 10 5656PRTArtificial SequenceSynthetic
Polypeptide 565Ala Asn Tyr Trp Leu Lys 1 5 56610PRTArtificial
SequenceSynthetic Polypeptide 566Asp Pro Leu Val Ile Glu Leu Gly
Gln Lys 1 5 10 5678PRTArtificial SequenceSynthetic Polypeptide
567Ile Ile Asp Thr Ser Leu Thr Arg 1 5 56822PRTArtificial
SequenceSynthetic Polypeptide 568Asp Ser Trp Val Phe Gly Gly Ile
Asp Pro Gln Ser Gly Ala Ala Val 1 5 10 15 Val His Glu Ile Val Arg
20 56917PRTArtificial SequenceSynthetic Polypeptide 569Gly Val Ile
Leu Tyr Ser Asp Pro Ala Asp Tyr Phe Ala Pro Gly Val 1 5 10 15 Lys
57013PRTArtificial SequenceSynthetic Polypeptide 570Leu Gly Ser Gly
Asn Asp Phe Glu Val Phe Phe Gln Arg 1 5 10
57115PRTArtificial SequenceSynthetic Polypeptide 571Ser Tyr Pro Asp
Gly Trp Asn Leu Pro Gly Gly Gly Val Gln Arg 1 5 10 15
57214PRTArtificial SequenceSynthetic Polypeptide 572Thr Tyr Ser Val
Ser Phe Asp Ser Leu Phe Ser Ala Val Lys 1 5 10 5737PRTArtificial
SequenceSynthetic Polypeptide 573Asp Val Ser Tyr Leu Tyr Arg 1 5
5748PRTArtificial SequenceSynthetic Polypeptide 574Glu Lys Pro Gly
Pro Glu Asp Lys 1 5 57510PRTArtificial SequenceSynthetic
Polypeptide 575Gly Trp Asn Trp Thr Ser Gly Phe Asn Lys 1 5 10
5766PRTArtificial SequenceSynthetic Polypeptide 576Val Ser Asn Tyr
Ser Arg 1 5 57727PRTArtificial SequenceSynthetic Polypeptide 577Ala
Tyr Glu Gln Val Met His Tyr Pro Gly Tyr Gly Ser Pro Met Pro 1 5 10
15 Gly Ser Leu Ala Met Gly Pro Val Thr Asn Lys 20 25
57810PRTArtificial SequenceSynthetic Polypeptide 578Glu Ala Ala Gly
Ala Ala Gly Ser Gly Lys 1 5 10 57912PRTArtificial SequenceSynthetic
Polypeptide 579Met His Ser Ala Ser Ser Met Leu Gly Ala Val Lys 1 5
10 58019PRTArtificial SequenceSynthetic Polypeptide 580Met Leu Thr
Leu Ser Glu Ile Tyr Gln Trp Ile Met Asp Leu Phe Pro 1 5 10 15 Phe
Tyr Arg 58125PRTArtificial SequenceSynthetic Polypeptide 581Ser Tyr
Thr His Ala Lys Pro Pro Tyr Ser Tyr Ile Ser Leu Ile Thr 1 5 10 15
Met Ala Ile Gln Gln Ser Pro Asn Lys 20 25 58227PRTArtificial
SequenceSynthetic Polypeptide 582Thr Gly Leu Asp Ala Ser Pro Leu
Ala Ala Asp Thr Ser Tyr Tyr Gln 1 5 10 15 Gly Val Tyr Ser Arg Pro
Ile Met Asn Ser Ser 20 25 5836PRTArtificial SequenceSynthetic
Polypeptide 583Trp Gln Asn Ser Ile Arg 1 5 58412PRTArtificial
SequenceSynthetic Polypeptide 584Ala Glu Tyr Leu Pro Pro Ser Val
Ala Ser Ile Lys 1 5 10 5859PRTArtificial SequenceSynthetic
Polypeptide 585Ala Pro Ser Pro Leu Gly Pro Thr Arg 1 5
58612PRTArtificial SequenceSynthetic Polypeptide 586Glu Leu Leu Ser
Gly Ile Gly Asn Ile Ser Glu Arg 1 5 10 58713PRTArtificial
SequenceSynthetic Polypeptide 587Glu Pro Gly Ser Gln Pro Ala Gly
Pro Ala Ser Leu Arg 1 5 10 58811PRTArtificial SequenceSynthetic
Polypeptide 588Ser Ala Pro Gly Asp Pro Asn Ala Leu Val Lys 1 5 10
58910PRTArtificial SequenceSynthetic Polypeptide 589His Thr Leu Gly
Asp Ser Asp Asn Glu Ser 1 5 10 59011PRTArtificial SequenceSynthetic
Polypeptide 590Asn Val Asn Gln Ser Leu Leu Glu Leu His Lys 1 5 10
59113PRTArtificial SequenceSynthetic Polypeptide 591Gln Asn Tyr His
Gln Asp Ser Glu Ala Ala Ile Asn Arg 1 5 10 59210PRTArtificial
SequenceSynthetic Polypeptide 592Tyr Phe Leu His Gln Ser His Glu
Glu Arg 1 5 10 5937PRTArtificial SequenceSynthetic Polypeptide
593Ala Leu Phe Gln Asp Ile Lys 1 5 59413PRTArtificial
SequenceSynthetic Polypeptide 594Asp Asp Val Ala Leu Glu Gly Val
Ser His Phe Phe Arg 1 5 10 5959PRTArtificial SequenceSynthetic
Polypeptide 595Lys Pro Ala Glu Asp Glu Trp Gly Lys 1 5
59615PRTArtificial SequenceSynthetic Polypeptide 596Leu Gly Gly Pro
Glu Ala Gly Leu Gly Glu Tyr Leu Phe Glu Arg 1 5 10 15
59715PRTArtificial SequenceSynthetic Polypeptide 597Leu Asn Gln Ala
Leu Leu Asp Leu His Ala Leu Gly Ser Ala Arg 1 5 10 15
59810PRTArtificial SequenceSynthetic Polypeptide 598Met Gly Asp His
Leu Thr Asn Leu His Arg 1 5 10 59915PRTArtificial SequenceSynthetic
Polypeptide 599Gly Ala Leu Gln Asn Ile Ile Pro Ala Ser Thr Gly Ala
Ala Lys 1 5 10 15 60014PRTArtificial SequenceSynthetic Polypeptide
600Leu Ile Ser Trp Tyr Asp Asn Glu Phe Gly Tyr Ser Asn Arg 1 5 10
60114PRTArtificial SequenceSynthetic Polypeptide 601Leu Val Ile Asn
Gly Asn Pro Ile Thr Ile Phe Gln Glu Arg 1 5 10 60211PRTArtificial
SequenceSynthetic Polypeptide 602Val Val Asp Leu Met Ala His Met
Ala Ser Lys 1 5 10 60315PRTArtificial SequenceSynthetic Polypeptide
603Asp Gly Leu Leu Pro Glu Asn Thr Phe Ile Val Gly Tyr Ala Arg 1 5
10 15 60411PRTArtificial SequenceSynthetic Polypeptide 604Gly Gly
Tyr Phe Asp Glu Phe Gly Ile Ile Arg 1 5 10 60524PRTArtificial
SequenceSynthetic Polypeptide 605Ile Phe Thr Pro Leu Leu His Gln
Ile Glu Leu Glu Lys Pro Lys Pro 1 5 10 15 Ile Pro Tyr Ile Tyr Gly
Ser Arg 20 6067PRTArtificial SequenceSynthetic Polypeptide 606Leu
Pro Asp Ala Tyr Glu Arg 1 5 60716PRTArtificial SequenceSynthetic
Polypeptide 607Asn Ser Tyr Val Ala Gly Gln Tyr Asp Asp Ala Ala Ser
Tyr Gln Arg 1 5 10 15 6088PRTArtificial SequenceSynthetic
Polypeptide 608Ala Val Leu His Val Ala Leu Arg 1 5
60921PRTArtificial SequenceSynthetic Polypeptide 609Phe Asn His Phe
Ser Leu Thr Leu Asn Thr Asn His Gly His Ile Leu 1 5 10 15 Val Asp
Tyr Ser Lys 20 61017PRTArtificial SequenceSynthetic Polypeptide
610Thr Leu Ala Gln Leu Asn Pro Glu Ser Ser Leu Phe Ile Ile Ala Ser
1 5 10 15 Lys 61130PRTArtificial SequenceSynthetic Polypeptide
611Val Asp His Gln Thr Gly Pro Ile Val Trp Gly Glu Pro Gly Thr Asn
1 5 10 15 Gly Gln His Ala Phe Tyr Gln Leu Ile His Gln Gly Thr Lys
20 25 30 61215PRTArtificial SequenceSynthetic Polypeptide 612Val
Phe Glu Gly Asn Arg Pro Thr Asn Ser Ile Val Phe Thr Lys 1 5 10 15
61327PRTArtificial SequenceSynthetic Polypeptide 613Ala Ala Pro Pro
Ala Pro Asn Ala Pro Ala Ala Gly Glu Asp Thr Thr 1 5 10 15 Glu Thr
Ala Pro Ala Pro Gly Thr Pro Ala Arg 20 25 61419PRTArtificial
SequenceSynthetic Polypeptide 614Ala Leu Glu Ala Val Ala Ser Val
Thr Pro Thr Gly Pro Val Pro Asp 1 5 10 15 Pro Ala Arg
61510PRTArtificial SequenceSynthetic Polypeptide 615Leu Val Gln Phe
Glu Gln Glu Ile Glu Arg 1 5 10 61611PRTArtificial SequenceSynthetic
Polypeptide 616Val Gly Asp Ser Ser Leu Leu Ile Phe Val Arg 1 5 10
61717PRTArtificial SequenceSynthetic Polypeptide 617Val Ser Ser Pro
Ser Pro Glu Leu Gly Thr Thr Pro Ala Ser Ile Phe 1 5 10 15 Arg
61820PRTArtificial SequenceSynthetic Polypeptide 618Glu Ile Ile Leu
Val Asp Asp Tyr Ser Asn Asp Pro Glu Asp Gly Ala 1 5 10 15 Leu Leu
Gly Lys 20 61910PRTArtificial SequenceSynthetic Polypeptide 619Gly
Gly Phe Asp Trp Asn Leu Val Phe Lys 1 5 10 62011PRTArtificial
SequenceSynthetic Polypeptide 620Asn Phe Tyr Tyr Ala Ala Val Pro
Ser Ala Arg 1 5 10 62117PRTArtificial SequenceSynthetic Polypeptide
621Val Asp Leu Pro Ala Thr Ser Val Val Ile Thr Phe His Asn Glu Ala
1 5 10 15 Arg 62211PRTArtificial SequenceSynthetic Polypeptide
622Trp Tyr Leu Glu Asn Val Tyr Pro Glu Leu Arg 1 5 10
62312PRTArtificial SequenceSynthetic Polypeptide 623Asp Gly Glu Ala
Thr Leu Glu Val Asp Gly Thr Arg 1 5 10 62415PRTArtificial
SequenceSynthetic Polypeptide 624Glu Val Phe Glu Asn Asp Pro Glu
Thr Asp Tyr Phe Tyr Pro Arg 1 5 10 15 62513PRTArtificial
SequenceSynthetic Polypeptide 625Gly Gln Ser Glu Val Ser Ala Ala
Gln Leu Gln Glu Arg 1 5 10 62612PRTArtificial SequenceSynthetic
Polypeptide 626Ile Ala Val Ala Gly Asp Leu Phe Gln Pro Glu Arg 1 5
10 62717PRTArtificial SequenceSynthetic Polypeptide 627Ser Trp Asn
Trp Leu Asn Gly Glu Asp Thr Thr Ile Gln Glu Thr Val 1 5 10 15 Lys
62817PRTArtificial SequenceSynthetic Polypeptide 628Ala Pro Glu Pro
His Val Glu Glu Asp Asp Asp Asp Glu Leu Asp Ser 1 5 10 15 Lys
6297PRTArtificial SequenceSynthetic Polypeptide 629Asp Ile Val Ser
Gly Leu Lys 1 5 6309PRTArtificial SequenceSynthetic Polypeptide
630Leu Asn Tyr Lys Pro Pro Pro Gln Lys 1 5 63113PRTArtificial
SequenceSynthetic Polypeptide 631Gln Asp His Leu Ser Trp Glu Trp
Asn Leu Ser Ile Lys 1 5 10 6328PRTArtificial SequenceSynthetic
Polypeptide 632Ser Phe Phe Thr Asp Asp Asp Lys 1 5
63313PRTArtificial SequenceSynthetic Polypeptide 633Thr Leu Leu Gly
Asp Gly Pro Val Val Thr Asp Pro Lys 1 5 10 63422PRTArtificial
SequenceSynthetic Polypeptide 634Ala Gln Pro Val Gln Val Ala Glu
Gly Ser Glu Pro Asp Gly Phe Trp 1 5 10 15 Glu Ala Leu Gly Gly Lys
20 6358PRTArtificial SequenceSynthetic Polypeptide 635Glu Pro Gly
Leu Gln Ile Trp Arg 1 5 63624PRTArtificial SequenceSynthetic
Polypeptide 636Phe Asp Leu Val Pro Val Pro Thr Asn Leu Tyr Gly Asp
Phe Phe Thr 1 5 10 15 Gly Asp Ala Tyr Val Ile Leu Lys 20
6378PRTArtificial SequenceSynthetic Polypeptide 637Thr Ala Ser Asp
Phe Ile Thr Lys 1 5 63818PRTArtificial SequenceSynthetic
Polypeptide 638Thr Pro Ser Ala Ala Tyr Leu Trp Val Gly Thr Gly Ala
Ser Glu Ala 1 5 10 15 Glu Lys 6397PRTArtificial SequenceSynthetic
Polypeptide 639Asp Tyr Glu Ile Leu Phe Lys 1 5 64013PRTArtificial
SequenceSynthetic Polypeptide 640Asn Leu Asp Gly Ile Ser His Ala
Pro Asn Ala Val Lys 1 5 10 6418PRTArtificial SequenceSynthetic
Polypeptide 641Tyr Leu Glu Ser Ala Gly Ala Arg 1 5
64212PRTArtificial SequenceSynthetic Polypeptide 642Tyr Pro Val Tyr
Gly Val Gln Trp His Pro Glu Lys 1 5 10 6439PRTArtificial
SequenceSynthetic Polypeptide 643Tyr Tyr Ile Ala Ala Ser Tyr Val
Lys 1 5 64424PRTArtificial SequenceSynthetic Polypeptide 644Phe Leu
Ala Glu Leu Ala Tyr Asp Leu Asp Val Asp Asp Ala Pro Gly 1 5 10 15
Asn Ser Gln Gln Ala Thr Pro Lys 20 64519PRTArtificial
SequenceSynthetic Polypeptide 645Phe Leu Ile Ile Gln Asn Ala Ala
Val Phe Gln Glu Ala Phe Glu Ile 1 5 10 15 Val Val Arg
64612PRTArtificial SequenceSynthetic Polypeptide 646Gly Pro Glu Pro
Val Val Ser Gln Ile Ile Asp Lys 1 5 10 64720PRTArtificial
SequenceSynthetic Polypeptide 647Ile Phe Leu Gln Ala Leu Asn Leu
Gly Ile Glu Val Ile Asn Thr Thr 1 5 10 15 Asp His Leu Lys 20
6489PRTArtificial SequenceSynthetic Polypeptide 648Asn Gln Phe Asn
Leu His Glu Leu Lys 1 5 64910PRTArtificial SequenceSynthetic
Polypeptide 649Glu Leu Trp Ala Ala Leu Asn Ala Trp Lys 1 5 10
65011PRTArtificial SequenceSynthetic Polypeptide 650Ala Ser Gln Gly
Pro Pro Ser Ala Ile Ser Arg 1 5 10 65110PRTArtificial
SequenceSynthetic Polypeptide 651Glu Val Asn Tyr Glu Leu Val Thr
Gly Lys 1 5 10 65214PRTArtificial SequenceSynthetic Polypeptide
652Ile Leu Ser Glu Ser Leu Leu Thr Pro Ala Glu Tyr Gln Lys 1 5 10
65322PRTArtificial SequenceSynthetic Polypeptide 653Thr Ala Leu Glu
Gln Glu Leu Gly Leu Ala Ala Tyr Phe Val Ser Asn 1 5 10 15 Glu Val
Pro Leu Glu Lys 20 65413PRTArtificial SequenceSynthetic Polypeptide
654Thr Gly Ala Tyr Leu Gln Phe Leu Ser Val Leu Ser Arg 1 5 10
65518PRTArtificial SequenceSynthetic Polypeptide 655Ala Gln His Asn
Asp Ser Glu Gln Thr Gln Ser Pro Gln Gln Pro Gly 1 5 10 15 Ser Arg
65618PRTArtificial SequenceSynthetic Polypeptide 656Ala Leu Gly Asn
Gln Gln Pro Ser Trp Asp Ser Glu Asp Ser Ser Asn 1 5 10 15 Phe Lys
65714PRTArtificial SequenceSynthetic Polypeptide 657Ala Val Pro Leu
Pro Ala Gly Gly Gly Thr Val Leu Thr Lys 1 5 10 6588PRTArtificial
SequenceSynthetic Polypeptide 658Leu Ser Ala Pro Gly Ser Gln Arg 1
5 6599PRTArtificial SequenceSynthetic Polypeptide 659Asn Leu Leu
Gly Leu Ile Glu Ala Lys 1 5 6607PRTArtificial SequenceSynthetic
Polypeptide 660Asn Pro Gln Leu Asn Gln Gln 1 5 66118PRTArtificial
SequenceSynthetic Polypeptide 661Gly Val Pro Gln Ile Glu Val Thr
Phe Glu Ile Asp Val Asn Gly Ile 1 5 10 15 Leu Arg 6628PRTArtificial
SequenceSynthetic Polypeptide 662Leu Thr Pro Glu Glu Ile Glu Arg 1
5 66318PRTArtificial SequenceSynthetic Polypeptide 663Leu Tyr Gly
Ser Ala Gly Pro Pro Pro Thr Gly Glu Glu Asp Thr Ala 1 5 10 15 Glu
Lys 66412PRTArtificial SequenceSynthetic Polypeptide 664Thr Trp Asn
Asp Pro Ser Val Gln Gln Asp Ile Lys 1 5 10 66510PRTArtificial
SequenceSynthetic Polypeptide 665Val Tyr Glu Gly Glu Arg Pro Leu
Thr Lys 1 5 10 66611PRTArtificial SequenceSynthetic Polypeptide
666Ile Ile Ile Gln Glu Ser Ala Leu Asp Tyr Arg 1 5 10
6678PRTArtificial SequenceSynthetic Polypeptide 667Leu Asp Pro Ala
Leu Gln Asp Lys 1 5 6687PRTArtificial SequenceSynthetic Polypeptide
668Leu Ile Ala Gln Asp Tyr Lys 1 5 6697PRTArtificial
SequenceSynthetic Polypeptide 669Asn Asp Ile Asn Ile Leu Lys 1 5
67013PRTArtificial SequenceSynthetic Polypeptide 670Val Ala Glu Leu
Ser Ser Asp Asp Phe His Leu Asp Arg 1 5 10 67118PRTArtificial
SequenceSynthetic Polypeptide 671Ala Phe Leu Ala Ser Pro Glu Tyr
Val Asn Leu Pro Ile Asn Gly Asn 1 5 10 15 Gly Lys
67220PRTArtificial SequenceSynthetic Polypeptide 672Ala Leu Pro Gly
Gln Leu Lys Pro Phe Glu Thr Leu Leu Ser Gln Asn 1 5 10 15 Gln Gly
Gly Lys 20 67315PRTArtificial SequenceSynthetic Polypeptide 673Glu
Glu Val Val Thr Val Glu Thr Trp Gln Glu Gly Ser Leu Lys 1 5 10 15
67416PRTArtificial SequenceSynthetic Polypeptide 674Phe Gln Asp Gly
Asp Leu Thr Leu Tyr Gln Ser Asn Thr Ile Leu Arg 1 5 10 15
67513PRTArtificial SequenceSynthetic Polypeptide 675Tyr Ile Ser Leu
Ile Tyr Thr Asn Tyr Glu Ala Gly Lys 1 5 10 67630PRTArtificial
SequenceSynthetic Polypeptide 676Ala Gly Val Gln Gln Pro Val Tyr
Ala Thr Ile Gly Ser Gly Ile Val 1 5 10 15 Asn Thr Ala Phe Thr Val
Val Ser Leu Phe Val Val Glu Arg 20 25 30 67731PRTArtificial
SequenceSynthetic Polypeptide 677Gln Pro Ile Leu Ile Ala Val Val
Leu Gln Leu Ser Gln Gln Leu Ser 1 5 10 15 Gly Ile Asn Ala Val Phe
Tyr Tyr Ser Thr Ser Ile Phe Glu Lys 20 25 30 67810PRTArtificial
SequenceSynthetic Polypeptide 678Thr Phe Asp Glu Ile Ala Ser Gly
Phe Arg 1 5 10 67915PRTArtificial SequenceSynthetic Polypeptide
679Thr Pro Glu Glu Leu Phe His Pro Leu Gly Ala Asp Ser Gln Val 1 5
10 15 68013PRTArtificial SequenceSynthetic Polypeptide 680Val Ile
Glu Glu Phe Tyr Asn Gln Thr Trp Val His Arg 1 5 10
68111PRTArtificial
SequenceSynthetic Polypeptide 681Ala Phe Glu Gly Gln Ala His Gly
Ala Asp Arg 1 5 10 68231PRTArtificial SequenceSynthetic Polypeptide
682Asp Ala Gly Val Gln Glu Pro Ile Tyr Ala Thr Ile Gly Ala Gly Val
1 5 10 15 Val Asn Thr Ile Phe Thr Val Val Ser Leu Phe Leu Val Glu
Arg 20 25 30 68313PRTArtificial SequenceSynthetic Polypeptide
683Asp Gly Val Met Glu Met Asn Ser Ile Glu Pro Ala Lys 1 5 10
6846PRTArtificial SequenceSynthetic Polypeptide 684Phe Leu Leu Ile
Asn Arg 1 5 68515PRTArtificial SequenceSynthetic Polypeptide 685Leu
Trp Gly Thr Gln Asp Val Ser Gln Asp Ile Gln Glu Met Lys 1 5 10 15
68630PRTArtificial SequenceSynthetic Polypeptide 686Gln Pro Ile Ile
Ile Ser Ile Val Leu Gln Leu Ser Gln Gln Leu Ser 1 5 10 15 Gly Ile
Asn Ala Val Phe Tyr Tyr Ser Thr Gly Ile Phe Lys 20 25 30
6879PRTArtificial SequenceSynthetic Polypeptide 687Gln Val Thr Val
Leu Glu Leu Phe Arg 1 5 6889PRTArtificial SequenceSynthetic
Polypeptide 688Ser Val Glu Met Leu Ile Leu Gly Arg 1 5
6897PRTArtificial SequenceSynthetic Polypeptide 689Thr Phe Glu Asp
Ile Thr Arg 1 5 69031PRTArtificial SequenceSynthetic Polypeptide
690Val Thr Pro Ala Leu Ile Phe Ala Ile Thr Val Ala Thr Ile Gly Ser
1 5 10 15 Phe Gln Phe Gly Tyr Asn Thr Gly Val Ile Asn Ala Pro Glu
Lys 20 25 30 6919PRTArtificial SequenceSynthetic Polypeptide 691Ala
Gly Leu Gln Phe Pro Val Gly Arg 1 5 6927PRTArtificial
SequenceSynthetic Polypeptide 692His Leu Gln Leu Ala Ile Arg 1 5
6937PRTArtificial SequenceSynthetic Polypeptide 693Asn Asp Glu Glu
Leu Asn Lys 1 5 69429PRTArtificial SequenceSynthetic Polypeptide
694Val Gly Ala Gly Ala Pro Val Tyr Leu Ala Ala Val Leu Glu Tyr Leu
1 5 10 15 Thr Ala Glu Ile Leu Glu Leu Ala Gly Asn Ala Ala Arg 20 25
69531PRTArtificial SequenceSynthetic Polypeptide 695Gly Ala Leu Tyr
Thr Gly Phe Ser Ile Leu Val Thr Leu Leu Leu Ala 1 5 10 15 Gly Gln
Ala Thr Thr Ala Tyr Phe Leu Tyr Gln Gln Gln Gly Arg 20 25 30
6968PRTArtificial SequenceSynthetic Polypeptide 696Gly Ser Phe Pro
Glu Asn Leu Arg 1 5 69713PRTArtificial SequenceSynthetic
Polypeptide 697His Ser Leu Glu Gln Lys Pro Thr Asp Ala Pro Pro Lys
1 5 10 69810PRTArtificial SequenceSynthetic Polypeptide 698Leu Pro
Lys Pro Pro Lys Pro Val Ser Lys 1 5 10 69914PRTArtificial
SequenceSynthetic Polypeptide 699Leu Thr Val Thr Ser Gln Asn Leu
Gln Leu Glu Asn Leu Arg 1 5 10 70014PRTArtificial SequenceSynthetic
Polypeptide 700Asp Tyr Glu Ala Trp Leu Gly Ile His Asp Val His Gly
Arg 1 5 10 7018PRTArtificial SequenceSynthetic Polypeptide 701Glu
Ser Trp Val Leu Thr Ala Arg 1 5 70210PRTArtificial
SequenceSynthetic Polypeptide 702His Ile Phe Trp Glu Pro Asp Ala
Ser Lys 1 5 10 7038PRTArtificial SequenceSynthetic Polypeptide
703Val Val Asn Gly Ile Pro Thr Arg 1 5 7048PRTArtificial
SequenceSynthetic Polypeptide 704Trp Asp His Gln Thr Pro His Arg 1
5 70515PRTArtificial SequenceSynthetic Polypeptide 705Glu Glu Glu
Glu Gly Ile Ser Gln Glu Ser Ser Glu Glu Glu Gln 1 5 10 15
7068PRTArtificial SequenceSynthetic Polypeptide 706Ser Ser Gln Pro
Leu Ala Ser Lys 1 5 70710PRTArtificial SequenceSynthetic
Polypeptide 707Phe Phe Ala Asp Leu Leu Asp Tyr Ile Lys 1 5 10
70814PRTArtificial SequenceSynthetic Polypeptide 708Phe Val Val Gly
Tyr Ala Leu Asp Tyr Asn Glu Tyr Phe Arg 1 5 10 70913PRTArtificial
SequenceSynthetic Polypeptide 709Asn Val Leu Ile Val Glu Asp Ile
Ile Asp Thr Gly Lys 1 5 10 71016PRTArtificial SequenceSynthetic
Polypeptide 710Ser Val Gly Tyr Lys Pro Asp Phe Val Gly Phe Glu Ile
Pro Asp Lys 1 5 10 15 71113PRTArtificial SequenceSynthetic
Polypeptide 711Val Ile Gly Gly Asp Asp Leu Ser Thr Leu Thr Gly Lys
1 5 10 71218PRTArtificial SequenceSynthetic Polypeptide 712Glu Asp
Phe Leu Asn Pro Asp Val Leu Asp Ile Phe Ile Ser Ser Val 1 5 10 15
Gln Lys 7139PRTArtificial SequenceSynthetic Polypeptide 713Phe Leu
Ile Leu Leu Gly Ser Pro Lys 1 5 7148PRTArtificial SequenceSynthetic
Polypeptide 714Leu Pro Tyr Pro Phe Ser Asn Lys 1 5
71510PRTArtificial SequenceSynthetic Polypeptide 715Ser Val Gln Leu
Asn Gly Leu Thr Leu Lys 1 5 10 71614PRTArtificial SequenceSynthetic
Polypeptide 716Tyr Leu Leu Arg Pro Leu Gly Pro His Gly Leu Leu Ser
Lys 1 5 10 7177PRTArtificial SequenceSynthetic Polypeptide 717Asp
Tyr Ala Glu Val Gly Arg 1 5 71813PRTArtificial SequenceSynthetic
Polypeptide 718Thr Glu Gly Asp Gly Val Tyr Thr Leu Asn Asn Glu Lys
1 5 10 7199PRTArtificial SequenceSynthetic Polypeptide 719Val Gly
Tyr Val Ser Gly Trp Gly Arg 1 5 72010PRTArtificial
SequenceSynthetic Polypeptide 720Val Thr Ser Ile Gln Asp Trp Val
Gln Lys 1 5 10 72116PRTArtificial SequenceSynthetic Polypeptide
721Val Val Leu His Pro Asn Tyr Ser Gln Val Asp Ile Gly Leu Ile Lys
1 5 10 15 72211PRTArtificial SequenceSynthetic Polypeptide 722Asp
Asn Ser Thr Met Gly Tyr Met Ala Ala Lys 1 5 10 72315PRTArtificial
SequenceSynthetic Polypeptide 723His Leu Glu Ile Asn Pro Asp His
Ser Ile Ile Glu Thr Leu Arg 1 5 10 15 72413PRTArtificial
SequenceSynthetic Polypeptide 724Ser Leu Thr Asn Asp Trp Glu Asp
His Leu Ala Val Lys 1 5 10 72513PRTArtificial SequenceSynthetic
Polypeptide 725Thr Leu Thr Ile Val Asp Thr Gly Ile Gly Met Thr Lys
1 5 10 7269PRTArtificial SequenceSynthetic Polypeptide 726Ala Asp
His Gly Glu Pro Ile Gly Arg 1 5 72727PRTArtificial
SequenceSynthetic Polypeptide 727Asp Leu Val Val Leu Leu Phe Glu
Thr Ala Leu Leu Ser Ser Gly Phe 1 5 10 15 Ser Leu Glu Asp Pro Gln
Thr His Ser Asn Arg 20 25 72810PRTArtificial SequenceSynthetic
Polypeptide 728Ile Asp Ile Ile Pro Asn Pro Gln Glu Arg 1 5 10
72934PRTArtificial SequenceSynthetic Polypeptide 729Leu Gly Leu Gly
Ile Asp Glu Asp Glu Val Ala Ala Glu Glu Pro Asn 1 5 10 15 Ala Ala
Val Pro Asp Glu Ile Pro Pro Leu Glu Gly Asp Glu Asp Ala 20 25 30
Ser Arg 73015PRTArtificial SequenceSynthetic Polypeptide 730Asn Pro
Asp Asp Ile Thr Gln Glu Glu Tyr Gly Glu Phe Tyr Lys 1 5 10 15
73110PRTArtificial SequenceSynthetic Polypeptide 731Ala Gln Leu Gly
Gly Pro Glu Ala Ala Lys 1 5 10 7329PRTArtificial SequenceSynthetic
Polypeptide 732Asp Gly Val Val Glu Ile Thr Gly Lys 1 5
7338PRTArtificial SequenceSynthetic Polypeptide 733Gly Pro Ser Trp
Asp Pro Phe Arg 1 5 73417PRTArtificial SequenceSynthetic
Polypeptide 734Leu Ala Thr Gln Ser Asn Glu Ile Thr Ile Pro Val Thr
Phe Glu Ser 1 5 10 15 Arg 73510PRTArtificial SequenceSynthetic
Polypeptide 735Leu Phe Asp Gln Ala Phe Gly Leu Pro Arg 1 5 10
7369PRTArtificial SequenceSynthetic Polypeptide 736Gln Asp Glu His
Gly Tyr Ile Ser Arg 1 5 73710PRTArtificial SequenceSynthetic
Polypeptide 737Gln Leu Ser Ser Gly Val Ser Glu Ile Arg 1 5 10
7387PRTArtificial SequenceSynthetic Polypeptide 738Val Pro Phe Ser
Leu Leu Arg 1 5 73916PRTArtificial SequenceSynthetic Polypeptide
739Val Ser Leu Asp Val Asn His Phe Ala Pro Asp Glu Leu Thr Val Lys
1 5 10 15 74030PRTArtificial SequenceSynthetic Polypeptide 740Tyr
Thr Leu Pro Pro Gly Val Asp Pro Thr Gln Val Ser Ser Ser Leu 1 5 10
15 Ser Pro Glu Gly Thr Leu Thr Val Glu Ala Pro Met Pro Lys 20 25 30
74111PRTArtificial SequenceSynthetic Polypeptide 741Leu His Arg Pro
Pro Val Ile Val Leu Gln Arg 1 5 10 7428PRTArtificial
SequenceSynthetic Polypeptide 742Leu Pro Val Leu Leu Leu Gly Arg 1
5 74333PRTArtificial SequenceSynthetic Polypeptide 743Ser Ser Glu
Leu Arg Pro Gly Glu Phe Val Val Ala Ile Gly Ser Pro 1 5 10 15 Phe
Ser Leu Gln Asn Thr Val Thr Thr Gly Ile Val Ser Thr Thr Gln 20 25
30 Arg 74413PRTArtificial SequenceSynthetic Polypeptide 744Val Thr
Ala Gly Ile Ser Phe Ala Ile Pro Ser Asp Lys 1 5 10
74510PRTArtificial SequenceSynthetic Polypeptide 745Tyr Asn Phe Ile
Ala Asp Val Val Glu Lys 1 5 10 7469PRTArtificial SequenceSynthetic
Polypeptide 746Asp Phe Asn Pro Thr Ala Thr Val Lys 1 5
74710PRTArtificial SequenceSynthetic Polypeptide 747Phe Leu Leu Ser
Glu Ser Gly Ser Gly Lys 1 5 10 74811PRTArtificial SequenceSynthetic
Polypeptide 748His Ile Asp Leu Val Glu Gly Asp Glu Gly Arg 1 5 10
74911PRTArtificial SequenceSynthetic Polypeptide 749Leu Val Asp Glu
Tyr Ser Leu Asn Ala Gly Lys 1 5 10 75015PRTArtificial
SequenceSynthetic Polypeptide 750Ser Ala Asn Leu Val Ala Ala Thr
Leu Gly Ala Ile Leu Asn Arg 1 5 10 15 7518PRTArtificial
SequenceSynthetic Polypeptide 751His Pro Asp Trp Pro Pro Asp Arg 1
5 75228PRTArtificial SequenceSynthetic Polypeptide 752Asn Asp Gln
Leu Ala Trp Leu Trp Ala Glu Ser Thr Ala Leu Phe Pro 1 5 10 15 Ser
Val Tyr Leu Asp Glu Thr Leu Ala Ser Ser Arg 20 25
75330PRTArtificial SequenceSynthetic Polypeptide 753Gln Ala Ala Gly
Gly Ala Ser Glu Ala Trp Ala Gly Ser His Leu Thr 1 5 10 15 Ser Leu
Leu Ala Leu Ala Ala Leu Ala Phe Thr Trp Thr Leu 20 25 30
75421PRTArtificial SequenceSynthetic Polypeptide 754Thr Gln Glu Ser
Ala Gly Leu Ala Val Ile Asp Trp Glu Asp Trp Arg 1 5 10 15 Pro Val
Trp Val Arg 20 75528PRTArtificial SequenceSynthetic Polypeptide
755Val Pro Leu Asp Leu Asn Ala Phe Asp Val Gln Ala Ser Pro Asn Glu
1 5 10 15 Gly Phe Val Asn Gln Asn Ile Thr Ile Phe Tyr Arg 20 25
75612PRTArtificial SequenceSynthetic Polypeptide 756Phe Phe Gly Asp
Ser Ala Ala Ser Met Ala Ile Lys 1 5 10 75712PRTArtificial
SequenceSynthetic Polypeptide 757Phe Pro Glu His Glu Leu Thr Phe
Asp Pro Gln Arg 1 5 10 7589PRTArtificial SequenceSynthetic
Polypeptide 758Leu Ala Gly Leu Phe Asn Glu Gln Arg 1 5
75918PRTArtificial SequenceSynthetic Polypeptide 759Leu Gly Asn Thr
Ile Ser Ser Leu Phe Gly Gly Gly Thr Thr Pro Asp 1 5 10 15 Ala Lys
76012PRTArtificial SequenceSynthetic Polypeptide 760Leu Pro Ala Thr
Glu Lys Pro Val Leu Leu Ser Lys 1 5 10 76116PRTArtificial
SequenceSynthetic Polypeptide 761Val Ala Ile Val Lys Pro Gly Val
Pro Met Glu Ile Val Leu Asn Lys 1 5 10 15 7626PRTArtificial
SequenceSynthetic Polypeptide 762Ala Glu Val Leu Phe Arg 1 5
7636PRTArtificial SequenceSynthetic Polypeptide 763Glu Leu Ala Val
Phe Arg 1 5 7647PRTArtificial SequenceSynthetic Polypeptide 764His
Gly Leu Tyr Asn Leu Lys 1 5 7659PRTArtificial SequenceSynthetic
Polypeptide 765Leu Ile Gln Gly Ala Pro Thr Ile Arg 1 5
7666PRTArtificial SequenceSynthetic Polypeptide 766Val Thr Glu Gln
His Arg 1 5 76720PRTArtificial SequenceSynthetic Polypeptide 767Ala
Tyr Leu Leu Pro Ala Pro Pro Ala Pro Gly Asn Ala Ser Glu Ser 1 5 10
15 Glu Glu Asp Arg 20 7687PRTArtificial SequenceSynthetic
Polypeptide 768Phe His Pro Leu His Ser Lys 1 5 7698PRTArtificial
SequenceSynthetic Polypeptide 769Phe Leu Asn Val Leu Ser Pro Arg 1
5 77015PRTArtificial SequenceSynthetic Polypeptide 770Ser Ala Gly
Ser Val Glu Ser Pro Ser Val Ser Ser Thr His Arg 1 5 10 15
77111PRTArtificial SequenceSynthetic Polypeptide 771Tyr Gly Gln Pro
Leu Pro Gly Tyr Thr Thr Lys 1 5 10 77214PRTArtificial
SequenceSynthetic Polypeptide 772Ala Ser Val Ser Val Thr Ala Glu
Asp Glu Gly Thr Gln Arg 1 5 10 77316PRTArtificial SequenceSynthetic
Polypeptide 773Asp Gly Thr Phe Pro Leu Pro Ile Gly Glu Ser Val Thr
Val Thr Arg 1 5 10 15 77415PRTArtificial SequenceSynthetic
Polypeptide 774Leu Asn Pro Thr Val Thr Tyr Gly Asn Asp Ser Phe Ser
Ala Lys 1 5 10 15 77511PRTArtificial SequenceSynthetic Polypeptide
775Thr Phe Leu Thr Val Tyr Trp Thr Pro Glu Arg 1 5 10
77614PRTArtificial SequenceSynthetic Polypeptide 776Val Glu Leu Ala
Pro Leu Pro Ser Trp Gln Pro Val Gly Lys 1 5 10 7777PRTArtificial
SequenceSynthetic Polypeptide 777Ala Asp Gln Glu Gly Ala Arg 1 5
77823PRTArtificial SequenceSynthetic Polypeptide 778Glu Glu Ser Thr
Tyr Leu Pro Leu Thr Ser Met Gln Pro Thr Glu Ala 1 5 10 15 Met Gly
Glu Glu Pro Ser Arg 20 7798PRTArtificial SequenceSynthetic
Polypeptide 779Gly Asn Pro Tyr Pro Glu Leu Arg 1 5
7809PRTArtificial SequenceSynthetic Polypeptide 780Ile Ala Leu Glu
Thr Ser Leu Ser Lys 1 5 78118PRTArtificial SequenceSynthetic
Polypeptide 781Gln Pro Ala Val Glu Glu Pro Ala Glu Val Thr Ala Thr
Val Leu Ala 1 5 10 15 Ser Arg 78220PRTArtificial SequenceSynthetic
Polypeptide 782Thr Glu Leu Asp Met Gln Pro Gln Gly Leu Gly Leu Phe
Val Asn Thr 1 5 10 15 Ser Ala Pro Arg 20 78310PRTArtificial
SequenceSynthetic Polypeptide 783Thr Phe Val Leu Pro Val Thr Pro
Pro Arg 1 5 10 78419PRTArtificial SequenceSynthetic Polypeptide
784Val Glu Leu Ala Pro Leu Pro Pro Trp Gln Pro Val Gly Gln Asn Phe
1 5 10 15 Thr Leu Arg 78530PRTArtificial SequenceSynthetic
Polypeptide 785Val Gln Val Thr Leu Asp Gly Val Pro Ala Ala Ala Pro
Gly Gln Pro 1 5 10 15 Ala Gln Leu Gln Leu Asn Ala Thr Glu Ser Asp
Asp Gly Arg 20 25 30 7868PRTArtificial SequenceSynthetic
Polypeptide 786Ala Thr Asp Phe Val Ala Asp Arg 1 5
7879PRTArtificial SequenceSynthetic Polypeptide 787Asp Ile Phe Gln
Glu Ile Phe Asp Lys 1 5 7887PRTArtificial SequenceSynthetic
Polypeptide 788Ile Ile Trp Gln Phe Ile Lys 1 5 78911PRTArtificial
SequenceSynthetic Polypeptide 789Leu Ile Leu Pro His Val Asp Ile
Gln Leu Lys 1 5 10 7909PRTArtificial SequenceSynthetic Polypeptide
790Tyr Phe Asp Leu Gly Leu Pro Asn Arg 1 5 79116PRTArtificial
SequenceSynthetic Polypeptide 791Gly Ile Tyr Ala Tyr Gly Phe Glu
Lys Pro Ser Ala Ile Gln Gln Arg 1 5 10 15 79214PRTArtificial
SequenceSynthetic Polypeptide 792Gly Tyr Asp Val Ile Ala Gln Ala
Gln Ser Gly Thr Gly Lys 1
5 10 79315PRTArtificial SequenceSynthetic Polypeptide 793Leu Gln
Met Glu Ala Pro His Ile Ile Val Gly Thr Pro Gly Arg 1 5 10 15
79413PRTArtificial SequenceSynthetic Polypeptide 794Met Phe Val Leu
Asp Glu Ala Asp Glu Met Leu Ser Arg 1 5 10 7957PRTArtificial
SequenceSynthetic Polypeptide 795Val Phe Asp Met Leu Asn Arg 1 5
79610PRTArtificial SequenceSynthetic Polypeptide 796Val Leu Ile Thr
Thr Asp Leu Leu Ala Arg 1 5 10 79710PRTArtificial SequenceSynthetic
Polypeptide 797Glu Gly Thr Glu Ala Ser Leu Gln Ile Arg 1 5 10
79810PRTArtificial SequenceSynthetic Polypeptide 798Ile Ser Ser Leu
Pro Thr Gln Leu Phe Lys 1 5 10 7998PRTArtificial SequenceSynthetic
Polypeptide 799Thr His Pro Gly Gly Glu Gln Lys 1 5
8008PRTArtificial SequenceSynthetic Polypeptide 800Tyr Gln Pro Pro
Ser Thr Asn Lys 1 5 80111PRTArtificial SequenceSynthetic
Polypeptide 801Leu Glu Pro Leu Val Asn Asp Leu Thr Leu Arg 1 5 10
80212PRTArtificial SequenceSynthetic Polypeptide 802Leu Glu Thr Asn
Glu Phe Gln Gln Leu Gln Ser Lys 1 5 10 80312PRTArtificial
SequenceSynthetic Polypeptide 803Asn Ile Gly Asp Leu Leu Ser Ser
Ser Ile Asp Arg 1 5 10 80411PRTArtificial SequenceSynthetic
Polypeptide 804Ser Ser Gly Gly Gly Gly Trp Ala Asp Pro Arg 1 5 10
80511PRTArtificial SequenceSynthetic Polypeptide 805Thr Val Thr Phe
Ala Asn Asp Leu Lys Pro Lys 1 5 10 80623PRTArtificial
SequenceSynthetic Polypeptide 806Phe Ile Asp Asn Thr Leu Tyr Phe
Ile Ala Glu Asp Asp Glu Asn Leu 1 5 10 15 Glu Ser Asp Tyr Phe Gly
Lys 20 8078PRTArtificial SequenceSynthetic Polypeptide 807Ser Asp
Ile Ile Phe Phe Gln Arg 1 5 8088PRTArtificial SequenceSynthetic
Polypeptide 808Ser Val Pro Gly His Asp Asn Lys 1 5
8098PRTArtificial SequenceSynthetic Polypeptide 809Asp His Gln Glu
Pro Asn Pro Lys 1 5 8109PRTArtificial SequenceSynthetic Polypeptide
810Asn Leu Leu Ala Phe Tyr Val Asp Arg 1 5 8118PRTArtificial
SequenceSynthetic Polypeptide 811Gln Glu Ala Thr Asn Ala Thr Arg 1
5 81214PRTArtificial SequenceSynthetic Polypeptide 812Ser Leu Gly
Glu Leu Asp Val Phe Leu Ala Trp Ile Asn Lys 1 5 10
81317PRTArtificial SequenceSynthetic Polypeptide 813Val Ile His Asp
Asn Tyr Asp Gln Leu Glu Val His Ala Ala Ala Ile 1 5 10 15 Lys
81412PRTArtificial SequenceSynthetic Polypeptide 814Glu Ala Ser Leu
Ala Asp Asn Asn Thr Asp Val Arg 1 5 10 81517PRTArtificial
SequenceSynthetic Polypeptide 815Gln Val Leu Asn Phe Thr Leu Glu
Glu Val Leu Phe Pro Gln Ser Asp 1 5 10 15 Arg 81611PRTArtificial
SequenceSynthetic Polypeptide 816Ser Asn Phe Gln Gln Pro Tyr Ile
Thr Asn Arg 1 5 10 8177PRTArtificial SequenceSynthetic Polypeptide
817Glu Glu Leu Thr Pro Gln Lys 1 5 81824PRTArtificial
SequenceSynthetic Polypeptide 818Glu Gly Tyr Leu Glu Thr Val Ala
Ala Tyr Tyr Glu Glu Gln His Pro 1 5 10 15 Glu Leu Thr Pro Leu Leu
Glu Lys 20 81913PRTArtificial SequenceSynthetic Polypeptide 819Leu
Gln Thr Trp Trp His Gly Val Leu Ala Trp Val Lys 1 5 10
82013PRTArtificial SequenceSynthetic Polypeptide 820Val Val Ala Leu
Val His Ala Val Gln Ala Leu Trp Lys 1 5 10 8216PRTArtificial
SequenceSynthetic Polypeptide 821Ser Leu Glu Glu Asn Lys 1 5
8226PRTArtificial SequenceSynthetic Polypeptide 822Glu Asn Trp Val
Gln Arg 1 5 8239PRTArtificial SequenceSynthetic Polypeptide 823Thr
Tyr Ser Lys Pro Phe His Pro Lys 1 5 8249PRTArtificial
SequenceSynthetic Polypeptide 824Glu Ala Thr Thr Asn Ala Pro Phe
Arg 1 5 82513PRTArtificial SequenceSynthetic Polypeptide 825Leu Glu
Glu Ser Tyr Thr Leu Asn Ser Asp Leu Ala Arg 1 5 10
82621PRTArtificial SequenceSynthetic Polypeptide 826Leu His Glu Trp
Thr Lys Pro Glu Asn Leu Asp Phe Ile Glu Val Asn 1 5 10 15 Val Ser
Leu Pro Arg 20 82713PRTArtificial SequenceSynthetic Polypeptide
827Thr Phe His Phe Asn Thr Val Glu Glu Val His Ser Arg 1 5 10
82814PRTArtificial SequenceSynthetic Polypeptide 828Thr Tyr Asn Phe
Leu Pro Glu Phe Leu Val Ser Thr Gln Lys 1 5 10 82915PRTArtificial
SequenceSynthetic Polypeptide 829Gly Asp Asp Thr Pro Leu His Leu
Ala Ala Ser His Gly His Arg 1 5 10 15 8307PRTArtificial
SequenceSynthetic Polypeptide 830His Ser Gly Ile Asp Phe Lys 1 5
83111PRTArtificial SequenceSynthetic Polypeptide 831Leu Asn Glu Asn
His Ser Gly Glu Leu Trp Lys 1 5 10 8327PRTArtificial
SequenceSynthetic Polypeptide 832Gln Leu Asn Phe Leu Thr Lys 1 5
8339PRTArtificial SequenceSynthetic Polypeptide 833Trp Gln Gly Asn
Asp Ile Val Val Lys 1 5 8348PRTArtificial SequenceSynthetic
Polypeptide 834Ala Glu Val Trp Leu Phe Leu Lys 1 5
83510PRTArtificial SequenceSynthetic Polypeptide 835Glu Gly Ser Asp
Leu Ser Val Val Glu Arg 1 5 10 8369PRTArtificial SequenceSynthetic
Polypeptide 836Gly His Ser Pro Phe Ala Asn Leu Lys 1 5
83718PRTArtificial SequenceSynthetic Polypeptide 837His Pro Gln Gly
Ser Leu Asp Thr Gly Glu Glu Ala Glu Glu Val Gly 1 5 10 15 Leu Lys
8388PRTArtificial SequenceSynthetic Polypeptide 838Ser Glu Leu Leu
Leu Ser Glu Lys 1 5 83913PRTArtificial SequenceSynthetic
Polypeptide 839Ala Leu Pro Gly Thr Pro Val Ala Ser Ser Gln Pro Arg
1 5 10 84016PRTArtificial SequenceSynthetic Polypeptide 840Glu Val
Pro Leu Leu Gln Ser Leu Trp Leu Ala His Asn Glu Ile Arg 1 5 10 15
84110PRTArtificial SequenceSynthetic Polypeptide 841Leu Pro Gly Leu
Pro Glu Gly Ala Phe Arg 1 5 10 84227PRTArtificial SequenceSynthetic
Polypeptide 842Ser Leu Asp Leu Ser His Asn Leu Ile Ser Asp Phe Ala
Trp Ser Asp 1 5 10 15 Leu His Asn Leu Ser Ala Leu Gln Leu Leu Lys
20 25 84314PRTArtificial SequenceSynthetic Polypeptide 843Thr Val
Ala Ala Gly Ala Leu Ala Ser Leu Ser His Leu Lys 1 5 10
84419PRTArtificial SequenceSynthetic Polypeptide 844Asp Leu Asp Gly
Asn Gly Tyr Pro Asp Leu Ile Val Gly Ser Phe Gly 1 5 10 15 Val Asp
Lys 84518PRTArtificial SequenceSynthetic Polypeptide 845Leu Leu Glu
Ser Ser Leu Ser Ser Ser Glu Gly Glu Glu Pro Val Glu 1 5 10 15 Tyr
Lys 84610PRTArtificial SequenceSynthetic Polypeptide 846Ser Leu Gln
Trp Phe Gly Ala Thr Val Arg 1 5 10 84711PRTArtificial
SequenceSynthetic Polypeptide 847Ser Ser Ala Ser Ser Gly Pro Gln
Ile Leu Lys 1 5 10 84814PRTArtificial SequenceSynthetic Polypeptide
848Val Thr Ala Pro Pro Glu Ala Glu Tyr Ser Gly Leu Val Arg 1 5 10
84910PRTArtificial SequenceSynthetic Polypeptide 849Leu Phe Thr Ala
Leu Phe Pro Phe Glu Lys 1 5 10 85013PRTArtificial SequenceSynthetic
Polypeptide 850Ser Leu Pro Ile Ser Leu Val Phe Leu Val Pro Val Arg
1 5 10 85112PRTArtificial SequenceSynthetic Polypeptide 851Ser Leu
Val Lys Pro Ile Thr Gln Leu Leu Gly Arg 1 5 10 85210PRTArtificial
SequenceSynthetic Polypeptide 852Val Gln Ser Leu Val Leu Gly Ala
Pro Arg 1 5 10 85310PRTArtificial SequenceSynthetic Polypeptide
853Tyr Val Ile Gly Val Gly Asp Ala Phe Arg 1 5 10
85419PRTArtificial SequenceSynthetic Polypeptide 854Ala Leu Val Gln
Thr Glu Asp His Leu Leu Leu Phe Leu Gln Gln Leu 1 5 10 15 Ala Gly
Lys 85513PRTArtificial SequenceSynthetic Polypeptide 855Phe Asn Val
Glu Asp Gly Glu Ile Val Gln Gln Val Arg 1 5 10 85616PRTArtificial
SequenceSynthetic Polypeptide 856His Leu Leu Ile Gly Leu Pro Ser
Gly Ala Ile Leu Ser Leu Pro Lys 1 5 10 15 85714PRTArtificial
SequenceSynthetic Polypeptide 857Leu Phe Gly Ile Glu Ser Ser Ser
Gly Thr Ile Leu Trp Lys 1 5 10 85810PRTArtificial SequenceSynthetic
Polypeptide 858Val Leu Leu Leu Ile Asp Asp Glu Tyr Lys 1 5 10
8597PRTArtificial SequenceSynthetic Polypeptide 859Asp Trp Ser His
Tyr Phe Lys 1 5 86019PRTArtificial SequenceSynthetic Polypeptide
860Gly Leu Gln Ala Gln Ile Ala Ser Ser Gly Leu Thr Val Glu Val Asp
1 5 10 15 Ala Pro Lys 8617PRTArtificial SequenceSynthetic
Polypeptide 861Leu Ala Ser Tyr Leu Asp Arg 1 5 86211PRTArtificial
SequenceSynthetic Polypeptide 862Leu Gln Leu Glu Thr Glu Ile Glu
Ala Leu Lys 1 5 10 8639PRTArtificial SequenceSynthetic Polypeptide
863Val Val Ser Glu Thr Asn Asp Thr Lys 1 5 86411PRTArtificial
SequenceSynthetic Polypeptide 864Ala Pro Ser Ile His Gly Gly Ser
Gly Gly Arg 1 5 10 86523PRTArtificial SequenceSynthetic Polypeptide
865Phe Gly Ala Gln Leu Ala His Ile Gln Ala Leu Ile Ser Gly Ile Glu
1 5 10 15 Ala Gln Leu Gly Asp Val Arg 20 8668PRTArtificial
SequenceSynthetic Polypeptide 866Phe Gly Pro Gly Val Ala Phe Arg 1
5 86721PRTArtificial SequenceSynthetic Polypeptide 867Gly Gln Val
Gly Gly Gln Val Ser Val Glu Val Asp Ser Ala Pro Gly 1 5 10 15 Thr
Asp Leu Ala Lys 20 86817PRTArtificial SequenceSynthetic Polypeptide
868Ser Leu Leu Glu Gly Gln Glu Asp His Tyr Asn Asn Leu Ser Ala Ser
1 5 10 15 Lys 8698PRTArtificial SequenceSynthetic Polypeptide
869Ile Ser Ser Ser Ser Phe Ser Arg 1 5 8709PRTArtificial
SequenceSynthetic Polypeptide 870Leu Gln Ala Glu Ile Glu Gly Leu
Lys 1 5 8719PRTArtificial SequenceSynthetic Polypeptide 871Ser Tyr
Thr Ser Gly Pro Gly Ser Arg 1 5 8728PRTArtificial SequenceSynthetic
Polypeptide 872Trp Ser Leu Leu Gln Gln Gln Lys 1 5
87310PRTArtificial SequenceSynthetic Polypeptide 873Tyr Glu Glu Leu
Gln Ser Leu Ala Gly Lys 1 5 10 87420PRTArtificial SequenceSynthetic
Polypeptide 874Ile Asn Ser Val Gly Ser Thr Ala Ser Ser Ser Gln Pro
Leu Leu Val 1 5 10 15 His Asp Asp Val 20 87513PRTArtificial
SequenceSynthetic Polypeptide 875Leu Val Val Gln Ser Ser Ile Asp
Ser Ser Ala Phe Lys 1 5 10 87610PRTArtificial SequenceSynthetic
Polypeptide 876Gln Ala Thr Leu Thr Ile Ser Ser Ala Arg 1 5 10
87710PRTArtificial SequenceSynthetic Polypeptide 877Thr Ser Ala Tyr
Phe Asn Phe Ala Phe Lys 1 5 10 8789PRTArtificial SequenceSynthetic
Polypeptide 878Tyr Val Ser Glu Leu His Leu Thr Arg 1 5
87910PRTArtificial SequenceSynthetic Polypeptide 879Glu Val Glu Val
Ile Gly Gly Ala Asp Lys 1 5 10 88018PRTArtificial SequenceSynthetic
Polypeptide 880Lys Pro Phe Gly Ala Ile Leu Asn Leu Val Pro Leu Ala
Glu Ser Val 1 5 10 15 Val Lys 88119PRTArtificial SequenceSynthetic
Polypeptide 881Ile Leu Gln Leu Ile Leu Leu Ala Leu Ala Thr Gly Leu
Val Gly Gly 1 5 10 15 Glu Thr Arg 8826PRTArtificial
SequenceSynthetic Polypeptide 882Leu Pro His Thr Leu Arg 1 5
88318PRTArtificial SequenceSynthetic Polypeptide 883Thr Ala Thr Glu
Ser Phe Pro His Pro Gly Phe Asn Asn Ser Leu Pro 1 5 10 15 Asn Lys
88412PRTArtificial SequenceSynthetic Polypeptide 884Tyr Ile Val His
Leu Gly Gln His Asn Leu Gln Lys 1 5 10 8858PRTArtificial
SequenceSynthetic Polypeptide 885Val Glu Ala Gly Glu Gln Val Arg 1
5 88616PRTArtificial SequenceSynthetic Polypeptide 886Val Ser Gly
Trp Gly Thr Thr Thr Ser Pro Gln Val Asn Tyr Pro Lys 1 5 10 15
8876PRTArtificial SequenceSynthetic Polypeptide 887Tyr Val Leu Trp
Ile Arg 1 5 88810PRTArtificial SequenceSynthetic Polypeptide 888Gln
Val Thr His Pro Asn Tyr Asn Ser Arg 1 5 10 88912PRTArtificial
SequenceSynthetic Polypeptide 889Val Leu Gly Ser Gly Thr Trp Pro
Ser Ala Pro Lys 1 5 10 89013PRTArtificial SequenceSynthetic
Polypeptide 890Val Ser Gly Trp Gly Thr Ile Ser Ser Pro Ile Ala Arg
1 5 10 89111PRTArtificial SequenceSynthetic Polypeptide 891Glu Ser
Ser Gln Glu Gln Ser Ser Val Val Arg 1 5 10 89212PRTArtificial
SequenceSynthetic Polypeptide 892Leu Ser Glu Leu Ile Gln Pro Leu
Pro Leu Glu Arg 1 5 10 8937PRTArtificial SequenceSynthetic
Polypeptide 893Tyr Thr Asn Trp Ile Gln Lys 1 5 8948PRTArtificial
SequenceSynthetic Polypeptide 894Asp Phe Val Gln Pro Pro Thr Lys 1
5 89519PRTArtificial SequenceSynthetic Polypeptide 895Asp Ile Pro
Thr Asn Ser Pro Glu Leu Glu Glu Thr Leu Thr His Thr 1 5 10 15 Ile
Thr Lys 89619PRTArtificial SequenceSynthetic Polypeptide 896Gly His
Gly Leu Gly His Gly His Glu Gln Gln His Gly Leu Gly His 1 5 10 15
Gly His Lys 89718PRTArtificial SequenceSynthetic Polypeptide 897Leu
Asp Asp Asp Leu Glu His Gln Gly Gly His Val Leu Asp His Gly 1 5 10
15 His Lys 89811PRTArtificial SequenceSynthetic Polypeptide 898Thr
Val Gly Ser Asp Thr Phe Tyr Ser Phe Lys 1 5 10 8998PRTArtificial
SequenceSynthetic Polypeptide 899Ala Pro Ile Ile Ala Val Thr Arg 1
5 90014PRTArtificial SequenceSynthetic Polypeptide 900Asp Pro Val
Gln Glu Ala Trp Ala Glu Asp Val Asp Leu Arg 1 5 10
9019PRTArtificial SequenceSynthetic Polypeptide 901Gly Asp Tyr Pro
Leu Glu Ala Val Arg 1 5 90213PRTArtificial SequenceSynthetic
Polypeptide 902Ile Tyr Val Asp Asp Gly Leu Ile Ser Leu Gln Val Lys
1 5 10 90311PRTArtificial SequenceSynthetic Polypeptide 903Leu Asp
Ile Asp Ser Pro Pro Ile Thr Ala Arg 1 5 10 90413PRTArtificial
SequenceSynthetic Polypeptide 904Asp Ala Leu Glu Ser Thr Leu Ala
Glu Thr Glu Ala Arg 1 5 10 90515PRTArtificial SequenceSynthetic
Polypeptide 905Leu Asn Val Glu Val Asp Ala Ala Pro Pro Val Asp Leu
Asn Arg 1 5 10 15 9069PRTArtificial SequenceSynthetic Polypeptide
906Leu Pro Ser Leu Ser Pro Val Ala Arg 1 5 9079PRTArtificial
SequenceSynthetic Polypeptide 907Leu Val Val Glu Ile Asp Asn Ala
Lys 1 5 9088PRTArtificial SequenceSynthetic Polypeptide 908Tyr Glu
Thr Glu Val Ser Leu Arg 1 5 90912PRTArtificial SequenceSynthetic
Polypeptide 909Asp Thr Glu Gln Thr Leu Tyr Gln Val Gln Glu Arg 1 5
10 91010PRTArtificial SequenceSynthetic Polypeptide 910Ile Gln Gly
Thr Leu Gln Pro His Ala Arg 1 5 10 91111PRTArtificial
SequenceSynthetic Polypeptide 911Ser Leu Ala Asp Val Asp Ala Ile
Leu Ala Arg 1 5 10 91226PRTArtificial SequenceSynthetic Polypeptide
912Thr Gly Gly Ser Ala Gln Pro Glu Thr Pro Tyr Ser Gly Pro Gly Leu
1 5
10 15 Leu Ile Asp Ser Leu Val Leu Leu Pro Arg 20 25
91323PRTArtificial SequenceSynthetic Polypeptide 913Val Leu Glu Leu
Ser Ile Pro Ala Ser Ala Glu Gln Ile Gln His Leu 1 5 10 15 Ala Gly
Ala Ile Ala Glu Arg 20 9149PRTArtificial SequenceSynthetic
Polypeptide 914Asp Gln Leu Ile Tyr Asn Leu Leu Lys 1 5
9158PRTArtificial SequenceSynthetic Polypeptide 915Phe Ile Ile Pro
Asn Val Val Lys 1 5 91617PRTArtificial SequenceSynthetic
Polypeptide 916Leu Leu Ile Val Ser Asn Pro Val Asp Ile Leu Thr Tyr
Val Ala Trp 1 5 10 15 Lys 9179PRTArtificial SequenceSynthetic
Polypeptide 917Leu Val Ile Ile Thr Ala Gly Ala Arg 1 5
91810PRTArtificial SequenceSynthetic Polypeptide 918Thr Leu His Pro
Asp Leu Gly Thr Asp Lys 1 5 10 9199PRTArtificial SequenceSynthetic
Polypeptide 919Asp Tyr Ser Val Thr Ala Asn Ser Lys 1 5
9208PRTArtificial SequenceSynthetic Polypeptide 920Phe Ile Ile Pro
Gln Ile Val Lys 1 5 9219PRTArtificial SequenceSynthetic Polypeptide
921Gly Leu Thr Ser Val Ile Asn Gln Lys 1 5 92216PRTArtificial
SequenceSynthetic Polypeptide 922Leu Ile Ala Pro Val Ala Glu Glu
Glu Ala Thr Val Pro Asn Asn Lys 1 5 10 15 9236PRTArtificial
SequenceSynthetic Polypeptide 923Asn Val Asn Val Phe Lys 1 5
92410PRTArtificial SequenceSynthetic Polypeptide 924Asp Gly Gly Ala
Trp Gly Thr Glu Gln Arg 1 5 10 9258PRTArtificial SequenceSynthetic
Polypeptide 925Gly Glu Val Ala Pro Asp Ala Lys 1 5
9268PRTArtificial SequenceSynthetic Polypeptide 926Leu Pro Asp Gly
Tyr Glu Phe Lys 1 5 9278PRTArtificial SequenceSynthetic Polypeptide
927Ser Phe Val Leu Asn Leu Gly Lys 1 5 92811PRTArtificial
SequenceSynthetic Polypeptide 928Gly Asn Asp Val Ala Phe His Phe
Asn Pro Arg 1 5 10 9297PRTArtificial SequenceSynthetic Polypeptide
929Ile Ala Leu Asp Phe Gln Arg 1 5 93011PRTArtificial
SequenceSynthetic Polypeptide 930Ile Gln Val Leu Val Glu Pro Asp
His Phe Lys 1 5 10 9317PRTArtificial SequenceSynthetic Polypeptide
931Leu Asp Asn Asn Trp Gly Arg 1 5 93214PRTArtificial
SequenceSynthetic Polypeptide 932Val Ala Val Asn Asp Ala His Leu
Leu Gln Tyr Asn His Arg 1 5 10 93321PRTArtificial SequenceSynthetic
Polypeptide 933Phe Ala Val Asn Phe Gln Thr Gly Phe Ser Gly Asn Asp
Ile Ala Phe 1 5 10 15 His Phe Asn Pro Arg 20 9348PRTArtificial
SequenceSynthetic Polypeptide 934Phe Asp Glu Asn Ala Val Val Arg 1
5 93513PRTArtificial SequenceSynthetic Polypeptide 935Asn Thr Gln
Ile Asp Asn Ser Trp Gly Ser Glu Glu Arg 1 5 10 93614PRTArtificial
SequenceSynthetic Polypeptide 936Ser Ile Leu Leu Ser Gly Thr Val
Leu Pro Ser Ala Gln Arg 1 5 10 93714PRTArtificial SequenceSynthetic
Polypeptide 937Val Ala Val Asp Gly Gln His Leu Phe Glu Tyr Tyr His
Arg 1 5 10 93812PRTArtificial SequenceSynthetic Polypeptide 938Ala
Ser His Glu Glu Val Glu Gly Leu Val Glu Lys 1 5 10
93910PRTArtificial SequenceSynthetic Polypeptide 939Ala Val Asp Thr
Trp Ser Trp Gly Glu Arg 1 5 10 9409PRTArtificial SequenceSynthetic
Polypeptide 940Ser Thr His Thr Leu Asp Leu Ser Arg 1 5
9416PRTArtificial SequenceSynthetic Polypeptide 941Val Glu Ile Phe
Tyr Arg 1 5 94213PRTArtificial SequenceSynthetic Polypeptide 942Tyr
Ser Ser Asp Tyr Phe Gln Ala Pro Ser Asp Tyr Arg 1 5 10
9439PRTArtificial SequenceSynthetic Polypeptide 943Ala Gln Leu Ala
Pro Ser Ala Thr Lys 1 5 94416PRTArtificial SequenceSynthetic
Polypeptide 944Leu Glu Glu Trp Leu Ser His Val Val Gly Ala Val Tyr
Ala Pro Lys 1 5 10 15 94513PRTArtificial SequenceSynthetic
Polypeptide 945Leu Asn Val Ala Leu Asp Val Gly Ile Pro Leu Pro Lys
1 5 10 94611PRTArtificial SequenceSynthetic Polypeptide 946Ser Val
Ala Gly Asp Ile Ile Asp Phe Pro Lys 1 5 10 94724PRTArtificial
SequenceSynthetic Polypeptide 947Val Leu Asn Ile Asn Phe Ser Asn
Ser Val Leu Glu Ile Val Glu Asn 1 5 10 15 Ala Val Val Leu Thr Val
Ala Ser 20 94813PRTArtificial SequenceSynthetic Polypeptide 948Gly
Leu Leu Pro Asn Leu Val Asp Asn Leu Val Asn Arg 1 5 10
94922PRTArtificial SequenceSynthetic Polypeptide 949Ile Leu Asn Ile
Asp Phe Ser Asn Ala Asp Ile Asp Val Leu Glu Asp 1 5 10 15 Leu Leu
Val Leu Ser Ala 20 9508PRTArtificial SequenceSynthetic Polypeptide
950Ile Val Glu Leu Thr Leu Pro Arg 1 5 95114PRTArtificial
SequenceSynthetic Polypeptide 951Leu Leu Pro Gly Val Gly Val Tyr
Leu Ser Leu Tyr Thr Arg 1 5 10 95212PRTArtificial SequenceSynthetic
Polypeptide 952Tyr Gly Glu Ile Leu Glu Ser Glu Gly Ser Ile Arg 1 5
10 95321PRTArtificial SequenceSynthetic Polypeptide 953Asp Ala Gly
Ile Glu Pro Gly Pro Asp Thr Tyr Leu Ala Leu Leu Asn 1 5 10 15 Ala
Tyr Ala Glu Lys 20 95410PRTArtificial SequenceSynthetic Polypeptide
954Asn Val Gln Gly Ile Ile Glu Ile Leu Lys 1 5 10
95514PRTArtificial SequenceSynthetic Polypeptide 955Ser Gly Gly Leu
Gly Gly Ser His Ala Leu Leu Leu Leu Arg 1 5 10 95611PRTArtificial
SequenceSynthetic Polypeptide 956Thr Val Leu Asp Gln Gln Gln Thr
Pro Ser Arg 1 5 10 95717PRTArtificial SequenceSynthetic Polypeptide
957Thr Val Gln Leu Thr Ser Ser Glu Leu Glu Ser Thr Leu Glu Thr Leu
1 5 10 15 Lys 95814PRTArtificial SequenceSynthetic Polypeptide
958Ala Ala Leu Ser Gly Ala Asn Val Leu Thr Leu Ile Glu Lys 1 5 10
95916PRTArtificial SequenceSynthetic Polypeptide 959Thr Val Leu Trp
Pro Asn Gly Leu Ser Leu Asp Ile Pro Ala Gly Arg 1 5 10 15
96011PRTArtificial SequenceSynthetic Polypeptide 960Val Phe Phe Thr
Asp Tyr Gly Gln Ile Pro Lys 1 5 10 96118PRTArtificial
SequenceSynthetic Polypeptide 961Leu Pro Ser Gly Leu Pro Val Ser
Leu Leu Thr Leu Tyr Leu Asp Asn 1 5 10 15 Asn Lys
96221PRTArtificial SequenceSynthetic Polypeptide 962Asn Ile Pro Thr
Val Asn Glu Asn Leu Glu Asn Tyr Tyr Leu Glu Val 1 5 10 15 Asn Gln
Leu Glu Lys 20 96310PRTArtificial SequenceSynthetic Polypeptide
963Asn Asn Gln Ile Asp His Ile Asp Glu Lys 1 5 10
96411PRTArtificial SequenceSynthetic Polypeptide 964Ser Leu Glu Asp
Leu Gln Leu Thr His Asn Lys 1 5 10 96514PRTArtificial
SequenceSynthetic Polypeptide 965Ser Leu Glu Tyr Leu Asp Leu Ser
Phe Asn Gln Ile Ala Arg 1 5 10 9667PRTArtificial SequenceSynthetic
Polypeptide 966Asp Pro Glu Asp Ser Gln Arg 1 5 9677PRTArtificial
SequenceSynthetic Polypeptide 967Thr Asp Glu Gly Asp Asn Arg 1 5
96810PRTArtificial SequenceSynthetic Polypeptide 968Val Trp Thr Asp
Ala Asn Leu Thr Ala Arg 1 5 10 96910PRTArtificial SequenceSynthetic
Polypeptide 969Asn Trp Ala Pro Gly Glu Pro Asn Asn Arg 1 5 10
9708PRTArtificial SequenceSynthetic Polypeptide 970Gln Pro Gln Asn
Gly Ser Val Arg 1 5 97110PRTArtificial SequenceSynthetic
Polypeptide 971Tyr Thr His Leu Val Ala Ile Gln Asn Lys 1 5 10
97212PRTArtificial SequenceSynthetic Polypeptide 972Glu Val Ala Ala
Trp Thr Tyr His Tyr Ser Thr Lys 1 5 10 9738PRTArtificial
SequenceSynthetic Polypeptide 973Asn Glu Ile Asp Tyr Leu Asn Lys 1
5 97410PRTArtificial SequenceSynthetic Polypeptide 974Tyr Thr Asp
Leu Val Ala Ile Gln Asn Lys 1 5 10 97511PRTArtificial
SequenceSynthetic Polypeptide 975His Trp Phe Gln Ala Gly Tyr Ser
Thr Ser Arg 1 5 10 97613PRTArtificial SequenceSynthetic Polypeptide
976Asn Gln Gly Thr Ser Asp Phe Leu Pro Ser Arg Pro Arg 1 5 10
9777PRTArtificial SequenceSynthetic Polypeptide 977Thr Pro Ile Leu
Leu Ile Arg 1 5 97820PRTArtificial SequenceSynthetic Polypeptide
978Val Ser Val Asn Pro Ser Tyr Leu Val Pro Glu Ser Asp Tyr Thr Asn
1 5 10 15 Asn Val Val Arg 20 97932PRTArtificial SequenceSynthetic
Polypeptide 979Tyr Arg Pro Gly Tyr Gly Thr Gly Tyr Phe Gln Tyr Gly
Leu Pro Asp 1 5 10 15 Leu Val Ala Asp Pro Tyr Tyr Ile Gln Ala Ser
Thr Tyr Val Gln Lys 20 25 30 9809PRTArtificial SequenceSynthetic
Polypeptide 980Gly Gly Pro Gln Gln Pro His Asn Lys 1 5
9816PRTArtificial SequenceSynthetic Polypeptide 981Leu Asn Leu Thr
Ser Arg 1 5 98211PRTArtificial SequenceSynthetic Polypeptide 982Leu
Thr Gly Gly Ala Ala Gly His Gln Asp Arg 1 5 10 9839PRTArtificial
SequenceSynthetic Polypeptide 983Ser Asn Ser Gly Gln Tyr Pro Ala
Lys 1 5 9846PRTArtificial SequenceSynthetic Polypeptide 984Thr Tyr
Phe Ser Pro Arg 1 5 98511PRTArtificial SequenceSynthetic
Polypeptide 985Glu Ala Ala Leu Leu Glu Glu Glu Glu Gly Val 1 5 10
9867PRTArtificial SequenceSynthetic Polypeptide 986Ile Ala Tyr Pro
Ser Leu Arg 1 5 98725PRTArtificial SequenceSynthetic Polypeptide
987Gln Pro Asn Glu Gly Ser Ser Ser Gln Glu Glu Glu Gly Pro Ser Thr
1 5 10 15 Ser Pro Asp Ala Glu Ser Leu Phe Arg 20 25
9887PRTArtificial SequenceSynthetic Polypeptide 988Val Leu Glu His
Val Val Arg 1 5 9898PRTArtificial SequenceSynthetic Polypeptide
989Tyr Glu Phe Leu Trp Gly Pro Arg 1 5 99025PRTArtificial
SequenceSynthetic Polypeptide 990Ala Pro Glu Pro Ile Ser Thr Gln
Ser His Ser Val Leu Ile Leu Phe 1 5 10 15 His Ser Asp Asn Ser Gly
Glu Asn Arg 20 25 99115PRTArtificial SequenceSynthetic Polypeptide
991Ala Pro Gly Glu Leu Glu His Gly Leu Ile Thr Phe Ser Thr Arg 1 5
10 15 99211PRTArtificial SequenceSynthetic Polypeptide 992Asp Ser
Asp Leu Leu Ser Pro Ser Asp Phe Lys 1 5 10 99311PRTArtificial
SequenceSynthetic Polypeptide 993Ser Asp Glu Asn Glu Gln His Leu
Gly Val Lys 1 5 10 99415PRTArtificial SequenceSynthetic Polypeptide
994Thr Gly Val Ile Thr Ser Pro Asp Phe Pro Asn Pro Tyr Pro Lys 1 5
10 15 99510PRTArtificial SequenceSynthetic Polypeptide 995Glu Ser
Ala Phe Glu Phe Leu Ser Ser Ala 1 5 10 99610PRTArtificial
SequenceSynthetic Polypeptide 996Gly Glu Phe Val Thr Thr Val Gln
Gln Arg 1 5 10 9979PRTArtificial SequenceSynthetic Polypeptide
997Leu Gly Val Thr Ala Asn Asp Val Lys 1 5 99820PRTArtificial
SequenceSynthetic Polypeptide 998Asn Val Ile Ile Trp Gly Asn His
Ser Ser Thr Gln Tyr Pro Asp Val 1 5 10 15 Asn His Ala Lys 20
99926PRTArtificial SequenceSynthetic Polypeptide 999Val Leu Val Thr
Gly Ala Ala Gly Gln Ile Ala Tyr Ser Leu Leu Tyr 1 5 10 15 Ser Ile
Gly Asn Gly Ser Val Phe Gly Lys 20 25 100022PRTArtificial
SequenceSynthetic Polypeptide 1000Leu Thr Leu Tyr Asp Ile Ala His
Thr Pro Gly Val Ala Ala Asp Leu 1 5 10 15 Ser His Ile Glu Thr Lys
20 100119PRTArtificial SequenceSynthetic Polypeptide 1001Val Ala
Val Leu Gly Ala Ser Gly Gly Ile Gly Gln Pro Leu Ser Leu 1 5 10 15
Leu Leu Lys 100214PRTArtificial SequenceSynthetic Polypeptide
1002Val Asp Phe Pro Gln Asp Gln Leu Thr Ala Leu Thr Gly Arg 1 5 10
100312PRTArtificial SequenceSynthetic Polypeptide 1003Val Asn Val
Pro Val Ile Gly Gly His Ala Gly Lys 1 5 10 10047PRTArtificial
SequenceSynthetic Polypeptide 1004Val Ser Ser Phe Glu Glu Lys 1 5
10057PRTArtificial SequenceSynthetic Polypeptide 1005Ile Gly Gly
Ala Gln Asn Arg 1 5 100614PRTArtificial SequenceSynthetic
Polypeptide 1006His Glu Val His Phe Leu His Glu Glu Ser Ile Leu Glu
Arg 1 5 10 100719PRTArtificial SequenceSynthetic Polypeptide
1007His Phe Thr Glu Asp Gly Asn Ile Leu Gln Leu Ala Asn Leu Pro Asp
1 5 10 15 Leu Tyr Lys 100816PRTArtificial SequenceSynthetic
Polypeptide 1008Leu Gln Ser Phe Glu Asp Leu Ala Ser Ile Ser Thr Tyr
Gly Phe Arg 1 5 10 15 100912PRTArtificial SequenceSynthetic
Polypeptide 1009Thr Leu Pro Asn Ala Ser Thr Val Asp Asn Ile Arg 1 5
10 10109PRTArtificial SequenceSynthetic Polypeptide 1010Trp Thr Val
Glu His Ile Val Tyr Lys 1 5 101111PRTArtificial SequenceSynthetic
Polypeptide 1011Asp Gly Phe Phe Tyr Phe Phe His Gly Thr Arg 1 5 10
101210PRTArtificial SequenceSynthetic Polypeptide 1012Asp Ile Tyr
Ser Ser Phe Gly Phe Pro Arg 1 5 10 101310PRTArtificial
SequenceSynthetic Polypeptide 1013Ile Glu Asn Tyr Thr Pro Asp Leu
Pro Arg 1 5 10 101410PRTArtificial SequenceSynthetic Polypeptide
1014Leu Thr Phe Asp Ala Ile Thr Thr Ile Arg 1 5 10
101514PRTArtificial SequenceSynthetic Polypeptide 1015Ser Gln Asn
Pro Val Gln Pro Ile Gly Pro Gln Thr Pro Lys 1 5 10
101613PRTArtificial SequenceSynthetic Polypeptide 1016Phe Pro Val
His Ala Ala Leu Val Trp Gly Pro Glu Lys 1 5 10 101711PRTArtificial
SequenceSynthetic Polypeptide 1017Phe Pro Trp Gln Leu Val Gln Glu
Gln Val Arg 1 5 10 101814PRTArtificial SequenceSynthetic
Polypeptide 1018Gly Gly Gln Leu Gln Pro Gly Tyr Pro Ala Leu Ala Ser
Arg 1 5 10 101921PRTArtificial SequenceSynthetic Polypeptide
1019Gly Val Pro Ser Glu Ile Asp Ala Ala Phe Gln Asp Ala Asp Gly Tyr
1 5 10 15 Ala Tyr Phe Leu Arg 20 102017PRTArtificial
SequenceSynthetic Polypeptide 1020Val Trp Ser Asp Val Thr Pro Leu
Thr Phe Thr Glu Val His Glu Gly 1 5 10 15 Arg 102125PRTArtificial
SequenceSynthetic Polypeptide 1021Phe Leu Leu Ile Leu Leu Leu Gln
Ala Thr Ala Ser Gly Ala Leu Pro 1 5 10 15 Leu Asn Ser Ser Thr Ser
Leu Glu Lys 20 25 102210PRTArtificial SequenceSynthetic Polypeptide
1022Gly Ile Gln Ser Leu Tyr Gly Asp Pro Lys 1 5 10
10238PRTArtificial SequenceSynthetic Polypeptide 1023Ile Asp Ala
Val Phe Tyr Ser Lys 1 5 102426PRTArtificial SequenceSynthetic
Polypeptide 1024Thr Ser Val Asn Leu Ile Ser Ser Leu Trp Pro Thr Leu
Pro Ser Gly 1 5 10 15 Ile Glu Ala Ala Tyr Glu Ile Glu Ala Arg 20 25
102519PRTArtificial SequenceSynthetic Polypeptide 1025Tyr Tyr Tyr
Phe Phe Gln Gly Ser Asn Gln Phe Glu Tyr Asp Phe Leu 1 5 10 15 Leu
Gln Arg 10268PRTArtificial SequenceSynthetic Polypeptide 1026Ala
Val Asp Ser Glu Tyr Pro Lys 1 5 10276PRTArtificial
SequenceSynthetic Polypeptide 1027Phe Asn Glu Glu Leu Arg 1
5 10289PRTArtificial SequenceSynthetic Polypeptide 1028Phe Tyr Gly
Leu Gln Val Thr Gly Lys 1 5 102915PRTArtificial SequenceSynthetic
Polypeptide 1029His Trp Val Phe Asp Glu Ala Ser Leu Glu Pro Gly Tyr
Pro Lys 1 5 10 15 10309PRTArtificial SequenceSynthetic Polypeptide
1030Val Trp Glu Ser Ala Thr Pro Leu Arg 1 5 103112PRTArtificial
SequenceSynthetic Polypeptide 1031Ala Phe Gln Val Trp Ser Asp Val
Thr Pro Leu Arg 1 5 10 103212PRTArtificial SequenceSynthetic
Polypeptide 1032Ile Asp Ala Val Tyr Glu Ala Pro Gln Glu Glu Lys 1 5
10 103319PRTArtificial SequenceSynthetic Polypeptide 1033Ile Ile
Gly Tyr Thr Pro Asp Leu Asp Pro Glu Thr Val Asp Asp Ala 1 5 10 15
Phe Ala Arg 103429PRTArtificial SequenceSynthetic Polypeptide
1034Leu Ile Ala Asp Ala Trp Asn Ala Ile Pro Asp Asn Leu Asp Ala Val
1 5 10 15 Val Asp Leu Gln Gly Gly Gly His Ser Tyr Phe Phe Lys 20 25
103512PRTArtificial SequenceSynthetic Polypeptide 1035Gln Asp Ile
Val Phe Asp Gly Ile Ala Gln Ile Arg 1 5 10 103629PRTArtificial
SequenceSynthetic Polypeptide 1036Asp Ser Ile Tyr Asn Ala Val Ser
Ile Trp Ser Asn Val Thr Pro Leu 1 5 10 15 Ile Phe Gln Gln Val Gln
Asn Gly Asp Ala Asp Ile Lys 20 25 10376PRTArtificial
SequenceSynthetic Polypeptide 1037His Thr Leu Thr Tyr Arg 1 5
10388PRTArtificial SequenceSynthetic Polypeptide 1038Ile Gln His
Leu Tyr Gly Glu Lys 1 5 103911PRTArtificial SequenceSynthetic
Polypeptide 1039Thr Phe Gln Leu Ser Ala Asp Asp Ile Gln Arg 1 5 10
10409PRTArtificial SequenceSynthetic Polypeptide 1040Asp Leu Pro
His Ile Thr Val Asp Arg 1 5 10416PRTArtificial SequenceSynthetic
Polypeptide 1041Ile Val Ser Tyr Thr Arg 1 5 10427PRTArtificial
SequenceSynthetic Polypeptide 1042Leu Ser Gln Asp Asp Ile Lys 1 5
10438PRTArtificial SequenceSynthetic Polypeptide 1043Asn Ala Asn
Ser Leu Glu Ala Lys 1 5 104415PRTArtificial SequenceSynthetic
Polypeptide 1044Ala Phe Ala Leu Trp Ser Ala Val Thr Pro Leu Thr Phe
Thr Arg 1 5 10 15 10459PRTArtificial SequenceSynthetic Polypeptide
1045Ala Val Ile Asp Asp Ala Phe Ala Arg 1 5 10469PRTArtificial
SequenceSynthetic Polypeptide 1046Phe Gln Thr Phe Glu Gly Asp Leu
Lys 1 5 104715PRTArtificial SequenceSynthetic Polypeptide 1047Leu
Gly Leu Gly Ala Asp Val Ala Gln Val Thr Gly Ala Leu Arg 1 5 10 15
104811PRTArtificial SequenceSynthetic Polypeptide 1048Ser Leu Gly
Pro Ala Leu Leu Leu Leu Gln Lys 1 5 10 10499PRTArtificial
SequenceSynthetic Polypeptide 1049Glu Gln Ile Leu Gly Asp Glu Ala
Arg 1 5 105012PRTArtificial SequenceSynthetic Polypeptide 1050Ser
Leu Ala Ala Ser Ser Ser Phe Tyr Gly Gln Arg 1 5 10
105111PRTArtificial SequenceSynthetic Polypeptide 1051Thr Leu Pro
Ser Gly Leu Asp Asp Tyr Pro Arg 1 5 10 105218PRTArtificial
SequenceSynthetic Polypeptide 1052Val Asp Pro Ala Leu Phe Pro Pro
Val Pro Leu Phe Thr Ala Val Pro 1 5 10 15 Ser Arg
10539PRTArtificial SequenceSynthetic Polypeptide 1053Val Pro Pro
Glu Phe Leu Val Gln Arg 1 5 105413PRTArtificial SequenceSynthetic
Polypeptide 1054Phe Leu His Gln Asp Ile Asp Ser Gly Gln Gly Ile Arg
1 5 10 105511PRTArtificial SequenceSynthetic Polypeptide 1055Gly
His Gln Ala Phe Asp Val Gly Gln Pro Arg 1 5 10 105611PRTArtificial
SequenceSynthetic Polypeptide 1056Thr Tyr His Ser Val Gly Asp Ser
Val Leu Arg 1 5 10 105712PRTArtificial SequenceSynthetic
Polypeptide 1057Val Pro Ile Asp Gly Pro Pro Ile Asp Ile Gly Arg 1 5
10 105811PRTArtificial SequenceSynthetic Polypeptide 1058Tyr Val
Asp Gln Val Leu Gln Leu Val Tyr Lys 1 5 10 105910PRTArtificial
SequenceSynthetic Polypeptide 1059Ala Asp Gly Ala Leu Thr Gln Glu
Glu Lys 1 5 10 10609PRTArtificial SequenceSynthetic Polypeptide
1060Asp Phe Glu Ile Ile Ser Asp Thr Lys 1 5 106116PRTArtificial
SequenceSynthetic Polypeptide 1061Gly Val Val Ala Glu Phe Asp Ser
Pro Ala Asn Leu Ile Ala Ala Arg 1 5 10 15 106215PRTArtificial
SequenceSynthetic Polypeptide 1062Ile Asp Gly Leu Asn Val Ala Asp
Ile Gly Leu His Asp Leu Arg 1 5 10 15 106317PRTArtificial
SequenceSynthetic Polypeptide 1063Asn Val Asp Pro Asn Pro Tyr Pro
Glu Thr Ser Ala Gly Phe Leu Ser 1 5 10 15 Arg 106417PRTArtificial
SequenceSynthetic Polypeptide 1064Glu Gly Thr Ile Asn Val His Asp
Val Glu Thr Gln Phe Asn Gln Tyr 1 5 10 15 Lys 106511PRTArtificial
SequenceSynthetic Polypeptide 1065Gln Gly Gly Phe Leu Gly Leu Ser
Asn Ile Lys 1 5 10 10669PRTArtificial SequenceSynthetic Polypeptide
1066Ser Ser Val Pro Ser Ser Thr Glu Lys 1 5 106724PRTArtificial
SequenceSynthetic Polypeptide 1067Val Ser Ala Gly Asn Gly Gly Ser
Ser Leu Ser Tyr Thr Asn Pro Ala 1 5 10 15 Val Ala Ala Thr Ser Ala
Asn Leu 20 10689PRTArtificial SequenceSynthetic Polypeptide 1068Tyr
Val Pro Pro Ser Ser Thr Asp Arg 1 5 106919PRTArtificial
SequenceSynthetic Polypeptide 1069Ala Leu Phe Ser Ser Asn Leu Asp
Pro Ser Leu Val Glu Gln Val Phe 1 5 10 15 Leu Asp Lys
107011PRTArtificial SequenceSynthetic Polypeptide 1070Asp Ser Leu
Tyr Val Asn Gly Phe Asn Pro Arg 1 5 10 10718PRTArtificial
SequenceSynthetic Polypeptide 1071Leu Thr Leu Leu Arg Pro Glu Lys 1
5 107211PRTArtificial SequenceSynthetic Polypeptide 1072Val Leu Gln
Gly Leu Leu Thr Pro Leu Phe Arg 1 5 10 107319PRTArtificial
SequenceSynthetic Polypeptide 1073Val Pro Thr Gly Thr Ile Thr Glu
Val Ser Ser Thr Gly Val Asn Ser 1 5 10 15 Ser Ser Lys
107415PRTArtificial SequenceSynthetic Polypeptide 1074Phe Leu Asn
Ser Asn Ser Gly Leu Gln Gly Leu Gln Phe Tyr Arg 1 5 10 15
107510PRTArtificial SequenceSynthetic Polypeptide 1075Ile Gly Leu
Ala Ser Ala Leu Gln Pro Arg 1 5 10 107614PRTArtificial
SequenceSynthetic Polypeptide 1076Asn Asp Val Val Phe Gln Pro Ile
Ser Gly Glu Asp Val Arg 1 5 10 107712PRTArtificial
SequenceSynthetic Polypeptide 1077Ser Leu Glu Pro Phe Thr Leu Glu
Ile Leu Ala Arg 1 5 10 107812PRTArtificial SequenceSynthetic
Polypeptide 1078Ser Thr Ala Ala Pro Ile Pro Ile Leu Pro Glu Arg 1 5
10 107914PRTArtificial SequenceSynthetic Polypeptide 1079Ala Val
Thr Leu Ser Leu Asp Gly Gly Asp Thr Ala Ile Arg 1 5 10
108010PRTArtificial SequenceSynthetic Polypeptide 1080Leu Thr Asp
Pro Asn Ser Ala Phe Ser Arg 1 5 10 108111PRTArtificial
SequenceSynthetic Polypeptide 1081Leu Thr Pro Leu Gln Phe Gly Asn
Leu Gln Lys 1 5 10 108214PRTArtificial SequenceSynthetic
Polypeptide 1082Ser Val Val Gly Asp Ala Leu Glu Phe Gly Asn Ser Trp
Lys 1 5 10 108313PRTArtificial SequenceSynthetic Polypeptide
1083Thr Gly Leu Leu Val Glu Gln Ser Gly Asp Tyr Ile Lys 1 5 10
10849PRTArtificial SequenceSynthetic Polypeptide 1084Trp Val Gly
Asp Leu Pro Asn Gly Arg 1 5 108511PRTArtificial SequenceSynthetic
Polypeptide 1085Glu His Phe Gln Asp Asp Val Phe Asn Glu Lys 1 5 10
108616PRTArtificial SequenceSynthetic Polypeptide 1086Gly Asp Leu
Glu Glu Tyr Gly Gln Asp Leu Leu His Thr Val Phe Lys 1 5 10 15
108721PRTArtificial SequenceSynthetic Polypeptide 1087Ser Thr Gln
Ala Pro Leu Ile Ile Arg Pro Asp Ser Gly Asn Pro Leu 1 5 10 15 Asp
Thr Val Leu Lys 20 108810PRTArtificial SequenceSynthetic
Polypeptide 1088Tyr Asp Gly His Leu Pro Ile Glu Ile Lys 1 5 10
108915PRTArtificial SequenceSynthetic Polypeptide 1089Tyr Leu Leu
Glu Thr Ser Gly Asn Leu Asp Gly Leu Glu Tyr Lys 1 5 10 15
109011PRTArtificial SequenceSynthetic Polypeptide 1090Ala Ser Ser
Ser Phe Gln Ala Asn Gly Thr Lys 1 5 10 10919PRTArtificial
SequenceSynthetic Polypeptide 1091Phe Ala Ile Gln Tyr Gly Thr Gly
Arg 1 5 109216PRTArtificial SequenceSynthetic Polypeptide 1092Gly
Ala Asp Leu Gly Trp Gly Glu Thr Ala Gln Ala Gln Phe Pro Gly 1 5 10
15 109319PRTArtificial SequenceSynthetic Polypeptide 1093Leu Gly
Ala Pro Ser Pro Gly Asp Lys Pro Ile Phe Val Pro Leu Ser 1 5 10 15
Asn Tyr Arg 10949PRTArtificial SequenceSynthetic Polypeptide
1094Val Asp Gly Ile Leu Ser Glu Asp Lys 1 5 109512PRTArtificial
SequenceSynthetic Polypeptide 1095Ala Glu Ala Leu Phe Asp Phe Thr
Gly Asn Ser Lys 1 5 10 10968PRTArtificial SequenceSynthetic
Polypeptide 1096Asp Ala Glu Gly Asp Leu Val Arg 1 5
109715PRTArtificial SequenceSynthetic Polypeptide 1097Asp Ile Ala
Val Glu Glu Asp Leu Ser Ser Thr Pro Leu Leu Lys 1 5 10 15
109812PRTArtificial SequenceSynthetic Polypeptide 1098Gly Ala Thr
Gly Ile Phe Pro Leu Ser Phe Val Lys 1 5 10 109911PRTArtificial
SequenceSynthetic Polypeptide 1099Ser Val Ser Pro Gln Gly Asn Ser
Val Asp Arg 1 5 10 110010PRTArtificial SequenceSynthetic
Polypeptide 1100Asp Arg Pro Phe Phe Ala Gly Leu Val Lys 1 5 10
11017PRTArtificial SequenceSynthetic Polypeptide 1101Glu His Tyr
Val Asp Leu Lys 1 5 110214PRTArtificial SequenceSynthetic
Polypeptide 1102Asn Ile Ile His Gly Ser Asp Ser Val Glu Ser Ala Glu
Lys 1 5 10 110312PRTArtificial SequenceSynthetic Polypeptide
1103Thr Phe Ile Ala Ile Lys Pro Asp Gly Val Gln Arg 1 5 10
11047PRTArtificial SequenceSynthetic Polypeptide 1104Ala Ser Glu
Glu His Leu Lys 1 5 110510PRTArtificial SequenceSynthetic
Polypeptide 1105Asp Arg Pro Phe Phe Pro Gly Leu Val Lys 1 5 10
110615PRTArtificial SequenceSynthetic Polypeptide 1106Glu Ile Ser
Leu Trp Phe Lys Pro Glu Glu Leu Val Asp Tyr Lys 1 5 10 15
110710PRTArtificial SequenceSynthetic Polypeptide 1107Asn Ile Ile
His Gly Ser Asp Ser Val Lys 1 5 10 11089PRTArtificial
SequenceSynthetic Polypeptide 1108Phe Glu Ala Pro Leu Phe Asn Ala
Arg 1 5 110917PRTArtificial SequenceSynthetic Polypeptide 1109Ile
Leu Gln Asp Ile Ala Ser Gly Ser His Pro Phe Ser Gln Val Leu 1 5 10
15 Lys 111019PRTArtificial SequenceSynthetic Polypeptide 1110Leu
Val Asn Gln Gln Leu Leu Ala Asp Pro Leu Val Pro Pro Gln Leu 1 5 10
15 Thr Ile Lys 111116PRTArtificial SequenceSynthetic Polypeptide
1111Asn Asp Gly Ala Ala Ile Leu Ala Ala Val Ser Ser Ile Ala Gln Lys
1 5 10 15 111210PRTArtificial SequenceSynthetic Polypeptide 1112Ser
Ala Thr Tyr Val Asn Thr Glu Gly Arg 1 5 10 111318PRTArtificial
SequenceSynthetic Polypeptide 1113Glu Pro Ala Val Ile Gly Arg Pro
Asp Phe Glu His Ala Val Glu Ala 1 5 10 15 Ser Lys
111413PRTArtificial SequenceSynthetic Polypeptide 1114Gly Phe Thr
Pro Val Val Asp Asp Pro Val Thr Glu Arg 1 5 10 111510PRTArtificial
SequenceSynthetic Polypeptide 1115Gly Asn Ala Val Leu Gln Ser Gln
Val Lys 1 5 10 111610PRTArtificial SequenceSynthetic Polypeptide
1116Asn Ile Gly Ala Phe Ile Ser Glu Ala Lys 1 5 10
111719PRTArtificial SequenceSynthetic Polypeptide 1117Thr Asp Pro
Gly Ser Ile Phe Asp Leu Asp Pro Leu Glu Asp Asn Ile 1 5 10 15 Gln
Ser Arg 111814PRTArtificial SequenceSynthetic Polypeptide 1118Asp
Ser Val Ser Asp Gly Phe Val Gln Glu Asn Gln Pro Arg 1 5 10
111911PRTArtificial SequenceSynthetic Polypeptide 1119Asp Tyr Ser
Pro Glu Leu Ala Glu Leu Ile Arg 1 5 10 112010PRTArtificial
SequenceSynthetic Polypeptide 1120Gly Ser Tyr Gly Glu Val Thr Leu
Val Lys 1 5 10 112113PRTArtificial SequenceSynthetic Polypeptide
1121Leu Leu Gly Ser Ser Asp Ser Pro Ala Ser Ala Ser Arg 1 5 10
11228PRTArtificial SequenceSynthetic Polypeptide 1122Val Asp Val
Thr Ser Thr Gln Lys 1 5 11236PRTArtificial SequenceSynthetic
Polypeptide 1123Ala Gly Asp Trp Trp Lys 1 5 112415PRTArtificial
SequenceSynthetic Polypeptide 1124Asp Ser Tyr Phe Tyr Ala Val Ser
Asp Leu Gln Val Gly Gly Arg 1 5 10 15 112510PRTArtificial
SequenceSynthetic Polypeptide 1125Phe Thr Val Asn Ile Ile Ser Val
Tyr Lys 1 5 10 112616PRTArtificial SequenceSynthetic Polypeptide
1126Leu His Thr Phe Gly Asp Glu Asn Glu Asp Asp Ser Glu Leu Ala Arg
1 5 10 15 11278PRTArtificial SequenceSynthetic Polypeptide 1127Ser
Ser Leu Val Ile Gln Trp Arg 1 5 112819PRTArtificial
SequenceSynthetic Polypeptide 1128Leu Val Gln Leu Ala Gly Ala Pro
Glu Pro Phe Glu Pro Ala Gln Pro 1 5 10 15 Asp Ala Tyr
112916PRTArtificial SequenceSynthetic Polypeptide 1129Ser Asn Ala
Thr Gln Leu Asp Gly Pro Ala Gly Ala Leu Leu Leu Arg 1 5 10 15
11307PRTArtificial SequenceSynthetic Polypeptide 1130Glu Leu Thr
Ser Glu Leu Lys 1 5 11316PRTArtificial SequenceSynthetic
Polypeptide 1131Ile Thr Leu Tyr Gly Arg 1 5 113211PRTArtificial
SequenceSynthetic Polypeptide 1132Ser Tyr Pro Gly Leu Thr Ser Tyr
Leu Val Arg 1 5 10 113315PRTArtificial SequenceSynthetic
Polypeptide 1133Val Pro Leu Gln Gln Asn Phe Gln Asp Asn Gln Phe Gln
Gly Lys 1 5 10 15 113413PRTArtificial SequenceSynthetic Polypeptide
1134Trp Tyr Val Val Gly Leu Ala Gly Asn Ala Ile Leu Arg 1 5 10
113514PRTArtificial SequenceSynthetic Polypeptide 1135Gly Asp Gly
Asp Val Ala Trp Gln His Thr Gln Leu Phe Arg 1 5 10
11369PRTArtificial SequenceSynthetic Polypeptide 1136Ile Gly Asn
Thr Ala Phe Ser Thr Arg 1 5 113712PRTArtificial SequenceSynthetic
Polypeptide 1137Ile Ile Val Glu Leu Val Glu Phe Ile Ser Pro Lys 1 5
10 113811PRTArtificial SequenceSynthetic Polypeptide 1138Leu Leu
Leu Thr Tyr Ala Asp Asn Ile Leu Arg 1 5 10 113927PRTArtificial
SequenceSynthetic Polypeptide 1139Ser Ser Gln Gln Pro Ala Ala Ser
Thr Gln Leu Pro Thr Thr Pro Ser 1 5 10 15 Ser Asn Pro Ser Gly Leu
Asn Gln His Thr Arg 20 25 114014PRTArtificial SequenceSynthetic
Polypeptide 1140Ser Val Asp Pro Asp Ser Pro Ala Glu Ala Ser Gly Leu
Arg 1 5 10 114112PRTArtificial SequenceSynthetic Polypeptide
1141Glu Phe Pro Val Tyr Leu Trp Gln Pro Phe Phe Arg 1 5 10
114213PRTArtificial SequenceSynthetic Polypeptide 1142Glu Val Asn
Glu Val Ser Gln Asn Phe Gln Thr Thr Lys 1 5 10 114323PRTArtificial
SequenceSynthetic Polypeptide 1143Gly Glu Ser Leu Ser Leu Pro Gly
Pro Ser Pro Pro Pro Asp Gly Thr 1
5 10 15 Glu Gln Val Ile Ile Ser Arg 20 114411PRTArtificial
SequenceSynthetic Polypeptide 1144Asn Asp Tyr Ala Val Glu Ser Tyr
Glu Asn Lys 1 5 10 114514PRTArtificial SequenceSynthetic
Polypeptide 1145Val Leu Thr Ser Glu Asp Glu Tyr Asn Leu Leu Ser Asp
Arg 1 5 10 11468PRTArtificial SequenceSynthetic Polypeptide 1146Gly
Tyr Phe Leu Phe Arg Pro Arg 1 5 114714PRTArtificial
SequenceSynthetic Polypeptide 1147Val Asp Glu Glu Phe Gln Ser Pro
Phe Ala Ser Gln Ser Arg 1 5 10 114829PRTArtificial
SequenceSynthetic Polypeptide 1148Glu Gly Asn Lys Pro Val Leu Phe
Gln Gly Asn Thr Asn Pro Thr Asp 1 5 10 15 Val Val Val Ala Val Phe
Pro Lys Pro Leu Ile Thr Arg 20 25 114915PRTArtificial
SequenceSynthetic Polypeptide 1149Phe Val Ser Asp Tyr Glu Thr His
Gly Ala Gly Phe Ser Ile Arg 1 5 10 15 115013PRTArtificial
SequenceSynthetic Polypeptide 1150Phe Val Thr Ala Val Gly Thr Gln
Gly Ala Ile Ser Lys 1 5 10 115121PRTArtificial SequenceSynthetic
Polypeptide 1151Ile Glu Ser Pro Gly Tyr Leu Thr Ser Pro Gly Tyr Pro
His Ser Tyr 1 5 10 15 His Pro Ser Glu Lys 20 115214PRTArtificial
SequenceSynthetic Polypeptide 1152Ser Phe Glu Gly Asn Asn Asn Tyr
Asp Thr Pro Glu Leu Arg 1 5 10 11536PRTArtificial SequenceSynthetic
Polypeptide 1153Glu Ala Ile Asn Phe Arg 1 5 115420PRTArtificial
SequenceSynthetic Polypeptide 1154Ile Ile Ile Leu Leu Gly Phe Leu
Gly Ala Thr Leu Ser Ala Pro Leu 1 5 10 15 Ile Pro Gln Arg 20
11556PRTArtificial SequenceSynthetic Polypeptide 1155Ser Pro Gln
Gln Thr Arg 1 5 115617PRTArtificial SequenceSynthetic Polypeptide
1156Ala Ile Pro Val Ala Gln Asp Leu Asn Ala Pro Ser Asp Trp Asp Ser
1 5 10 15 Arg 115719PRTArtificial SequenceSynthetic Polypeptide
1157Asp Ser Tyr Glu Thr Ser Gln Leu Asp Asp Gln Ser Ala Glu Thr His
1 5 10 15 Ser His Lys 11589PRTArtificial SequenceSynthetic
Polypeptide 1158Gly Asp Ser Val Val Tyr Gly Leu Arg 1 5
115913PRTArtificial SequenceSynthetic Polypeptide 1159Ile Ser His
Glu Leu Asp Ser Ala Ser Ser Glu Val Asn 1 5 10 116016PRTArtificial
SequenceSynthetic Polypeptide 1160Tyr Pro Asp Ala Val Ala Thr Trp
Leu Asn Pro Asp Pro Ser Gln Lys 1 5 10 15 11619PRTArtificial
SequenceSynthetic Polypeptide 1161Asp Gly Glu Ala Phe Leu Leu Thr
Asn 1 5 116216PRTArtificial SequenceSynthetic Polypeptide 1162Gln
Gly Val Leu Asp Leu Pro Asn Asp Val Val Glu Gly Ser Ala Arg 1 5 10
15 116312PRTArtificial SequenceSynthetic Polypeptide 1163Ser Asp
Pro Leu Ala Phe Ile Thr Phe Ser Ala Lys 1 5 10 116417PRTArtificial
SequenceSynthetic Polypeptide 1164Ser Glu Val Thr Gln Ala Pro Gly
Gln Tyr Thr Val Asp Val Glu Gly 1 5 10 15 Arg 116511PRTArtificial
SequenceSynthetic Polypeptide 1165Ser Phe Leu Val Glu Pro Glu Gly
Ile Glu Lys 1 5 10 116614PRTArtificial SequenceSynthetic
Polypeptide 1166Asp His Val Val Ser Asp Phe Ser Glu His Gly Ser Leu
Lys 1 5 10 116713PRTArtificial SequenceSynthetic Polypeptide
1167Phe Gly Leu Gly Ala Glu Val Gly Ile Ser Thr Ser Arg 1 5 10
116812PRTArtificial SequenceSynthetic Polypeptide 1168Gly Pro Val
Gly Leu Glu Gly Leu Leu Thr Thr Lys 1 5 10 116910PRTArtificial
SequenceSynthetic Polypeptide 1169His Glu Ile Leu Leu Ser Gln Ser
Val Arg 1 5 10 117016PRTArtificial SequenceSynthetic Polypeptide
1170Ile Leu His Leu Leu Thr Gln Glu Ala Leu Ser Ile His Gly Val Lys
1 5 10 15 117110PRTArtificial SequenceSynthetic Polypeptide 1171Asp
Ile Pro His Trp Leu Asn Pro Thr Arg 1 5 10 117215PRTArtificial
SequenceSynthetic Polypeptide 1172Glu Gln Val Asp Phe Gln His His
Gln Leu Ala Glu Ala Phe Lys 1 5 10 15 117310PRTArtificial
SequenceSynthetic Polypeptide 1173Gly Tyr Ile Glu His Phe Ser Leu
Trp Lys 1 5 10 117413PRTArtificial SequenceSynthetic Polypeptide
1174Leu Asp Gly Ser Thr His Leu Asn Ile Phe Phe Ala Lys 1 5 10
117516PRTArtificial SequenceSynthetic Polypeptide 1175Val Ser Phe
Ser Ser Pro Leu Val Ala Ile Ser Gly Val Ala Leu Arg 1 5 10 15
117610PRTArtificial SequenceSynthetic Polypeptide 1176Ala Leu Glu
Ser Glu Leu Gln Gln Leu Arg 1 5 10 117716PRTArtificial
SequenceSynthetic Polypeptide 1177Glu Leu Pro Leu Ser Pro Ala Phe
Phe Gly Glu Asp Gly Ile Phe Arg 1 5 10 15 117810PRTArtificial
SequenceSynthetic Polypeptide 1178Glu Gln Glu Pro Glu Leu Ser Phe
Leu Lys 1 5 10 117910PRTArtificial SequenceSynthetic Polypeptide
1179Gly Leu Glu Glu Glu Asn Ala Gln Leu Arg 1 5 10
118015PRTArtificial SequenceSynthetic Polypeptide 1180Gln Glu Gly
Leu Thr Phe Phe Gly Thr Glu Leu Ala Pro Val Arg 1 5 10 15
118111PRTArtificial SequenceSynthetic Polypeptide 1181Ile Ala Asn
Pro Val Glu Gly Ser Ser Gly Arg 1 5 10 118213PRTArtificial
SequenceSynthetic Polypeptide 1182Ile Ile Thr Leu Thr Gly Pro Thr
Asn Ala Ile Phe Lys 1 5 10 11836PRTArtificial SequenceSynthetic
Polypeptide 1183Leu Asn Gln Val Ala Arg 1 5 11849PRTArtificial
SequenceSynthetic Polypeptide 1184Gln Gly Ala Asn Ile Asn Glu Ile
Arg 1 5 118521PRTArtificial SequenceSynthetic Polypeptide 1185Gln
Val Thr Ile Thr Gly Ser Ala Ala Ser Ile Ser Leu Ala Gln Tyr 1 5 10
15 Leu Ile Asn Ala Arg 20 11868PRTArtificial SequenceSynthetic
Polypeptide 1186Ala Phe Ala Met Ile Ile Asp Lys 1 5
118720PRTArtificial SequenceSynthetic Polypeptide 1187Glu Ser Thr
Gly Ala Gln Val Gln Val Ala Gly Asp Met Leu Pro Asn 1 5 10 15 Ser
Thr Glu Arg 20 118823PRTArtificial SequenceSynthetic Polypeptide
1188Gly Val Thr Ile Pro Tyr Arg Pro Lys Pro Ser Ser Ser Pro Val Ile
1 5 10 15 Phe Ala Gly Gly Gln Asp Arg 20 118911PRTArtificial
SequenceSynthetic Polypeptide 1189Ile Ala Asn Pro Val Glu Gly Ser
Thr Asp Arg 1 5 10 119013PRTArtificial SequenceSynthetic
Polypeptide 1190Ile Ile Thr Leu Ala Gly Pro Thr Asn Ala Ile Phe Lys
1 5 10 119131PRTArtificial SequenceSynthetic Polypeptide 1191Leu
His Gln Leu Ala Met Gln Gln Ser His Phe Pro Met Thr His Gly 1 5 10
15 Asn Thr Gly Phe Ser Gly Ile Glu Ser Ser Ser Pro Glu Val Lys 20
25 30 119211PRTArtificial SequenceSynthetic Polypeptide 1192Leu Ser
Ser Glu Thr Gly Gly Met Gly Ser Ser 1 5 10 119317PRTArtificial
SequenceSynthetic Polypeptide 1193Met Asp Thr Gly Val Ile Glu Gly
Gly Leu Asn Val Thr Leu Thr Ile 1 5 10 15 Arg 11948PRTArtificial
SequenceSynthetic Polypeptide 1194Gln Met Ser Gly Ala Gln Ile Lys 1
5 119521PRTArtificial SequenceSynthetic Polypeptide 1195Gln Val Thr
Ile Thr Gly Ser Ala Ala Ser Ile Ser Leu Ala Gln Tyr 1 5 10 15 Leu
Ile Asn Val Arg 20 119616PRTArtificial SequenceSynthetic
Polypeptide 1196Glu Gly Asp Ser Ile Thr Tyr Ala Ile Glu Asn Gly Asp
Pro Gln Arg 1 5 10 15 119715PRTArtificial SequenceSynthetic
Polypeptide 1197Gly Gly Pro Pro Ala Thr Ile Val Ala Ile Asp Glu Glu
Ser Arg 1 5 10 15 119815PRTArtificial SequenceSynthetic Polypeptide
1198Gly Thr Ala Gly Gly Pro Asp Pro Thr Ile Glu Leu Ser Leu Lys 1 5
10 15 119913PRTArtificial SequenceSynthetic Polypeptide 1199Val Gly
Ala Val Leu Leu Asn Leu Gln Ala Thr Asp Arg 1 5 10
120014PRTArtificial SequenceSynthetic Polypeptide 1200Val Gln Ala
Asp Ser Leu Glu Val Val Leu Ala Asn Leu Arg 1 5 10
12017PRTArtificial SequenceSynthetic Polypeptide 1201Ile Glu Asp
Glu Glu Gly Ser 1 5 12029PRTArtificial SequenceSynthetic
Polypeptide 1202Leu Ser Gln Thr Ser Asn Val Asp Lys 1 5
12038PRTArtificial SequenceSynthetic Polypeptide 1203Ser Glu Gly
Phe Asp Thr Tyr Arg 1 5 12047PRTArtificial SequenceSynthetic
Polypeptide 1204Tyr Leu Asn Phe Phe Thr Lys 1 5 12056PRTArtificial
SequenceSynthetic Polypeptide 1205Tyr Tyr Leu Ala Pro Lys 1 5
120626PRTArtificial SequenceSynthetic Polypeptide 1206Phe Gly Leu
Asn Thr Val Leu Thr Thr Asp Asn Ser Asp Leu Phe Ile 1 5 10 15 Asn
Ser Ile Gly Ile Val Pro Ser Val Arg 20 25 120718PRTArtificial
SequenceSynthetic Polypeptide 1207Ile Ala Ile Ile Gly Ala Gly Ile
Gly Gly Thr Ser Ala Ala Tyr Tyr 1 5 10 15 Leu Arg
12089PRTArtificial SequenceSynthetic Polypeptide 1208Ile Phe Ser
Gln Glu Thr Leu Thr Lys 1 5 12098PRTArtificial SequenceSynthetic
Polypeptide 1209Thr Leu Leu Glu Thr Leu Gln Lys 1 5
121013PRTArtificial SequenceSynthetic Polypeptide 1210Tyr Gln Ser
His Asp Tyr Ala Phe Ser Ser Val Glu Lys 1 5 10 12118PRTArtificial
SequenceSynthetic Polypeptide 1211Ala His Gly Val His Ala Thr Lys 1
5 12128PRTArtificial SequenceSynthetic Polypeptide 1212Glu Glu Asp
Thr Gly Arg Pro Arg 1 5 121318PRTArtificial SequenceSynthetic
Polypeptide 1213Leu Leu Glu Ile Asp Ser Val Gly Ser Glu Asp Ser Leu
Asp Thr Ser 1 5 10 15 Leu Arg 12147PRTArtificial SequenceSynthetic
Polypeptide 1214Ser Gln Ile His Ser Ile Arg 1 5 12158PRTArtificial
SequenceSynthetic Polypeptide 1215Thr Val Ile Tyr Glu Ile Pro Arg 1
5 12167PRTArtificial SequenceSynthetic Polypeptide 1216Ser Phe Asp
Asp Leu Gln Arg 1 5 121712PRTArtificial SequenceSynthetic
Polypeptide 1217Ser His Ser Gly Gly Glu Leu Glu Ser Leu Ala Arg 1 5
10 12189PRTArtificial SequenceSynthetic Polypeptide 1218Ser Pro Gly
Gly Ser Gln Glu Gln Arg 1 5 121912PRTArtificial SequenceSynthetic
Polypeptide 1219Asp Thr Ser Ala Thr Pro Gln Ser Ala Ser Ile Lys 1 5
10 12209PRTArtificial SequenceSynthetic Polypeptide 1220Gly Asn Gly
Tyr Val Gln Ser Pro Arg 1 5 12219PRTArtificial SequenceSynthetic
Polypeptide 1221Leu Ala Asn Val Val Phe Phe Pro Arg 1 5
122212PRTArtificial SequenceSynthetic Polypeptide 1222Ser Asp Asp
Tyr Phe Val Ala Lys Pro Gly Phe Lys 1 5 10 122317PRTArtificial
SequenceSynthetic Polypeptide 1223Tyr Asp Phe Val Glu Val Glu Asp
Ile Ser Glu Thr Ser Thr Ile Ile 1 5 10 15 Arg 12248PRTArtificial
SequenceSynthetic Polypeptide 1224Asp Pro Asn Ile Val Ile Ala Lys 1
5 122511PRTArtificial SequenceSynthetic Polypeptide 1225Glu Leu Ser
Asp Phe Ile Ser Tyr Leu Gln Arg 1 5 10 122631PRTArtificial
SequenceSynthetic Polypeptide 1226Phe Ala His Thr Asn Val Glu Ser
Leu Val Asn Glu Tyr Asp Asp Asn 1 5 10 15 Gly Glu Gly Ile Ile Leu
Phe Arg Pro Ser His Leu Thr Asn Lys 20 25 30 122713PRTArtificial
SequenceSynthetic Polypeptide 1227Ser Glu Pro Ile Pro Glu Ser Asn
Asp Gly Pro Val Lys 1 5 10 12288PRTArtificial SequenceSynthetic
Polypeptide 1228Thr Val Ala Tyr Thr Glu Gln Lys 1 5
122920PRTArtificial SequenceSynthetic Polypeptide 1229Glu Glu Asn
Gly Val Leu Val Leu Asn Asp Ala Asn Phe Asp Asn Phe 1 5 10 15 Val
Ala Asp Lys 20 123019PRTArtificial SequenceSynthetic Polypeptide
1230Glu Val Ser Gln Pro Asp Trp Thr Pro Pro Pro Glu Val Thr Leu Val
1 5 10 15 Leu Thr Lys 123110PRTArtificial SequenceSynthetic
Polypeptide 1231Phe Asp Val Ser Gly Tyr Pro Thr Ile Lys 1 5 10
123211PRTArtificial SequenceSynthetic Polypeptide 1232Phe His His
Thr Phe Ser Thr Glu Ile Ala Lys 1 5 10 12338PRTArtificial
SequenceSynthetic Polypeptide 1233Phe Ile Glu Glu His Ala Thr Lys 1
5 123411PRTArtificial SequenceSynthetic Polypeptide 1234Gly Glu Ser
Pro Val Asp Tyr Asp Gly Gly Arg 1 5 10 123517PRTArtificial
SequenceSynthetic Polypeptide 1235His His Ser Leu Gly Gly Gln Tyr
Gly Val Gln Gly Phe Pro Thr Ile 1 5 10 15 Lys 123614PRTArtificial
SequenceSynthetic Polypeptide 1236Asn Leu Glu Pro Glu Trp Ala Ala
Ala Ala Ser Glu Val Lys 1 5 10 123710PRTArtificial
SequenceSynthetic Polypeptide 1237Asn Arg Pro Glu Asp Tyr Gln Gly
Gly Arg 1 5 10 12389PRTArtificial SequenceSynthetic Polypeptide
1238Asn Ser Tyr Leu Glu Val Leu Leu Lys 1 5 123916PRTArtificial
SequenceSynthetic Polypeptide 1239Asp Gln Asn Phe Val Ile Leu Glu
Phe Pro Val Glu Glu Gln Asp Arg 1 5 10 15 124013PRTArtificial
SequenceSynthetic Polypeptide 1240Glu Asp Thr Ile Val Ser Gln Thr
Gln Asp Phe Thr Lys 1 5 10 124114PRTArtificial SequenceSynthetic
Polypeptide 1241Ser Glu Leu Val Thr Val Thr Glu Ser Phe Ser Thr Pro
Lys 1 5 10 124211PRTArtificial SequenceSynthetic Polypeptide
1242Ser Thr Glu Ser Tyr Phe Ile Pro Glu Val Arg 1 5 10
124316PRTArtificial SequenceSynthetic Polypeptide 1243Val Ile Ala
Pro Val Asp Glu Val Gln Ile Ser Ile Leu Ser Ser Lys 1 5 10 15
124412PRTArtificial SequenceSynthetic Polypeptide 1244Asp Thr Asp
Thr Gly Ala Leu Leu Phe Ile Gly Lys 1 5 10 124511PRTArtificial
SequenceSynthetic Polypeptide 1245Glu Leu Leu Asp Thr Val Thr Ala
Pro Gln Lys 1 5 10 124612PRTArtificial SequenceSynthetic
Polypeptide 1246Leu Gln Ser Leu Phe Asp Ser Pro Asp Phe Ser Lys 1 5
10 12479PRTArtificial SequenceSynthetic Polypeptide 1247Leu Ser Tyr
Glu Gly Glu Val Thr Lys 1 5 124810PRTArtificial SequenceSynthetic
Polypeptide 1248Thr Val Gln Ala Val Leu Thr Val Pro Lys 1 5 10
12498PRTArtificial SequenceSynthetic Polypeptide 1249Ala Val Ser
Asn Glu Ile Val Arg 1 5 125012PRTArtificial SequenceSynthetic
Polypeptide 1250Phe Pro Thr Asp Gln Leu Thr Pro Asp Gln Glu Arg 1 5
10 125110PRTArtificial SequenceSynthetic Polypeptide 1251Ile Ala
Asn Val Phe Thr Asn Ala Phe Arg 1 5 10 12527PRTArtificial
SequenceSynthetic Polypeptide 1252Val Phe Phe Ala Ser Trp Arg 1 5
125312PRTArtificial SequenceSynthetic Polypeptide 1253Val Val Leu
Glu Gly Gly Ile Asp Pro Ile Leu Arg 1 5 10 125422PRTArtificial
SequenceSynthetic Polypeptide 1254Leu Ser Leu Pro Leu Leu Leu Leu
Leu Leu Gly Ala Trp Ala Ile Pro 1 5 10 15 Gly Gly Leu Gly Asp Arg
20 12558PRTArtificial SequenceSynthetic Polypeptide 1255Asn Trp Gln
Asp Tyr Gly Val Arg 1 5 125614PRTArtificial SequenceSynthetic
Polypeptide 1256Ala Leu Pro Phe Trp Asn Glu Glu Ile Val Pro Gln Ile
Lys 1 5 10
125710PRTArtificial SequenceSynthetic Polypeptide 1257Ala Met Glu
Ala Val Ala Ala Gln Gly Lys 1 5 10 125818PRTArtificial
SequenceSynthetic Polypeptide 1258Phe Ser Gly Trp Tyr Asp Ala Asp
Leu Ser Pro Ala Gly His Glu Glu 1 5 10 15 Ala Lys
125911PRTArtificial SequenceSynthetic Polypeptide 1259His Gly Glu
Ser Ala Trp Asn Leu Glu Asn Arg 1 5 10 126018PRTArtificial
SequenceSynthetic Polypeptide 1260Asn Leu Lys Pro Ile Lys Pro Met
Gln Phe Leu Gly Asp Glu Glu Thr 1 5 10 15 Val Arg
126113PRTArtificial SequenceSynthetic Polypeptide 1261Ile His Thr
Tyr Val Tyr Glu Phe Ile Tyr Leu Val Arg 1 5 10 126227PRTArtificial
SequenceSynthetic Polypeptide 1262Leu Asp Pro Ser Pro Phe Ile Ala
Asp Phe Gln Thr Thr Ala Glu Glu 1 5 10 15 Leu Gly Leu Leu Ser Ser
Ser Pro Asn Leu Leu 20 25 126318PRTArtificial SequenceSynthetic
Polypeptide 1263Val Val Ser Glu Glu Thr Leu Leu Phe Gln Thr Glu Leu
Tyr Phe Thr 1 5 10 15 Pro Arg 126411PRTArtificial SequenceSynthetic
Polypeptide 1264Asp Ala Val Thr Thr Thr Val Thr Gly Ala Lys 1 5 10
126511PRTArtificial SequenceSynthetic Polypeptide 1265Glu Val Ser
Asp Ser Leu Leu Thr Ser Ser Lys 1 5 10 126616PRTArtificial
SequenceSynthetic Polypeptide 1266Leu Pro Ile Leu Asn Gln Pro Ser
Thr Gln Ile Val Ala Asn Ala Lys 1 5 10 15 126718PRTArtificial
SequenceSynthetic Polypeptide 1267Ser Glu Leu Leu Val Glu Gln Tyr
Leu Pro Leu Thr Glu Glu Glu Leu 1 5 10 15 Glu Lys
126814PRTArtificial SequenceSynthetic Polypeptide 1268Ser Val Val
Ser Gly Ser Ile Asn Thr Val Leu Gly Ser Arg 1 5 10
126915PRTArtificial SequenceSynthetic Polypeptide 1269Asp Thr Val
Ala Thr Gln Leu Ser Glu Ala Val Asp Ala Thr Arg 1 5 10 15
127017PRTArtificial SequenceSynthetic Polypeptide 1270Ile Ala Thr
Ser Leu Asp Gly Phe Asp Val Ala Ser Val Gln Gln Gln 1 5 10 15 Arg
127114PRTArtificial SequenceSynthetic Polypeptide 1271Leu Glu Glu
Asn Leu Pro Ile Leu Gln Gln Pro Thr Glu Lys 1 5 10
127218PRTArtificial SequenceSynthetic Polypeptide 1272Ser Glu Glu
Trp Ala Asp Asn His Leu Pro Leu Thr Asp Ala Glu Leu 1 5 10 15 Ala
Arg 127316PRTArtificial SequenceSynthetic Polypeptide 1273Thr Leu
Thr Ala Ala Ala Val Ser Gly Ala Gln Pro Ile Leu Ser Lys 1 5 10 15
127418PRTArtificial SequenceSynthetic Polypeptide 1274Ala Gln Val
Glu Glu Phe Leu Ala Gln His Gly Ser Glu Tyr Gln Ser 1 5 10 15 Val
Lys 127515PRTArtificial SequenceSynthetic Polypeptide 1275Ile Phe
Gln Asn Leu Asp Gly Ala Leu Asp Glu Val Val Leu Lys 1 5 10 15
127612PRTArtificial SequenceSynthetic Polypeptide 1276Leu Gln Leu
Asn Tyr Leu Gly Asn Tyr Ile Pro Arg 1 5 10 127712PRTArtificial
SequenceSynthetic Polypeptide 1277Leu Thr His Tyr His Glu Gly Leu
Pro Thr Thr Arg 1 5 10 127818PRTArtificial SequenceSynthetic
Polypeptide 1278Asn Leu Ala Tyr Asp Thr Leu Pro Val Leu Ile His Gly
Asn Gly Pro 1 5 10 15 Thr Lys 127914PRTArtificial SequenceSynthetic
Polypeptide 1279Ile Val Gly Pro Glu Glu Asn Leu Ser Gln Ala Glu Ala
Arg 1 5 10 128019PRTArtificial SequenceSynthetic Polypeptide
1280Ile Val Gln Gln Trp Asn Leu Gln Asp Asn Asp Asp Asp Gln Leu Phe
1 5 10 15 Tyr Thr Lys 128111PRTArtificial SequenceSynthetic
Polypeptide 1281Leu Thr His Leu His Glu Gly Leu Pro Val Lys 1 5 10
128217PRTArtificial SequenceSynthetic Polypeptide 1282Leu Trp Ser
Asn Phe Trp Gly Ala Leu Ser Pro Asp Gly Tyr Tyr Ala 1 5 10 15 Arg
128312PRTArtificial SequenceSynthetic Polypeptide 1283Ser Glu Asp
Tyr Val Asp Ile Val Gln Gly Asn Arg 1 5 10 12849PRTArtificial
SequenceSynthetic Polypeptide 1284Ile Gly Asn Phe Ser Thr Asp Ile
Lys 1 5 12858PRTArtificial SequenceSynthetic Polypeptide 1285Ile
Ser Phe Asp Glu Phe Ile Lys 1 5 128619PRTArtificial
SequenceSynthetic Polypeptide 1286Val Asp Thr Asp Gly Asn Gly Tyr
Ile Ser Phe Asn Glu Leu Asn Asp 1 5 10 15 Leu Phe Lys
12877PRTArtificial SequenceSynthetic Polypeptide 1287Val Pro Val
Asp Trp Asn Arg 1 5 128822PRTArtificial SequenceSynthetic
Polypeptide 1288Tyr Pro Ala Leu His Lys Pro Glu Asn Gln Asp Ile Asp
Trp Gly Ala 1 5 10 15 Leu Glu Gly Glu Thr Arg 20
128911PRTArtificial SequenceSynthetic Polypeptide 1289Leu Asp Ile
Thr Ala Glu Ile Leu Ala Val Arg 1 5 10 129014PRTArtificial
SequenceSynthetic Polypeptide 1290Leu Gln Val Asn Thr Pro Leu Val
Gly Ala Ser Leu Leu Arg 1 5 10 129110PRTArtificial
SequenceSynthetic Polypeptide 1291Leu Tyr Val Thr Ile Pro Leu Gly
Ile Lys 1 5 10 129219PRTArtificial SequenceSynthetic Polypeptide
1292Val Thr Asp Pro Gln Leu Leu Glu Leu Gly Leu Val Gln Ser Pro Asp
1 5 10 15 Gly His Arg 129315PRTArtificial SequenceSynthetic
Polypeptide 1293Val Thr Ser Val Ile Pro Gly Leu Asn Asn Ile Ile Asp
Ile Lys 1 5 10 15 129415PRTArtificial SequenceSynthetic Polypeptide
1294Glu Leu Pro Val Pro Ile Tyr Val Thr Gln Gly Glu Ala Gln Arg 1 5
10 15 129517PRTArtificial SequenceSynthetic Polypeptide 1295Gly Pro
Ser Gly Ala Glu Glu Ala Thr Val Glu Tyr Gly Val Thr Ser 1 5 10 15
Arg 12969PRTArtificial SequenceSynthetic Polypeptide 1296Gly Pro
Val Asp Ala Val Thr Gly Lys 1 5 129715PRTArtificial
SequenceSynthetic Polypeptide 1297Gln Leu Ala Gly Ser Gln Pro Phe
Ser Ser Glu Gly Leu Gly Arg 1 5 10 15 129824PRTArtificial
SequenceSynthetic Polypeptide 1298Ser Gln Pro Pro Gly Ile Ser Ser
Gln His Phe Thr Tyr Gln Asp Pro 1 5 10 15 Val Leu Leu Ser Leu Ser
Pro Arg 20 12997PRTArtificial SequenceSynthetic Polypeptide 1299Phe
Trp Val Asn Ile Leu Lys 1 5 130016PRTArtificial SequenceSynthetic
Polypeptide 1300Leu Asn Thr Ile Gly His Tyr Glu Ile Ser Asn Gly Ser
Thr Ile Lys 1 5 10 15 13019PRTArtificial SequenceSynthetic
Polypeptide 1301Asn Pro Gln Phe Val Phe Asp Ile Lys 1 5
130211PRTArtificial SequenceSynthetic Polypeptide 1302Gly Phe Glu
Pro Gly Val Thr Asn Ile Leu Lys 1 5 10 130312PRTArtificial
SequenceSynthetic Polypeptide 1303Ile Ile Asp Gly Val Pro Val Glu
Ile Thr Glu Lys 1 5 10 130418PRTArtificial SequenceSynthetic
Polypeptide 1304Ile Ile His Gly Asn Gln Ile Ala Thr Asn Gly Val Val
His Val Ile 1 5 10 15 Asp Arg 130520PRTArtificial SequenceSynthetic
Polypeptide 1305Leu Leu Tyr Pro Ala Asp Thr Pro Val Gly Asn Asp Gln
Leu Leu Glu 1 5 10 15 Ile Leu Asn Lys 20 130623PRTArtificial
SequenceSynthetic Polypeptide 1306Val Leu Thr Gln Ile Gly Thr Ser
Ile Gln Asp Phe Ile Glu Ala Glu 1 5 10 15 Asp Asp Leu Ser Ser Phe
Arg 20 130717PRTArtificial SequenceSynthetic Polypeptide 1307Asp
Pro Tyr Gln Glu Glu Glu Trp Pro Gln Gly Phe Gly Gln Leu Thr 1 5 10
15 Lys 130811PRTArtificial SequenceSynthetic Polypeptide 1308Phe
Leu Phe Gly Ile Tyr Gln Gln Ala Glu Lys 1 5 10 13097PRTArtificial
SequenceSynthetic Polypeptide 1309Phe Val Thr Leu Leu Tyr Arg 1 5
13109PRTArtificial SequenceSynthetic Polypeptide 1310His Val Ala
Asp Gly Glu Asp His Ala 1 5 13118PRTArtificial SequenceSynthetic
Polypeptide 1311Leu Thr Glu Pro Val Val Pro Lys 1 5
131214PRTArtificial SequenceSynthetic Polypeptide 1312Ala Asn Glu
Gly Thr Val Gly Val Ser Ala Ala Thr Glu Arg 1 5 10
13138PRTArtificial SequenceSynthetic Polypeptide 1313Asp Gln Ala
Gln Glu Thr Leu Lys 1 5 131414PRTArtificial SequenceSynthetic
Polypeptide 1314His Glu Thr His Gly Gly Glu Asp Val Ala Val Phe Ser
Lys 1 5 10 131511PRTArtificial SequenceSynthetic Polypeptide
1315Leu Asp Gly Leu Asp Leu Val Asp Thr Trp Lys 1 5 10
13167PRTArtificial SequenceSynthetic Polypeptide 1316Phe Pro Asp
Glu Asn Phe Lys 1 5 131711PRTArtificial SequenceSynthetic
Polypeptide 1317Ile Glu Val Glu Lys Pro Phe Ala Ile Ala Lys 1 5 10
131813PRTArtificial SequenceSynthetic Polypeptide 1318Thr Val Asp
Asn Phe Val Ala Leu Ala Thr Gly Glu Lys 1 5 10 13198PRTArtificial
SequenceSynthetic Polypeptide 1319Val Ile Phe Gly Leu Phe Gly Lys 1
5 13206PRTArtificial SequenceSynthetic Polypeptide 1320Val Tyr Phe
Asp Leu Arg 1 5 13218PRTArtificial SequenceSynthetic Polypeptide
1321Ala Asp Glu Gly Ile Ser Phe Arg 1 5 132211PRTArtificial
SequenceSynthetic Polypeptide 1322Ala Thr Ala Val Met Pro Asp Gly
Gln Phe Lys 1 5 10 13238PRTArtificial SequenceSynthetic Polypeptide
1323Asp Ile Ser Leu Ser Asp Tyr Lys 1 5 13248PRTArtificial
SequenceSynthetic Polypeptide 1324Gly Leu Phe Ile Ile Asp Asp Lys 1
5 13259PRTArtificial SequenceSynthetic Polypeptide 1325Ile Gly His
Pro Ala Pro Asn Phe Lys 1 5 132610PRTArtificial SequenceSynthetic
Polypeptide 1326Leu Val Gln Ala Phe Gln Phe Thr Asp Lys 1 5 10
132716PRTArtificial SequenceSynthetic Polypeptide 1327Gln Gly Gly
Leu Gly Pro Met Asn Ile Pro Leu Val Ser Asp Pro Lys 1 5 10 15
132811PRTArtificial SequenceSynthetic Polypeptide 1328Gln Ile Thr
Val Asn Asp Leu Pro Val Gly Arg 1 5 10 13297PRTArtificial
SequenceSynthetic Polypeptide 1329Ser Val Asp Glu Thr Leu Arg 1 5
133010PRTArtificial SequenceSynthetic Polypeptide 1330Thr Ile Ala
Gln Asp Tyr Gly Val Leu Lys 1 5 10 133114PRTArtificial
SequenceSynthetic Polypeptide 1331Asp Tyr Gly Val Tyr Leu Glu Asp
Ser Gly His Thr Leu Arg 1 5 10 133213PRTArtificial
SequenceSynthetic Polypeptide 1332Ile Pro Leu Leu Ser Asp Leu Thr
His Gln Ile Ser Lys 1 5 10 133319PRTArtificial SequenceSynthetic
Polypeptide 1333Ile Ser Lys Pro Ala Pro Tyr Trp Glu Gly Thr Ala Val
Ile Asp Gly 1 5 10 15 Glu Phe Lys 133411PRTArtificial
SequenceSynthetic Polypeptide 1334Gln Ile Thr Leu Asn Asp Leu Pro
Val Gly Arg 1 5 10 133512PRTArtificial SequenceSynthetic
Polypeptide 1335Val Ser Val Ala Asp His Ser Leu His Leu Ser Lys 1 5
10 133612PRTArtificial SequenceSynthetic Polypeptide 1336Asp Ser
Pro Ser Val Trp Ala Ala Val Pro Gly Lys 1 5 10 133714PRTArtificial
SequenceSynthetic Polypeptide 1337Ser Ser Phe Tyr Val Asn Gly Leu
Thr Leu Gly Gly Gln Lys 1 5 10 133814PRTArtificial
SequenceSynthetic Polypeptide 1338Ser Thr Gly Gly Ala Pro Thr Phe
Asn Val Thr Val Thr Lys 1 5 10 133916PRTArtificial
SequenceSynthetic Polypeptide 1339Thr Phe Val Asn Ile Thr Pro Ala
Glu Val Gly Val Leu Val Gly Lys 1 5 10 15 13407PRTArtificial
SequenceSynthetic Polypeptide 1340Ile Glu Glu Tyr Ile Ser Lys 1 5
13418PRTArtificial SequenceSynthetic Polypeptide 1341Ile Tyr Glu
Tyr Val Glu Ser Arg 1 5 13429PRTArtificial SequenceSynthetic
Polypeptide 1342Gln Thr Gln Val Asn Glu Ala Thr Lys 1 5
134311PRTArtificial SequenceSynthetic Polypeptide 1343Val Asp Ser
Phe His Glu Ser Thr Glu Gly Lys 1 5 10 134421PRTArtificial
SequenceSynthetic Polypeptide 1344Val Ile Val Asp Ala Asn Asn Leu
Thr Val Glu Ile Glu Asn Glu Leu 1 5 10 15 Asn Ile Ile His Lys 20
134520PRTArtificial SequenceSynthetic Polypeptide 1345Ala Met Glu
Val Asp Glu Arg Pro Thr Glu Gln Tyr Ser Asp Ile Gly 1 5 10 15 Gly
Leu Asp Lys 20 134612PRTArtificial SequenceSynthetic Polypeptide
1346Gly Val Leu Met Tyr Gly Pro Pro Gly Thr Gly Lys 1 5 10
134716PRTArtificial SequenceSynthetic Polypeptide 1347Leu Ala Gly
Pro Gln Leu Val Gln Met Phe Ile Gly Asp Gly Ala Lys 1 5 10 15
134816PRTArtificial SequenceSynthetic Polypeptide 1348Gln Ile Gln
Glu Leu Val Glu Ala Ile Val Leu Pro Met Asn His Lys 1 5 10 15
134910PRTArtificial SequenceSynthetic Polypeptide 1349Val Asp Ile
Leu Asp Pro Ala Leu Leu Arg 1 5 10 135010PRTArtificial
SequenceSynthetic Polypeptide 1350Ala Val Gly Leu Leu Thr Val Ile
Ser Lys 1 5 10 135114PRTArtificial SequenceSynthetic Polypeptide
1351Ala Gly Tyr Leu Thr Leu Tyr Gly Ile Glu Ala Leu Pro Arg 1 5 10
135212PRTArtificial SequenceSynthetic Polypeptide 1352Asp Pro Glu
Ile Tyr Thr Asp Pro Glu Val Phe Lys 1 5 10 135314PRTArtificial
SequenceSynthetic Polypeptide 1353Glu Val Val Val Asp Leu Ala Met
Pro Met Ala Asp Gly Arg 1 5 10 135423PRTArtificial
SequenceSynthetic Polypeptide 1354Gly Glu Leu Glu Ser Ile Leu Trp
Gln Ala Glu Gln Pro Val Ser Gln 1 5 10 15 Thr Thr Thr Leu Pro Gln
Lys 20 135512PRTArtificial SequenceSynthetic Polypeptide 1355His
Gly Asp Ile Phe Thr Ile Leu Val Gly Gly Arg 1 5 10
135615PRTArtificial SequenceSynthetic Polypeptide 1356Ile Phe Asp
Val Gln Leu Pro His Tyr Ser Pro Ser Asp Glu Lys 1 5 10 15
135711PRTArtificial SequenceSynthetic Polypeptide 1357Leu Leu Leu
Phe Pro Phe Leu Ser Pro Gln Arg 1 5 10 135811PRTArtificial
SequenceSynthetic Polypeptide 1358Val His Ser Ala Asp Val Phe His
Thr Phe Arg 1 5 10 135917PRTArtificial SequenceSynthetic
Polypeptide 1359Val Leu Asp Ser Thr Pro Val Leu Asp Ser Val Leu Ser
Glu Ser Leu 1 5 10 15 Arg 136015PRTArtificial SequenceSynthetic
Polypeptide 1360Tyr Gly Phe Gly Leu Met Gln Pro Glu His Asp Val Pro
Val Arg 1 5 10 15 136113PRTArtificial SequenceSynthetic Polypeptide
1361Phe Gly Ser Leu Leu Pro Ile His Pro Val Thr Ser Gly 1 5 10
136229PRTArtificial SequenceSynthetic Polypeptide 1362Leu Asp Glu
Glu Ala Glu Asn Leu Val Ala Thr Val Val Pro Thr His 1 5 10 15 Leu
Ala Ala Ala Val Pro Glu Val Ala Val Tyr Leu Lys 20 25
136322PRTArtificial SequenceSynthetic Polypeptide 1363Thr Gly Pro
Phe Ala Glu His Ser Asn Gln Leu Trp Asn Ile Ser Ala 1 5 10 15 Val
Pro Ser Trp Ser Lys 20 136410PRTArtificial SequenceSynthetic
Polypeptide 1364Val Asp Asp Gln Ile Ala Ile Val Phe Lys 1 5 10
136513PRTArtificial SequenceSynthetic Polypeptide 1365Trp Ile Asp
Glu Thr Pro Pro Val Asp Gln Pro Ser Arg 1 5 10 136611PRTArtificial
SequenceSynthetic Polypeptide 1366Asp Leu Gln Tyr Ser Thr Asp Tyr
Thr Phe Lys 1 5 10 136716PRTArtificial SequenceSynthetic
Polypeptide 1367Ser Glu Ala
Ala His Gln Gly Val Ile Thr Trp Asn Pro Pro Gln Arg 1 5 10 15
136812PRTArtificial SequenceSynthetic Polypeptide 1368Thr Leu Ile
Leu Asp Val Pro Pro Gly Val Glu Lys 1 5 10 136911PRTArtificial
SequenceSynthetic Polypeptide 1369Tyr Asp Leu Gln Asn Leu Lys Pro
Tyr Thr Lys 1 5 10 137011PRTArtificial SequenceSynthetic
Polypeptide 1370Tyr Val Asp Ile Leu Pro Tyr Asp Tyr Asn Arg 1 5 10
137126PRTArtificial SequenceSynthetic Polypeptide 1371Ala Gly Ser
Pro Thr Ala Pro Val His Asp Glu Ser Leu Val Gly Pro 1 5 10 15 Val
Asp Pro Ser Ser Gly Gln Gln Ser Arg 20 25 137214PRTArtificial
SequenceSynthetic Polypeptide 1372Ala Val Ser Ile Ser Pro Thr Asn
Val Ile Leu Thr Trp Lys 1 5 10 137314PRTArtificial
SequenceSynthetic Polypeptide 1373Thr Pro Ser Ser Thr Gly Pro Ser
Pro Val Phe Asp Ile Lys 1 5 10 137412PRTArtificial
SequenceSynthetic Polypeptide 1374Val Ile Thr Glu Pro Ile Pro Val
Ser Asp Leu Arg 1 5 10 137517PRTArtificial SequenceSynthetic
Polypeptide 1375Val Leu Leu Glu Ser Ile Gly Ser His Glu Glu Leu Thr
Gln Asp Ser 1 5 10 15 Arg 137612PRTArtificial SequenceSynthetic
Polypeptide 1376Glu Gly Pro Pro Ser Glu His Ser Gly Ile Ser Arg 1 5
10 137714PRTArtificial SequenceSynthetic Polypeptide 1377Glu Asn
Ser Ser Ser Gln Asp Pro Gln Thr Glu Gly Thr Arg 1 5 10
13789PRTArtificial SequenceSynthetic Polypeptide 1378Gln Ala Glu
Leu Thr Val Gln Val Lys 1 5 13797PRTArtificial SequenceSynthetic
Polypeptide 1379Ser Val Asp Ile Trp Leu Arg 1 5 138013PRTArtificial
SequenceSynthetic Polypeptide 1380Val Leu Ala Lys Pro Gln Asn Thr
Ala Glu Val Gln Lys 1 5 10 138110PRTArtificial SequenceSynthetic
Polypeptide 1381Asp Asn Ile Asn Ile Glu Glu Ala Ala Arg 1 5 10
138217PRTArtificial SequenceSynthetic Polypeptide 1382Ile Leu Val
Asn His Gln Ser Phe Pro Asn Glu Glu Asn Asp Val Asp 1 5 10 15 Lys
13837PRTArtificial SequenceSynthetic Polypeptide 1383Leu Asp Gln
Glu Thr Leu Arg 1 5 138417PRTArtificial SequenceSynthetic
Polypeptide 1384Val His Leu Pro Asn Gly Ser Pro Ile Pro Ala Val Leu
Leu Ala Asn 1 5 10 15 Lys 138511PRTArtificial SequenceSynthetic
Polypeptide 1385Val Leu Val Ile Gly Glu Leu Gly Val Gly Lys 1 5 10
138619PRTArtificial SequenceSynthetic Polypeptide 1386Ala Glu Leu
Asn Gln Ser Glu Glu Pro Glu Ala Gly Glu Ser Ser Thr 1 5 10 15 Gly
Gly Pro 13878PRTArtificial SequenceSynthetic Polypeptide 1387Ile
Gly Glu Pro Leu Val Leu Lys 1 5 138821PRTArtificial
SequenceSynthetic Polypeptide 1388Val Leu Pro Asn Gly Ser Leu Phe
Leu Pro Ala Val Gly Ile Gln Asp 1 5 10 15 Glu Gly Ile Phe Arg 20
138915PRTArtificial SequenceSynthetic Polypeptide 1389Val Leu Ser
Pro Gln Gly Gly Gly Pro Trp Asp Ser Val Ala Arg 1 5 10 15
139024PRTArtificial SequenceSynthetic Polypeptide 1390Val Tyr Gln
Ile Pro Gly Lys Pro Glu Ile Val Asp Ser Ala Ser Glu 1 5 10 15 Leu
Thr Ala Gly Val Pro Asn Lys 20 139111PRTArtificial
SequenceSynthetic Polypeptide 1391Phe Asn Val Trp Asp Thr Ala Gly
Gln Glu Lys 1 5 10 139211PRTArtificial SequenceSynthetic
Polypeptide 1392Leu Val Leu Val Gly Asp Gly Gly Thr Gly Lys 1 5 10
13937PRTArtificial SequenceSynthetic Polypeptide 1393Asn Val Pro
Asn Trp His Arg 1 5 139412PRTArtificial SequenceSynthetic
Polypeptide 1394Ala Ser Val Asp Glu Leu Phe Ala Glu Ile Val Arg 1 5
10 13958PRTArtificial SequenceSynthetic Polypeptide 1395Glu Val Ser
Tyr Gly Glu Gly Lys 1 5 139615PRTArtificial SequenceSynthetic
Polypeptide 1396Ser Ala Leu Thr Val Gln Phe Val Thr Gly Ser Phe Ile
Glu Lys 1 5 10 15 13977PRTArtificial SequenceSynthetic Polypeptide
1397Val Asp Leu Glu Gly Glu Arg 1 5 139811PRTArtificial
SequenceSynthetic Polypeptide 1398Val Val Val Leu Gly Ser Gly Gly
Val Gly Lys 1 5 10 139915PRTArtificial SequenceSynthetic
Polypeptide 1399Ser Ala Leu Thr Val Gln Phe Val Thr Gly Thr Phe Ile
Glu Lys 1 5 10 15 14007PRTArtificial SequenceSynthetic Polypeptide
1400Val Asp Leu Glu Pro Glu Arg 1 5 14019PRTArtificial
SequenceSynthetic Polypeptide 1401Val Pro Leu Ile Leu Val Gly Asn
Lys 1 5 140214PRTArtificial SequenceSynthetic Polypeptide 1402Ala
Gly Asp Gly Asp Gly Trp Val Ser Leu Ala Glu Leu Arg 1 5 10
14039PRTArtificial SequenceSynthetic Polypeptide 1403Ala Trp Ile
Ala His Thr Gln Gln Arg 1 5 140413PRTArtificial SequenceSynthetic
Polypeptide 1404Asp Ile Val Ile Ala Glu Thr Leu Glu Asp Leu Asp Arg
1 5 10 140513PRTArtificial SequenceSynthetic Polypeptide 1405Glu
Phe Asp Gln Leu Thr Pro Glu Glu Ser Gln Ala Arg 1 5 10
14067PRTArtificial SequenceSynthetic Polypeptide 1406Val Gly Trp
Glu Glu Leu Arg 1 5 14078PRTArtificial SequenceSynthetic
Polypeptide 1407Val Phe Gln Phe Leu Asn Ala Lys 1 5
14087PRTArtificial SequenceSynthetic Polypeptide 1408Asp Val Asp
Ala Val Asp Lys 1 5 140915PRTArtificial SequenceSynthetic
Polypeptide 1409Glu Leu Leu Gln Thr Glu Leu Ser Gly Phe Leu Asp Ala
Gln Lys 1 5 10 15 141025PRTArtificial SequenceSynthetic Polypeptide
1410Asp Gln Glu Val Asn Phe Gln Glu Tyr Val Thr Phe Leu Gly Ala Leu
1 5 10 15 Ala Leu Ile Tyr Asn Glu Ala Leu Lys 20 25
14117PRTArtificial SequenceSynthetic Polypeptide 1411Glu Leu Thr
Ile Gly Ser Lys 1 5 14128PRTArtificial SequenceSynthetic
Polypeptide 1412Leu Gln Asp Ala Glu Ile Ala Arg 1 5
141313PRTArtificial SequenceSynthetic Polypeptide 1413Asp Pro Asn
His Phe Arg Pro Ala Gly Leu Pro Glu Lys 1 5 10 14149PRTArtificial
SequenceSynthetic Polypeptide 1414Glu Ala Asn Tyr Ile Gly Ser Asp
Lys 1 5 141520PRTArtificial SequenceSynthetic Polypeptide 1415Phe
Phe Gly His Gly Ala Glu Asp Ser Leu Ala Asp Gln Ala Ala Asn 1 5 10
15 Glu Trp Gly Arg 20 141614PRTArtificial SequenceSynthetic
Polypeptide 1416Ser Phe Phe Ser Phe Leu Gly Glu Ala Phe Asp Gly Ala
Arg 1 5 10 141716PRTArtificial SequenceSynthetic Polypeptide
1417Phe Ser Asn Ile Ser Glu Gly Leu Ser Asn Tyr Ser Ile Ile Asp Lys
1 5 10 15 14189PRTArtificial SequenceSynthetic Polypeptide 1418Leu
Phe Thr Pro Glu Glu Phe Phe Arg 1 5 14197PRTArtificial
SequenceSynthetic Polypeptide 1419Leu Val Ala Asn Leu Pro Lys 1 5
142034PRTArtificial SequenceSynthetic Polypeptide 1420Asp Thr Gln
Leu Leu Thr Ala Ile Pro Thr Ser Pro Glu Pro Thr Gly 1 5 10 15 Leu
Glu Ala Thr Ala Ala Ser Thr Ser Thr Leu Pro Ala Gly Glu Gly 20 25
30 Pro Lys 142117PRTArtificial SequenceSynthetic Polypeptide
1421Glu Gly Glu Ala Val Val Leu Pro Glu Val Glu Pro Gly Leu Thr Ala
1 5 10 15 Arg 14229PRTArtificial SequenceSynthetic Polypeptide
1422Glu Gln Glu Ala Thr Pro Arg Pro Arg 1 5 142329PRTArtificial
SequenceSynthetic Polypeptide 1423Glu Thr Thr Gln Leu Pro Thr Thr
His Leu Ala Ser Thr Thr Thr Ala 1 5 10 15 Thr Thr Ala Gln Glu Pro
Ala Thr Ser His Pro His Arg 20 25 142412PRTArtificial
SequenceSynthetic Polypeptide 1424Gln Ala Asn Gly Gly Ala Tyr Gln
Lys Pro Thr Lys 1 5 10 142513PRTArtificial SequenceSynthetic
Polypeptide 1425Asp Ile Leu Gln Leu Ile Gly Phe Ala Asn Leu Pro Arg
1 5 10 142611PRTArtificial SequenceSynthetic Polypeptide 1426Asp
Tyr Pro Asp Glu Val Leu Gln Phe Ala Arg 1 5 10 142711PRTArtificial
SequenceSynthetic Polypeptide 1427Glu Val Leu Trp Pro Pro Gln Pro
Gly Gln Arg 1 5 10 142813PRTArtificial SequenceSynthetic
Polypeptide 1428Leu Phe Leu Gly Gly Leu Asp Ala Leu Tyr Ser Leu Arg
1 5 10 142924PRTArtificial SequenceSynthetic Polypeptide 1429Val
Ile Ala Leu Gln Ala Gly Gly Ser Ala Glu Pro Glu Glu Val Val 1 5 10
15 Leu Glu Glu Leu Gln Val Phe Lys 20 143012PRTArtificial
SequenceSynthetic Polypeptide 1430Leu Ala Tyr Val Tyr Gln Asn Asn
Ile Tyr Leu Lys 1 5 10 143125PRTArtificial SequenceSynthetic
Polypeptide 1431Asn Val Asp Tyr Leu Leu Ile His Gly Thr Ala Asp Asp
Asn Val His 1 5 10 15 Phe Gln Asn Ser Ala Gln Ile Ala Lys 20 25
143211PRTArtificial SequenceSynthetic Polypeptide 1432Gln Phe Val
Tyr Leu Glu Ser Asp Tyr Ser Lys 1 5 10 143314PRTArtificial
SequenceSynthetic Polypeptide 1433Ser Val Phe Ala Val Asn Trp Ile
Ser Tyr Leu Ala Ser Lys 1 5 10 14349PRTArtificial SequenceSynthetic
Polypeptide 1434Thr Gln Glu His Ile Glu Glu Ser Arg 1 5
14359PRTArtificial SequenceSynthetic Polypeptide 1435Ala Val Leu
Ser Ala Glu Gln Leu Arg 1 5 143613PRTArtificial SequenceSynthetic
Polypeptide 1436Asp Glu Glu Val His Ala Gly Leu Gly Glu Leu Leu Arg
1 5 10 143726PRTArtificial SequenceSynthetic Polypeptide 1437Asp
Gln Ala Val Glu Asn Ile Leu Val Ser Pro Val Val Val Ala Ser 1 5 10
15 Ser Leu Gly Leu Val Ser Leu Gly Gly Lys 20 25
143812PRTArtificial SequenceSynthetic Polypeptide 1438Asp Thr Gln
Ser Gly Ser Leu Leu Phe Ile Gly Arg 1 5 10 143911PRTArtificial
SequenceSynthetic Polypeptide 1439Gly Val Val Glu Val Thr His Asp
Leu Gln Lys 1 5 10 144021PRTArtificial SequenceSynthetic
Polypeptide 1440Gly Pro Pro Gly Leu Pro Ala His Leu Asp Glu Glu Leu
Gln Ala Thr 1 5 10 15 Leu His Asp Phe Arg 20 14417PRTArtificial
SequenceSynthetic Polypeptide 1441His Gln Ile Leu Gln Thr Arg 1 5
144214PRTArtificial SequenceSynthetic Polypeptide 1442Tyr Ser Asp
Gly Thr Pro Val Asn Tyr Thr Asn Trp Tyr Arg 1 5 10
14437PRTArtificial SequenceSynthetic Polypeptide 1443Val Pro Leu
Pro Val Asp Lys 1 5 144412PRTArtificial SequenceSynthetic
Polypeptide 1444Ala Gly Tyr Pro Leu Glu His Pro Phe Asp Phe Arg 1 5
10 144515PRTArtificial SequenceSynthetic Polypeptide 1445Ala Leu
Pro Ser Gln Gly Leu Ser Ser Ser Ala Val Leu Glu Lys 1 5 10 15
14466PRTArtificial SequenceSynthetic Polypeptide 1446Asp Phe Asp
Ile Tyr Arg 1 5 144718PRTArtificial SequenceSynthetic Polypeptide
1447Gly Ile Phe Val Phe Gly Asn Pro Gln Leu Ser Val Ile Ala Leu Gly
1 5 10 15 Ser Arg 144816PRTArtificial SequenceSynthetic Polypeptide
1448Thr Pro Glu Ile Val Ala Pro Gln Ser Ala His Ala Ala Phe Asn Lys
1 5 10 15 144910PRTArtificial SequenceSynthetic Polypeptide 1449Ala
Tyr Glu Asp Glu Tyr Ser Tyr Phe Lys 1 5 10 145016PRTArtificial
SequenceSynthetic Polypeptide 1450Gly Gln Gly Tyr Asp Gly Tyr Asp
Gly Gln Asn Tyr Tyr His His Gln 1 5 10 15 145111PRTArtificial
SequenceSynthetic Polypeptide 1451Ile Glu Asp Ser Glu Glu Asn Gly
Val Phe Lys 1 5 10 14528PRTArtificial SequenceSynthetic Polypeptide
1452Thr Thr Ser Pro Pro Phe Gly Lys 1 5 145319PRTArtificial
SequenceSynthetic Polypeptide 1453Thr Thr Thr Ser Pro Asn Gly Gly
Phe Glu Pro Thr Thr Pro Pro Gln 1 5 10 15 Val Tyr Arg
145426PRTArtificial SequenceSynthetic Polypeptide 1454Ser Ser Gly
Leu Phe Pro Phe Leu Val Leu Leu Ala Leu Gly Thr Leu 1 5 10 15 Ala
Pro Trp Ala Val Glu Gly Ser Gly Lys 20 25 14558PRTArtificial
SequenceSynthetic Polypeptide 1455Asn Gln Gly Ser Gly Ala Gly Arg 1
5 145610PRTArtificial SequenceSynthetic Polypeptide 1456Val Ala Gln
Leu Glu Gln Val Tyr Ile Arg 1 5 10 14575PRTArtificial
SequenceSynthetic Polypeptide 1457Asn Phe Phe Trp Lys 1 5
145814PRTArtificial SequenceSynthetic Polypeptide 1458Ala Ile Trp
Asn Val Ile Asn Trp Glu Asn Val Thr Glu Arg 1 5 10
145925PRTArtificial SequenceSynthetic Polypeptide 1459Phe Asn Gly
Gly Gly His Ile Asn His Ser Ile Phe Trp Thr Asn Leu 1 5 10 15 Ser
Pro Asn Gly Gly Gly Glu Pro Lys 20 25 146014PRTArtificial
SequenceSynthetic Polypeptide 1460Gly Asp Val Thr Ala Gln Ile Ala
Leu Gln Pro Ala Leu Lys 1 5 10 146120PRTArtificial
SequenceSynthetic Polypeptide 1461Leu Thr Ala Ala Ser Val Gly Val
Gln Gly Ser Gly Trp Gly Trp Leu 1 5 10 15 Gly Phe Asn Lys 20
14628PRTArtificial SequenceSynthetic Polypeptide 1462Asn Val Arg
Pro Asp Tyr Leu Lys 1 5 146311PRTArtificial SequenceSynthetic
Polypeptide 1463Glu Asn Gln Glu Val Ile Leu Glu Glu Val Arg 1 5 10
146415PRTArtificial SequenceSynthetic Polypeptide 1464Glu Ser Ala
Pro Gly Leu Ile Ile Ala Thr Gly Ser Val Gly Lys 1 5 10 15
146512PRTArtificial SequenceSynthetic Polypeptide 1465Leu His Gly
Gly Ser Ala Pro Leu Pro Gln Asp Arg 1 5 10 146610PRTArtificial
SequenceSynthetic Polypeptide 1466Gly Leu Val Leu Ser Gly Val Leu
His Lys 1 5 10 146723PRTArtificial SequenceSynthetic Polypeptide
1467Asn Leu Ile Pro Glu Gly Asn Ile Gly Ser Asn Thr Thr Leu Val Leu
1 5 10 15 Val Asn Ala Ile Tyr Phe Lys 20 146816PRTArtificial
SequenceSynthetic Polypeptide 1468Gln Tyr Thr Ser Phe His Phe Ala
Ser Leu Glu Asp Val Gln Ala Lys 1 5 10 15 14697PRTArtificial
SequenceSynthetic Polypeptide 1469Val Asp Leu His Leu Pro Arg 1 5
14707PRTArtificial SequenceSynthetic Polypeptide 1470Val Leu Glu
Ile Pro Tyr Lys 1 5 147114PRTArtificial SequenceSynthetic
Polypeptide 1471Asp Glu Leu Asn Ala Asp His Pro Phe Ile Tyr Ile Ile
Arg 1 5 10 147221PRTArtificial SequenceSynthetic Polypeptide
1472Asp Leu Thr Asp Gly His Phe Glu Asn Ile Leu Ala Asp Asn Ser Val
1 5 10 15 Asn Asp Gln Thr Lys 20 147311PRTArtificial
SequenceSynthetic Polypeptide 1473Asp Val Glu Asp Glu Ser Thr Gly
Leu Glu Lys 1 5 10 147415PRTArtificial SequenceSynthetic
Polypeptide 1474Asp Val Pro Phe Gly Phe Gln Thr Val Thr Ser Asp Val
Asn Lys 1 5 10 15 147512PRTArtificial SequenceSynthetic Polypeptide
1475Ile Leu Val Val Asn Ala Ala Tyr Phe Val Gly Lys 1 5 10
147612PRTArtificial SequenceSynthetic Polypeptide 1476Ala Phe Ile
Pro Pro Ala Pro Val Leu Pro Ser Arg 1 5 10 14777PRTArtificial
SequenceSynthetic Polypeptide 1477Ala Leu Pro Pro Ile Ala Arg 1 5
14788PRTArtificial SequenceSynthetic Polypeptide 1478Trp Ser Gln
Thr Ala Phe Pro Lys 1 5 14798PRTArtificial SequenceSynthetic
Polypeptide 1479Tyr Ser Ile Thr Phe Thr Gly Lys 1 5
148010PRTArtificial SequenceSynthetic Polypeptide 1480Asp Glu Asp
Asn Asn Leu Leu Thr Glu Lys 1 5 10 14819PRTArtificial
SequenceSynthetic Polypeptide 1481Asn Val Leu Val Thr Leu Tyr Glu
Arg 1 5 14828PRTArtificial SequenceSynthetic Polypeptide 1482Glu
Val Leu Asp Gln Val Glu Arg 1 5 148314PRTArtificial
SequenceSynthetic Polypeptide 1483Gly Pro Ser Ala Ala Phe Ala Pro
Ala Ala Ala Glu Pro Lys 1 5 10 148416PRTArtificial
SequenceSynthetic Polypeptide 1484Leu Phe Gly Gly Phe Asn Ser Ser
Asp Thr Val Thr Ser Pro Gln Arg 1 5 10 15 14859PRTArtificial
SequenceSynthetic Polypeptide 1485Leu Leu Leu Asn Ala Glu Asn Pro
Arg 1 5 148615PRTArtificial SequenceSynthetic Polypeptide 1486Thr
Gln Phe Asn Ser Leu Gln Gln Leu Val Ala Tyr Tyr Ser Lys 1 5 10 15
148729PRTArtificial SequenceSynthetic Polypeptide 1487Gly Thr Trp
Asn Gly Pro Trp Val Ser Thr Glu Val Leu Ala Ala Ala 1 5 10 15 Ile
Gly Leu Val Ile Tyr Tyr Leu Ala Phe Ser Ala Lys 20 25
148819PRTArtificial SequenceSynthetic Polypeptide 1488Asn Asn Glu
Asp Ile Ser Ile Ile Pro Pro Leu Phe Thr Val Ser Val 1 5 10 15 Asp
His Arg 14896PRTArtificial SequenceSynthetic Polypeptide 1489Gln
Phe Pro Val Thr Arg 1 5 149010PRTArtificial SequenceSynthetic
Polypeptide 1490Ser Ala His Ala Gly Thr Tyr Glu Val Arg 1 5 10
149110PRTArtificial SequenceSynthetic Polypeptide 1491Tyr Gln Val
Ser Trp Ser Leu Asp His Lys 1 5 10 149217PRTArtificial
SequenceSynthetic Polypeptide 1492Phe Asn Gln Ala Gln Ser Gly Asn
Ile Gln Ser Thr Val Met Leu Asp 1 5 10 15 Lys 149316PRTArtificial
SequenceSynthetic Polypeptide 1493Leu Leu Gly Pro Asn Ala Ser Pro
Asp Gly Leu Ile Pro Trp Thr Arg 1 5 10 15 149413PRTArtificial
SequenceSynthetic Polypeptide 1494Thr Glu Leu Ile Ser Val Ser Glu
Val His Pro Ser Arg 1 5 10 149513PRTArtificial SequenceSynthetic
Polypeptide 1495Val Met Ala Ala Glu Asn Ile Pro Glu Asn Pro Leu Lys
1 5 10 149610PRTArtificial SequenceSynthetic Polypeptide 1496Tyr
Thr Tyr Glu His Asp Pro Ile Thr Lys 1 5 10 149714PRTArtificial
SequenceSynthetic Polypeptide 1497Ala Ile Leu Ser Thr Lys Pro Pro
Gly Thr Phe Leu Leu Arg 1 5 10 149821PRTArtificial
SequenceSynthetic Polypeptide 1498Glu Ser His Ala Thr Leu Val Phe
His Asn Leu Leu Gly Glu Ile Asp 1 5 10 15 Gln Gln Tyr Ser Arg 20
149916PRTArtificial SequenceSynthetic Polypeptide 1499Leu Glu Asn
Trp Ile Thr Ser Leu Ala Glu Ser Gln Leu Gln Thr Arg 1 5 10 15
150026PRTArtificial SequenceSynthetic Polypeptide 1500Leu Leu Gln
Thr Ala Ala Thr Ala Ala Gln Gln Gly Gly Gln Ala Asn 1 5 10 15 His
Pro Thr Ala Ala Val Val Thr Glu Lys 20 25 150114PRTArtificial
SequenceSynthetic Polypeptide 1501Val Val Glu Asn Leu Gln Asp Asp
Phe Asp Phe Asn Tyr Lys 1 5 10 15028PRTArtificial SequenceSynthetic
Polypeptide 1502Ser Phe Leu Tyr Ser Ala Ala Lys 1 5
150311PRTArtificial SequenceSynthetic Polypeptide 1503Val Ala Ala
Gln Asn Ser Ala Glu Val Val Arg 1 5 10 150412PRTArtificial
SequenceSynthetic Polypeptide 1504Glu Asn Asp Tyr Tyr Thr Pro Thr
Gly Glu Phe Arg 1 5 10 150515PRTArtificial SequenceSynthetic
Polypeptide 1505Phe Glu Ser Val Ile His Glu Phe Asp Pro Tyr Phe Asn
Tyr Arg 1 5 10 15 15069PRTArtificial SequenceSynthetic Polypeptide
1506Phe Leu Ala Glu Glu Gly Phe Tyr Lys 1 5 150711PRTArtificial
SequenceSynthetic Polypeptide 1507Phe Tyr Ser Leu Leu Asp Pro Ser
Tyr Ala Lys 1 5 10 15087PRTArtificial SequenceSynthetic Polypeptide
1508Ile Ile Phe Asp Asp Phe Arg 1 5 15099PRTArtificial
SequenceSynthetic Polypeptide 1509Ala Ala Glu Asp Tyr Gly Val Ile
Lys 1 5 15108PRTArtificial SequenceSynthetic Polypeptide 1510Leu
Gly Phe Gln Val Trp Leu Lys 1 5 151114PRTArtificial
SequenceSynthetic Polypeptide 1511Leu Val Asn Ser Leu Tyr Pro Asp
Gly Ser Lys Pro Val Lys 1 5 10 15126PRTArtificial SequenceSynthetic
Polypeptide 1512Asn Asp Gly His Tyr Arg 1 5 15137PRTArtificial
SequenceSynthetic Polypeptide 1513Asn Gly Val Ile Leu Ser Lys 1 5
15148PRTArtificial SequenceSynthetic Polypeptide 1514Ala Gly Ser
Glu Val Ile Ser Arg 1 5 151510PRTArtificial SequenceSynthetic
Polypeptide 1515Ala Ser Ser Thr Gln Gln Glu Ile Ser Arg 1 5 10
151611PRTArtificial SequenceSynthetic Polypeptide 1516Leu Gln Gly
Glu Ala Pro Gln Ser Ala Leu Arg 1 5 10 15179PRTArtificial
SequenceSynthetic Polypeptide 1517Leu Ser Glu Glu Ile Asp Gln Leu
Arg 1 5 151812PRTArtificial SequenceSynthetic Polypeptide 1518Tyr
Gln Asp Val Tyr Val Glu Leu Ser His Ile Lys 1 5 10
151915PRTArtificial SequenceSynthetic Polypeptide 1519Ala Val Phe
Val Asp Leu Glu Pro Thr Val Ile Asp Glu Val Arg 1 5 10 15
15209PRTArtificial SequenceSynthetic Polypeptide 1520Glu Ile Ile
Asp Leu Val Leu Asp Arg 1 5 152115PRTArtificial SequenceSynthetic
Polypeptide 1521Ala Ile Leu Val Asp Leu Glu Pro Gly Thr Met Asp Ser
Val Arg 1 5 10 15 152212PRTArtificial SequenceSynthetic Polypeptide
1522Glu Val Asp Glu Gln Met Leu Asn Val Gln Asn Lys 1 5 10
152310PRTArtificial SequenceSynthetic Polypeptide 1523Phe Pro Gly
Gln Leu Asn Ala Asp Leu Arg 1 5 10 152418PRTArtificial
SequenceSynthetic Polypeptide 1524Gly His Tyr Thr Glu Gly Ala Glu
Leu Val Asp Ser Val Leu Asp Val 1 5 10 15 Val Arg
152510PRTArtificial SequenceSynthetic Polypeptide 1525Ile Ser Glu
Gln Phe Thr Ala Met Phe Arg 1 5 10 152610PRTArtificial
SequenceSynthetic Polypeptide 1526Leu Ala Val Asn Met Val Pro Phe
Pro Arg 1 5 10 152714PRTArtificial SequenceSynthetic Polypeptide
1527Leu His Phe Phe Met Pro Gly Phe Ala Pro Leu Thr Ser Arg 1 5 10
152817PRTArtificial SequenceSynthetic Polypeptide 1528Met Ser Ala
Thr Phe Ile Gly Asn Ser Thr Ala Ile Gln Glu Leu Phe 1 5 10 15 Lys
152914PRTArtificial SequenceSynthetic Polypeptide 1529Asn Ser Ser
Tyr Phe Val Glu Trp Ile Pro Asn Asn Val Lys 1 5 10
153026PRTArtificial SequenceSynthetic Polypeptide 1530Ser Gly Pro
Phe Gly Gln Ile Phe Arg Pro Asp Asn Phe Val Phe Gly 1 5 10 15 Gln
Ser Gly Ala Gly Asn Asn Trp Ala Lys 20 25 153115PRTArtificial
SequenceSynthetic Polypeptide 1531Ala Leu Thr Val Pro Glu Leu Thr
Gln Gln Met Phe Asp Ala Lys 1 5 10 15 153212PRTArtificial
SequenceSynthetic Polypeptide 1532Glu Val Asp Glu Gln Met Leu Ala
Ile Gln Ser Lys 1 5 10 153312PRTArtificial SequenceSynthetic
Polypeptide 1533Ile Ser Val Tyr Tyr Asn Glu Ala Ser Ser His Lys 1 5
10 153417PRTArtificial SequenceSynthetic Polypeptide 1534Met Ser
Ser Thr Phe Ile Gly Asn Ser Thr Ala Ile Gln Glu Leu Phe 1 5 10 15
Lys 15359PRTArtificial SequenceSynthetic Polypeptide 1535Tyr Leu
Thr Val Ala Thr Val Phe Arg 1 5 153612PRTArtificial
SequenceSynthetic Polypeptide 1536Ile Met Asn Thr Phe Ser Val Val
Pro Ser Pro Lys 1 5 10 153717PRTArtificial SequenceSynthetic
Polypeptide 1537Met Ala Val Thr Phe Ile Gly Asn Ser Thr Ala Ile Gln
Glu Leu Phe 1 5 10 15 Lys 15389PRTArtificial SequenceSynthetic
Polypeptide 1538Tyr Leu Thr Val Ala Ala Val Phe Arg 1 5
153911PRTArtificial SequenceSynthetic Polypeptide 1539Phe Ala Thr
Glu Ala Ala Ile Thr Ile Leu Arg 1 5 10 154011PRTArtificial
SequenceSynthetic Polypeptide 1540Ile His Pro Thr Ser Val Ile Ser
Gly Tyr Arg 1 5 10 154112PRTArtificial SequenceSynthetic
Polypeptide 1541Leu Gly Val Gln Val Val Ile Thr Asp Pro Glu Lys 1 5
10 154210PRTArtificial SequenceSynthetic Polypeptide 1542Ser Ser
Leu Gly Pro Val Gly Leu Asp Lys 1 5 10 154315PRTArtificial
SequenceSynthetic Polypeptide 1543Tyr Ile Asn Glu Asn Leu Ile Val
Asn Thr Asp Glu Leu Gly Arg 1 5 10 15 15448PRTArtificial
SequenceSynthetic Polypeptide 1544Ala Tyr Ile Leu Asn Leu Val Lys 1
5 154514PRTArtificial SequenceSynthetic Polypeptide 1545Gly Asp Val
Thr Ile Thr Asn Asp Gly Ala Thr Ile Leu Lys 1 5 10
154613PRTArtificial SequenceSynthetic Polypeptide 1546Gly Ile His
Pro Thr Ile Ile Ser Glu Ser Phe Gln Lys 1 5 10 15478PRTArtificial
SequenceSynthetic Polypeptide 1547Ile Asp Asp Val Val Asn Thr Arg 1
5 154813PRTArtificial SequenceSynthetic Polypeptide 1548Val Ile Asp
Pro Ala Thr Ala Thr Ser Val Asp Leu Arg 1 5 10 154910PRTArtificial
SequenceSynthetic Polypeptide 1549Ala Val Asp Asp Gly Val Asn Thr
Phe Lys 1 5 10 155010PRTArtificial SequenceSynthetic Polypeptide
1550Asp Ile Asp Glu Val Ser Ser Leu Leu Arg 1 5 10
155111PRTArtificial SequenceSynthetic Polypeptide 1551Leu Ala Thr
Asn Ala Ala Val Thr Val Leu Arg 1 5 10 155210PRTArtificial
SequenceSynthetic Polypeptide 1552Leu Tyr Ala Val His Gln Glu Gly
Asn Lys 1 5 10 155314PRTArtificial SequenceSynthetic Polypeptide
1553Asn Val Gly Leu Asp Ile Glu Ala Glu Val Pro Ala Val Lys 1 5 10
15549PRTArtificial SequenceSynthetic Polypeptide 1554Ala Leu Gln
Phe Leu Glu Glu Val Lys 1 5 155513PRTArtificial SequenceSynthetic
Polypeptide 1555Ala Gln Ala Ala Leu Ala Val Asn Ile Ser Ala Ala Arg
1 5 10 155617PRTArtificial SequenceSynthetic Polypeptide 1556Ala
Gln Leu Gly Val Gln Ala Phe Ala Asp Ala Leu Leu Ile Ile Pro 1 5 10
15 Lys 155712PRTArtificial SequenceSynthetic Polypeptide 1557Gly
Ile Asp Pro Phe Ser Leu Asp Ala Leu Ser Lys 1 5 10
15589PRTArtificial SequenceSynthetic Polypeptide 1558Gly Leu Val
Leu Asp His Gly Ala Arg 1 5 155913PRTArtificial SequenceSynthetic
Polypeptide 1559Gln Ala Asp Leu Tyr Ile Ser Glu Gly Leu His Pro Arg
1 5 10 156010PRTArtificial SequenceSynthetic Polypeptide 1560Thr
Glu Val Asn Ser Gly Phe Phe Tyr Lys 1 5 10 156125PRTArtificial
SequenceSynthetic Polypeptide 1561Val Ala Thr Ala Gln Asp Asp Ile
Thr Gly Asp Gly Thr Thr Ser Asn 1 5 10 15 Val Leu Ile Ile Gly Glu
Leu Leu Lys 20 25 156221PRTArtificial SequenceSynthetic Polypeptide
1562Val His Ala Glu Leu Ala Asp Val Leu Thr Glu Ala Val Val Asp Ser
1 5 10 15 Ile Leu Ala Ile Lys 20 156316PRTArtificial
SequenceSynthetic Polypeptide 1563Val Leu Ala Gln Asn Ser Gly Phe
Asp Leu Gln Glu Thr Leu Val Lys 1 5 10 15 156413PRTArtificial
SequenceSynthetic Polypeptide 1564His Phe Asn Val Asn Thr Asp Tyr
Gln Asn Pro Val Arg 1 5 10 156525PRTArtificial SequenceSynthetic
Polypeptide 1565Ser Glu Asp Glu Glu Asp Leu Gly Asn Ala Arg Pro Ser
Ala Pro Ser 1 5 10 15 Thr Leu Phe Asp Phe Leu Glu Ser Lys 20 25
156618PRTArtificial SequenceSynthetic Polypeptide 1566Ser Asn Ile
Gly Thr Glu Gly Gly Pro Pro Pro Phe Val Pro Phe Gly 1 5 10 15 Gln
Lys 156710PRTArtificial SequenceSynthetic Polypeptide 1567Ser Val
Leu Glu Gly Ser Gly Leu Pro Arg 1 5 10 15689PRTArtificial
SequenceSynthetic Polypeptide 1568Thr Ala Ala Ile Ala Glu Val Ala
Lys 1 5 156914PRTArtificial SequenceSynthetic Polypeptide 1569Ala
Val Asp Ile Pro Gly Leu Glu Ala Ala Thr Pro Tyr Arg 1 5 10
157016PRTArtificial SequenceSynthetic Polypeptide 1570Gly Leu Glu
Pro Gly Gln Glu Tyr Asn Val Leu Leu Thr Ala Glu Lys 1 5 10 15
157125PRTArtificial SequenceSynthetic Polypeptide 1571Thr Ala His
Ile Ser Gly Leu Pro Pro Ser Thr Asp Phe Ile Val Tyr 1 5 10 15 Leu
Ser Gly Leu Ala Pro Ser Ile Arg 20 25 157223PRTArtificial
SequenceSynthetic Polypeptide 1572Thr Val Ser Gly Asn Thr Val Glu
Tyr Ala Leu Thr Asp Leu Glu Pro 1 5 10 15 Ala Thr Glu Tyr Thr Leu
Arg 20 157316PRTArtificial SequenceSynthetic Polypeptide 1573Tyr
Ala Pro Ile Ser Gly Gly Asp His Ala Glu Val Asp Val Pro Lys 1 5 10
15 157416PRTArtificial SequenceSynthetic Polypeptide 1574Asp Ala
Gln Gly Gln Pro Gln Ala Val Pro Val Ser Gly Asp Leu Arg 1 5 10 15
157523PRTArtificial SequenceSynthetic Polypeptide 1575Gly Phe Glu
Glu Ser Glu Pro Leu Thr Gly Phe Leu Thr Thr Val Pro 1 5 10 15 Asp
Gly Pro Thr Gln Leu Arg 20 157618PRTArtificial SequenceSynthetic
Polypeptide 1576Val Pro Gly His Glu Asp Gly Val Thr Ile Ser Gly Leu
Glu Pro Asp 1 5 10 15 His Lys 157721PRTArtificial SequenceSynthetic
Polypeptide 1577Val Ser Tyr Gln Leu Ala Asp Gly Gly Glu Pro Gln Ser
Val Gln Val 1 5 10 15 Asp Gly Gln Ala Arg 20 15789PRTArtificial
SequenceSynthetic Polypeptide 1578Tyr Glu Val Thr Val Val Ser Val
Arg 1 5 157912PRTArtificial SequenceSynthetic Polypeptide 1579Gly
Ile Leu Leu Tyr Gly Pro Pro Gly Thr Gly Lys 1 5 10
158017PRTArtificial SequenceSynthetic Polypeptide 1580Gly Pro Glu
Leu Leu Thr Met Trp Phe Gly Glu Ser Glu Ala Asn Val 1 5 10 15 Arg
158113PRTArtificial SequenceSynthetic Polypeptide 1581Ile Val Ser
Gln Leu Leu Thr Leu Met Asp Gly Leu Lys 1 5 10 158213PRTArtificial
SequenceSynthetic Polypeptide 1582Leu Asp Gln Leu Ile Tyr Ile Pro
Leu Pro Asp Glu Lys 1 5 10 158320PRTArtificial SequenceSynthetic
Polypeptide 1583Leu Ile Val Asp Glu Ala Ile Asn Glu Asp Asn Ser Val
Val Ser Leu 1 5 10 15 Ser Gln Pro Lys 20 15848PRTArtificial
SequenceSynthetic Polypeptide 1584Met Asp Glu Leu Gln Leu Phe Arg 1
5 158517PRTArtificial SequenceSynthetic Polypeptide 1585Asn Ala Pro
Ala Ile Ile Phe Ile Asp Glu Leu Asp Ala Ile Ala Pro 1 5 10 15 Lys
158615PRTArtificial SequenceSynthetic Polypeptide 1586Val Ile Asn
Gln Ile Leu Thr Glu Met Asp Gly Met Ser Thr Lys 1 5 10 15
158712PRTArtificial SequenceSynthetic Polypeptide 1587Trp Ala Leu
Ser Gln Ser Asn Pro Ser Ala Leu Arg 1 5 10 158821PRTArtificial
SequenceSynthetic Polypeptide 1588Gly Gly Thr Leu Ser Thr Pro Gln
Thr Gly Ser Glu Asn Asp Ala Leu 1 5 10 15 Tyr Glu Tyr Leu Arg 20
158912PRTArtificial SequenceSynthetic Polypeptide 1589Leu Asp Thr
Leu Ala Gln Glu Val Ala Leu Leu Lys 1 5 10 159014PRTArtificial
SequenceSynthetic Polypeptide 1590Asn Trp Glu Thr
Glu Ile Thr Ala Gln Pro Asp Gly Gly Lys 1 5 10 159110PRTArtificial
SequenceSynthetic Polypeptide 1591Asp Leu Ile Tyr Thr Leu Tyr Tyr
Trp Lys 1 5 10 15928PRTArtificial SequenceSynthetic Polypeptide
1592Glu Asn Ser Pro Leu Asn Val Ser 1 5 159321PRTArtificial
SequenceSynthetic Polypeptide 1593Thr Ile Leu Glu Trp Glu Pro Lys
Pro Val Asn Gln Val Tyr Thr Val 1 5 10 15 Gln Ile Ser Thr Lys 20
159412PRTArtificial SequenceSynthetic Polypeptide 1594Thr Asn Thr
Asn Glu Phe Leu Ile Asp Val Asp Lys 1 5 10 15959PRTArtificial
SequenceSynthetic Polypeptide 1595Val Asn Val Thr Val Glu Asp Glu
Arg 1 5 159615PRTArtificial SequenceSynthetic Polypeptide 1596Gly
Phe Val Glu Pro Asp His Tyr Val Val Val Gly Ala Gln Arg 1 5 10 15
159710PRTArtificial SequenceSynthetic Polypeptide 1597Leu Thr Thr
Asp Phe Gly Asn Ala Glu Lys 1 5 10 15988PRTArtificial
SequenceSynthetic Polypeptide 1598Leu Thr Val Ser Asn Val Leu Lys 1
5 159916PRTArtificial SequenceSynthetic Polypeptide 1599Ser Ala Phe
Ser Asn Leu Phe Gly Gly Glu Pro Leu Ser Tyr Thr Arg 1 5 10 15
160014PRTArtificial SequenceSynthetic Polypeptide 1600Ser Ser Gly
Leu Pro Asn Ile Pro Val Gln Thr Ile Ser Arg 1 5 10
16019PRTArtificial SequenceSynthetic Polypeptide 1601His Glu Lys
Pro Ser Ala Leu Leu Lys 1 5 16029PRTArtificial SequenceSynthetic
Polypeptide 1602Asp Glu Leu Asn Gly Phe Phe Asn Lys 1 5
160315PRTArtificial SequenceSynthetic Polypeptide 1603His Pro Lys
Pro Ser Pro Phe Ile Gly Asn Leu Thr Phe Phe Arg 1 5 10 15
160416PRTArtificial SequenceSynthetic Polypeptide 1604Gln Gln His
Arg Pro Phe Thr Tyr Leu Pro Phe Gly Ala Gly Pro Arg 1 5 10 15
160513PRTArtificial SequenceSynthetic Polypeptide 1605Gln Val Leu
Val Glu Asn Phe Ser Asn Phe Thr Asn Arg 1 5 10 160610PRTArtificial
SequenceSynthetic Polypeptide 1606Ser Val Ala Asp Ser Val Leu Phe
Leu Arg 1 5 10 160717PRTArtificial SequenceSynthetic Polypeptide
1607His Glu Asn Thr Ser Ser Ser Pro Ile Gln Tyr Glu Phe Ser Leu Thr
1 5 10 15 Arg 160810PRTArtificial SequenceSynthetic Polypeptide
1608Val Leu Tyr Leu Ser Ala Phe Thr Ser Lys 1 5 10
160915PRTArtificial SequenceSynthetic Polypeptide 1609Phe Val Gly
Thr Pro Glu Val Asn Gln Thr Thr Leu Tyr Gln Arg 1 5 10 15
161012PRTArtificial SequenceSynthetic Polypeptide 1610Gly Phe Gln
Ala Leu Gly Asp Ala Ala Asp Ile Arg 1 5 10 16119PRTArtificial
SequenceSynthetic Polypeptide 1611Ser Glu Glu Phe Leu Ile Ala Gly
Lys 1 5 161212PRTArtificial SequenceSynthetic Polypeptide 1612Glu
Gly Pro Phe Gly Thr Leu Val Tyr Thr Ile Lys 1 5 10
16137PRTArtificial SequenceSynthetic Polypeptide 1613Gly Trp Ala
Pro Pro Asp Lys 1 5 16148PRTArtificial SequenceSynthetic
Polypeptide 1614Ser Ile Ile Asn Ala Thr Asp Pro 1 5
16158PRTArtificial SequenceSynthetic Polypeptide 1615Tyr Gln Tyr
Leu Leu Thr Gly Arg 1 5 161612PRTArtificial SequenceSynthetic
Polypeptide 1616Asp Gly Thr Ser Glu Asn Ser Pro Leu Ile Gly Arg 1 5
10 161711PRTArtificial SequenceSynthetic Polypeptide 1617Ile Pro
Asp Pro Leu Val Ala Thr Gly Asn Lys 1 5 10 161812PRTArtificial
SequenceSynthetic Polypeptide 1618Leu Asn Gly Thr Ile Thr Thr Pro
Gly Trp Pro Lys 1 5 10 161911PRTArtificial SequenceSynthetic
Polypeptide 1619Val Pro Leu Gln Phe Ser Gly Gln Asn Glu Lys 1 5 10
162015PRTArtificial SequenceSynthetic Polypeptide 1620Tyr Asp Tyr
Val Glu Ile Trp Ser Gly Leu Ser Ser Glu Ser Lys 1 5 10 15
162114PRTArtificial SequenceSynthetic Polypeptide 1621Ala Ala Pro
Phe Leu Thr Tyr Phe Gly Leu Phe Gln Val His 1 5 10
16228PRTArtificial SequenceSynthetic Polypeptide 1622Ile Asn Ser
Ser Ser Pro Leu Arg 1 5 162312PRTArtificial SequenceSynthetic
Polypeptide 1623Leu Asp Leu Leu Val Asp Gly Val Leu Ala Leu Arg 1 5
10 16249PRTArtificial SequenceSynthetic Polypeptide 1624Gln Ile Gly
Glu Phe Ile Val Thr Arg 1 5 16258PRTArtificial SequenceSynthetic
Polypeptide 1625Thr Leu Pro Trp Ala His Leu Lys 1 5
162612PRTArtificial SequenceSynthetic Polypeptide 1626Asp Ile Thr
Ser Asp Ser Glu Asn Ser Asn Phe Arg 1 5 10 16277PRTArtificial
SequenceSynthetic Polypeptide 1627Ile Gln Thr Ile Ile Leu Lys 1 5
162811PRTArtificial SequenceSynthetic Polypeptide 1628Asn Asp Asn
Val Gln Asp Thr Ala Glu Gln Lys 1 5 10 16297PRTArtificial
SequenceSynthetic Polypeptide 1629Asn Glu Ile Gln Ser Leu Val 1 5
163012PRTArtificial SequenceSynthetic Polypeptide 1630Ser Val Asn
Ala Gln Val Thr Asp Ile Asn Ser Lys 1 5 10 163129PRTArtificial
SequenceSynthetic Polypeptide 1631Glu Leu Ala Ser Gln Pro Asp Val
Asp Gly Phe Leu Val Gly Gly Ala 1 5 10 15 Ser Leu Lys Pro Glu Phe
Val Asp Ile Ile Asn Ala Lys 20 25 163212PRTArtificial
SequenceSynthetic Polypeptide 1632Ser Asn Val Ser Asp Ala Val Ala
Gln Ser Thr Arg 1 5 10 163313PRTArtificial SequenceSynthetic
Polypeptide 1633Thr Ala Thr Pro Gln Gln Ala Gln Glu Val His Glu Lys
1 5 10 16347PRTArtificial SequenceSynthetic Polypeptide 1634Val Val
Phe Glu Gln Thr Lys 1 5 163515PRTArtificial SequenceSynthetic
Polypeptide 1635Val Val Leu Ala Tyr Glu Pro Val Trp Ala Ile Gly Thr
Gly Lys 1 5 10 15 163620PRTArtificial SequenceSynthetic Polypeptide
1636Ala Asp Ala Val Thr Leu Asp Gly Gly Phe Ile Tyr Glu Ala Gly Leu
1 5 10 15 Ala Pro Tyr Lys 20 163711PRTArtificial SequenceSynthetic
Polypeptide 1637Phe Gln Leu Phe Gly Ser Pro Ser Gly Gln Lys 1 5 10
163813PRTArtificial SequenceSynthetic Polypeptide 1638Leu Arg Pro
Val Ala Ala Glu Val Tyr Gly Thr Glu Arg 1 5 10 16399PRTArtificial
SequenceSynthetic Polypeptide 1639Val Pro Ser His Ala Val Val Ala
Arg 1 5 16409PRTArtificial SequenceSynthetic Polypeptide 1640Tyr
Tyr Gly Tyr Thr Gly Ala Phe Arg 1 5 16419PRTArtificial
SequenceSynthetic Polypeptide 1641Phe Gln Asp Leu Val Asp Ala Val
Arg 1 5 164218PRTArtificial SequenceSynthetic Polypeptide 1642Phe
Thr Gly Ser Gln Pro Phe Gly Gln Gly Val Glu His Ala Thr Ala 1 5 10
15 Asn Lys 164312PRTArtificial SequenceSynthetic Polypeptide
1643Phe Val Phe Gly Thr Thr Pro Glu Asp Ile Leu Arg 1 5 10
16449PRTArtificial SequenceSynthetic Polypeptide 1644Gly Phe Leu
Leu Leu Ala Ser Leu Arg 1 5 164512PRTArtificial SequenceSynthetic
Polypeptide 1645Gly Thr Ser Gln Asn Asp Pro Asn Trp Val Val Arg 1 5
10 164622PRTArtificial SequenceSynthetic Polypeptide 1646Thr Ser
Glu Ser Gly Glu Leu His Gly Leu Thr Thr Glu Glu Glu Phe 1 5 10 15
Val Glu Gly Ile Tyr Lys 20 16476PRTArtificial SequenceSynthetic
Polypeptide 1647Val Glu Ile Asp Thr Lys 1 5 164811PRTArtificial
SequenceSynthetic Polypeptide 1648Ala Leu Gln Glu Ala Leu Val Leu
Ser Asp Arg 1 5 10 164917PRTArtificial SequenceSynthetic
Polypeptide 1649Glu Gln Glu Glu Leu Leu Ala Pro Ala Asp Gly Thr Val
Glu Leu Val 1 5 10 15 Arg 16507PRTArtificial SequenceSynthetic
Polypeptide 1650Leu Ser Glu Ala Asp Ile Arg 1 5 165112PRTArtificial
SequenceSynthetic Polypeptide 1651Thr Leu Val Gly Val Gly Ala Ser
Leu Gly Leu Arg 1 5 10 165213PRTArtificial SequenceSynthetic
Polypeptide 1652Val Ala Ala Ala Leu Asp Asp Gly Ser Ala Leu Gly Arg
1 5 10 16539PRTArtificial SequenceSynthetic Polypeptide 1653Asp Leu
Ser Gln Asn Phe Pro Thr Lys 1 5 16549PRTArtificial
SequenceSynthetic Polypeptide 1654Phe Thr Ile Leu Asp Ser Gln Gly
Lys 1 5 165525PRTArtificial SequenceSynthetic Polypeptide 1655Ile
Ile Gly Pro Leu Glu Asp Ser Glu Leu Phe Asn Gln Asp Asp Phe 1 5 10
15 His Leu Leu Glu Asn Ile Ile Leu Lys 20 25 165613PRTArtificial
SequenceSynthetic Polypeptide 1656Leu Gly Ile Glu Gly Leu Ser Leu
His Asn Val Leu Lys 1 5 10 165717PRTArtificial SequenceSynthetic
Polypeptide 1657Tyr Val Leu Glu Pro Glu Ile Ser Phe Thr Ser Asp Asn
Ser Phe Ala 1 5 10 15 Lys 16589PRTArtificial SequenceSynthetic
Polypeptide 1658Ala Asn Pro Gly Ala Trp Ile Leu Arg 1 5
165919PRTArtificial SequenceSynthetic Polypeptide 1659Phe Leu Gly
Pro Leu Asp Glu Asp Phe Tyr Ala Glu Asp Phe Tyr Leu 1 5 10 15 Leu
Glu Lys 166011PRTArtificial SequenceSynthetic Polypeptide 1660Ile
Ile Phe Val Asp Ala Asp Gln Ile Val Arg 1 5 10 166114PRTArtificial
SequenceSynthetic Polypeptide 1661Ile Leu Phe Leu Asp Val Leu Phe
Pro Leu Ala Val Asp Lys 1 5 10 166210PRTArtificial
SequenceSynthetic Polypeptide 1662Ile Asn Glu Glu Asn Thr Ala Ile
Ser Arg 1 5 10 166310PRTArtificial SequenceSynthetic Polypeptide
1663Gly Gly Thr Leu Thr Gln Tyr Glu Gly Lys 1 5 10
166412PRTArtificial SequenceSynthetic Polypeptide 1664Gly Leu Pro
Asp Asn Ile Ser Ser Val Leu Asn Lys 1 5 10 166512PRTArtificial
SequenceSynthetic Polypeptide 1665Gly Thr Val Ile Ile Ile Ala Asn
His Gly Asp Arg 1 5 10 166612PRTArtificial SequenceSynthetic
Polypeptide 1666Ile Asp Ile Pro Pro Gly Ala Val Leu Glu Asn Lys 1 5
10 166715PRTArtificial SequenceSynthetic Polypeptide 1667Ile Phe
Asn Thr Asn Asn Leu Trp Ile Ser Leu Ala Ala Val Lys 1 5 10 15
166814PRTArtificial SequenceSynthetic Polypeptide 1668Ile Gln Arg
Pro Pro Glu Asp Ser Ile Gln Pro Tyr Glu Lys 1 5 10
16699PRTArtificial SequenceSynthetic Polypeptide 1669Leu Val Glu
Ile Ala Gln Val Pro Lys 1 5 167018PRTArtificial SequenceSynthetic
Polypeptide 1670Asn Glu Asn Thr Phe Leu Asp Leu Thr Val Gln Gln Ile
Glu His Leu 1 5 10 15 Asn Lys 167112PRTArtificial SequenceSynthetic
Polypeptide 1671Ser Phe Glu Asn Ser Leu Gly Ile Asn Val Pro Arg 1 5
10 167220PRTArtificial SequenceSynthetic Polypeptide 1672Thr Leu
Asp Gly Gly Leu Asn Val Ile Gln Leu Glu Thr Ala Val Gly 1 5 10 15
Ala Ala Ile Lys 20 167313PRTArtificial SequenceSynthetic
Polypeptide 1673Leu Trp Glu Glu Gly Glu Glu Leu Glu Leu Val Glu Lys
1 5 10 16749PRTArtificial SequenceSynthetic Polypeptide 1674Leu Trp
Gly Gly Thr Leu Leu Trp Thr 1 5 167510PRTArtificial
SequenceSynthetic Polypeptide 1675Leu Val Asp Thr Leu Pro Gln Lys
Pro Arg 1 5 10 167627PRTArtificial SequenceSynthetic Polypeptide
1676Val Ile Glu Thr Leu Leu Met Asp Thr Pro Ser Ser Tyr Glu Ala Ala
1 5 10 15 Met Glu Leu Phe Ser Pro Asp Gln Asp Met Arg 20 25
16778PRTArtificial SequenceSynthetic Polypeptide 1677Ala Asp Asp
Tyr Glu Gln Val Lys 1 5 167827PRTArtificial SequenceSynthetic
Polypeptide 1678Leu His Leu Gln Ser Thr Asp Tyr Gly Asn Phe Leu Ala
Asn Glu Ala 1 5 10 15 Ser Pro Leu Thr Val Ser Val Ile Asp Asp Arg
20 25 167913PRTArtificial SequenceSynthetic Polypeptide 1679Leu Leu
Phe Glu Gly Ala Gly Ser Asn Pro Gly Asp Lys 1 5 10
168011PRTArtificial SequenceSynthetic Polypeptide 1680Leu Tyr Pro
Glu Gly Leu Ala Gln Leu Ala Arg 1 5 10 168110PRTArtificial
SequenceSynthetic Polypeptide 1681Asn Val Ala Asp Tyr Tyr Pro Glu
Tyr Lys 1 5 10 168210PRTArtificial SequenceSynthetic Polypeptide
1682Leu Gln Ala Glu Thr Glu Leu Ile Asn Arg 1 5 10
168313PRTArtificial SequenceSynthetic Polypeptide 1683Asn Asp Gln
Asn Leu Tyr Gln Val Phe Ile Asn Tyr Lys 1 5 10 168426PRTArtificial
SequenceSynthetic Polypeptide 1684Gln Phe Gln Leu Ser Ile Glu Asn
Leu Asn Gln Pro Val Leu Leu Phe 1 5 10 15 Gly Arg Pro Gln Gly Asp
Gly Glu Ile Arg 20 25 168525PRTArtificial SequenceSynthetic
Polypeptide 1685Thr Pro Ile Ala Leu Ala Thr Gly Ile Arg Pro Phe Pro
Thr Glu Glu 1 5 10 15 Ser Ile Asn Asp Glu Asp Ile Tyr Lys 20 25
168616PRTArtificial SequenceSynthetic Polypeptide 1686Val Thr Trp
Asp Ser Ala Gln Val Phe Asp Leu Ala Gln Thr Leu Arg 1 5 10 15
16877PRTArtificial SequenceSynthetic Polypeptide 1687Gln Leu Glu
Leu Asn Glu Arg 1 5 16889PRTArtificial SequenceSynthetic
Polypeptide 1688Ser Trp Ser Val Tyr Val Gly Ala Arg 1 5
16897PRTArtificial SequenceSynthetic Polypeptide 1689Asp Leu Glu
Glu Gln Leu Arg 1 5 169031PRTArtificial SequenceSynthetic
Polypeptide 1690Glu Ala Pro Ala Ala Ala Ala Ala Phe Glu Ser Gly Leu
Asp Leu Ser 1 5 10 15 Asp Ala Glu Pro Asp Ala Gly Glu Ala Thr Ala
Tyr Ala Ser Lys 20 25 30 16918PRTArtificial SequenceSynthetic
Polypeptide 1691Glu Gln Ala Asn Leu Asn Ser Arg 1 5
169212PRTArtificial SequenceSynthetic Polypeptide 1692Phe Ala Ala
Ala His Tyr Asn Thr Glu Ile Leu Lys 1 5 10 16938PRTArtificial
SequenceSynthetic Polypeptide 1693Asn Gln Pro Leu Asn Pro Gly Lys 1
5 169410PRTArtificial SequenceSynthetic Polypeptide 1694Ala Ala Ser
Ser Leu Glu Glu Leu Leu Arg 1 5 10 16957PRTArtificial
SequenceSynthetic Polypeptide 1695Asp Leu Ile Gln His Pro Lys 1 5
169612PRTArtificial SequenceSynthetic Polypeptide 1696Phe Ala Ala
Thr Phe Tyr Asp Ile Glu Thr Leu Lys 1 5 10 169719PRTArtificial
SequenceSynthetic Polypeptide 1697Gln Leu Phe Glu Ile Ser Val Pro
Leu Thr Ser Val Pro Glu Leu Val 1 5 10 15 Pro Val Lys
16988PRTArtificial SequenceSynthetic Polypeptide 1698Val Ile Asp
Glu Glu Trp Gln Arg 1 5 169911PRTArtificial SequenceSynthetic
Polypeptide 1699Ala Phe Pro Ser Pro Glu Val Val Trp Leu Lys 1 5 10
170016PRTArtificial SequenceSynthetic Polypeptide 1700Ala Val Ser
Ser Phe Pro Asp Pro Ala Leu Tyr Pro Leu Gly Ser Arg 1 5 10 15
170117PRTArtificial SequenceSynthetic Polypeptide 1701Gly Ser Val
Glu Ser Ser Ala Tyr Leu Thr Val Gln Gly Thr Ser Asp 1 5 10 15 Lys
170214PRTArtificial SequenceSynthetic Polypeptide 1702Leu Gly Asp
Leu Leu Gln Ala Asn Val Gln Gln Asp Gly Lys 1 5 10
170311PRTArtificial SequenceSynthetic Polypeptide 1703Asn Ile Leu
Leu Ser Glu Asn Asn Val Val Lys 1 5 10 170423PRTArtificial
SequenceSynthetic Polypeptide 1704Ala Thr Trp Leu Ser Leu Phe Ser
Ser Glu Glu Ser Asn Leu Gly Ala 1 5 10 15 Asn Asn Tyr Asp Asp Tyr
Arg 20
17058PRTArtificial SequenceSynthetic Polypeptide 1705Ala Val Arg
Pro Gly Tyr Pro Lys 1 5 170614PRTArtificial SequenceSynthetic
Polypeptide 1706Asp Ser Trp Glu Asp Ile Phe Glu Leu Leu Phe Trp Gly
Arg 1 5 10 170715PRTArtificial SequenceSynthetic Polypeptide
1707Asp Val Trp Gly Ile Glu Gly Pro Ile Asp Ala Ala Phe Thr Arg 1 5
10 15 170812PRTArtificial SequenceSynthetic Polypeptide 1708Phe Glu
Asp Gly Val Leu Asp Pro Asp Tyr Pro Arg 1 5 10 17099PRTArtificial
SequenceSynthetic Polypeptide 1709Ala Gly Asp Leu Gln Val Arg Pro
Arg 1 5 171011PRTArtificial SequenceSynthetic Polypeptide 1710Gln
Ala Trp Val Ser Gln Gly Gly Gly Ala Lys 1 5 10 17119PRTArtificial
SequenceSynthetic Polypeptide 1711Val Asn Glu Leu Gly Arg Pro Ala
Arg 1 5 17127PRTArtificial SequenceSynthetic Polypeptide 1712Glu
Asn Arg Pro Asp Ala Arg 1 5 171319PRTArtificial SequenceSynthetic
Polypeptide 1713Glu Ser Ala Phe Val His Ala Ile Ala Ser Ala Gly Val
Ala Phe Ala 1 5 10 15 Val Thr Arg 17149PRTArtificial
SequenceSynthetic Polypeptide 1714Gly Trp Val Glu Thr Leu Arg Pro
Arg 1 5 17157PRTArtificial SequenceSynthetic Polypeptide 1715His
Gln Gly Ser Pro Gly Lys 1 5 17165PRTArtificial SequenceSynthetic
Polypeptide 1716Tyr Thr Tyr Phe Lys 1 5 171711PRTArtificial
SequenceSynthetic Polypeptide 1717Gly Val Ala Ala Gly Ser Ser Ser
Ser Val Lys 1 5 10 17188PRTArtificial SequenceSynthetic Polypeptide
1718Ile His Thr His Gly Val Phe Arg 1 5 171932PRTArtificial
SequenceSynthetic Polypeptide 1719Asn Gln Gly Tyr Ser Thr Val Thr
Phe Asp Gly Thr Pro Ser Tyr Gly 1 5 10 15 His Thr Pro Ser His His
Ala Ala Gln Phe Pro Asn His Ser Phe Lys 20 25 30 17206PRTArtificial
SequenceSynthetic Polypeptide 1720Ser Asp Glu Leu Val Arg 1 5
172118PRTArtificial SequenceSynthetic Polypeptide 1721Tyr Gly Pro
Phe Gly Pro Pro Pro Pro Ser Gln Ala Ser Ser Gly Gln 1 5 10 15 Ala
Arg 172218PRTArtificial SequenceSynthetic Polypeptide 1722Asp Ile
Val Glu Tyr Tyr Asn Asp Ser Asn Gly Ser His Val Leu Gln 1 5 10 15
Gly Arg 17237PRTArtificial SequenceSynthetic Polypeptide 1723Asp
Tyr Ile Glu Phe Asn Lys 1 5 172416PRTArtificial SequenceSynthetic
Polypeptide 1724Glu Ile Pro Ala Trp Val Pro Phe Asp Pro Ala Ala Gln
Ile Thr Lys 1 5 10 15 172510PRTArtificial SequenceSynthetic
Polypeptide 1725Trp Glu Ala Glu Pro Val Tyr Val Gln Arg 1 5 10
172612PRTArtificial SequenceSynthetic Polypeptide 1726Tyr Ser Leu
Thr Tyr Ile Tyr Thr Gly Leu Ser Lys 1 5 10 172730PRTArtificial
SequenceSynthetic Polypeptide 1727Leu Asp Gly Gln Ile Ser Ser Ala
Tyr Pro Ser Gln Glu Gly Gln Val 1 5 10 15 Leu Val Gly Ile Tyr Gly
Gln Tyr Gln Leu Leu Gly Ile Lys 20 25 30 172821PRTArtificial
SequenceSynthetic Polypeptide 1728Leu Gly Ala Leu Gly Gly Asn Thr
Gln Glu Val Thr Leu Gln Pro Gly 1 5 10 15 Glu Tyr Ile Thr Lys 20
17299PRTArtificial SequenceSynthetic Polypeptide 1729Val Ser Val
Gly Leu Leu Leu Val Lys 1 5 173016PRTArtificial SequenceSynthetic
Polypeptide 1730Tyr Phe Ser Thr Thr Glu Asp Tyr Asp His Glu Ile Thr
Gly Leu Arg 1 5 10 15 17316PRTArtificial SequenceSynthetic
Polypeptide 1731Tyr Phe Tyr Phe Gly Lys 1 5
* * * * *
References